CBIS - Vor dem Ausbruch, verdoppeln in wenigen Tagen !!!! - 500 Beiträge pro Seite
eröffnet am 11.11.09 11:12:30 von
neuester Beitrag 09.11.20 10:35:17 von
neuester Beitrag 09.11.20 10:35:17 von
Beiträge: 481
ID: 1.154.177
ID: 1.154.177
Aufrufe heute: 0
Gesamt: 119.817
Gesamt: 119.817
Aktive User: 0
ISIN: US1376481016 · WKN: A0RM6Z
0,0110
EUR
0,00 %
0,0000 EUR
Letzter Kurs 21.11.19 Stuttgart
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
22,080 | +359,04 | |
1,6200 | +88,59 | |
0,7500 | +50,00 | |
1,5400 | +33,91 | |
0,7630 | +26,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
5,0101 | -15,80 | |
3,8500 | -16,12 | |
7,5000 | -16,67 | |
1,8500 | -20,94 | |
3,6400 | -38,62 |
Invest Alert : CBIS | Big opportunity NOW! - breakthrough phytocannabinoid pharmaceutical products
Invest in 21st century research that does well for its
shareholders by developing treatments for patients with
H1N1 Swine Flu & H1N5 Avian Flu, Chronic Pain, and Post
Traumatic Stree Disorder (PTSD)
Trading Symbol: CBIS
Company Profile
Cannabis Science, Inc. is at the forefront of medical marijuana
research and development. The Company works with
world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce, and commercialize phytocannabinoidbased
pharmaceutical products. In sum, we are dedicated
to the creation of FDA approved cannabis-based medicines,
both with and without psychoactive properties, to treat
disease and the symptoms of disease, as well as for general
health maintenance.
The Market Opportunity
Whole Plant Pharmaceutical:
1. Psychoactive Medicines
2. Neutroceuticals and Topical Creams
3. Research & Development
4. Formal testing / Licensing (FDA, State or Federal)
5. Commercial Licensing
6. Commercialization (Manufacturing / Production)
7. Multiple-Market (Countries) Penetration
Breaking News: Cannabis Science Reports Obama
Administration Issues New Medical Marijuana Policy;
One More Step Toward Legalization As the Federal
Government Won’t Prosecute Medical Marijuana if
Compliant with State Law.
Monday, October 19, 2009 - COLORADO SPRINGS,
Colo. -- Cannabis Science Inc. (OTCBB: CBIS - News)
an emerging pharmaceutical cannabis company, is
very pleased with the latest announcement by the
Obama Administration. The Company sees it as
definitely one giant step closer to the legalization of
Medical Cannabis/Marijuana, as a Government
supported legal medical treatment.
Our Mission
Cannabis Science’s mission is to bring together science
and compassion by learning from science what nature
teaches us and by listening to the experiences of those
whose lives have been improved by their use of the
cannabis plant.
“Cannabis Science is a patientoriented
company that will do well
for its shareholders by doing good for
the patients who need its products.”
Executive Summary
Board of Directors
Dr Robert J Meamede, PhD - President & CEO
Richard Cowan - Director& Chief Financial Officer
Scientific Advisory Board
Dr Mitch Earleywine
Dr Ritchard L Fishman
Policy Advisory Board
Robert Raich
Sean T McAllister
Warren Edson
Robert J Corry, Jr
Brian Vicente, Esq
Trading Symbol: CBIS
Initial Products: Delivery:
1. H1N1/H1N5 1. Lozenge
2. PTSD 2. Strips
3. Pain Management 3. Cream
4. Cold & Flu 4. Liquid
5. Asthma 5. Pills
6. Digestive Illnesses
7. Cancer
8. AIDS
9. Bird Flu
10. Arthritis
11. Anti-Aging
12. MRSA (Flesh Eating Disease)
13. MS
14. Glaucoma
The Cannabis Competitive Advantage
Cannabis Science’s first candidate product is an Oral Cannabis
Extract-Based Medicine. The advantage of our unique
Cannabis Based Medicines is that they will be FDA approved
and they will provide fast, effective delivery of prescription
dosages of the therapeutic cannabinoids that can be
covered by health insurance plans.
The Company has completed its review of the FDA licensing
requirements and has made key progress with mapping out
its initial cannabis drug medicines for FDA clinical trials. The
Company has determined that it can have more than one
product in clinical testing and trials at the same time. This
news comes following the identification of two distinct
parallel paths in developing pharmaceutical products for
FDA approval.
The first being the highly publicized H1N1 Swine flu and the
deadly H1N5 Avian flu, and the second being a newly
formed initiative for Veterans who suffer from Post Traumatic
Stress Disorder (PTSD). The third will be for cronic
pain treatment. Together with these initiatives, Cannabis
Science is laying a solid foundation for entrance into the
FDA and other government regulatory agencies for developing
medicines for Influenza, PTSD, cronic pain, and other
ailments.
The Company looks forward to announcing its continued
progress with these initiatives through the development of
an online progress chart that will become available at the
www.cannabisscience.com website in the near future.
Preliminary informal patient trials were carried out by the
Vancouver Island Compassion Society (VICS) in Victoria,
B.C., Canada has anecdotally established the safety and
efficacy of the product.
Non-psychoactive hemp-based consumer products –
everything from paper to soap and lotions to clothing to
roasted seeds – already constitute a rapidly growing
market in the US and elsewhere.
Cannabis Science will be different from other pharmaceutical
companies in a variety of ways:
1. It was founded by patients who use the Cannabis
Plant to treat their own medical conditions. Consequently,
it is very much oriented toward the community
of medical cannabis patients.
2. Cannabis Science’s approach to product development
will also be patient oriented, looking to the medical
cannabis patient community for ideas for medical cannabis
products that can be scientifically formulated, FDA
approved, and produced at the lowest cost in forms that
will be attractive to the patients.
3. Cannabis Science will focus on a relatively new and
under-explored niche in the pharmaceutical market:
Whole-plant cannabinoid compounds derived from certified
organic ingredients, using proprietary genetics and
patentable production methods. (Cannabis Science may
eventually develop non-cannabis medicines, but for the
foreseeable future it will concentrate its activities on this
one plant.)
Our First Products
H1N1 Swine Flu & H1N5 Avian Flu
According to the CDC the Avian flu (H5N1) has a 63%
mortality rate. Unfortunately, the Swine flu, while causing
death at a much lower rate than the Avian flu, also
appears to result in death via a similar mechanism. The
common cause of death with these strains is organ
failure, especially as seen in the lungs with the development
of Adult Respiratory Distress Syndrome (ARDS).
ARDS is caused by an excess immune-generated inflammatory
response that leads to apoptosis (cell death) and
subsequently to organ failure. The Company's approach
will mimic how the human body uses endocannabinoids
(cannabinoids that occur naturally in the body) to regulate
immune activity and cell survival, by regulating
inflammatory biochemistry.
Excessive inflammatory responses are associated with
numerous disease states including autoimmune diseases,
neurological imbalances, and cardiovascular disease.
Phytocannabinoids provide a natural means to supplement
illness-specific endocannabinoid deficiencies
Veterans Post Traumatic Stress Disorder (PTSD)
and Chronic Pain
Our Veterans PTSD Program is designed to test the
efficacy of our cannabis extract-based oral medicine to
provide immediate relief of the negative consequences of
PTSD in our military veterans. We will carry out clinical
trials to demonstrate that the physical (chronic pain) and
emotional conditions (PTSD) of those in need can be
improved with our formulations. We are rapidly moving
forward with our program designed to test the efficacy of
our cannabis extract-based oral medicine to provide
immediate relief of the negative consequences of PTSD in
our military veterans.
Invest in 21st century research that does well for its
shareholders by developing treatments for patients with
H1N1 Swine Flu & H1N5 Avian Flu, Chronic Pain, and Post
Traumatic Stree Disorder (PTSD)
Trading Symbol: CBIS
Company Profile
Cannabis Science, Inc. is at the forefront of medical marijuana
research and development. The Company works with
world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce, and commercialize phytocannabinoidbased
pharmaceutical products. In sum, we are dedicated
to the creation of FDA approved cannabis-based medicines,
both with and without psychoactive properties, to treat
disease and the symptoms of disease, as well as for general
health maintenance.
The Market Opportunity
Whole Plant Pharmaceutical:
1. Psychoactive Medicines
2. Neutroceuticals and Topical Creams
3. Research & Development
4. Formal testing / Licensing (FDA, State or Federal)
5. Commercial Licensing
6. Commercialization (Manufacturing / Production)
7. Multiple-Market (Countries) Penetration
Breaking News: Cannabis Science Reports Obama
Administration Issues New Medical Marijuana Policy;
One More Step Toward Legalization As the Federal
Government Won’t Prosecute Medical Marijuana if
Compliant with State Law.
Monday, October 19, 2009 - COLORADO SPRINGS,
Colo. -- Cannabis Science Inc. (OTCBB: CBIS - News)
an emerging pharmaceutical cannabis company, is
very pleased with the latest announcement by the
Obama Administration. The Company sees it as
definitely one giant step closer to the legalization of
Medical Cannabis/Marijuana, as a Government
supported legal medical treatment.
Our Mission
Cannabis Science’s mission is to bring together science
and compassion by learning from science what nature
teaches us and by listening to the experiences of those
whose lives have been improved by their use of the
cannabis plant.
“Cannabis Science is a patientoriented
company that will do well
for its shareholders by doing good for
the patients who need its products.”
Executive Summary
Board of Directors
Dr Robert J Meamede, PhD - President & CEO
Richard Cowan - Director& Chief Financial Officer
Scientific Advisory Board
Dr Mitch Earleywine
Dr Ritchard L Fishman
Policy Advisory Board
Robert Raich
Sean T McAllister
Warren Edson
Robert J Corry, Jr
Brian Vicente, Esq
Trading Symbol: CBIS
Initial Products: Delivery:
1. H1N1/H1N5 1. Lozenge
2. PTSD 2. Strips
3. Pain Management 3. Cream
4. Cold & Flu 4. Liquid
5. Asthma 5. Pills
6. Digestive Illnesses
7. Cancer
8. AIDS
9. Bird Flu
10. Arthritis
11. Anti-Aging
12. MRSA (Flesh Eating Disease)
13. MS
14. Glaucoma
The Cannabis Competitive Advantage
Cannabis Science’s first candidate product is an Oral Cannabis
Extract-Based Medicine. The advantage of our unique
Cannabis Based Medicines is that they will be FDA approved
and they will provide fast, effective delivery of prescription
dosages of the therapeutic cannabinoids that can be
covered by health insurance plans.
The Company has completed its review of the FDA licensing
requirements and has made key progress with mapping out
its initial cannabis drug medicines for FDA clinical trials. The
Company has determined that it can have more than one
product in clinical testing and trials at the same time. This
news comes following the identification of two distinct
parallel paths in developing pharmaceutical products for
FDA approval.
The first being the highly publicized H1N1 Swine flu and the
deadly H1N5 Avian flu, and the second being a newly
formed initiative for Veterans who suffer from Post Traumatic
Stress Disorder (PTSD). The third will be for cronic
pain treatment. Together with these initiatives, Cannabis
Science is laying a solid foundation for entrance into the
FDA and other government regulatory agencies for developing
medicines for Influenza, PTSD, cronic pain, and other
ailments.
The Company looks forward to announcing its continued
progress with these initiatives through the development of
an online progress chart that will become available at the
www.cannabisscience.com website in the near future.
Preliminary informal patient trials were carried out by the
Vancouver Island Compassion Society (VICS) in Victoria,
B.C., Canada has anecdotally established the safety and
efficacy of the product.
Non-psychoactive hemp-based consumer products –
everything from paper to soap and lotions to clothing to
roasted seeds – already constitute a rapidly growing
market in the US and elsewhere.
Cannabis Science will be different from other pharmaceutical
companies in a variety of ways:
1. It was founded by patients who use the Cannabis
Plant to treat their own medical conditions. Consequently,
it is very much oriented toward the community
of medical cannabis patients.
2. Cannabis Science’s approach to product development
will also be patient oriented, looking to the medical
cannabis patient community for ideas for medical cannabis
products that can be scientifically formulated, FDA
approved, and produced at the lowest cost in forms that
will be attractive to the patients.
3. Cannabis Science will focus on a relatively new and
under-explored niche in the pharmaceutical market:
Whole-plant cannabinoid compounds derived from certified
organic ingredients, using proprietary genetics and
patentable production methods. (Cannabis Science may
eventually develop non-cannabis medicines, but for the
foreseeable future it will concentrate its activities on this
one plant.)
Our First Products
H1N1 Swine Flu & H1N5 Avian Flu
According to the CDC the Avian flu (H5N1) has a 63%
mortality rate. Unfortunately, the Swine flu, while causing
death at a much lower rate than the Avian flu, also
appears to result in death via a similar mechanism. The
common cause of death with these strains is organ
failure, especially as seen in the lungs with the development
of Adult Respiratory Distress Syndrome (ARDS).
ARDS is caused by an excess immune-generated inflammatory
response that leads to apoptosis (cell death) and
subsequently to organ failure. The Company's approach
will mimic how the human body uses endocannabinoids
(cannabinoids that occur naturally in the body) to regulate
immune activity and cell survival, by regulating
inflammatory biochemistry.
Excessive inflammatory responses are associated with
numerous disease states including autoimmune diseases,
neurological imbalances, and cardiovascular disease.
Phytocannabinoids provide a natural means to supplement
illness-specific endocannabinoid deficiencies
Veterans Post Traumatic Stress Disorder (PTSD)
and Chronic Pain
Our Veterans PTSD Program is designed to test the
efficacy of our cannabis extract-based oral medicine to
provide immediate relief of the negative consequences of
PTSD in our military veterans. We will carry out clinical
trials to demonstrate that the physical (chronic pain) and
emotional conditions (PTSD) of those in need can be
improved with our formulations. We are rapidly moving
forward with our program designed to test the efficacy of
our cannabis extract-based oral medicine to provide
immediate relief of the negative consequences of PTSD in
our military veterans.
Antwort auf Beitrag Nr.: 38.363.801 von Lawuki2005 am 11.11.09 11:12:30NEWS stehen an !!!!!!!!!!!!
wahrscheinlich ab Donnerstag 12.11.09
Kurse oberhalb 1 Dollar sehr sehr wahrscheinlich
wahrscheinlich ab Donnerstag 12.11.09
Kurse oberhalb 1 Dollar sehr sehr wahrscheinlich
Alle NEWS werden ab sofort auch in DEUTSCH erscheinen.
Frankfurt Listing noch dieses Jahr
Frankfurt Listing noch dieses Jahr
Antwort auf Beitrag Nr.: 38.364.525 von tradepunk am 11.11.09 12:42:50Medizinischer Cannabis !!!!!!!!!!!!!!!!!
Zulassung USA unter Obama-Regierung steht unmittelbar bevor.
Lawuki
Zulassung USA unter Obama-Regierung steht unmittelbar bevor.
Lawuki
Antwort auf Beitrag Nr.: 38.364.581 von Lawuki2005 am 11.11.09 12:48:39Ich weiß ja! Aber auch diese Entwicklung ist schon absolut positiv für die (Pharma)-Konzern-beherrschten Amis. CBIS ist mir auch bekannt. Den Juli-Hype habe ich aber leider auch nicht mitgemacht. Seitdem hält sich der Kurs bei einer MK von rd. 10 Mio.$. Du könntest schon recht haben, daß demnächst nochmal ein Schub nach oben kommt.
Antwort auf Beitrag Nr.: 38.364.825 von tradepunk am 11.11.09 13:19:29Nicht demnächst !!!!!!!!
AB Donnerstag !!!!!!!
AB Donnerstag !!!!!!!
CNN Reports President Obama Declares National Emergency To Deal With The "Rapid Increase In Illness" From The H1N1 Influenza Virus; Cannabis Science Continues Progress On Its Research To Show Cannabis Can Reduce Risk of Death from "Swine Flu"
San Francisco. Die Weltgesundheitsorganisation (WHO) hat eine Schweinegrippe-Pandemie ausgerufen, indem sie die Pandemie-Warnung von der Stufe 5 auf 6 erhöhte. So wurde die Schweinegrippe zur ersten globalen Grippe-Epidemie in 41 Jahren. Jetzt, wo die H1N1-„Schweinegrippe“ auf Pandemie-Stufe befördert wurde, durch Berichte von Ausbrüchen in Asien, dem Mittleren Osten und Europa, fordert der Geschäftsführer der in San Francisco, USA, beheimateten Cannabis Science Inc. (OTCBB: CBIS.OB), Steven Kubby, die Gesundheitsbeamten in der ganzen Welt auf, „medizinisches Cannabis ernst zu nehmen“.
Gemäss der Firma, welche in Cannabis-Forschung und –Entwicklung für medizinische Zwecke spezialisiert ist, könnte die Welt ein Mittel zur Bekämpfung der Auswirkungen dieser tödlichen Krankheit zur Verfügung haben. Dr. Robert Melamede, Direktor und Chefforscher für CSI, berichtet: „Forschungen über die Anwendung von Cannabis-Extrakten und multi-cannabinoiden Verbindungen haben wissenschaftliche Begründungen für die Wirksamkeit von medizinischem Marijuana bei der Behandlung von ein paar der schlimmsten Krankheiten, denen die Menschheit zurzeit gegenüber steht, ergeben, dies sowohl für Infektionskrankheiten, wie Grippe und Aids, als auch für Autoimmun-Krankheiten, wie ALS (Lou Gehrigs Krankheit), Multiple Sklerose, Arthritis und Diabetes, sowie Nervenleiden, wie Alzheimer, Gehirnschläge und –schäden, und nicht zuletzt für einige Arten von Krebs.“
Dr. Melamede führte weiter aus: „Die hohe Sterblichkeitsrate gewisser Grippestämme kann auf die hohe Entzündungsreaktion, welche vom Tumor-Nekrose-Faktor (TNF) gesteuert werden, zurückgeführt werden. Endocannabinoide sind der Weg der Natur die TNF-Aktivität zu kontrollieren. Phyto-Cannabinoide können die natürlichen Endocannabinoide imitieren und so starken Entzündungen als Antwort des Immunsystems vorbeugen.“
Nachdem er gehört hatte, dass die WHO die Schweinegrippe auf Pandemie-Stufe gehoben hat, sagte der Geschäftsführer von CSI, Steve Kubby: „Regierungen in der ganzen Welt sollten ernsthaft die Vorteile von medizinischem Cannabis zur Kenntnis nehmen.“¨
Am Mittwoch erklärte die WHO, dass 74 Länder etwa 27’737 Fälle von Schweinegrippe, inklusive 141 Todesfällen gemeldet hätten. Es gibt über 90 bestätigte Fälle in den USA, mit Berichten über Ansteckungen in 11 Staaten und einem Todesfall, ein 23 Monate altes Kind in Texas. Symptome sind hohes Fieber, Körperschmerzen, Husten, Halsschmerzen und starke Verstopfung der Atemwege.
Der Chefforscher von CSI, Dr. Melamede, glaubt, dass das Potential von Cannabinoiden, welche auf natürliche Weise starken Entzündungsreaktionen durch das Immunsystem vorbeugen, enorm ist. Er stellte fest, dass „wir, basierend auf kürzlich erfolgte Entdeckungen zur Rolle des Endocannabinoid-Systems bei der Erhaltung der menschlichen Gesundheit, eine einzigartige Lösung für die Bedrohung durch tödliche Grippe-Stämme haben könnten, von welcher wir glauben, dass sie, wenn durchgeführt, Millionen von Leben retten könnte.
Über Cannabis Science Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Cannabis Science Inc
www.cannabisscience.com
Gemäss der Firma, welche in Cannabis-Forschung und –Entwicklung für medizinische Zwecke spezialisiert ist, könnte die Welt ein Mittel zur Bekämpfung der Auswirkungen dieser tödlichen Krankheit zur Verfügung haben. Dr. Robert Melamede, Direktor und Chefforscher für CSI, berichtet: „Forschungen über die Anwendung von Cannabis-Extrakten und multi-cannabinoiden Verbindungen haben wissenschaftliche Begründungen für die Wirksamkeit von medizinischem Marijuana bei der Behandlung von ein paar der schlimmsten Krankheiten, denen die Menschheit zurzeit gegenüber steht, ergeben, dies sowohl für Infektionskrankheiten, wie Grippe und Aids, als auch für Autoimmun-Krankheiten, wie ALS (Lou Gehrigs Krankheit), Multiple Sklerose, Arthritis und Diabetes, sowie Nervenleiden, wie Alzheimer, Gehirnschläge und –schäden, und nicht zuletzt für einige Arten von Krebs.“
Dr. Melamede führte weiter aus: „Die hohe Sterblichkeitsrate gewisser Grippestämme kann auf die hohe Entzündungsreaktion, welche vom Tumor-Nekrose-Faktor (TNF) gesteuert werden, zurückgeführt werden. Endocannabinoide sind der Weg der Natur die TNF-Aktivität zu kontrollieren. Phyto-Cannabinoide können die natürlichen Endocannabinoide imitieren und so starken Entzündungen als Antwort des Immunsystems vorbeugen.“
Nachdem er gehört hatte, dass die WHO die Schweinegrippe auf Pandemie-Stufe gehoben hat, sagte der Geschäftsführer von CSI, Steve Kubby: „Regierungen in der ganzen Welt sollten ernsthaft die Vorteile von medizinischem Cannabis zur Kenntnis nehmen.“¨
Am Mittwoch erklärte die WHO, dass 74 Länder etwa 27’737 Fälle von Schweinegrippe, inklusive 141 Todesfällen gemeldet hätten. Es gibt über 90 bestätigte Fälle in den USA, mit Berichten über Ansteckungen in 11 Staaten und einem Todesfall, ein 23 Monate altes Kind in Texas. Symptome sind hohes Fieber, Körperschmerzen, Husten, Halsschmerzen und starke Verstopfung der Atemwege.
Der Chefforscher von CSI, Dr. Melamede, glaubt, dass das Potential von Cannabinoiden, welche auf natürliche Weise starken Entzündungsreaktionen durch das Immunsystem vorbeugen, enorm ist. Er stellte fest, dass „wir, basierend auf kürzlich erfolgte Entdeckungen zur Rolle des Endocannabinoid-Systems bei der Erhaltung der menschlichen Gesundheit, eine einzigartige Lösung für die Bedrohung durch tödliche Grippe-Stämme haben könnten, von welcher wir glauben, dass sie, wenn durchgeführt, Millionen von Leben retten könnte.
Über Cannabis Science Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Cannabis Science Inc
www.cannabisscience.com
Antwort auf Beitrag Nr.: 38.365.218 von Lawuki2005 am 11.11.09 14:09:28Es ist seit Jahrhunderten bekannt, daß man viele Krankheiten mit Cannabis heilen kann. Es heißt allgemein, ca. 1/3 aller herkömmlichen Arzneimittel könnten durch Cannabisprodukte ersetzt werden. Für viele Krankheiten gibt es gar keine andere Möglichkeit, als den Einsatz von Cannabis (z.B. Glaukom oder Übelkeit in der Chemotherapie bei Krebspatienten).
Allerdings kann man die Prohibition von einigen bestimmten Heilkräutern niemals aufheben, da die Pharmas (und speziell in diesem Fall zusätzlich auch die Alkohol- und Tabaklobby) hier sehr vehement dagegen vorgehen und ihre Interessen vertreten.
Jedoch sehe ich auch gerade deshalb den Vorstoß von CBIS als sehr positiv an. Würd's ihnen ja wünschen, daß Vernunft siegt...
Der Zeitpunkt ist passend!
Allerdings kann man die Prohibition von einigen bestimmten Heilkräutern niemals aufheben, da die Pharmas (und speziell in diesem Fall zusätzlich auch die Alkohol- und Tabaklobby) hier sehr vehement dagegen vorgehen und ihre Interessen vertreten.
Jedoch sehe ich auch gerade deshalb den Vorstoß von CBIS als sehr positiv an. Würd's ihnen ja wünschen, daß Vernunft siegt...
Der Zeitpunkt ist passend!
Antwort auf Beitrag Nr.: 38.365.218 von Lawuki2005 am 11.11.09 14:09:28Wo finde ich den Artikel?
Antwort auf Beitrag Nr.: 38.365.714 von tradepunk am 11.11.09 15:01:47Beim googlen entdeckt.
Ist aus Juli.
Du hast Recht, die Zeit ist passend.
Und Obama signalisiert wohl Zustimmung.
Ist mächtig was im Busch.
CBIS hat erst kürzlich 4 Fachanwälte eingestellt, um Obamas Vorgaben punktgenau zu erfüllen.
Könnte sein, daß genau das jetzt passiert.
Dann knallt es bestimmt durch die Decke.
Lawuki
Ist aus Juli.
Du hast Recht, die Zeit ist passend.
Und Obama signalisiert wohl Zustimmung.
Ist mächtig was im Busch.
CBIS hat erst kürzlich 4 Fachanwälte eingestellt, um Obamas Vorgaben punktgenau zu erfüllen.
Könnte sein, daß genau das jetzt passiert.
Dann knallt es bestimmt durch die Decke.
Lawuki
Hier nochmal die Meldung von vor 4 Wochen, die das ankündigt was nun unmittelbar bevor steht.
Breaking News: Cannabis Science Reports Obama Administration Issues New Medical Marijuana Policy; One More Step Toward Legalization As The Federal Government Won't Prosecute Medical Marijuana If Compliant With State Law
Oct. 19, 2009 (Business Wire) -- Cannabis Science Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company, is very pleased with the latest announcement by the Obama Administration. The Company sees it as definitely one giant step closer to the legalization of Medical Cannabis/Marijuana, as a Government supported legal medical treatment.
The Obama Administration said that it would not interfere with medical marijuana programs that are compliant with the laws of the states in which they operate. Two Justice Department officials described the new policy to The Associated Press, saying prosecutors will be told it is not a good use of their time to arrest people who use or provide medical marijuana in strict compliance with state laws.
Dr. Robert Melamede Ph.D. Cannabis Science President and CEO explained, “ Although we have never been vulnerable to federal charges in the way that growers and dispensaries might be, this new announcement means that intrastate research in Colorado, California and other states with medical marijuana laws is now explicitly protected from federal prosecution. Clearly, the Obama Administration is moving in the right direction for Cannabis Science Inc., to succeed in its business model.”
Previously, Cannabis Science announced initial product development targets and completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time. This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first being the highly publicized H1N1 Swine flu and the deadly H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD). Together with these initiatives, Cannabis Science is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for Influenza, PTSD and other ailments.
Dr. Robert Melamede added, “This latest announcement by the Obama Administration clears the way for CBIS to move aggressively in integrating product development and research with local patient groups on a variety of programs. Working within states that have approved the medical use of marijuana, Cannabis Science will be well-ahead in the drive for products that truly help the patients, independently of when Federal laws finally catch up with the states."
Breaking News: Cannabis Science Reports Obama Administration Issues New Medical Marijuana Policy; One More Step Toward Legalization As The Federal Government Won't Prosecute Medical Marijuana If Compliant With State Law
Oct. 19, 2009 (Business Wire) -- Cannabis Science Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company, is very pleased with the latest announcement by the Obama Administration. The Company sees it as definitely one giant step closer to the legalization of Medical Cannabis/Marijuana, as a Government supported legal medical treatment.
The Obama Administration said that it would not interfere with medical marijuana programs that are compliant with the laws of the states in which they operate. Two Justice Department officials described the new policy to The Associated Press, saying prosecutors will be told it is not a good use of their time to arrest people who use or provide medical marijuana in strict compliance with state laws.
Dr. Robert Melamede Ph.D. Cannabis Science President and CEO explained, “ Although we have never been vulnerable to federal charges in the way that growers and dispensaries might be, this new announcement means that intrastate research in Colorado, California and other states with medical marijuana laws is now explicitly protected from federal prosecution. Clearly, the Obama Administration is moving in the right direction for Cannabis Science Inc., to succeed in its business model.”
Previously, Cannabis Science announced initial product development targets and completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time. This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first being the highly publicized H1N1 Swine flu and the deadly H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD). Together with these initiatives, Cannabis Science is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for Influenza, PTSD and other ailments.
Dr. Robert Melamede added, “This latest announcement by the Obama Administration clears the way for CBIS to move aggressively in integrating product development and research with local patient groups on a variety of programs. Working within states that have approved the medical use of marijuana, Cannabis Science will be well-ahead in the drive for products that truly help the patients, independently of when Federal laws finally catch up with the states."
Das schreibt www.stockhottips.com
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is urging that US government recognize that phytocannabinoid pharmaceutical products can help reduce Adult Respiratory Distress Syndrome (ARDS)-associated deaths from both the Avian and Swine Influenza infections, as President Obama declares a national emergency. President Obama signed the declaration late Friday and announced it Saturday.
President Obama stated, “The 2009 H1N1 pandemic continues to evolve. The rates of illness continue to rise rapidly within many communities across the nation, and the potential exists for the pandemic to overburden health care resources in some localities.”
President Obama continued with, “Thus, in recognition of the continuing progression of the pandemic, and in further preparation as a nation, we are taking additional steps to facilitate our response.”
Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, “Clearly, there is little time to gear up the mass production of pharmaceutical cannabis products to meet the immediate needs of this national emergency. However, President Obama’s new policy of federal tolerance of medical marijuana where is it legal under state laws, makes it possible for Cannabis Science to work with the medical marijuana patients and providers in some states to help develop products to meet patients’ needs. If the situation is dire enough to justify calling it a “National Emergency”, then surely medical ethics require that we work diligently with all relevant research.”
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is urging that US government recognize that phytocannabinoid pharmaceutical products can help reduce Adult Respiratory Distress Syndrome (ARDS)-associated deaths from both the Avian and Swine Influenza infections, as President Obama declares a national emergency. President Obama signed the declaration late Friday and announced it Saturday.
President Obama stated, “The 2009 H1N1 pandemic continues to evolve. The rates of illness continue to rise rapidly within many communities across the nation, and the potential exists for the pandemic to overburden health care resources in some localities.”
President Obama continued with, “Thus, in recognition of the continuing progression of the pandemic, and in further preparation as a nation, we are taking additional steps to facilitate our response.”
Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, “Clearly, there is little time to gear up the mass production of pharmaceutical cannabis products to meet the immediate needs of this national emergency. However, President Obama’s new policy of federal tolerance of medical marijuana where is it legal under state laws, makes it possible for Cannabis Science to work with the medical marijuana patients and providers in some states to help develop products to meet patients’ needs. If the situation is dire enough to justify calling it a “National Emergency”, then surely medical ethics require that we work diligently with all relevant research.”
Diese Woche wird noch ein deutsches Profil von CBIS veröffentlicht.
Bald bekommt man sie nicht mehr unter 0,50 USD.
Bald bekommt man sie nicht mehr unter 0,50 USD.
Antwort auf Beitrag Nr.: 38.365.159 von Lawuki2005 am 11.11.09 14:03:14cannabis reduziert das Risiko an der neuen Influenza zu erkranken, weil das Zeugs in geschlossenen Räumen verkifft wird, zu denen fremde keinen Zutritt haben. Daher kann man sich da auch nicht anstecken
Das ist naturmedizin pur!
Listing in Frankfurt heißt nicht automatisch NEWS hier zu bekommen und heißt auch nicht irgendwas.
Accomplia wurde vom Markt genommen. Ein endocannabinoidantagonist zum Abspecken mit schweren Depressionen als Nebenwirkung.
Dronabinol ein Agonist ist bereits Mixbar, aber nur auf Privatrezept. Ist ein potentes Schmerzmittel, hebt die Stimmung und fördert den Appetitt, derzeit ideal in der Paliativmedizin, aber nicht zugelassen. Kleines Fläschechen kostet eben mal 400 €. Wird Tropfenweise angewendet und eignet sich zum Selbstmord, auf ex getrunken. ....schöner Tod
Das ist naturmedizin pur!
Listing in Frankfurt heißt nicht automatisch NEWS hier zu bekommen und heißt auch nicht irgendwas.
Accomplia wurde vom Markt genommen. Ein endocannabinoidantagonist zum Abspecken mit schweren Depressionen als Nebenwirkung.
Dronabinol ein Agonist ist bereits Mixbar, aber nur auf Privatrezept. Ist ein potentes Schmerzmittel, hebt die Stimmung und fördert den Appetitt, derzeit ideal in der Paliativmedizin, aber nicht zugelassen. Kleines Fläschechen kostet eben mal 400 €. Wird Tropfenweise angewendet und eignet sich zum Selbstmord, auf ex getrunken. ....schöner Tod
Antwort auf Beitrag Nr.: 38.367.846 von dottore am 11.11.09 18:06:32Hi dottore
Das Listing wird Ende des Jahres angestrebt. Ist jetzt zweitrangig.
Die News werden ab sofort auch auf Deutsch erscheinen.
Immer 1 Tag nach dem US Release.
Auf Deutsch und in Deutschland, über diverse Ticker und auf diversen financial Webseiten.
Deutsches Profil wie schon gesagt, noch diese Woche.
Und NEWS stehen trotzdem an!
lawuki
Das Listing wird Ende des Jahres angestrebt. Ist jetzt zweitrangig.
Die News werden ab sofort auch auf Deutsch erscheinen.
Immer 1 Tag nach dem US Release.
Auf Deutsch und in Deutschland, über diverse Ticker und auf diversen financial Webseiten.
Deutsches Profil wie schon gesagt, noch diese Woche.
Und NEWS stehen trotzdem an!
lawuki
Immerhin schon mal +8,89 %
Morgen dürften die 0,50 nachhaltig durchbrochen werden, und dann dürfte es Richtung 1 Dollar laufen.
Und immer schön daran denken. Bei 0,45 von mir empfohlen.
Morgen dürften die 0,50 nachhaltig durchbrochen werden, und dann dürfte es Richtung 1 Dollar laufen.
Und immer schön daran denken. Bei 0,45 von mir empfohlen.
Trotzdem komisch!!
Da empfiehlt man was, und fast alle reagieren zurückhaltend und mißtrauisch.
Geht der Ran erst los, springen die meißten zu spät auf.
Ich glaube hier kann man noch rechtzeitig dabei sein.
Da empfiehlt man was, und fast alle reagieren zurückhaltend und mißtrauisch.
Geht der Ran erst los, springen die meißten zu spät auf.
Ich glaube hier kann man noch rechtzeitig dabei sein.
Kaufsignal, gestern die
50-Tages-Linie durchbrochen
50-Tages-Linie durchbrochen
Das letzte mal gab es so eine schöne Kerze Mitte September, und danach ging es auch steil nach oben.
DJ PRESSEMITTEILUNG: www.penstox.de/ Cannabis Science Inc.: Firmenprofil auf www.penstox.de veröffentlicht
Auf den Seiten von www.penstox.de wurde ein Firmenprofil zu Cannabis Science Inc.
(USA – OTCBB:CBIS) veröffentlicht.
Unter folgender Adresse kann das Firmenprofil abgerufen werden:
http://penstox.de/index.php?page=/Seiten/Company-Profil-----…
Über Cannabis Science Inc.:
Cannabis Science Inc. ist ein börsennotiertes Unternehmen, welches an der Front der Erforschung und Entwicklung von medizinischen Cannabis tätig ist. Cannabis Science Inc. arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft und verwendet wissenschaftliche Methoden, um in Hinblick auf kritische Krankheiten, pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, zu produzieren und zu kommerzialisieren.
Kurz gesagt, widmet sich Cannabis Science Inc. der Entwicklung von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptone zu behandeln, sowie der allgemeinen Erhaltung der Gesundheit.
Aussender:
www.penstox.de
Das Penny Stock Portal
penstox@aol.com
(Dies ist eine Mitteilung von www.penstox.de, für den Inhalt ist ausschließlich www.penstox.de verantwortlich.)
(END) Dow Jones Newswires
November 12, 2009 05:43 ET (10:43 GMT)
Copyright (c) 2009 Dow Jones & Company, Inc.
Quelleow Jones 12.11.2009 11:43
Auf den Seiten von www.penstox.de wurde ein Firmenprofil zu Cannabis Science Inc.
(USA – OTCBB:CBIS) veröffentlicht.
Unter folgender Adresse kann das Firmenprofil abgerufen werden:
http://penstox.de/index.php?page=/Seiten/Company-Profil-----…
Über Cannabis Science Inc.:
Cannabis Science Inc. ist ein börsennotiertes Unternehmen, welches an der Front der Erforschung und Entwicklung von medizinischen Cannabis tätig ist. Cannabis Science Inc. arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft und verwendet wissenschaftliche Methoden, um in Hinblick auf kritische Krankheiten, pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, zu produzieren und zu kommerzialisieren.
Kurz gesagt, widmet sich Cannabis Science Inc. der Entwicklung von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptone zu behandeln, sowie der allgemeinen Erhaltung der Gesundheit.
Aussender:
www.penstox.de
Das Penny Stock Portal
penstox@aol.com
(Dies ist eine Mitteilung von www.penstox.de, für den Inhalt ist ausschließlich www.penstox.de verantwortlich.)
(END) Dow Jones Newswires
November 12, 2009 05:43 ET (10:43 GMT)
Copyright (c) 2009 Dow Jones & Company, Inc.
Quelleow Jones 12.11.2009 11:43
von www.penstox.de
Cannabis Science Inc. wollen mit medizinischen Cannabis gegen die „Schweinegrippe“ H1N1 vorgehen.
Cannabis Science Inc.
„CBIS“
(USA – OTCBB: CBIS)
Cannabis Science Inc. ist ein börsennotiertes Unternehmen, welches an der Front der Erforschung und Entwicklung von medizinischen Cannabis tätig ist. Cannabis Science Inc. arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft und verwendet wissenschaftliche Methoden, um in Hinblick auf kritische Krankheiten, pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren.
Kurz gesagt, widmet sich Cannabis Science Inc. der Entwicklung von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptone zu behandeln, sowie der allgemeinen Erhaltung der Gesundheit.
Forschungen über die Anwendungen von Cannabis-Extrakten und multi-cannabinoiden Verbindungen begründen wissenschaftlich die Wirksamkeit von medizinischen Cannabis bei der Behandlung von einigen der schlimmsten Krankheiten, denen die Menschheit zurzeit gegenüber steht.
Das gilt für Autoimmun-Krankheiten, wie ALS, Multiple Sklerose, Arthritis, Diabetes und Nervenleiden wie Alzheimer, Gehirnschläge sowie für einige Arten von Krebs.
Aber auch Infektionskrankheiten Grippe (auch „Schweinegrippe“) können behandelt werden.
Dr. Melamede, Direktor und Chefforscher von Cannabis Science Inc. sagt: „Die hohe Sterblichkeitsrate gewisser Grippestämme kann auf die hohe Entzündungsreaktion, welche vom Tumor-Nekrose-Faktor (TNF) gesteuert werden, zurückgeführt werden. Endocannabinoide sind der Weg der Natur die TNF-Aktivität zu kontrollieren. Phyto-Cannabinoide können die natürlichen Endocannabinoide imitieren und so starken Entzündungen als Antwort des Immunsystems vorbeugen.
Nachdem die Schweinegrippe auf Pandemie-Stufe gesetzt wurde, riet Steve Kubby, Geschäftsführer von Cannabis Science: „Regierungen in der ganzen Welt sollen ernsthaft die Vorteile von medizinischen Cannabis zur Kenntnis nehmen.“
Die USA reagierten. Am 19. Oktober 2009 verkündet die Obama-Regierung, dass man den Einsatz von medizinischen Cannabis zur Bekämpfung von Krankheiten im gesetzlichen Rahmen erlauben will.
Cannabis Science Inc. reagierte ebenfalls und beschäftigt vier Fachanwälte mit der Aufgabe den Weg zum Einsatz von medizinischen Cannabis in Abstimmung mit den Gesetzen zu ebnen.
Dies würde nicht nur ein Durchbruch bei der Behandlung von Krankheiten darstellen, sondern auch ein Durchbruch für Cannabis Science Inc.
Die Aktie notiert derzeit bei 0,49 US Dollar. Bei gerade mal 22 Mio. ausgegebenen Aktien macht das eine Marktkapitalisierung von unter 11 Millionen US Dollar.
Wir halten das aufgrund des bevorstehenden Einsatzes der Cannabis-Produkte für deutlich unterbewertet.
Der Kurs hat auf die aktuelle Entwicklung noch nicht reagiert. Das wird er aber nachholen.
Kurse unterhalb eines Dollars wird es bald nicht mehr geben. Wir halten folgende Kursziele für realistisch:
1,00 US Dollar bis Januar 2010
2,50 US Dollar bis Juni 2010
Unser Urteil: strong buy
Cannabis Science Inc. wollen mit medizinischen Cannabis gegen die „Schweinegrippe“ H1N1 vorgehen.
Cannabis Science Inc.
„CBIS“
(USA – OTCBB: CBIS)
Cannabis Science Inc. ist ein börsennotiertes Unternehmen, welches an der Front der Erforschung und Entwicklung von medizinischen Cannabis tätig ist. Cannabis Science Inc. arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft und verwendet wissenschaftliche Methoden, um in Hinblick auf kritische Krankheiten, pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren.
Kurz gesagt, widmet sich Cannabis Science Inc. der Entwicklung von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptone zu behandeln, sowie der allgemeinen Erhaltung der Gesundheit.
Forschungen über die Anwendungen von Cannabis-Extrakten und multi-cannabinoiden Verbindungen begründen wissenschaftlich die Wirksamkeit von medizinischen Cannabis bei der Behandlung von einigen der schlimmsten Krankheiten, denen die Menschheit zurzeit gegenüber steht.
Das gilt für Autoimmun-Krankheiten, wie ALS, Multiple Sklerose, Arthritis, Diabetes und Nervenleiden wie Alzheimer, Gehirnschläge sowie für einige Arten von Krebs.
Aber auch Infektionskrankheiten Grippe (auch „Schweinegrippe“) können behandelt werden.
Dr. Melamede, Direktor und Chefforscher von Cannabis Science Inc. sagt: „Die hohe Sterblichkeitsrate gewisser Grippestämme kann auf die hohe Entzündungsreaktion, welche vom Tumor-Nekrose-Faktor (TNF) gesteuert werden, zurückgeführt werden. Endocannabinoide sind der Weg der Natur die TNF-Aktivität zu kontrollieren. Phyto-Cannabinoide können die natürlichen Endocannabinoide imitieren und so starken Entzündungen als Antwort des Immunsystems vorbeugen.
Nachdem die Schweinegrippe auf Pandemie-Stufe gesetzt wurde, riet Steve Kubby, Geschäftsführer von Cannabis Science: „Regierungen in der ganzen Welt sollen ernsthaft die Vorteile von medizinischen Cannabis zur Kenntnis nehmen.“
Die USA reagierten. Am 19. Oktober 2009 verkündet die Obama-Regierung, dass man den Einsatz von medizinischen Cannabis zur Bekämpfung von Krankheiten im gesetzlichen Rahmen erlauben will.
Cannabis Science Inc. reagierte ebenfalls und beschäftigt vier Fachanwälte mit der Aufgabe den Weg zum Einsatz von medizinischen Cannabis in Abstimmung mit den Gesetzen zu ebnen.
Dies würde nicht nur ein Durchbruch bei der Behandlung von Krankheiten darstellen, sondern auch ein Durchbruch für Cannabis Science Inc.
Die Aktie notiert derzeit bei 0,49 US Dollar. Bei gerade mal 22 Mio. ausgegebenen Aktien macht das eine Marktkapitalisierung von unter 11 Millionen US Dollar.
Wir halten das aufgrund des bevorstehenden Einsatzes der Cannabis-Produkte für deutlich unterbewertet.
Der Kurs hat auf die aktuelle Entwicklung noch nicht reagiert. Das wird er aber nachholen.
Kurse unterhalb eines Dollars wird es bald nicht mehr geben. Wir halten folgende Kursziele für realistisch:
1,00 US Dollar bis Januar 2010
2,50 US Dollar bis Juni 2010
Unser Urteil: strong buy
Ich würde mir schnell welche ins Depot legen.
Antwort auf Beitrag Nr.: 38.373.233 von Lawuki2005 am 12.11.09 13:16:19Ich freu mich schon auf das Gesicht von meinem Nachbarn, wenn ich ihm erzähle, daß ich Geld mit Cannabis verdiene! (Der arme Mensch ist beim RD tätig)
Solltes ja auch fairer Weise sagen, daß es medizinischer Cannabis ist.
Nach +8,89 % gestern,
hoffe ich, daß es heute weiter geht.
Spätestens nach NEWS geht es steil Richtung Norden.
Und es soll bald soweit sein.
Lawuki
Nach +8,89 % gestern,
hoffe ich, daß es heute weiter geht.
Spätestens nach NEWS geht es steil Richtung Norden.
Und es soll bald soweit sein.
Lawuki
Ich würde noch schnell um 15.30 Uhr in Amiland zuschlagen.
Antwort auf Beitrag Nr.: 38.373.832 von Lawuki2005 am 12.11.09 14:25:17Im Prinzip ist jeder Cannabis medizinisch! Der Pflanze selbst ist es wohl ziemlich egal, ob sie jetzt vernünftig zu Heilungszwecken verwendet wird oder nur aus niederen Beweggründen, wie z.B. zur persönlichen Belustigung, einfach weggekifft wird!
Ich hoffe doch, wir reden hier schon von der Originalpflanze, nur eben im kontrollierten Anbau und einer kontrollierten Verwendung. Sollte es sich hier um den x-ten Versuch mit synthetischen Cannabinoiden handeln, würde ich auf der Stelle wieder Abstand von der Company nehmen. (Das geht nämlich nicht bzw. führt eher zu gegenteiligen als den gewünschten Effekten!)
Natürlich die Originalpflanze.
Deshalb muß man ja Hand in Hand mit den Gesetzgebern arbeiten.
Lawuki
Deshalb muß man ja Hand in Hand mit den Gesetzgebern arbeiten.
Lawuki
Antwort auf Beitrag Nr.: 38.374.595 von Lawuki2005 am 12.11.09 15:40:00Gut, dann hatte ichs ja schon richtig verstanden. Ich erinnere mich auch an einen TV-Bericht, in dem schon solche Anlagen in den USA gezeigt wurde. Vielleicht warens ja sogar welche von CBIS? Die sind sehr gut bewacht und mit hohen Zäunen umgeben. Da hat die Dorfjugend nix zu lachen! (Obwohl Lachen ja auch gesund ist!)
ASK schon mal angehoben. Lediglich Volummen fehlt. Noch!!
Bei entsprechender NEWS geht das wirklich sehr sehr schnell.
Das ASK ist recht dünn. Nicht viele die verkaufen wollen.
Bei entsprechender NEWS geht das wirklich sehr sehr schnell.
Das ASK ist recht dünn. Nicht viele die verkaufen wollen.
Und wieder ein Chartsignal:
Stochastic kreuzt bullish 2009-11-12 15:55:11
Stochastic kreuzt bullish 2009-11-12 15:55:11
Amerika denkt um !!!!
aus der Los Angeles Times vom 11.11.2009
Medical marijuana gets a boost from major doctors group
The American Medical Assn. changes its policy to promote clinical research and development of cannabis-based medicines and alternative delivery methods.
The American Medical Assn. on Tuesday urged the federal government to reconsider its classification of marijuana as a dangerous drug with no accepted medical use, a significant shift that puts the prestigious group behind calls for more research.
The nation's largest physicians organization, with about 250,000 member doctors, the AMA has maintained since 1997 that marijuana should remain a Schedule I controlled substance, the most restrictive category, which also includes heroin and LSD.
In changing its policy, the group said its goal was to clear the way to conduct clinical research, develop cannabis-based medicines and devise alternative ways to deliver the drug.
"Despite more than 30 years of clinical research, only a small number of randomized, controlled trials have been conducted on smoked cannabis," said Dr. Edward Langston, an AMA board member, noting that the limited number of studies was "insufficient to satisfy the current standards for a prescription drug product."
The decision by the organization's delegates at a meeting in Houston marks another step in the evolving view of marijuana, which an AMA report notes was once linked by the federal government to homicidal mania. Since California voters approved the use of medical marijuana in 1996, marijuana has moved steadily into the cultural mainstream spurred by the growing awareness that it can have beneficial effects for some chronically ill people.
This year, the Obama administration sped up that drift when it ordered federal narcotics agents not to arrest medical marijuana users and providers who follow state laws. Polls show broadening support for marijuana legalization.
Thirteen states allow the use of medical marijuana, and about a dozen more have considered it this year.
The AMA, however, also adopted as part of its new policy a sentence that admonishes: "This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product."
The association also rejected a proposal to issue a more forceful call for marijuana to be rescheduled.
Nevertheless, marijuana advocates welcomed the development. "They're clearly taking an open-minded stance and acknowledging that the evidence warrants a review. That is very big," said Bruce Mirken, a spokesman for the Marijuana Policy Project. "It's not surprising that they are moving cautiously and one step at a time, but this is still a very significant change."
Advocates also noted that the AMA rejected an amendment that they said would have undercut the medical marijuana movement. The measure would have made it AMA's policy that "smoking is an inherently unsafe delivery method for any therapeutic agent, and therefore smoked marijuana should not be recommended for medical use."
Dr. Michael M. Miller, a psychiatrist who practices addiction medicine, proposed the amendment. "Smoking is a bad delivery system because you're combusting something and inhaling it," he said.
Reaction from the federal government was muted.
Dawn Dearden with the Drug Enforcement Administration said: "At this point, it's still a Schedule I drug, and we're going to treat it as such." The Food and Drug Administration declined to comment.
In a statement, the office of the White House drug czar reiterated the administration's opposition to legalization and said that it would defer to "the FDA's judgment that the raw marijuana plant cannot meet the standards for identity, strength, quality, purity, packaging and labeling required of medicine."
The DEA classifies drugs into five schedules, with the fifth being the least-restrictive. Schedule II drugs, such as cocaine and morphine, are considered to have a high potential for abuse, but also to have accepted medical uses.
Several petitions have been filed to reschedule marijuana. The first, filed in 1972, bounced back and forth between the DEA and the courts until it died in 1994. A petition filed in 2002 is under consideration.
Kris Hermes, a spokesman for Americans for Safe Access, said that advocates hoped the petition would receive more attention. "Given the change of heart by the AMA, there is every opportunity for the Obama administration to do just that," he said.
In a report released with its new policy, the AMA notes that the organization was "virtually alone" in opposing the first federal restrictions on marijuana, which were adopted in 1937. Cannabis had been used in various medicinal products for years, but fell into disuse in the early 20th century.
Sunil Aggarwal, a medical student at the University of Washington, helped spark the AMA's reconsideration after he researched marijuana's effect on 186 chronically ill patients. "I had reason to believe that there was medical good that could come from these products, and I wanted to see AMA policy reflect that," he said.
The AMA is not the only major doctors organization to rethink marijuana. Last year, the American College of Physicians, the second-largest physician group, called for "rigorous scientific evaluation of the potential therapeutic benefits of medical marijuana" and an "evidence-based review of marijuana's status as a Schedule I controlled substance."
Last month, the California Medical Assn. passed resolutions that declared the criminalization of marijuana "a failed public health policy" and called on the organization to take part in the debate on changing current policy.
john.hoeffel@latimes.com
Copyright © 2009, The Los Angeles Times
aus der Los Angeles Times vom 11.11.2009
Medical marijuana gets a boost from major doctors group
The American Medical Assn. changes its policy to promote clinical research and development of cannabis-based medicines and alternative delivery methods.
The American Medical Assn. on Tuesday urged the federal government to reconsider its classification of marijuana as a dangerous drug with no accepted medical use, a significant shift that puts the prestigious group behind calls for more research.
The nation's largest physicians organization, with about 250,000 member doctors, the AMA has maintained since 1997 that marijuana should remain a Schedule I controlled substance, the most restrictive category, which also includes heroin and LSD.
In changing its policy, the group said its goal was to clear the way to conduct clinical research, develop cannabis-based medicines and devise alternative ways to deliver the drug.
"Despite more than 30 years of clinical research, only a small number of randomized, controlled trials have been conducted on smoked cannabis," said Dr. Edward Langston, an AMA board member, noting that the limited number of studies was "insufficient to satisfy the current standards for a prescription drug product."
The decision by the organization's delegates at a meeting in Houston marks another step in the evolving view of marijuana, which an AMA report notes was once linked by the federal government to homicidal mania. Since California voters approved the use of medical marijuana in 1996, marijuana has moved steadily into the cultural mainstream spurred by the growing awareness that it can have beneficial effects for some chronically ill people.
This year, the Obama administration sped up that drift when it ordered federal narcotics agents not to arrest medical marijuana users and providers who follow state laws. Polls show broadening support for marijuana legalization.
Thirteen states allow the use of medical marijuana, and about a dozen more have considered it this year.
The AMA, however, also adopted as part of its new policy a sentence that admonishes: "This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product."
The association also rejected a proposal to issue a more forceful call for marijuana to be rescheduled.
Nevertheless, marijuana advocates welcomed the development. "They're clearly taking an open-minded stance and acknowledging that the evidence warrants a review. That is very big," said Bruce Mirken, a spokesman for the Marijuana Policy Project. "It's not surprising that they are moving cautiously and one step at a time, but this is still a very significant change."
Advocates also noted that the AMA rejected an amendment that they said would have undercut the medical marijuana movement. The measure would have made it AMA's policy that "smoking is an inherently unsafe delivery method for any therapeutic agent, and therefore smoked marijuana should not be recommended for medical use."
Dr. Michael M. Miller, a psychiatrist who practices addiction medicine, proposed the amendment. "Smoking is a bad delivery system because you're combusting something and inhaling it," he said.
Reaction from the federal government was muted.
Dawn Dearden with the Drug Enforcement Administration said: "At this point, it's still a Schedule I drug, and we're going to treat it as such." The Food and Drug Administration declined to comment.
In a statement, the office of the White House drug czar reiterated the administration's opposition to legalization and said that it would defer to "the FDA's judgment that the raw marijuana plant cannot meet the standards for identity, strength, quality, purity, packaging and labeling required of medicine."
The DEA classifies drugs into five schedules, with the fifth being the least-restrictive. Schedule II drugs, such as cocaine and morphine, are considered to have a high potential for abuse, but also to have accepted medical uses.
Several petitions have been filed to reschedule marijuana. The first, filed in 1972, bounced back and forth between the DEA and the courts until it died in 1994. A petition filed in 2002 is under consideration.
Kris Hermes, a spokesman for Americans for Safe Access, said that advocates hoped the petition would receive more attention. "Given the change of heart by the AMA, there is every opportunity for the Obama administration to do just that," he said.
In a report released with its new policy, the AMA notes that the organization was "virtually alone" in opposing the first federal restrictions on marijuana, which were adopted in 1937. Cannabis had been used in various medicinal products for years, but fell into disuse in the early 20th century.
Sunil Aggarwal, a medical student at the University of Washington, helped spark the AMA's reconsideration after he researched marijuana's effect on 186 chronically ill patients. "I had reason to believe that there was medical good that could come from these products, and I wanted to see AMA policy reflect that," he said.
The AMA is not the only major doctors organization to rethink marijuana. Last year, the American College of Physicians, the second-largest physician group, called for "rigorous scientific evaluation of the potential therapeutic benefits of medical marijuana" and an "evidence-based review of marijuana's status as a Schedule I controlled substance."
Last month, the California Medical Assn. passed resolutions that declared the criminalization of marijuana "a failed public health policy" and called on the organization to take part in the debate on changing current policy.
john.hoeffel@latimes.com
Copyright © 2009, The Los Angeles Times
Wem das hier alles zu oberflächlich ist,
oder wer mit seiner zeit nicht weiß wohin,
oder wer Mutter und Vater erschlagen hat,
liest sich das mal durch.....
http://edoc.ub.uni-muenchen.de/9028/1/Nadig_Alexandra.pdf
oder wer mit seiner zeit nicht weiß wohin,
oder wer Mutter und Vater erschlagen hat,
liest sich das mal durch.....
http://edoc.ub.uni-muenchen.de/9028/1/Nadig_Alexandra.pdf
Normal kaufen Insider ja vor einer News ein.
Wann kommt die Meldung Deiner Meinung nach ?
Wann kommt die Meldung Deiner Meinung nach ?
Heute oder Montag
Heute letzte Möglichkeit zu 0,50 einzusteigen.
Indianer-Ehrenwort
Indianer-Ehrenwort
Also heute spätestens sollten NEWS kommen.
Lassen wir uns mal überraschen.
Lassen wir uns mal überraschen.
NEWS kommen definitiv
HEUTE
letzte Chance zum einsteigen !!!
HEUTE
letzte Chance zum einsteigen !!!
Antwort auf Beitrag Nr.: 38.396.688 von Lawuki2005 am 16.11.09 17:59:48Woher Dein definitives Wissen?
Believe it or not.
Antwort auf Beitrag Nr.: 38.380.631 von Moneymaker123 am 13.11.09 11:23:51Hat er dich auch per BM angeschrieben?
Frage mich warum er dann nicht alles auf dem Markt aufkauft, wenn er sich da so sicher ist.
Frage mich warum er dann nicht alles auf dem Markt aufkauft, wenn er sich da so sicher ist.
In Portland hat am Freitag der erste Coffee-Shop der USA aufgemacht!
Meinst Du diese NEWS?
Monday, November 16. 2009
The USA's First Cannabis Cafe Opens in Portland, Oregon
The USA's first Cannabis Cafe opened its doors this past Friday at (appropriately) 4:20 P.M. The cafe is located at 700 N.E. Dekum St. For many medical marijuana users the cafe marks a step in the right direction. The idea of the cafe is to begin to normalize the use of marijuana as a medicine and allow users to not feel so ostracized by society. Don't book your plane ticket just yet, Portland isn't about to become the US Amsterdam. The only people permitted in the Cannabis Cafe are those licensed to smoke who also hold membership in the lobbying group Oregon NORML. Patrons can bring their own weed or smoke "donated marijuana." This is because Oregon law states that medical marijuana may not be sold.
People from all over Oregon came for the grand opening.
Gordon Cederholm, 45, of Milwaukie has lived with HIV for 25 years and said he was skeptical about using marijuana as medicine when he got his Oregon card less than a year ago.
"At first, I thought: What does being a pothead have to do with it?'" he said. "I didn't know the benefits in marijuana. Now, I find that I'm a better person when I smoke." [Oregon Live]
http://www.passportmagazine.com/blog/index.php?/archives/332…
Meinst Du diese NEWS?
Monday, November 16. 2009
The USA's First Cannabis Cafe Opens in Portland, Oregon
The USA's first Cannabis Cafe opened its doors this past Friday at (appropriately) 4:20 P.M. The cafe is located at 700 N.E. Dekum St. For many medical marijuana users the cafe marks a step in the right direction. The idea of the cafe is to begin to normalize the use of marijuana as a medicine and allow users to not feel so ostracized by society. Don't book your plane ticket just yet, Portland isn't about to become the US Amsterdam. The only people permitted in the Cannabis Cafe are those licensed to smoke who also hold membership in the lobbying group Oregon NORML. Patrons can bring their own weed or smoke "donated marijuana." This is because Oregon law states that medical marijuana may not be sold.
People from all over Oregon came for the grand opening.
Gordon Cederholm, 45, of Milwaukie has lived with HIV for 25 years and said he was skeptical about using marijuana as medicine when he got his Oregon card less than a year ago.
"At first, I thought: What does being a pothead have to do with it?'" he said. "I didn't know the benefits in marijuana. Now, I find that I'm a better person when I smoke." [Oregon Live]
http://www.passportmagazine.com/blog/index.php?/archives/332…
Cannabis Science Hails The American Medical Association For Urging The United States To Facilitate Clinical Research and Development of Cannabinoid-Based Medicines...
Nov. 16, 2009 (Business Wire) -- Cannabis Science Hails The American Medical Association For Urging The United States To Facilitate Clinical Research and Development of Cannabinoid-Based Medicines Which Validates The Company’s Strategy To Produce Critically Important FDA Approved Cannabinoid-Based Medicines For Patients
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is hailing the call by the American Medical Association's House of Delegates for “marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines."
Richard Cowan, Cannabis Science CFO, noted, “The AMA has officially joined the other medical groups in their recognition of the medical value of cannabis. Last year, the American College of Physicians also called for a reclassification of cannabis' Schedule I status. Previously, many other health organizations, including the American Nurses Association and the American Public Health Association, have called for the legal recognition of medical cannabis.”
Under federal law, all substances in Schedule I are defined as possessing "no currently accepted use in treatment in the United States" and also having a high potential for abuse. In 1970 Congress classified marijuana, and all of the cannabinoids (even those with no psychoactive properties) as Schedule I substances upon passage of the Controlled Substances Act. This classification was supposed to be temporary, but blocking research kept it in Schedule I.
Dr. Robert Melamede, PhD., Cannabis Science Inc. President and CEO, stated, “It is now clear that the AMA has embraced the plethora of peer reviewed science supporting the medical applications of the cannabis plant. Their call for the US to facilitate ‘research and development of cannabinoid-based medicines’ is an important validation of our company’s strategy and should make it much easier for us to develop and market products that will help patients. Most people would be shocked to know that the federal government has actually been blocking research on the medical benefits of cannabis while supporting research aimed at demonstrating the negatives. Now that the AMA has embraced this modern science, and President Obama has created new Federal policies and guidelines, the Federal Government can no longer ignore the importance of cannabinoid-based medicines.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Nov. 16, 2009 (Business Wire) -- Cannabis Science Hails The American Medical Association For Urging The United States To Facilitate Clinical Research and Development of Cannabinoid-Based Medicines Which Validates The Company’s Strategy To Produce Critically Important FDA Approved Cannabinoid-Based Medicines For Patients
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is hailing the call by the American Medical Association's House of Delegates for “marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines."
Richard Cowan, Cannabis Science CFO, noted, “The AMA has officially joined the other medical groups in their recognition of the medical value of cannabis. Last year, the American College of Physicians also called for a reclassification of cannabis' Schedule I status. Previously, many other health organizations, including the American Nurses Association and the American Public Health Association, have called for the legal recognition of medical cannabis.”
Under federal law, all substances in Schedule I are defined as possessing "no currently accepted use in treatment in the United States" and also having a high potential for abuse. In 1970 Congress classified marijuana, and all of the cannabinoids (even those with no psychoactive properties) as Schedule I substances upon passage of the Controlled Substances Act. This classification was supposed to be temporary, but blocking research kept it in Schedule I.
Dr. Robert Melamede, PhD., Cannabis Science Inc. President and CEO, stated, “It is now clear that the AMA has embraced the plethora of peer reviewed science supporting the medical applications of the cannabis plant. Their call for the US to facilitate ‘research and development of cannabinoid-based medicines’ is an important validation of our company’s strategy and should make it much easier for us to develop and market products that will help patients. Most people would be shocked to know that the federal government has actually been blocking research on the medical benefits of cannabis while supporting research aimed at demonstrating the negatives. Now that the AMA has embraced this modern science, and President Obama has created new Federal policies and guidelines, the Federal Government can no longer ignore the importance of cannabinoid-based medicines.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Ob die Amis die News auch erst übersetzen müssen? - Heute -8% bei 82.000 St. Umsatz!
Mist ich habe die letzte Chance verpasst zu 50 cent einzusteigen. Jetzt bekomm ich sie nur noch für 45 cent...
Warum wird hier gelöscht?
Das kann man doch für die Threadhistorie festhalten: gestern 74k Umsatz; SK .41$!
Das kann man doch für die Threadhistorie festhalten: gestern 74k Umsatz; SK .41$!
Cannabis Science Appoints Three Distinguished Physicians As New Members To Its Scientific Advisory Board: Dr. Ben Johnson, Dr. Alan Shackleford, and Dr. William Courtney
Nov. 30, 2009 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is honored to announce that Dr. Ben Johnson, Dr. Allan Shackleford and Dr. William Courtney have accepted its request to become members of its recently formed Scientific Advisory Board. The formation of the Scientific Advisory Board was announced on August 6th with the appointment of Dr. Mitch Earlywine Ph. D. as its first member, and the appointment Dr. Ritchard L. Fishman M.D. was announced on August 18th. Given the addition of several prominent scientists and physicians with their knowledge base, the company’s clinical trials focus, product development, and design procedures for submitting products to the FDA can be advanced much faster.
Dr. Ben Johnson is a complementary and alternative medicine physician. After earning a degree in Osteopathy from the University of Health Sciences in Kansas City, he has since earned an M.D. degree and an N.M.D as well. He resigned as a founder and director of the Immune Recovery Clinic in Atlanta, Georgia after working there for several years to devote full time to The Healing Codes (A stress healing program that he uses to cure himself of Lou Gehbrig’s disease). In addition, Dr. Johnson served in the armed forces during Vietnam and was a flight surgeon in the army reserve for many years. He was a Senior Aviation Medical Examiner for the FAA for 12 years.
Currently, Dr. Johnson is owner of Dr. Ben Johnson Services, LLC, a business that promotes products for natural health care. He consults regularly with patients and health care professionals across the world, and his expertise is centered in the field of complimentary oncology.
Dr. Alan Shackleford, a Denver physician, is a graduate of University of Heidelburg School of Medicine. He has an extensive background in clinical medicine, nutrition support, metabolism analysis, micro vascular surgical techniques and stress management techniques in the treatment of obesity and performance anxiety. Aside from his clinical work, he was also an instructor in German and in genetics at the University of Maryland, and he was also a lecturer at Harvard medical school in clinical training for behavioral medicine.
Dr. William L. Courtney has an extensive medical education that began with a Bachelor of Science in Microbiology from the University of Michigan. He also received his Doctor of Medicine from Wayne State University, and Interned for Residency in Psychiatry at California Pacific Medical Center and went on to earned his Post Doctorate in Forensic Examination and Forensic Medicine. Dr. Courtney is currently a member of International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney has also been teaching Continuing Medical Education (CME) courses in clinical cannabis. He also hosted the 2nd International CB2 Conference in Ft Bragg, California, and teaches a Survey Course on Endogenous Cannabinoid System for College of the Redwoods. He also works with dispensaries interested in providing medical marijuana to patients.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, “We have been enormously gratified by the very positive reaction to the company’s plans by those who are most familiar with the need for medical cannabis products. The fact that so many prominent experts understand the importance of what we are doing and support our efforts shows that we are on the right path. We are putting together a very powerful team and with their help we will successfully blend the revolutionary power of capitalism with activism moving the company forward.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Nov. 30, 2009 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is honored to announce that Dr. Ben Johnson, Dr. Allan Shackleford and Dr. William Courtney have accepted its request to become members of its recently formed Scientific Advisory Board. The formation of the Scientific Advisory Board was announced on August 6th with the appointment of Dr. Mitch Earlywine Ph. D. as its first member, and the appointment Dr. Ritchard L. Fishman M.D. was announced on August 18th. Given the addition of several prominent scientists and physicians with their knowledge base, the company’s clinical trials focus, product development, and design procedures for submitting products to the FDA can be advanced much faster.
Dr. Ben Johnson is a complementary and alternative medicine physician. After earning a degree in Osteopathy from the University of Health Sciences in Kansas City, he has since earned an M.D. degree and an N.M.D as well. He resigned as a founder and director of the Immune Recovery Clinic in Atlanta, Georgia after working there for several years to devote full time to The Healing Codes (A stress healing program that he uses to cure himself of Lou Gehbrig’s disease). In addition, Dr. Johnson served in the armed forces during Vietnam and was a flight surgeon in the army reserve for many years. He was a Senior Aviation Medical Examiner for the FAA for 12 years.
Currently, Dr. Johnson is owner of Dr. Ben Johnson Services, LLC, a business that promotes products for natural health care. He consults regularly with patients and health care professionals across the world, and his expertise is centered in the field of complimentary oncology.
Dr. Alan Shackleford, a Denver physician, is a graduate of University of Heidelburg School of Medicine. He has an extensive background in clinical medicine, nutrition support, metabolism analysis, micro vascular surgical techniques and stress management techniques in the treatment of obesity and performance anxiety. Aside from his clinical work, he was also an instructor in German and in genetics at the University of Maryland, and he was also a lecturer at Harvard medical school in clinical training for behavioral medicine.
Dr. William L. Courtney has an extensive medical education that began with a Bachelor of Science in Microbiology from the University of Michigan. He also received his Doctor of Medicine from Wayne State University, and Interned for Residency in Psychiatry at California Pacific Medical Center and went on to earned his Post Doctorate in Forensic Examination and Forensic Medicine. Dr. Courtney is currently a member of International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney has also been teaching Continuing Medical Education (CME) courses in clinical cannabis. He also hosted the 2nd International CB2 Conference in Ft Bragg, California, and teaches a Survey Course on Endogenous Cannabinoid System for College of the Redwoods. He also works with dispensaries interested in providing medical marijuana to patients.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, “We have been enormously gratified by the very positive reaction to the company’s plans by those who are most familiar with the need for medical cannabis products. The fact that so many prominent experts understand the importance of what we are doing and support our efforts shows that we are on the right path. We are putting together a very powerful team and with their help we will successfully blend the revolutionary power of capitalism with activism moving the company forward.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc. ernennt drei weitere ausgezeichnete Ärzte als Mitglieder in ihren wissenschaftlichen Beirat. Dabei handelt es sich um Dr. Ben Johnson, Dr. Alan Shackleford und Dr. William Courtney
30. November 2009, Cannabis Science Inc. (NASD OTCBB: CBIS) ein aufstrebendes pharmazeutisches Cannabis-Unternehmen ist geehrt, bekannt geben zu dürfen, dass Dr. Ben Johnson, Dr. Allan Shackleford und Dr. William Courtney die Mitgliedschaft in dem kürzlich gegründeten wissenschaftlichen Beirat zugestimmt haben. Die Bildung des wissenschaftlichen Beirats begann am 6. August 2009, mit der Ernennung von Dr. Mitch Earlywine pH D. als erstes Mitglied und der Ernennung von Dr. Ritchard L. Fishman M.D. am 18. August 2008. Angesichts der Unterstützung von mehreren prominenten Wissenschaftlern und Ärzten mit ihrem Wissen, können die in den Unternehmens-Mittelpunkt gerückten klinischen Tests und Produktentwicklungen forciert werden. Auch das Verfahren für die Einreichung der Produkte bei der FDA (Food and Drug Administration, US-amerikanische Behörde für Lebensmittel- und Arzneimittelsicherheit) wird dadurch beschleunigt.
Dr. Ben Johnson ist ein Ergänzungs- und Alternativmediziner. Er absolvierte sein Medizinstudium an der University of Health Sciences in Kansas City. Er ist M.D. (Doctor of Medicine) mit Schwerpunkt Osteopathie. Er war Gründer und Leiter der Immune Recovery-Klinik in Atlanta, Georgia. Nach mehreren Jahren trat er zurück, um sich ganz auf die Behandlung des Lou-Gehrig-Syndroms (Amyotrophische Lateralsklerose) unter der er auch leidet, zu konzentrieren. Dr. Johnson diente den US-Streitkräften während des Vietnam-Krieges. Darüber hinaus war er Fliegerarzt in die Armee-Reserve für viele Jahre. Er war ein Senior Aviation Medical Examiner für die FAA für 12 Jahren.
Derzeit ist Dr. Johnson Eigentümer von Dr. Ben Johnson Services, LLC, ein Unternehmen, welches Produkte vertreibt, die das natürliche Gesundheitswesen unterstützen. Er berät regelmäßig Patienten und Fachleute aus dem Gesundheitswesen aus der ganzen Welt. Seine Schwerpunkt-Kompetenz liegt im Bereich der Onkologie.
Dr. Alan Shackleford, ein Arzt aus Denver ist Absolvent der Universität Heidelberg (Medizinstudium). Er hat ein umfangreiches Wissen in der klinischen Medizin, Ernährung, Stoffwechsel-Analyse, und chirurgische Mikrogefäßtechniken sowie Stress-Management-Techniken zur Behandlung von Fettleibigkeit und Angst. Abgesehen von seiner klinischen Arbeit war er auch als Kursleiter in Deutsch und in Genetik an der Universität Maryland beschäftigt. Er war Dozent für Verhaltensmedizin in der klinischen Ausbildung an der medizinischen Schule von Harvard.
Dr. William L. Courtney hat eine umfassende medizinische Ausbildung, die mit einen Bachelor Of Science in der Mikrobiologie an der University of Michigan begann. Er erhielt seinen Doktor der Medizin von der Wayne State University und interniert am California Pacific Medical Center. Er erwarb einen weiteren Doktor in forensische Untersuchung und forensische Medizin. Dr. Courtney ist Mitglied der International Cannabinoid Research Society und der International Association von Cannabis as Medicine und der Society of Clinical Cannabis. Dr. Courtney hält auch Continuing Medical Education (CME) Kurse im Umgang mit klinischem Cannabis. Er leitete auch die zweite internationale CB2-Konferenz in Ft. Bragg, Kalifornien. Er arbeitet auch mit Praxen zusammen, die daran interessiert sind, medizinischen Marihuana an Patienten zu verabreichen.
Dr. Robert Melamede, Ph. D., Präsident & CEO der Cannabis Science Inc. sagte, "Wir haben uns enorm über die sehr positiven Reaktionen über unsere Unternehmens-Pläne, durch diejenigen, die mit der Notwendigkeit medizinischer Cannabisprodukte am meisten vertraut sind, gefreut. Die Tatsache, dass so viele bekannte Fachleute und Experten die Bedeutung von dem was wir tun verstehen und unsere Bemühungen unterstützen, zeigt dass wir auf dem richtigen Weg sind. Wir sind dabei ein sehr starkes Team aufzustellen und mit ihrer Hilfe werden wir die revolutionäre Macht des Kapitalismus mit dem Aktivismus erfolgreich vermischen, der die Gesellschaft vorwärts treibt." „
Weitere Informationen über Cannabis Science, Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Wertpapiergesetzes von 1933 und Abschnitt 21E des Securities Act von 1934. Jede Aussage in dieser Pressemitteilung mit Worten wie z. B. "rechnen", "beabsichtigen“, "glauben", "planen", "schätzen", "erwarten", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act von 1995. Zukunftsgerichtete Aussagen sind mit Risiken und Unsicherheiten behaftet und basieren auf den gegenwärtigen Erwartungen. Daher können die tatsächlichen Ergebnisse wesentlich von den Erwartungen in den in die Zukunft gerichtete Aussagen abweichen. Neben der Entwicklung der globalen Wirtschaft, der Auswirkungen des Wettbewerbs, ist das Unternehmen abhängig von den bevorstehenden Regelungen hinsichtlich der Verwendung und Entwicklung von auf Cannabis basierenden Medikamenten. Cannabis Science ist nicht verpflichtet diese in die Zukunft gerichteten Aussagen zu aktualisieren.
Kontakt:
Cannabis Science Inc.
E-Mail: info@cannabisscience.com
www.canabisscience.com
Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Bitte englische Originalmeldung beachten! Mitteilung übermittelt durch penstox.de. Für den Inhalt ist der
Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt
30. November 2009, Cannabis Science Inc. (NASD OTCBB: CBIS) ein aufstrebendes pharmazeutisches Cannabis-Unternehmen ist geehrt, bekannt geben zu dürfen, dass Dr. Ben Johnson, Dr. Allan Shackleford und Dr. William Courtney die Mitgliedschaft in dem kürzlich gegründeten wissenschaftlichen Beirat zugestimmt haben. Die Bildung des wissenschaftlichen Beirats begann am 6. August 2009, mit der Ernennung von Dr. Mitch Earlywine pH D. als erstes Mitglied und der Ernennung von Dr. Ritchard L. Fishman M.D. am 18. August 2008. Angesichts der Unterstützung von mehreren prominenten Wissenschaftlern und Ärzten mit ihrem Wissen, können die in den Unternehmens-Mittelpunkt gerückten klinischen Tests und Produktentwicklungen forciert werden. Auch das Verfahren für die Einreichung der Produkte bei der FDA (Food and Drug Administration, US-amerikanische Behörde für Lebensmittel- und Arzneimittelsicherheit) wird dadurch beschleunigt.
Dr. Ben Johnson ist ein Ergänzungs- und Alternativmediziner. Er absolvierte sein Medizinstudium an der University of Health Sciences in Kansas City. Er ist M.D. (Doctor of Medicine) mit Schwerpunkt Osteopathie. Er war Gründer und Leiter der Immune Recovery-Klinik in Atlanta, Georgia. Nach mehreren Jahren trat er zurück, um sich ganz auf die Behandlung des Lou-Gehrig-Syndroms (Amyotrophische Lateralsklerose) unter der er auch leidet, zu konzentrieren. Dr. Johnson diente den US-Streitkräften während des Vietnam-Krieges. Darüber hinaus war er Fliegerarzt in die Armee-Reserve für viele Jahre. Er war ein Senior Aviation Medical Examiner für die FAA für 12 Jahren.
Derzeit ist Dr. Johnson Eigentümer von Dr. Ben Johnson Services, LLC, ein Unternehmen, welches Produkte vertreibt, die das natürliche Gesundheitswesen unterstützen. Er berät regelmäßig Patienten und Fachleute aus dem Gesundheitswesen aus der ganzen Welt. Seine Schwerpunkt-Kompetenz liegt im Bereich der Onkologie.
Dr. Alan Shackleford, ein Arzt aus Denver ist Absolvent der Universität Heidelberg (Medizinstudium). Er hat ein umfangreiches Wissen in der klinischen Medizin, Ernährung, Stoffwechsel-Analyse, und chirurgische Mikrogefäßtechniken sowie Stress-Management-Techniken zur Behandlung von Fettleibigkeit und Angst. Abgesehen von seiner klinischen Arbeit war er auch als Kursleiter in Deutsch und in Genetik an der Universität Maryland beschäftigt. Er war Dozent für Verhaltensmedizin in der klinischen Ausbildung an der medizinischen Schule von Harvard.
Dr. William L. Courtney hat eine umfassende medizinische Ausbildung, die mit einen Bachelor Of Science in der Mikrobiologie an der University of Michigan begann. Er erhielt seinen Doktor der Medizin von der Wayne State University und interniert am California Pacific Medical Center. Er erwarb einen weiteren Doktor in forensische Untersuchung und forensische Medizin. Dr. Courtney ist Mitglied der International Cannabinoid Research Society und der International Association von Cannabis as Medicine und der Society of Clinical Cannabis. Dr. Courtney hält auch Continuing Medical Education (CME) Kurse im Umgang mit klinischem Cannabis. Er leitete auch die zweite internationale CB2-Konferenz in Ft. Bragg, Kalifornien. Er arbeitet auch mit Praxen zusammen, die daran interessiert sind, medizinischen Marihuana an Patienten zu verabreichen.
Dr. Robert Melamede, Ph. D., Präsident & CEO der Cannabis Science Inc. sagte, "Wir haben uns enorm über die sehr positiven Reaktionen über unsere Unternehmens-Pläne, durch diejenigen, die mit der Notwendigkeit medizinischer Cannabisprodukte am meisten vertraut sind, gefreut. Die Tatsache, dass so viele bekannte Fachleute und Experten die Bedeutung von dem was wir tun verstehen und unsere Bemühungen unterstützen, zeigt dass wir auf dem richtigen Weg sind. Wir sind dabei ein sehr starkes Team aufzustellen und mit ihrer Hilfe werden wir die revolutionäre Macht des Kapitalismus mit dem Aktivismus erfolgreich vermischen, der die Gesellschaft vorwärts treibt." „
Weitere Informationen über Cannabis Science, Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Wertpapiergesetzes von 1933 und Abschnitt 21E des Securities Act von 1934. Jede Aussage in dieser Pressemitteilung mit Worten wie z. B. "rechnen", "beabsichtigen“, "glauben", "planen", "schätzen", "erwarten", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act von 1995. Zukunftsgerichtete Aussagen sind mit Risiken und Unsicherheiten behaftet und basieren auf den gegenwärtigen Erwartungen. Daher können die tatsächlichen Ergebnisse wesentlich von den Erwartungen in den in die Zukunft gerichtete Aussagen abweichen. Neben der Entwicklung der globalen Wirtschaft, der Auswirkungen des Wettbewerbs, ist das Unternehmen abhängig von den bevorstehenden Regelungen hinsichtlich der Verwendung und Entwicklung von auf Cannabis basierenden Medikamenten. Cannabis Science ist nicht verpflichtet diese in die Zukunft gerichteten Aussagen zu aktualisieren.
Kontakt:
Cannabis Science Inc.
E-Mail: info@cannabisscience.com
www.canabisscience.com
Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Bitte englische Originalmeldung beachten! Mitteilung übermittelt durch penstox.de. Für den Inhalt ist der
Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt
Naja, News kommen und Kurs sinkt... das nächste Mal wenn defitiv ne News kommt sollten wir shorten =)
Scherz bei Seite, wie gehts hier weiter?
Scherz bei Seite, wie gehts hier weiter?
Cannabis Science Inc. Reports on Litigation Settlement and Debt Elimination A Vote of Confidence in Dr. Melamede, and "The Huge Potential of Our Company"
Dec. 2, 2009 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares.
Richard Cowan, CFO, stated, “Settlement of the K & D and South Beach lawsuits frees up our management team to focus on testing and launching our new OTC products, and removes an impediment to traditional funding mechanisms. The biggest news here is dropping debt, which significantly improves our balance sheet and gives us the ability to leverage our product roll-outs. I think that this settlement is also a vote of confidence in Dr. Melamede, and a recognition of the huge potential of our company.”
The agreements provide for the issuance of 3,680,000 shares of common stock in settlement of the K & D and South Beach litigation. The litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex Thereapeutics, and debt incurred by South Beach for the Company’s operating expenses. Cowan explained, “It is very positive that the Company will extinguish nearly $900,000 in debt owed to creditors, eliminating over half of its current liabilities, as part of these agreements.”
Dr. Robert Melamede, CEO and President, added, “We’re pleased to have this litigation behind us. Apart from the financing options that now open up, this lets me and our exemplary advisory boards get back to the science of cannabis and the development and exploitation of cannabis-based drugs and nutraceuticals for the consumer market. We are especially interested in partial cannabis extracts, which appear to provide substantial health benefits without triggering DEA prohibitions, and the prospect of OTC nutraceutical formulations from our research. This is a great time for cannabis science, generally and our company in particular.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dec. 2, 2009 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares.
Richard Cowan, CFO, stated, “Settlement of the K & D and South Beach lawsuits frees up our management team to focus on testing and launching our new OTC products, and removes an impediment to traditional funding mechanisms. The biggest news here is dropping debt, which significantly improves our balance sheet and gives us the ability to leverage our product roll-outs. I think that this settlement is also a vote of confidence in Dr. Melamede, and a recognition of the huge potential of our company.”
The agreements provide for the issuance of 3,680,000 shares of common stock in settlement of the K & D and South Beach litigation. The litigation concerned provisions of the original Asset Acquisition Agreement between K & D and Cannex Thereapeutics, and debt incurred by South Beach for the Company’s operating expenses. Cowan explained, “It is very positive that the Company will extinguish nearly $900,000 in debt owed to creditors, eliminating over half of its current liabilities, as part of these agreements.”
Dr. Robert Melamede, CEO and President, added, “We’re pleased to have this litigation behind us. Apart from the financing options that now open up, this lets me and our exemplary advisory boards get back to the science of cannabis and the development and exploitation of cannabis-based drugs and nutraceuticals for the consumer market. We are especially interested in partial cannabis extracts, which appear to provide substantial health benefits without triggering DEA prohibitions, and the prospect of OTC nutraceutical formulations from our research. This is a great time for cannabis science, generally and our company in particular.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc. berichtet über Beilegung von Rechtsstreitigkeiten, Schuldentilgung, das große Vertrauen in Dr. Melamede sowie über das riesige Potenzial von Cannabis Science Inc.
2. Dezember 2009, Cannabis Science Inc. (NASD OTCBB: CBIS), ein aufstrebendes pharmazeutisches Cannabis Unternehmen, meldete heute, dass es ausstehende Rechtsstreitigkeiten mit K & D Equity Investments, Inc. und South Beach Live, Inc., beigelegt hat, und Vereinbarungen mit ihren größten Gläubigern getroffen hat, die bestehenden Schulden in Aktien umzuwandeln.
Richard Cowan, CFO von Cannabis Science Inc., erklärt, "Die Beilegung der Gerichtsverfahren mit K & D und South Beach entlastet unser Management-Team. Wir konzentrieren und jetzt auf unsere Tests und unsere neuen OTC-Produkte. Das wichtigste ist, die Schuldentilgung verbessert unsere Bilanz erheblich und gibt uns der Fähigkeit, unsere Produkteinführungen zu forcieren. Ich glaube, dass dieses Entgegenkommen auch ein Vertrauensvotum in Dr. Melamede und eine Anerkennung des riesigen Potenzials unseres Unternehmens ist."
Die Abkommen besagt, dass 3.680,000 Stammaktien zur Beilegung der Rechtsstreitigkeiten an K & D und South Beach ausgegeben werden. Die Rechtsstreitigkeiten betrafen Bestimmungen des ursprünglichen Abkommens über den Erwerb des Anlagevermögens zwischen K & D und Cannex Thereapeutics, sowie die Schulden an South Beach Live Inc., die durch den Betrieb der Gesellschaft entstanden sind. Cowan erklärt, "Es ist sehr positiv, dass es unserem Unternehmen mit dieser Abmachung gelingt fast 900,000 $ Schulden zu löschen. Das sind mehr als die Hälfte der gegenwärtigen Verbindlichkeiten unseres Unternehmens."
Dr. Robert Melamede, CEO und Präsident, fügt hinzu, „Wir sind erfreut, diese Rechtsstreitigkeiten hinter uns zuhaben. Abgesehen von den Finanzierungsoptionen, die sich jetzt wieder eröffnen, hab ich und unser Beirat nun wieder die Möglichkeit, uns auf die Wissenschaft von Cannabis und die Entwicklung von Produkten zu konzentrieren. Dies ist eine großartige Zeit für die Cannabis Wissenschaft, im Allgemeinen und im Besonderen für unser Unternehmen. "
Weitere Informationen über Cannabis Science, Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Wertpapiergesetzes von 1933 und Abschnitt 21E des Securities Act von 1934. Jede Aussage in dieser Pressemitteilung mit Worten wie z. B. "rechnen", "beabsichtigen“, "glauben", "planen", "schätzen", "erwarten", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act von 1995. Zukunftsgerichtete Aussagen sind mit Risiken und Unsicherheiten behaftet und basieren auf den gegenwärtigen Erwartungen. Daher können die tatsächlichen Ergebnisse wesentlich von den Erwartungen in den in die Zukunft gerichtete Aussagen abweichen. Neben der Entwicklung der globalen Wirtschaft, der Auswirkungen des Wettbewerbs, ist das Unternehmen abhängig von den bevorstehenden Regelungen hinsichtlich der Verwendung und Entwicklung von auf Cannabis basierenden Medikamenten. Cannabis Science ist nicht verpflichtet diese in die Zukunft gerichteten Aussagen zu aktualisieren.
Kontakt:
Cannabis Science Inc.
E-Mail: info@cannabisscience.com
www.canabisscience.com
Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Bitte englische Originalmeldung beachten! Mitteilung übermittelt durch penstox.de. Für den Inhalt ist der
Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt
2. Dezember 2009, Cannabis Science Inc. (NASD OTCBB: CBIS), ein aufstrebendes pharmazeutisches Cannabis Unternehmen, meldete heute, dass es ausstehende Rechtsstreitigkeiten mit K & D Equity Investments, Inc. und South Beach Live, Inc., beigelegt hat, und Vereinbarungen mit ihren größten Gläubigern getroffen hat, die bestehenden Schulden in Aktien umzuwandeln.
Richard Cowan, CFO von Cannabis Science Inc., erklärt, "Die Beilegung der Gerichtsverfahren mit K & D und South Beach entlastet unser Management-Team. Wir konzentrieren und jetzt auf unsere Tests und unsere neuen OTC-Produkte. Das wichtigste ist, die Schuldentilgung verbessert unsere Bilanz erheblich und gibt uns der Fähigkeit, unsere Produkteinführungen zu forcieren. Ich glaube, dass dieses Entgegenkommen auch ein Vertrauensvotum in Dr. Melamede und eine Anerkennung des riesigen Potenzials unseres Unternehmens ist."
Die Abkommen besagt, dass 3.680,000 Stammaktien zur Beilegung der Rechtsstreitigkeiten an K & D und South Beach ausgegeben werden. Die Rechtsstreitigkeiten betrafen Bestimmungen des ursprünglichen Abkommens über den Erwerb des Anlagevermögens zwischen K & D und Cannex Thereapeutics, sowie die Schulden an South Beach Live Inc., die durch den Betrieb der Gesellschaft entstanden sind. Cowan erklärt, "Es ist sehr positiv, dass es unserem Unternehmen mit dieser Abmachung gelingt fast 900,000 $ Schulden zu löschen. Das sind mehr als die Hälfte der gegenwärtigen Verbindlichkeiten unseres Unternehmens."
Dr. Robert Melamede, CEO und Präsident, fügt hinzu, „Wir sind erfreut, diese Rechtsstreitigkeiten hinter uns zuhaben. Abgesehen von den Finanzierungsoptionen, die sich jetzt wieder eröffnen, hab ich und unser Beirat nun wieder die Möglichkeit, uns auf die Wissenschaft von Cannabis und die Entwicklung von Produkten zu konzentrieren. Dies ist eine großartige Zeit für die Cannabis Wissenschaft, im Allgemeinen und im Besonderen für unser Unternehmen. "
Weitere Informationen über Cannabis Science, Inc.
Cannabis Science Inc. ist an der Front der Erforschung und Entwicklung von medizinischem Marijuana. Die Firma arbeitet weltweit zusammen mit Autoritäten der Phytocannabinoid-Wissenschaft, dabei auf kritische Krankheiten zielend, und verwendet wissenschaftliche Methoden, um pharmazeutische Produkte auf Phytocannabinoid-Basis zu entwickeln, produzieren und zu kommerzialisieren. Kurz gesagt, widmen wir uns der Kreation von Arzneien auf Cannabis-Basis, mit oder ohne psychoaktive Wirkung, um Krankheiten und Symptome von Krankheiten zu behandeln, und der allgemeinen Gesunderhaltung.
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Wertpapiergesetzes von 1933 und Abschnitt 21E des Securities Act von 1934. Jede Aussage in dieser Pressemitteilung mit Worten wie z. B. "rechnen", "beabsichtigen“, "glauben", "planen", "schätzen", "erwarten", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act von 1995. Zukunftsgerichtete Aussagen sind mit Risiken und Unsicherheiten behaftet und basieren auf den gegenwärtigen Erwartungen. Daher können die tatsächlichen Ergebnisse wesentlich von den Erwartungen in den in die Zukunft gerichtete Aussagen abweichen. Neben der Entwicklung der globalen Wirtschaft, der Auswirkungen des Wettbewerbs, ist das Unternehmen abhängig von den bevorstehenden Regelungen hinsichtlich der Verwendung und Entwicklung von auf Cannabis basierenden Medikamenten. Cannabis Science ist nicht verpflichtet diese in die Zukunft gerichteten Aussagen zu aktualisieren.
Kontakt:
Cannabis Science Inc.
E-Mail: info@cannabisscience.com
www.canabisscience.com
Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Bitte englische Originalmeldung beachten! Mitteilung übermittelt durch penstox.de. Für den Inhalt ist der
Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt
Antwort auf Beitrag Nr.: 38.506.026 von rz87 am 03.12.09 21:53:32Hallo rz87,
ja du hast Recht. News kommen jetzt regelmäßig. Sogar gute News.
Warum steigt der Kurs nicht?
Meine persönliche Meinung ist:
Das Unternehmen ist noch zu unbekannt.
Das zeigt auch das niedrige Volumen täglich.
Man muß sich aber vor Augen halten.
Cannabis Science ist Weltmarktführer. Kein anderes Unternehmen auf der Welt ist in Sachen Cannabis-Forschung und Produktentwicklung soweit.
Wenn jetzt von der Obama-Regierung, wie signalisiert, die Erlaubnis zum Einsatz von medizinischen Cannabis kommt, dann knallt es wirklich.
Die haben so wenig Shares im Unlauf, wenn die Nachfrage steigt, dann steigt es richtig.
Aber noch sind die zu unbekannt.
Ich hoffe nicht mehr lange.
ja du hast Recht. News kommen jetzt regelmäßig. Sogar gute News.
Warum steigt der Kurs nicht?
Meine persönliche Meinung ist:
Das Unternehmen ist noch zu unbekannt.
Das zeigt auch das niedrige Volumen täglich.
Man muß sich aber vor Augen halten.
Cannabis Science ist Weltmarktführer. Kein anderes Unternehmen auf der Welt ist in Sachen Cannabis-Forschung und Produktentwicklung soweit.
Wenn jetzt von der Obama-Regierung, wie signalisiert, die Erlaubnis zum Einsatz von medizinischen Cannabis kommt, dann knallt es wirklich.
Die haben so wenig Shares im Unlauf, wenn die Nachfrage steigt, dann steigt es richtig.
Aber noch sind die zu unbekannt.
Ich hoffe nicht mehr lange.
kann hier jemand mal bitte einen realtime chart von new york hier rein stellen?
vielen dank!
vielen dank!
Cannabis Science Outlines Objectives For The New Year; Highlights Include Moving Towards Contracts and Licensing Agreements For Research and Development of New Medicines
2010-01-11 15:24 ET - News Release
COLORADA SPRINGS, Colo. -- (Business Wire)
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."
Richard Cowan, Cannabis Science Inc.'s CFO said, "The fact that other groups are willing to enter into licensing agreements with us is further evidence of their respect for Dr. Melamede and his standing in the scientific community Dr. Melamede, is the retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, where he also continues to teach."
On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.
Dr. Robert Melamede, Cannabis Science President and CEO, explained, "These surveys are an example of what we mean when we Cannabis Science Inc. is truly a patient-oriented company. We have their trust because we are patients ourselves. By working with patients both in person and online, we can further develop our knowledge base and add staff and consultants where they are needed."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contacts:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Peter Glaser, 1-888-889-0888
Investor Relations
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Science Inc.
2010-01-11 15:24 ET - News Release
COLORADA SPRINGS, Colo. -- (Business Wire)
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."
Richard Cowan, Cannabis Science Inc.'s CFO said, "The fact that other groups are willing to enter into licensing agreements with us is further evidence of their respect for Dr. Melamede and his standing in the scientific community Dr. Melamede, is the retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, where he also continues to teach."
On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.
Dr. Robert Melamede, Cannabis Science President and CEO, explained, "These surveys are an example of what we mean when we Cannabis Science Inc. is truly a patient-oriented company. We have their trust because we are patients ourselves. By working with patients both in person and online, we can further develop our knowledge base and add staff and consultants where they are needed."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contacts:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Peter Glaser, 1-888-889-0888
Investor Relations
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Science Inc.
Hatte sich wohl ne kleine Auszeit genommen die Aktie.
Jetzt scheint es ja wohl endlich loszugehen.
Fehlt jetzt nur ein Vertrag oder so.
Mal sehen was da kommt in den nächsten Tagen.
Jetzt scheint es ja wohl endlich loszugehen.
Fehlt jetzt nur ein Vertrag oder so.
Mal sehen was da kommt in den nächsten Tagen.
CBIS rockt und keiner merkts.
Keiner merkts, kann man so nicht sagen!!
Ich bin hier kurz vor Silvester noch eingestiegen und konnte noch ein paar zu 0,028 und zu 0,029 USD abstauben!!
Allerdings fehlt mir immer noch ein Realtime-Chart!!
Kannst du vielleicht mal einen Chart von New York in Realtime hier einstellen?
Ich denke, wir sehen demnächst noch deutlich höhere Kurse.
Aber warten wirs mal ab!!
Ich bin hier kurz vor Silvester noch eingestiegen und konnte noch ein paar zu 0,028 und zu 0,029 USD abstauben!!
Allerdings fehlt mir immer noch ein Realtime-Chart!!
Kannst du vielleicht mal einen Chart von New York in Realtime hier einstellen?
Ich denke, wir sehen demnächst noch deutlich höhere Kurse.
Aber warten wirs mal ab!!
Cannabis Science President To Appear Today On StockGoodies.com Live Radio Show As Part of National Educational Series On The Ground-Breaking Science of Medical Cannabis At 8:30AM Eastern
Jan. 13, 2010 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce today that it is continuing its efforts to inform the public about the importance of cannabis based medicines with an interview with Dr. Robert Melamede, Cannabis Science President and CEO on StockGoodies.com at 8:30 AM Eastern. Previously, the company has announced that has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The interview will also be available online, for those who miss the initial program.
Dr. Melamede will discuss the company's plans to bring products to market in 2010, as well as its longer-term plans for FDA approved cannabis-based pharmaceutical products. Dr. Melamede, retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, will discuss the wide variety of ailments that are currently being treated with cannabis as medical marijuana. He explained, "Cannabis Science Inc, as its name implies, is using the latest scientific techniques to develop standardized cannabis extracts that can be used in a variety of ways to help patients." He emphasized that Cannabis Science is a "patient oriented company" that works closely with the medical marijuana movement, observing what people need and what works best for them.
About Cannabis Science, Inc.
Jan. 13, 2010 (Business Wire) -- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce today that it is continuing its efforts to inform the public about the importance of cannabis based medicines with an interview with Dr. Robert Melamede, Cannabis Science President and CEO on StockGoodies.com at 8:30 AM Eastern. Previously, the company has announced that has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The interview will also be available online, for those who miss the initial program.
Dr. Melamede will discuss the company's plans to bring products to market in 2010, as well as its longer-term plans for FDA approved cannabis-based pharmaceutical products. Dr. Melamede, retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, will discuss the wide variety of ailments that are currently being treated with cannabis as medical marijuana. He explained, "Cannabis Science Inc, as its name implies, is using the latest scientific techniques to develop standardized cannabis extracts that can be used in a variety of ways to help patients." He emphasized that Cannabis Science is a "patient oriented company" that works closely with the medical marijuana movement, observing what people need and what works best for them.
About Cannabis Science, Inc.
Also hier ist ja im Moment auch nicht mehr viel los, naja ich bleibe hier mal investiert und warte mal ab, was passiert!!
Hoffe das es jetzt demnächst mal wieder nach oben dreht!!
Hoffe das es jetzt demnächst mal wieder nach oben dreht!!
March 10, 2010 - 12:31 PM EST
President Obama's Deputy Drug Czar Tom McClellan Comments in USA TODAY Article; Endorses Non-Smoked Medical Marijuana Delivery Systems Identical to the First Product Cannabis Science is Developing for FDA Clinical Trials for PTSD Targeting Our Veterans, Active Duty Troops, and Others Suffering from Disasters World-Wide
Mar. 10, 2010 (GlobeNewswire) --
COLORADO SPRINGS, Colo., March 10, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
Deputy Director McClellan said in the article that Obama administration still opposes smoking marijuana for its medicinal benefit. As well, he says more research is needed to deliver the medically useful ingredients in a non-smoked form. He then went on to say, "We have the safest medications in the world and it's not a coincidence. We have an enviable process by which we approve medications, and that's through the FDA (Food and Drug Administration)."
Dr. Robert Melamede, President and CEO of Cannabis Science, "With an open invitation like this from the Obama Administration, we at Cannabis Science feel more confident than ever that our efforts to provide our "wounded warriors" with an alternative to treatments that are not working will be fairly examined, when we submit our non-smoked cannabis pharmaceutical products to the FDA for clinical trials. We are doing precisely the sort of scientific research that Deputy Director McClellan is calling for."
Richard Cowan, Cannabis Science CFO and a former CEO of the National Organization for the Reform of Marijuana Laws (NORML), noted, "It is important that the Obama Administration is making such an open call that they want more FDA clinical trial research on the same types of drugs we are creating. Consequently, we will rapidly proceed with our development of a cannabis-based medicine for PTSD for FDA clinical trials. We hope they will share our sense of urgency, because PTSD is killing not only our veterans, but also our active duty troops. In January alone, more of our active US military troops died of suicide than were killed in Iraq and Afghanistan wars combined."
Both Dr. Melamede and Richard Cowan, are long-term advocates of the full legalization of marijuana, and support the rights of patients to use the plant to medicate, including smoking. The article reported that support for full legalization is growing rapidly (now up to 44% nationally and a majority in some states).
To view the USA Today article in its entirety, please visit http://www.usatoday.com/news/nation/2010-03-08-marijuana_N.h… to review.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Peter Glaser
Investor Relations
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Source: GlobeNewswire (March 10, 2010 - 12:31 PM EST)
News by QuoteMedia
http://otcbb.com/
President Obama's Deputy Drug Czar Tom McClellan Comments in USA TODAY Article; Endorses Non-Smoked Medical Marijuana Delivery Systems Identical to the First Product Cannabis Science is Developing for FDA Clinical Trials for PTSD Targeting Our Veterans, Active Duty Troops, and Others Suffering from Disasters World-Wide
Mar. 10, 2010 (GlobeNewswire) --
COLORADO SPRINGS, Colo., March 10, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
Deputy Director McClellan said in the article that Obama administration still opposes smoking marijuana for its medicinal benefit. As well, he says more research is needed to deliver the medically useful ingredients in a non-smoked form. He then went on to say, "We have the safest medications in the world and it's not a coincidence. We have an enviable process by which we approve medications, and that's through the FDA (Food and Drug Administration)."
Dr. Robert Melamede, President and CEO of Cannabis Science, "With an open invitation like this from the Obama Administration, we at Cannabis Science feel more confident than ever that our efforts to provide our "wounded warriors" with an alternative to treatments that are not working will be fairly examined, when we submit our non-smoked cannabis pharmaceutical products to the FDA for clinical trials. We are doing precisely the sort of scientific research that Deputy Director McClellan is calling for."
Richard Cowan, Cannabis Science CFO and a former CEO of the National Organization for the Reform of Marijuana Laws (NORML), noted, "It is important that the Obama Administration is making such an open call that they want more FDA clinical trial research on the same types of drugs we are creating. Consequently, we will rapidly proceed with our development of a cannabis-based medicine for PTSD for FDA clinical trials. We hope they will share our sense of urgency, because PTSD is killing not only our veterans, but also our active duty troops. In January alone, more of our active US military troops died of suicide than were killed in Iraq and Afghanistan wars combined."
Both Dr. Melamede and Richard Cowan, are long-term advocates of the full legalization of marijuana, and support the rights of patients to use the plant to medicate, including smoking. The article reported that support for full legalization is growing rapidly (now up to 44% nationally and a majority in some states).
To view the USA Today article in its entirety, please visit http://www.usatoday.com/news/nation/2010-03-08-marijuana_N.h… to review.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Peter Glaser
Investor Relations
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Source: GlobeNewswire (March 10, 2010 - 12:31 PM EST)
News by QuoteMedia
http://otcbb.com/
Antwort auf Beitrag Nr.: 39.108.103 von tradepunk am 10.03.10 20:12:13Scheint sich doch einiges zu tun! Und heute ist die Meldung immerhin einen 40%-Sprung auf derzeit 0,31$ wert...
Ist hier eigentlich noch irgendjemand investiert?
Ich bin es noch!!
Ich bin es noch!!
07.04.2010 12:25
PRESSEMITTEILUNG penstox.de/Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
DJ PRESSEMITTEILUNG penstox.de/Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
Diese Pressemitteilung wird im Auftrag von penstox.de versendet. Inhalt und Text der Mitteilung verantwortet ausschließlich die penstox.de.
Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
07. April 2010, Cannabis Medical Solutions, Inc. (OTCBB: CMSI) bietet eine Kombination von Kreditkarte und ID-Karte an, die es ermöglicht medizinischen Cannabis legal zu erwerben.
Cannabis Medical Solutions arbeitet bereits zusammen mit staatlichen Ausgabestellen in Kalifornien, Colorado, New Mexiko, Montana und New Jersey. Weitere US-Bundesstaaten sollen folgen. In insgesamt 14 US-Bundesstaaten ist der Konsum von medizinischen Cannabis im Rahmen der gesetzlichen Bestimmungen bereits möglich.
Cannabis Medical Solutions rechnet mit 30.000 Kartennutzern bis Juni 2010. Bei jedem Bezahlvorgang erhält Cannabis Medical Solutions eine Provision von 3 - 5 Prozent.
In Colorado kauft ein Patient medizinischen Cannabis für durchschnittlich 400 Dollar im Monat.
Cannabis Medical Solutions rechnet bei 30.000 ausgegebenen Karten bis Juni 2010 mit einem Provisionsumsatz von mindestens 4 - 10 Dollar je Karte und je Monat. Das wären monatliche Einnahmen von 120.000 - 300.000 Dollar.
Auf www.penstox.de haben wir ein ausführliches Firmenprofil (engl.) hinterlegt, so wie eine kurze deutschsprachige Zusammenfassung.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
PenStox.de:
PenStox.de ist ein europäisches Web Portal, welches Profile und Nachrichten von Penny Stock Unternehmen veröffentlicht. Wir sind kein lizenzierter Makler oder Finanzberater. Wir gehen davon aus, dass unsere Informationen zuverlässig und richtig sind, können aber keine Gewähr übernehmen. Unsere Veröffentlichungen dienen nur zu Informationszwecken. Wir empfehlen nicht den Kauf oder Verkauf einzelner Aktien. Vielmehr soll der Kapitalanleger dazu ermuntert werden, weitere Meinungen durch eingetragene Makler oder Finanzberater einzuholen, sowie sich selber ausführlich über die jeweiligen Unternehmen zu informieren.
Für die Richtigkeit unserer Übersetzungen können wir keine Haftung übernehmen. Bitte beachten Sie deshalb immer die englische Original-Meldung.
Kostenloser Newsletter: www.penstox.de
Kontakt: info@penstox.de
(END) Dow Jones Newswires
April 07, 2010 05:54 ET (09:54 GMT)
Copyright (c) 2010 Dow Jones&Company, Inc.
© 2010 Dow Jones News
Quelle: www.finanznachrichten.de
PRESSEMITTEILUNG penstox.de/Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
DJ PRESSEMITTEILUNG penstox.de/Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
Diese Pressemitteilung wird im Auftrag von penstox.de versendet. Inhalt und Text der Mitteilung verantwortet ausschließlich die penstox.de.
Cannabis Medical Solutions, Inc. (CMSI) bietet Online- und Wireless-Zahlungsmöglichkeiten für den Konsum von medizinischen Cannabis
07. April 2010, Cannabis Medical Solutions, Inc. (OTCBB: CMSI) bietet eine Kombination von Kreditkarte und ID-Karte an, die es ermöglicht medizinischen Cannabis legal zu erwerben.
Cannabis Medical Solutions arbeitet bereits zusammen mit staatlichen Ausgabestellen in Kalifornien, Colorado, New Mexiko, Montana und New Jersey. Weitere US-Bundesstaaten sollen folgen. In insgesamt 14 US-Bundesstaaten ist der Konsum von medizinischen Cannabis im Rahmen der gesetzlichen Bestimmungen bereits möglich.
Cannabis Medical Solutions rechnet mit 30.000 Kartennutzern bis Juni 2010. Bei jedem Bezahlvorgang erhält Cannabis Medical Solutions eine Provision von 3 - 5 Prozent.
In Colorado kauft ein Patient medizinischen Cannabis für durchschnittlich 400 Dollar im Monat.
Cannabis Medical Solutions rechnet bei 30.000 ausgegebenen Karten bis Juni 2010 mit einem Provisionsumsatz von mindestens 4 - 10 Dollar je Karte und je Monat. Das wären monatliche Einnahmen von 120.000 - 300.000 Dollar.
Auf www.penstox.de haben wir ein ausführliches Firmenprofil (engl.) hinterlegt, so wie eine kurze deutschsprachige Zusammenfassung.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
PenStox.de:
PenStox.de ist ein europäisches Web Portal, welches Profile und Nachrichten von Penny Stock Unternehmen veröffentlicht. Wir sind kein lizenzierter Makler oder Finanzberater. Wir gehen davon aus, dass unsere Informationen zuverlässig und richtig sind, können aber keine Gewähr übernehmen. Unsere Veröffentlichungen dienen nur zu Informationszwecken. Wir empfehlen nicht den Kauf oder Verkauf einzelner Aktien. Vielmehr soll der Kapitalanleger dazu ermuntert werden, weitere Meinungen durch eingetragene Makler oder Finanzberater einzuholen, sowie sich selber ausführlich über die jeweiligen Unternehmen zu informieren.
Für die Richtigkeit unserer Übersetzungen können wir keine Haftung übernehmen. Bitte beachten Sie deshalb immer die englische Original-Meldung.
Kostenloser Newsletter: www.penstox.de
Kontakt: info@penstox.de
(END) Dow Jones Newswires
April 07, 2010 05:54 ET (09:54 GMT)
Copyright (c) 2010 Dow Jones&Company, Inc.
© 2010 Dow Jones News
Quelle: www.finanznachrichten.de
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Announces New Merchant Services Agreements for Multiple Marijuana Dispensaries in California, Colorado and Montana
LOS ANGELES, April 7, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions, insurance and accounting services for medical marijuana dispensaries and high-risk merchant accounts and services, today announced the signing of new merchant agreements for the states of California, Colorado and Montana. Under the exclusive agreements, CMSI will provide merchant processing and POS solutions through its alliance network, enabling these dispensary operations to take credit card transactions legally and provide inventory control of patient medical marijuana.
Eighteen states have discussed medical marijuana through legislation or citizen initiatives this year, most visibly, California announced on March 24th, that this year's ballot would include a question to allow local governments to legalize and tax marijuana. In addition to saving the state of California millions of dollars in law enforcement, the Regulate, Control and Tax Cannabis Act will also give local governments the ability to tax marijuana. Proponents of the act estimate that $15 billion worth of gray-market and black market marijuana is sold each year in California according to the Associated Press. An excise tax on the retail sales of marijuana would bring in an estimated $1.3 billion a year or more in revenue. Some counties and cities within California currently tax medical marijuana dispensaries. These city and county taxes bring in as much as $350,000 per dispensary.
"It is our goal at Cannabis Medical Solutions to bring the banking industry for these businesses in line with the rapid favorable legislation of the states for legalization. We are quickly proving ourselves as the responsible choice for bringing cash alternatives and solutions to the medical marijuana industry through inventory control of medication, credit card services and state tax reporting for non-profits and profit reporting states. CMSI has partnered with the only banking solutions allowing legitimate bank accounts and merchant services without fear of cancellation of merchant accounts or freezing of funds for miscoding," stated Kyle Gotshalk, CEO of CMSI.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
800.420-CALL
http://www.cannabismedsolutions.com/
Cannabis Medical Solutions Announces New Merchant Services Agreements for Multiple Marijuana Dispensaries in California, Colorado and Montana
LOS ANGELES, April 7, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions, insurance and accounting services for medical marijuana dispensaries and high-risk merchant accounts and services, today announced the signing of new merchant agreements for the states of California, Colorado and Montana. Under the exclusive agreements, CMSI will provide merchant processing and POS solutions through its alliance network, enabling these dispensary operations to take credit card transactions legally and provide inventory control of patient medical marijuana.
Eighteen states have discussed medical marijuana through legislation or citizen initiatives this year, most visibly, California announced on March 24th, that this year's ballot would include a question to allow local governments to legalize and tax marijuana. In addition to saving the state of California millions of dollars in law enforcement, the Regulate, Control and Tax Cannabis Act will also give local governments the ability to tax marijuana. Proponents of the act estimate that $15 billion worth of gray-market and black market marijuana is sold each year in California according to the Associated Press. An excise tax on the retail sales of marijuana would bring in an estimated $1.3 billion a year or more in revenue. Some counties and cities within California currently tax medical marijuana dispensaries. These city and county taxes bring in as much as $350,000 per dispensary.
"It is our goal at Cannabis Medical Solutions to bring the banking industry for these businesses in line with the rapid favorable legislation of the states for legalization. We are quickly proving ourselves as the responsible choice for bringing cash alternatives and solutions to the medical marijuana industry through inventory control of medication, credit card services and state tax reporting for non-profits and profit reporting states. CMSI has partnered with the only banking solutions allowing legitimate bank accounts and merchant services without fear of cancellation of merchant accounts or freezing of funds for miscoding," stated Kyle Gotshalk, CEO of CMSI.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
800.420-CALL
http://www.cannabismedsolutions.com/
Source: Cannabis Science, Inc.
Dr. Robert Melamede, PhD., President & CEO of Cannabis Science, Reports High Level of Media Interest in Public Speaking Engagements, News Interviews, and Corporate Sponsorships at Several Cannabis Related Events Over the Next Few Weeks; Beginning in Denver Last Weekend; in Rhode Island This Week; Focusing on the Science of Bringing Cannabis Medicines to Our Patients Through the FDA Process
COLORADO SPRINGS, Colo., April 12, 2010 (GLOBE NEWSWIRE) -- Dr. Robert Melamede, CEO and President of Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, was pleased by the intense interest in Cannabis Science exhibited by the attendees of the Colorado Cannabis Convention, where attendance was estimated to have been in the tens of thousands, with over 300 cannabis-related businesses, including Cannabis Science, having booths.
Dr. Melamede explained, "Cannabis Science was presented as a patient-oriented company that works closely with the patient community so as to better understand their needs. We also look to the medical marijuana community as a source of ideas. I especially enjoyed meeting with the patients who came to the Cannabis Science booth and told us how medical cannabis changed their lives."
This week, Friday April 16, Dr. Melamede will be addressing the Sixth National Clinical Conference on Cannabis Therapeutics in Warwick, Rhode Island. The conference is sponsored by Patients Out of Time and the Rhode Island Patient Advocacy Coalition. Dr. Melamede will be speaking on the Endocannabinoid System, by which the human body produces substances similar to the phytocannabinoids found in cannabis. Dr. Melamede will be joining a distinguished roster of speakers that will include Raphael Mechoulam of the Hebrew University in Israel, who will deliver the conference's keynote address.
Dr. Melamede will present his hypotheses that the endocannabinoid system drove the evolution of vertebrates, particularly their immune system, nervous system and consciousness. Furthermore, because of the rapid rate of changes brought on by humans over the past 150 years, low doses of cannabis should now be regarded as an essential nutrient in order to decrease the tonic level of inflammation that is behind age related illnesses by increasing the homeostatic level of human anti-inflammatory cannabinoid activity.
Other topics at the conference include: 'Safety of Medical Cannabis Use;' 'Endocannabinoid System and Neuropathic Pain;' 'Oral Preparations;' 'The Endocannabinoid System and Reproductive Pain;' 'Growing Cannabis for Medicine;' 'Cannabinoid/Opioid Interactions,' and 'Medical Cannabis and the Struggle to Break the NIDA Monopoly.' 'Of particular interest for Cannabis Science will be the presentations by Michael Krawitz and Al Byrne regarding Veterans and Pain, PTSD, and Traumatic Brain Injuries.'
Conference agenda appears online at: http://medicalcannabis.com/Clinical-Conferences/2010-upcomin…
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
Investor Relations
Peter Glaser
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Quelle bei allen Nachrichten: www.finanznachrichten.de
Dr. Robert Melamede, PhD., President & CEO of Cannabis Science, Reports High Level of Media Interest in Public Speaking Engagements, News Interviews, and Corporate Sponsorships at Several Cannabis Related Events Over the Next Few Weeks; Beginning in Denver Last Weekend; in Rhode Island This Week; Focusing on the Science of Bringing Cannabis Medicines to Our Patients Through the FDA Process
COLORADO SPRINGS, Colo., April 12, 2010 (GLOBE NEWSWIRE) -- Dr. Robert Melamede, CEO and President of Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, was pleased by the intense interest in Cannabis Science exhibited by the attendees of the Colorado Cannabis Convention, where attendance was estimated to have been in the tens of thousands, with over 300 cannabis-related businesses, including Cannabis Science, having booths.
Dr. Melamede explained, "Cannabis Science was presented as a patient-oriented company that works closely with the patient community so as to better understand their needs. We also look to the medical marijuana community as a source of ideas. I especially enjoyed meeting with the patients who came to the Cannabis Science booth and told us how medical cannabis changed their lives."
This week, Friday April 16, Dr. Melamede will be addressing the Sixth National Clinical Conference on Cannabis Therapeutics in Warwick, Rhode Island. The conference is sponsored by Patients Out of Time and the Rhode Island Patient Advocacy Coalition. Dr. Melamede will be speaking on the Endocannabinoid System, by which the human body produces substances similar to the phytocannabinoids found in cannabis. Dr. Melamede will be joining a distinguished roster of speakers that will include Raphael Mechoulam of the Hebrew University in Israel, who will deliver the conference's keynote address.
Dr. Melamede will present his hypotheses that the endocannabinoid system drove the evolution of vertebrates, particularly their immune system, nervous system and consciousness. Furthermore, because of the rapid rate of changes brought on by humans over the past 150 years, low doses of cannabis should now be regarded as an essential nutrient in order to decrease the tonic level of inflammation that is behind age related illnesses by increasing the homeostatic level of human anti-inflammatory cannabinoid activity.
Other topics at the conference include: 'Safety of Medical Cannabis Use;' 'Endocannabinoid System and Neuropathic Pain;' 'Oral Preparations;' 'The Endocannabinoid System and Reproductive Pain;' 'Growing Cannabis for Medicine;' 'Cannabinoid/Opioid Interactions,' and 'Medical Cannabis and the Struggle to Break the NIDA Monopoly.' 'Of particular interest for Cannabis Science will be the presentations by Michael Krawitz and Al Byrne regarding Veterans and Pain, PTSD, and Traumatic Brain Injuries.'
Conference agenda appears online at: http://medicalcannabis.com/Clinical-Conferences/2010-upcomin…
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
Investor Relations
Peter Glaser
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Quelle bei allen Nachrichten: www.finanznachrichten.de
Noch eine News vom 01.04.2010
Apr 01, 2010 11:06 ET
KUSH Magazine Hosts a Mile High Weekend: Largest Cannabis Convention in U.S. Takes Root in Denver This Weekend
DENVER, CO--(Marketwire - April 1, 2010) - Amid a budding medical marijuana industry in the Mile High City, Denver, this weekend, will host the largest cannabis convention in U.S. history at the Colorado Convention Center. Hosted by KUSH Magazine and DailyBuds.com, an online source and "Facebook-like" connection about the growing medical marijuana industry, the convention will draw industry representatives from Holland, Italy and all 50 states, and will boast over 300 booths featuring everything from holistic healing to glass blowing, and a town hall meeting featuring elected officials from the city, state and federal level.
"I am thrilled to be able to bring the largest Cannabis Convention in history to Denver -- a convention that shows the incredible professionalism that this industry is experiencing in a city that is showing how cannabis can help both people and business," stated Michael Lerner, founder of KUSH Magazine and DailyBuds.com.
The weekend event will focus on entertainment and education for the industry. Highlighted by numerous events including a meet and greet with Cypress Hill and the early release of their new album, 420, exclusively for attendees, as well as cannabis cooking classes with 8 Rivers owner, Chef Scott Durrah, and cannabis cooking expert Chef Herb. There will also be a fashion show featuring hemp wedding gowns, a class about growing marijuana, and a "Know Your Rights" legal Panel with Warren Edson, Brian Vicente and Rob Corry to discuss your rights and responsibilities.
A legislative panel featuring elected officials from city, state and federal levels, including Congressman Jared Polis, will conduct a town hall meeting during the event to discuss the future of the medical marijuana industry, scheduled from 1:45-2:30 p.m. at the Convention Center.
The Colorado Cannabis Convention runs Friday, April 2nd from 4-10pm and Saturday, April 3rd from 10am-10pm. Tickets are available to the general public for $15. For more information, visit http://www.dailybuds.com
About Michael Lerner, KUSH Magazine and DailyBuds.com
Michael Lerner, 48, is an entrepreneur whose resume includes forming baseball camps for children and adults and the Executive Producer of the 2007 movie "Three Days to Vegas," starring Peter Falk and Rip Torn.
Along with Lerner, Kush magazine CEO Bob Selan, 55, a lawyer and co-founder of the baseball camp, created DailyBuds.com. The social networking site has become a staple of the industry receiving over 11 million page views per day.
Kush Colorado's magazine includes outstanding editorial on the lifestyle and industry that is growing in Colorado and across the nation. Colorado is the magazine's first foray outside Los Angeles, but it won't be the last.
Kush Michigan and clones in several other cities in California and Oregon are expected to roll off the presses shortly. Each magazine will feature locally-generated content. With medical-marijuana laws on the books in 14 states, Lerner expects the Kush brand to circulate in 34 cities by year end.
Apr 01, 2010 11:06 ET
KUSH Magazine Hosts a Mile High Weekend: Largest Cannabis Convention in U.S. Takes Root in Denver This Weekend
DENVER, CO--(Marketwire - April 1, 2010) - Amid a budding medical marijuana industry in the Mile High City, Denver, this weekend, will host the largest cannabis convention in U.S. history at the Colorado Convention Center. Hosted by KUSH Magazine and DailyBuds.com, an online source and "Facebook-like" connection about the growing medical marijuana industry, the convention will draw industry representatives from Holland, Italy and all 50 states, and will boast over 300 booths featuring everything from holistic healing to glass blowing, and a town hall meeting featuring elected officials from the city, state and federal level.
"I am thrilled to be able to bring the largest Cannabis Convention in history to Denver -- a convention that shows the incredible professionalism that this industry is experiencing in a city that is showing how cannabis can help both people and business," stated Michael Lerner, founder of KUSH Magazine and DailyBuds.com.
The weekend event will focus on entertainment and education for the industry. Highlighted by numerous events including a meet and greet with Cypress Hill and the early release of their new album, 420, exclusively for attendees, as well as cannabis cooking classes with 8 Rivers owner, Chef Scott Durrah, and cannabis cooking expert Chef Herb. There will also be a fashion show featuring hemp wedding gowns, a class about growing marijuana, and a "Know Your Rights" legal Panel with Warren Edson, Brian Vicente and Rob Corry to discuss your rights and responsibilities.
A legislative panel featuring elected officials from city, state and federal levels, including Congressman Jared Polis, will conduct a town hall meeting during the event to discuss the future of the medical marijuana industry, scheduled from 1:45-2:30 p.m. at the Convention Center.
The Colorado Cannabis Convention runs Friday, April 2nd from 4-10pm and Saturday, April 3rd from 10am-10pm. Tickets are available to the general public for $15. For more information, visit http://www.dailybuds.com
About Michael Lerner, KUSH Magazine and DailyBuds.com
Michael Lerner, 48, is an entrepreneur whose resume includes forming baseball camps for children and adults and the Executive Producer of the 2007 movie "Three Days to Vegas," starring Peter Falk and Rip Torn.
Along with Lerner, Kush magazine CEO Bob Selan, 55, a lawyer and co-founder of the baseball camp, created DailyBuds.com. The social networking site has become a staple of the industry receiving over 11 million page views per day.
Kush Colorado's magazine includes outstanding editorial on the lifestyle and industry that is growing in Colorado and across the nation. Colorado is the magazine's first foray outside Los Angeles, but it won't be the last.
Kush Michigan and clones in several other cities in California and Oregon are expected to roll off the presses shortly. Each magazine will feature locally-generated content. With medical-marijuana laws on the books in 14 states, Lerner expects the Kush brand to circulate in 34 cities by year end.
Apr 23, 2010 19:25 ET
Clifford J Perry, Former Medical Marijuana Inc EVP, to Launch Own "Cannabis Business University" Trade Marking and Branding the Name "CannaBizU.com"; Launch at THC EXPOSE at the Los Angeles Convention Center; Co-Promoting Official THC EXPOSE INDUSTRY PARTY; First National Seminar Event Scheduled for June in Honolulu
LOS ANGELES, CA--(Marketwire - April 23, 2010) - Clifford J Perry, Former EVP of Medical Marijuana Inc, has moved forward to pursue the launch of his own cannabis business seminar program after successfully organizing a similar event for MJNA. "We were all very pleased with the results of the Expo at the LA Convention Center in January, and I wish MJNA every success in their ventures as they go forward," Perry said. He cited "differences in management philosophies" in announcing the move.
Perry's new company, CannaBizInc.com, is making its debut at this weekend's THC EXPOSE at the Los Angeles Convention Center April 23, 24, 25, and it will be a co-promoter of the Official THC EXPOSE INDUSTRY PARTY Saturday night April 24th at the Vanguard in Hollywood, CA with Red Man, Barrington Levy, DJ Von Kiss. Other sponsors include Seedless, Chris Bliss Meibles, Concentr8, High Times, Advanced Nutrients, and Tonny Sorensen of Von Dutch fame, new HEMP clothing line, California Christiana Republic.
Perry, who has extensive experience in the educational seminar business and strategic alliances with other 420 industry professionals and celebrities, explained, "Proper education should be available to everyone and our online campus and local training centers will be able to deliver factual and up to the minute information to everyone. We all must learn the basics about how cannabis can contribute to Sustainable Family Farming, Conservation and Restoration of our natural ecological resources."
CannaBizU.com will not only run educational seminars on the emerging "Medicinal Cannabis" industries, but it will also explore other areas in which entrepreneurs may want to participate in the various cannabis industries globally.
Perry explained, "As the company grows, we will have more centers strategically placed, owned and operated by company trained and certified Licensees for educating both business and the public about the great opportunities that cannabis and hemp offer both new investors and existing businesses."
CannaBizU.com will hold its first seminar in Honolulu at the Hawaii Convention Center on June 5th & 6th, 2010. Speakers will include Dr. Robert J. Melamede, PhD. President and CEO of Cannabis Science Inc, and Richard Cowan, who has agreed to serve as Dean of Cannabis Business University. Cowan is the also CFO of Cannabis Science (OTCBB: CBIS) and a former Executive Director of NORML.
Other Lecturers will include prominent Medical Doctors and Legal Professionals from the Hawaiian Islands, Master Growers from the Emerald Triangle, Kyle Kushman & Shiloh along with US Army veteran Steve Tuck on behalf of his organization VetsCann.com, and co-author of California Prop 215, Dennis Peron.
CannaBusinessUniversity.com is committed to strategically positioning itself to become the leader in providing Research & Development, Communication, Networking, Education, Solutions for Professionals and Entrepreneurs in the imminent Medical Marijuana, Cannabis, Hemp industries as they develop.
Clifford J Perry, Former Medical Marijuana Inc EVP, to Launch Own "Cannabis Business University" Trade Marking and Branding the Name "CannaBizU.com"; Launch at THC EXPOSE at the Los Angeles Convention Center; Co-Promoting Official THC EXPOSE INDUSTRY PARTY; First National Seminar Event Scheduled for June in Honolulu
LOS ANGELES, CA--(Marketwire - April 23, 2010) - Clifford J Perry, Former EVP of Medical Marijuana Inc, has moved forward to pursue the launch of his own cannabis business seminar program after successfully organizing a similar event for MJNA. "We were all very pleased with the results of the Expo at the LA Convention Center in January, and I wish MJNA every success in their ventures as they go forward," Perry said. He cited "differences in management philosophies" in announcing the move.
Perry's new company, CannaBizInc.com, is making its debut at this weekend's THC EXPOSE at the Los Angeles Convention Center April 23, 24, 25, and it will be a co-promoter of the Official THC EXPOSE INDUSTRY PARTY Saturday night April 24th at the Vanguard in Hollywood, CA with Red Man, Barrington Levy, DJ Von Kiss. Other sponsors include Seedless, Chris Bliss Meibles, Concentr8, High Times, Advanced Nutrients, and Tonny Sorensen of Von Dutch fame, new HEMP clothing line, California Christiana Republic.
Perry, who has extensive experience in the educational seminar business and strategic alliances with other 420 industry professionals and celebrities, explained, "Proper education should be available to everyone and our online campus and local training centers will be able to deliver factual and up to the minute information to everyone. We all must learn the basics about how cannabis can contribute to Sustainable Family Farming, Conservation and Restoration of our natural ecological resources."
CannaBizU.com will not only run educational seminars on the emerging "Medicinal Cannabis" industries, but it will also explore other areas in which entrepreneurs may want to participate in the various cannabis industries globally.
Perry explained, "As the company grows, we will have more centers strategically placed, owned and operated by company trained and certified Licensees for educating both business and the public about the great opportunities that cannabis and hemp offer both new investors and existing businesses."
CannaBizU.com will hold its first seminar in Honolulu at the Hawaii Convention Center on June 5th & 6th, 2010. Speakers will include Dr. Robert J. Melamede, PhD. President and CEO of Cannabis Science Inc, and Richard Cowan, who has agreed to serve as Dean of Cannabis Business University. Cowan is the also CFO of Cannabis Science (OTCBB: CBIS) and a former Executive Director of NORML.
Other Lecturers will include prominent Medical Doctors and Legal Professionals from the Hawaiian Islands, Master Growers from the Emerald Triangle, Kyle Kushman & Shiloh along with US Army veteran Steve Tuck on behalf of his organization VetsCann.com, and co-author of California Prop 215, Dennis Peron.
CannaBusinessUniversity.com is committed to strategically positioning itself to become the leader in providing Research & Development, Communication, Networking, Education, Solutions for Professionals and Entrepreneurs in the imminent Medical Marijuana, Cannabis, Hemp industries as they develop.
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Discusses "Marijuana and Money" a CNBC Special Report
CMSI Continues Leading Role in Payment Processing and Financial Security Products to Medical Marijuana Dispensaries
LOS ANGELES, April 28, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced "Marijuana And Money", a special report by CNBC to its shareholders and investment audience. The special report now available online at http://www.cnbc.com/id/36022433/ covers the entire spectrum of the medical marijuana debate including legalization, state by state coverage, enforcement and the Wall Street perspective.
"We believe the recent front page coverage and national debate of medical marijuana is further proof of our chosen business model, and provides real opportunity to our present shareholders and investors alike. CMSI is the only public company within the medical marijuana sector with a clear and concise business model, enabling the medical marijuana industry with financial and banking partnerships as well as secure payment solutions to eliminate fraud and criminal activity often associated with the industry", stated Michael Friedman, for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Cannabis Medical Solutions Discusses "Marijuana and Money" a CNBC Special Report
CMSI Continues Leading Role in Payment Processing and Financial Security Products to Medical Marijuana Dispensaries
LOS ANGELES, April 28, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced "Marijuana And Money", a special report by CNBC to its shareholders and investment audience. The special report now available online at http://www.cnbc.com/id/36022433/ covers the entire spectrum of the medical marijuana debate including legalization, state by state coverage, enforcement and the Wall Street perspective.
"We believe the recent front page coverage and national debate of medical marijuana is further proof of our chosen business model, and provides real opportunity to our present shareholders and investors alike. CMSI is the only public company within the medical marijuana sector with a clear and concise business model, enabling the medical marijuana industry with financial and banking partnerships as well as secure payment solutions to eliminate fraud and criminal activity often associated with the industry", stated Michael Friedman, for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Announces New Merchant Services Agreements for Up to 30 Additional Medical Marijuana Dispensaries in Colorado and California
LOS ANGELES, May 4, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced the signing of an exclusive agreement with Specialized Payment Solutions Inc. of Colorado to provide merchant and financial services for up to thirty (30) medical marijuana dispensary clients throughout Colorado and California through its alliance partner network. Details of the agreement include that Specialized Payment Solutions will work with Cannabis Medical Solutions to provide banking, merchant and ATM services for existing clients, which presently represent approximately 30 dispensaries. The accounts are expected to reach over $7,000,000 in gross processing volume over the next year.
"It is clear that CMSI is becoming the 'go to' source for banking and payment solutions within the medical marijuana space across the country. We have worked hard to enable our clients to partner with the proper banking institutions, who understand this business, and therefore accounts we set up are in fact set up as medical dispensaries, not wellness centers or the like. The fact that we look at these businesses as a pharmacy, with the ability to administer or distribute a controlled substance, we insure that the bank has all the necessary paperwork to make an intelligent decision for underwriting this business, and for the merchant, we are allowing the owners to take alternative forms of payment without the worry of having accounts shut down for miscoding and monies held," stated Michael Friedman for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Cannabis Medical Solutions Announces New Merchant Services Agreements for Up to 30 Additional Medical Marijuana Dispensaries in Colorado and California
LOS ANGELES, May 4, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced the signing of an exclusive agreement with Specialized Payment Solutions Inc. of Colorado to provide merchant and financial services for up to thirty (30) medical marijuana dispensary clients throughout Colorado and California through its alliance partner network. Details of the agreement include that Specialized Payment Solutions will work with Cannabis Medical Solutions to provide banking, merchant and ATM services for existing clients, which presently represent approximately 30 dispensaries. The accounts are expected to reach over $7,000,000 in gross processing volume over the next year.
"It is clear that CMSI is becoming the 'go to' source for banking and payment solutions within the medical marijuana space across the country. We have worked hard to enable our clients to partner with the proper banking institutions, who understand this business, and therefore accounts we set up are in fact set up as medical dispensaries, not wellness centers or the like. The fact that we look at these businesses as a pharmacy, with the ability to administer or distribute a controlled substance, we insure that the bank has all the necessary paperwork to make an intelligent decision for underwriting this business, and for the merchant, we are allowing the owners to take alternative forms of payment without the worry of having accounts shut down for miscoding and monies held," stated Michael Friedman for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Source: Cannabis Science, Inc.
Cannabis Science New Management Files First 10K Annual Report, Opens In-House Investor Relations Department in Southern Florida, and Prepares to Announce Several Expansions and Advancements for Each of Its Divisions
COLORADO SPRINGS, Colo., May 7, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has successfully completed filing its first 10K annual report with the SEC under its new management, and that the 'E' has been officially removed from its OTCBB symbol. Its symbol (CBIS) is fully restored as of today.
Richard Cowan, Cannabis Science Inc., Chief Financial Officer, stated, "The delay was not the result of any substantive legal or accounting problems, but from the intricacies of reporting the financial transition in the company's business over the last year into our current business model under Cannabis Science President and CEO Dr. Robert Melamede PhD."
In an effort to promptly and effectively communicate the outstanding progress the Company has made, Cannabis Science has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.
Mr. Cowan concluded, "The past few months have been very positive for the Company's expansion and progress, and several new revenue opportunities are being assessed and negotiated. The Company will be making the required announcements over the next few days outlining the new business expansions and relationships. Most of these developments result from the enormous amount of interest and communications from the media, potential partners, patients, and our outstanding and growing list of shareholders. Our new Investor Relations Department will help us tremendously in our efforts to give timely and accurate information to our shareholders and the public. Mr. Friedman and his associates are very quickly ramping up their knowledge base in regards to our past, present, and future developments so please feel free to give us a call and introduce yourself."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
Investor Relations:
Mark J. Friedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Science New Management Files First 10K Annual Report, Opens In-House Investor Relations Department in Southern Florida, and Prepares to Announce Several Expansions and Advancements for Each of Its Divisions
COLORADO SPRINGS, Colo., May 7, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has successfully completed filing its first 10K annual report with the SEC under its new management, and that the 'E' has been officially removed from its OTCBB symbol. Its symbol (CBIS) is fully restored as of today.
Richard Cowan, Cannabis Science Inc., Chief Financial Officer, stated, "The delay was not the result of any substantive legal or accounting problems, but from the intricacies of reporting the financial transition in the company's business over the last year into our current business model under Cannabis Science President and CEO Dr. Robert Melamede PhD."
In an effort to promptly and effectively communicate the outstanding progress the Company has made, Cannabis Science has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.
Mr. Cowan concluded, "The past few months have been very positive for the Company's expansion and progress, and several new revenue opportunities are being assessed and negotiated. The Company will be making the required announcements over the next few days outlining the new business expansions and relationships. Most of these developments result from the enormous amount of interest and communications from the media, potential partners, patients, and our outstanding and growing list of shareholders. Our new Investor Relations Department will help us tremendously in our efforts to give timely and accurate information to our shareholders and the public. Mr. Friedman and his associates are very quickly ramping up their knowledge base in regards to our past, present, and future developments so please feel free to give us a call and introduce yourself."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
Investor Relations:
Mark J. Friedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Board Announces Increase in Authorized Shares and Stock Dividend
LOS ANGELES, May 12, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced that its board of directors has approved a resolution authorizing an increase in the number of authorized shares of the Corporation's common stock from 250,000,000 to 500,000,000. The Company's board of directors and majority shareholders have also voted for an issuance of a stock dividend to each shareholder of CMSI. Pursuant to the resolutions, holders of the company's common stock will each receive an additional nine shares of common stock for each share they own of the record date set for May 14, 2010. Distribution of the dividend will begin on June 1, 2010.
"The Board of Directors believes that an increase in the number of shares of authorized common stock and stock dividend will benefit CMSI and our stockholders by giving us needed flexibility in our corporate planning and in responding to developments in our business, including possible acquisition transactions, financings, stock dividends and other general corporate purposes," stated Kyle Gotshalk, CEO of Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Cannabis Medical Solutions Board Announces Increase in Authorized Shares and Stock Dividend
LOS ANGELES, May 12, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced that its board of directors has approved a resolution authorizing an increase in the number of authorized shares of the Corporation's common stock from 250,000,000 to 500,000,000. The Company's board of directors and majority shareholders have also voted for an issuance of a stock dividend to each shareholder of CMSI. Pursuant to the resolutions, holders of the company's common stock will each receive an additional nine shares of common stock for each share they own of the record date set for May 14, 2010. Distribution of the dividend will begin on June 1, 2010.
"The Board of Directors believes that an increase in the number of shares of authorized common stock and stock dividend will benefit CMSI and our stockholders by giving us needed flexibility in our corporate planning and in responding to developments in our business, including possible acquisition transactions, financings, stock dividends and other general corporate purposes," stated Kyle Gotshalk, CEO of Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Source: Cannabis Science, Inc.
Cannabis Science Inc. Adds Online Communication Specialists in Response to an Increasing Interest in Dr. Robert Melamede's Understanding of the Amazing Role Played by the Endocannabinoid System Worldwide
Bookings Include Dates in Australia, Toronto, Seattle, Michigan, as Well as the Hawaiian Islands
COLORADO SPRINGS, Colo., May 12, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system. Dr. Robert Melamede, PhD, Cannabis Science President and CEO has been accepting numerous invitations to speak about Cannabis Science at a wide variety of medical marijuana events around the world, including in the U.S., Australia and Canada, regarding his concepts of the unique role played by the endocannabinoid system in life and health.
The company is excited to launch a higher quality Internet Presence through the new Specialists who will be focusing on the Company website content, the website communication interactions, and social media networking sites. This was brought on after receiving such a high level of media interest from Dr. Melamede's public speaking engagements, and news interviews, the Company has been focusing on expanding its online communication outlets and corporate sponsorships. As well, the Internet specialists will be focusing on bringing investors, scientists and the general public to the Company website, plus its blogs, newsletters, and forums.
Included in his talks is his hypothesis "that endocannabinoid deficient people (backward-looking people, "BLPs") naturally concentrate in government, and this explains why cannabis prohibition exists in spite of the plant's anti-aging and anti-cancer properties". He furthermore states, "I am confident that cannabis science and the will of the people will continue to fuel the ever increasing demand for effective and safe cannabis-based medicines."
The Company is excited to provide these resources in conjunction with the previously announced educational series that will be presented on national television and the company's website shortly. Dr. Robert Melamede's worldwide media tour and the continued development of online resources will provide Cannabis Science with the ability to keep its Patients, Investors, Doctors, and Partners continually informed on new developments and upcoming events.
Dr. Melamede launched his media tour at the famous "Mardi Grass" festival in Nimbin, Queensland, Australia on May 1, 2010. In keeping with his stated objective of making Cannabis Science a patient-oriented company that works with the international medical marijuana movement, Dr. Melamede will be speaking in Kalamazoo, Michigan on July 10th – 11th, 2010 at an event sponsored by 420 University; and in Toronto, Ontario at the Medical Marijuana & Hemp Expo sponsored by Treating Yourself Magazine, a respected Canadian publication devoted to medical cannabis; on the weekend of July 16th -18th, 2010, (http://www.medicalmarijuana-hempexpo.com/). Dr. Melamede has also accepted an invitation to speak at a seminar sponsored by Cannabis Business University (http://www.cannabizu.com/) in Honolulu, Hawaii on the weekend of August 7th - 8th, 2010 and he is also expected to speak at the annual Seattle Hempfest on the weekend of August 20th – 22nd, 2010.
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Freedman, Investor Relations
1.877.431.2247
info@cannabisscience.com
www.cannabisscience.com
Cannabis Science Inc. Adds Online Communication Specialists in Response to an Increasing Interest in Dr. Robert Melamede's Understanding of the Amazing Role Played by the Endocannabinoid System Worldwide
Bookings Include Dates in Australia, Toronto, Seattle, Michigan, as Well as the Hawaiian Islands
COLORADO SPRINGS, Colo., May 12, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system. Dr. Robert Melamede, PhD, Cannabis Science President and CEO has been accepting numerous invitations to speak about Cannabis Science at a wide variety of medical marijuana events around the world, including in the U.S., Australia and Canada, regarding his concepts of the unique role played by the endocannabinoid system in life and health.
The company is excited to launch a higher quality Internet Presence through the new Specialists who will be focusing on the Company website content, the website communication interactions, and social media networking sites. This was brought on after receiving such a high level of media interest from Dr. Melamede's public speaking engagements, and news interviews, the Company has been focusing on expanding its online communication outlets and corporate sponsorships. As well, the Internet specialists will be focusing on bringing investors, scientists and the general public to the Company website, plus its blogs, newsletters, and forums.
Included in his talks is his hypothesis "that endocannabinoid deficient people (backward-looking people, "BLPs") naturally concentrate in government, and this explains why cannabis prohibition exists in spite of the plant's anti-aging and anti-cancer properties". He furthermore states, "I am confident that cannabis science and the will of the people will continue to fuel the ever increasing demand for effective and safe cannabis-based medicines."
The Company is excited to provide these resources in conjunction with the previously announced educational series that will be presented on national television and the company's website shortly. Dr. Robert Melamede's worldwide media tour and the continued development of online resources will provide Cannabis Science with the ability to keep its Patients, Investors, Doctors, and Partners continually informed on new developments and upcoming events.
Dr. Melamede launched his media tour at the famous "Mardi Grass" festival in Nimbin, Queensland, Australia on May 1, 2010. In keeping with his stated objective of making Cannabis Science a patient-oriented company that works with the international medical marijuana movement, Dr. Melamede will be speaking in Kalamazoo, Michigan on July 10th – 11th, 2010 at an event sponsored by 420 University; and in Toronto, Ontario at the Medical Marijuana & Hemp Expo sponsored by Treating Yourself Magazine, a respected Canadian publication devoted to medical cannabis; on the weekend of July 16th -18th, 2010, (http://www.medicalmarijuana-hempexpo.com/). Dr. Melamede has also accepted an invitation to speak at a seminar sponsored by Cannabis Business University (http://www.cannabizu.com/) in Honolulu, Hawaii on the weekend of August 7th - 8th, 2010 and he is also expected to speak at the annual Seattle Hempfest on the weekend of August 20th – 22nd, 2010.
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Freedman, Investor Relations
1.877.431.2247
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Science, Inc.
Cannabis Science Negotiates for a 7,500 Sq. Ft., Facility in Colorado Springs to Facilitate Both Research and Revenues in the Company's Five Divisions
COLORADO SPRINGS, Colo., May 13, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines.
With the rapid expansion occurring in the Company's five divisions: Horticulture, Analytical Labs, Manufacturing, Clinical Trials and Distribution, Cannabis Science is negotiating for a space that will allow continued growth for all of its current and future business operations. The past few months have proven to be very successful for the Company, with many new revenue opportunities developing as a result of its overwhelming interest from media, patients, partners and shareholders. Announcements of the recent Company developments are scheduled for the next few days. Cannabis Science is very pleased to be experiencing steady expansion in its five divisions.
1. Horticulture Division – Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.
2. Analytical Labs – State Of The Art Facilities For Developing Cannabis Based Extracts and Pharmaceutical Grade Drugs.
3. Manufacturing – Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.
4. Clinical Trials – Initial Clinical Trials for FDA Approval Will Target Veterans Suffering From Chronic Pain and PTSD.
5. Distribution – In State Dispensaries Today, National Pharmacies Tomorrow.
Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Science Negotiates for a 7,500 Sq. Ft., Facility in Colorado Springs to Facilitate Both Research and Revenues in the Company's Five Divisions
COLORADO SPRINGS, Colo., May 13, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines.
With the rapid expansion occurring in the Company's five divisions: Horticulture, Analytical Labs, Manufacturing, Clinical Trials and Distribution, Cannabis Science is negotiating for a space that will allow continued growth for all of its current and future business operations. The past few months have proven to be very successful for the Company, with many new revenue opportunities developing as a result of its overwhelming interest from media, patients, partners and shareholders. Announcements of the recent Company developments are scheduled for the next few days. Cannabis Science is very pleased to be experiencing steady expansion in its five divisions.
1. Horticulture Division – Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.
2. Analytical Labs – State Of The Art Facilities For Developing Cannabis Based Extracts and Pharmaceutical Grade Drugs.
3. Manufacturing – Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.
4. Clinical Trials – Initial Clinical Trials for FDA Approval Will Target Veterans Suffering From Chronic Pain and PTSD.
5. Distribution – In State Dispensaries Today, National Pharmacies Tomorrow.
Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California
LOS ANGELES, May 13, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced that the Company is presently in negotiations to acquire and open at least two medical marijuana dispensaries within the state of California.
"The network of medical marijuana dispensaries that CMSI has created by providing financial services to our clients in three states over the last six months, has presented a unique opportunity for our company and shareholders. It has always been a part of our business plan to not only partner with dispensaries on the merchant processing and financial security side, but to franchise, consult and brand licensed dispensaries throughout legal jurisdictions under the Cannabis Medical Solutions name. We are presently in the due diligence process and seeking legal advice with regard to federal legislation that would allow us to follow this path and provide a proven model of ownership, financial accountability to reporting state agencies and be within federal and state guidelines," stated Kyle Gotshalk, CEO for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California
LOS ANGELES, May 13, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today announced that the Company is presently in negotiations to acquire and open at least two medical marijuana dispensaries within the state of California.
"The network of medical marijuana dispensaries that CMSI has created by providing financial services to our clients in three states over the last six months, has presented a unique opportunity for our company and shareholders. It has always been a part of our business plan to not only partner with dispensaries on the merchant processing and financial security side, but to franchise, consult and brand licensed dispensaries throughout legal jurisdictions under the Cannabis Medical Solutions name. We are presently in the due diligence process and seeking legal advice with regard to federal legislation that would allow us to follow this path and provide a proven model of ownership, financial accountability to reporting state agencies and be within federal and state guidelines," stated Kyle Gotshalk, CEO for Cannabis Medical Solutions.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
Source: Cannabis Medical Solutions, Inc.
Cannabis Medical Solutions Announces Clarification Regarding Recently Announced Stock Dividend
LOS ANGELES, May 17, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today issued the following clarification regarding the recently announced stock dividend and forward stock split.
In response to questions from stockholders, the Company wishes to clarify for stockholders and brokers the procedure through which stockholders may obtain their dividend certificate or shares. On May12, 2010 Cannabis Medical Solutions Inc. (OTCBB:CMSI) announced that its Board of Directors had declared a special stock dividend. The company initially announced that the dividend would be payable to stockholders of record on May 14, 2010 with the dividend being paid on or about June 1, 2010.
This clarification and second announcement provides that the Financial Industry Regulatory Authority (FINRA) has advised the company of the operation of Nasdaq Rule 11140(b)(2), which states:
In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date. This has been interpreted by the Company and its advisors that the dividend will trade with the stock until June 1, 2010, the payable date. Purchasers on June 2, 2010 or later will not be entitled to the dividend. If a stockholder is already a record owner of the Company holding certificates for Cannabis Medical Solutions Class A common stock issued in the stockholders name prior to or by May 14, 2010, the shareholder does not need to take any further action. A Dividend Certificate will be mailed directly to the shareholder by the transfer agent. All Registered Shareholders who purchased shares in the open market as of the record date of June 1, 2010, will be issued shares electronically representing the dividend shares entitled.
Cannabis Medical Solutions recommends that non-registered shareholders after May 14, 2010 should contact their representatives (Brokerage firms, On-line trading companies etc.) to ensure they are credited with the stock dividend. They should not contact Island Stock Transfer directly as that will be done by the Brokerage Firm. The Brokerage Firm will provide proof of ownership to Island Transfer. Persons needing further information or interpretation should consult with their broker-dealer or legal advisors.
"This stock dividend is intended to lay the groundwork for the growth of our Company, allowing us to continue our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment for acquisition and enhance shareholder value" stated CEO Kyle Gotshalk.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
info@cannabismedsolutions.com
Cannabis Medical Solutions Announces Clarification Regarding Recently Announced Stock Dividend
LOS ANGELES, May 17, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (www.cannabismedsolutions.com) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts and services, today issued the following clarification regarding the recently announced stock dividend and forward stock split.
In response to questions from stockholders, the Company wishes to clarify for stockholders and brokers the procedure through which stockholders may obtain their dividend certificate or shares. On May12, 2010 Cannabis Medical Solutions Inc. (OTCBB:CMSI) announced that its Board of Directors had declared a special stock dividend. The company initially announced that the dividend would be payable to stockholders of record on May 14, 2010 with the dividend being paid on or about June 1, 2010.
This clarification and second announcement provides that the Financial Industry Regulatory Authority (FINRA) has advised the company of the operation of Nasdaq Rule 11140(b)(2), which states:
In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date. This has been interpreted by the Company and its advisors that the dividend will trade with the stock until June 1, 2010, the payable date. Purchasers on June 2, 2010 or later will not be entitled to the dividend. If a stockholder is already a record owner of the Company holding certificates for Cannabis Medical Solutions Class A common stock issued in the stockholders name prior to or by May 14, 2010, the shareholder does not need to take any further action. A Dividend Certificate will be mailed directly to the shareholder by the transfer agent. All Registered Shareholders who purchased shares in the open market as of the record date of June 1, 2010, will be issued shares electronically representing the dividend shares entitled.
Cannabis Medical Solutions recommends that non-registered shareholders after May 14, 2010 should contact their representatives (Brokerage firms, On-line trading companies etc.) to ensure they are credited with the stock dividend. They should not contact Island Stock Transfer directly as that will be done by the Brokerage Firm. The Brokerage Firm will provide proof of ownership to Island Transfer. Persons needing further information or interpretation should consult with their broker-dealer or legal advisors.
"This stock dividend is intended to lay the groundwork for the growth of our Company, allowing us to continue our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment for acquisition and enhance shareholder value" stated CEO Kyle Gotshalk.
About Cannabis Medical Solutions Inc.
Cannabis Medical Solutions Inc. (OTCBB:CMSI) (http://www.cannabismedsolutions.com/)" target="_blank" rel="nofollow ugc noopener">http://www.cannabismedsolutions.com/) has quickly become the most recognized brand and partner in both online and wireless niche merchant payment solutions. The Company offers a full spectrum of secure and reliable transaction processing solutions using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) terminals in conjunction with Industry Alliance Partners. The Company has recently focused on providing payment solutions to the licensed medical marijuana dispensaries throughout 14 states. In an effort to keep these businesses within the guidelines of CA Proposition 215 and SB 420, Cannabis Medical Solutions offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated dispensaries for both operators and members of collectives. CMSI will seek to capitalize on this presently untapped and much needed solution, and presently provides services to multiple locations throughout California, New Mexico, Colorado and Montana.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Medical Solutions Inc. to be materially different from the statements made herein.
CONTACT: Cannabis Medical Solutions Inc.
Investor Relations:
615.371.6148
800.420-CALL
http://www.cannabismedsolutions.com/
info@cannabismedsolutions.com
Cannabis Science Comments on Recent USA TODAY Article That The Obama Administration Refocuses Its Unsuccessful War On Drugs to a Public Health Fight and Speaks About the Growing Recognition of Marijuana for Medical Purposes
COLORADO SPRINGS, Colo., May 19, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that as reported in a recent article in USA TODAY the use of marijuana for Medical purposes is becoming more accepted by government officials and by the overwhelming majority of the people. According to the article, "a consensus is growing across the country that at least marijuana will someday be regulated and sold like tobacco and alcohol."
The Obama administration has recently announced the reassessment of its War On Drugs to be refocused as a Public Health Fight after 40 years, $1 Trillion dollars and thousands of lives lost. This has even brought out the support of various law enforcement personnel, including the Medford, Mass.-based Law Enforcement Against Prohibition, a group of over 13,000 police, judges, prison wardens, prosecutors and others who want to legalize and regulate all drugs. The Obama administration said it will not target marijuana dispensaries if they are compliant with state regulations.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, commented, "Cannabis Science is very pleased to see the growing support for the medical use of marijuana and looks forward to the upcoming Fall vote for South Dakota residents on whether to allow marijuana for medical practice use and the vote in November for by California voters that will decide whether to legalize marijuana. I encourage everyone in these States to vote so we can continue the increasing recognition of the benefits of medical marijuana. We are building a patient oriented company that supports the rights of the individual and opposes the use of state violence against sick and dying Americans, especially our veterans who have sacrificed so much for the freedom that they are now being denied."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, PhD., President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
COLORADO SPRINGS, Colo., May 19, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that as reported in a recent article in USA TODAY the use of marijuana for Medical purposes is becoming more accepted by government officials and by the overwhelming majority of the people. According to the article, "a consensus is growing across the country that at least marijuana will someday be regulated and sold like tobacco and alcohol."
The Obama administration has recently announced the reassessment of its War On Drugs to be refocused as a Public Health Fight after 40 years, $1 Trillion dollars and thousands of lives lost. This has even brought out the support of various law enforcement personnel, including the Medford, Mass.-based Law Enforcement Against Prohibition, a group of over 13,000 police, judges, prison wardens, prosecutors and others who want to legalize and regulate all drugs. The Obama administration said it will not target marijuana dispensaries if they are compliant with state regulations.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, commented, "Cannabis Science is very pleased to see the growing support for the medical use of marijuana and looks forward to the upcoming Fall vote for South Dakota residents on whether to allow marijuana for medical practice use and the vote in November for by California voters that will decide whether to legalize marijuana. I encourage everyone in these States to vote so we can continue the increasing recognition of the benefits of medical marijuana. We are building a patient oriented company that supports the rights of the individual and opposes the use of state violence against sick and dying Americans, especially our veterans who have sacrificed so much for the freedom that they are now being denied."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc.
Dr. Robert J. Melamede, PhD., President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Training University (CTU) Begins Classes in California
Cannabis Training University (CTU) Announces a New Training Program for the Booming Medical Cannabis Industry; CTU Hosts "Weekend Boot Camp Seminars" Led by Industry Experts; Learn the Latest in Medical Marijuana Growing Techniques From Top Instructors
SAN FRANCISCO, May 20, 2010 (GLOBE NEWSWIRE) -- The medical cannabis business is booming in California and Cannabis Training University is offering "Weekend Boot Camp Seminars" providing students with the training necessary to start a new career, advance existing knowledge and network with industry experts. Classes include guest speakers and instructors from all areas of the medical cannabis industry, including specialized attorneys, licensed physicians, advanced-level horticulturists, cannabis herbalists, and experienced cannabis chefs. Cannabis Training University (CTU) is the only cannabis educational program that dedicates a full day of instruction to horticulture and cannabis growing techniques. Special Guest Speaker at select locations is the "Guru of Ganja," Mr. Ed Rosenthal (EdRosenthal.com).
Company President Jeffrey Zorn said, "Our Weekend Boot Camp Seminars offer practical training for students to start or advance a career in the growing medical cannabis industry. When I developed the course curriculum, I spoke to industry experts and potential students. It helped me to prepare the best program in California and to attract the most knowledgeable and qualified cannabis industry faculty members in the United States."
Topics covered in the Weekend Boot Camp Seminar include:
* Opening a cannabis business (myths and realities)
* Legal documents necessary to form a collective, dispensary and delivery service
* Current laws and update on proposed legislation related to marijuana
* Cannabis cooking techniques and tips (including a book of recipes to take home)
* Tinctures, oils, liniments preparation demonstration
* Medical cannabis growing techniques (indoors and outdoors, plus the latest in Organic and Vegan Growing Techniques, the latest and most current grow techniques)
* How to save thousands of dollars when buying equipment and how to get maximum yield and potency out of your plants
Upcoming Weekend Boot Camp Seminars
July 10th and 11th - San Jose, CA
July 24th and 25th - Santa Rosa, CA
July 31st and August 1st - Santa Cruz, CA
Check out www.theCTU.com for additional dates, locations and new classes.
Students can register for upcoming seminars at www.theCTU.com. Tuition for the two day Weekend Boot Camp Seminar is only $250 when paid in advance.
About the Company
Cannabis Training University was founded in 2010 to provide expert-led training in the growing field of medical cannabis. Additional information can be found online at www.theCTU.com or you may contact: Jeffrey Zorn, Owner/President at (888) 562-4CTU (4288)
The CTU logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7507
CONTACT: CTU
Jeffrey Zorn
888-562-4CTU
Cannabis Training University (CTU) Announces a New Training Program for the Booming Medical Cannabis Industry; CTU Hosts "Weekend Boot Camp Seminars" Led by Industry Experts; Learn the Latest in Medical Marijuana Growing Techniques From Top Instructors
SAN FRANCISCO, May 20, 2010 (GLOBE NEWSWIRE) -- The medical cannabis business is booming in California and Cannabis Training University is offering "Weekend Boot Camp Seminars" providing students with the training necessary to start a new career, advance existing knowledge and network with industry experts. Classes include guest speakers and instructors from all areas of the medical cannabis industry, including specialized attorneys, licensed physicians, advanced-level horticulturists, cannabis herbalists, and experienced cannabis chefs. Cannabis Training University (CTU) is the only cannabis educational program that dedicates a full day of instruction to horticulture and cannabis growing techniques. Special Guest Speaker at select locations is the "Guru of Ganja," Mr. Ed Rosenthal (EdRosenthal.com).
Company President Jeffrey Zorn said, "Our Weekend Boot Camp Seminars offer practical training for students to start or advance a career in the growing medical cannabis industry. When I developed the course curriculum, I spoke to industry experts and potential students. It helped me to prepare the best program in California and to attract the most knowledgeable and qualified cannabis industry faculty members in the United States."
Topics covered in the Weekend Boot Camp Seminar include:
* Opening a cannabis business (myths and realities)
* Legal documents necessary to form a collective, dispensary and delivery service
* Current laws and update on proposed legislation related to marijuana
* Cannabis cooking techniques and tips (including a book of recipes to take home)
* Tinctures, oils, liniments preparation demonstration
* Medical cannabis growing techniques (indoors and outdoors, plus the latest in Organic and Vegan Growing Techniques, the latest and most current grow techniques)
* How to save thousands of dollars when buying equipment and how to get maximum yield and potency out of your plants
Upcoming Weekend Boot Camp Seminars
July 10th and 11th - San Jose, CA
July 24th and 25th - Santa Rosa, CA
July 31st and August 1st - Santa Cruz, CA
Check out www.theCTU.com for additional dates, locations and new classes.
Students can register for upcoming seminars at www.theCTU.com. Tuition for the two day Weekend Boot Camp Seminar is only $250 when paid in advance.
About the Company
Cannabis Training University was founded in 2010 to provide expert-led training in the growing field of medical cannabis. Additional information can be found online at www.theCTU.com or you may contact: Jeffrey Zorn, Owner/President at (888) 562-4CTU (4288)
The CTU logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7507
CONTACT: CTU
Jeffrey Zorn
888-562-4CTU
Source: Cannabis Science, Inc.
Cannabis Science Identifies Another Urgent Need for Its Pharmaceutical Products as Suicides and Sudden Deaths Among Vets With Post Traumatic Stress Disorder Linked to a Number of Widely-Prescribed FDA Approved Pharmaceuticals Such as Seroquel and Other Antipsychotics, Antidepressants, Mood Stabilizers, Sleep Inducers, Pain, and Seizure Medications
COLORADO SPRINGS, Colo., May 20, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, notes with great sadness that a widely prescribed medication has been linked to both suicides and sudden death among veterans suffering from PTSD. Numerous veterans who have contacted Cannabis Science have confirmed these problems.
According to an article by Martha Rosenberg, originally published on Alternet.org and published in March on NewsBlaze.com, at least 87 military men have died in the past six years while prescribed Seroquel and similar drugs. http://newsblaze.com/story/20100324080950rose.nb/topstory.ht…
Rosenberg reported, "Death certificates and other records collected by veteran family members suggest more than 100 similar deaths among Iraq and Afghanistan combat vets and other military personnel, many on PTSD cocktails with Seroquel and other antipsychotics, antidepressants, mood stabilizers, sleep inducers and pain and seizure medications."
Although not approved for PTSD, Pentagon purchases of Seroquel nearly doubled between 2003 and 2007. Elspeth Ritchie, medical director of the Army's Strategic Communications Office, told the Denver Post the drug is "increasingly utilized as an adjunct for PTSD." Seroquel had almost $5 billion in sales last year.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, noted, "Of course, after more than 5,000 years of use, cannabis has not been shown to have caused a single death, and it is now widely -- but illegally -- used by veterans and others with PTSD as we have reported. It is shameful that those who deserve the best treatment available are being denied access to cannabis while they are given a cocktail of powerful drugs that seems to be killing them."
On March 31, Cannabis Science issued a press release calling for public support for vets after the New York Times reported that VA Doctors are prohibited from "recommending" cannabis for Post Traumatic Stress Disorder (PTSD). Also, Cannabis Science has previously reported that Dr. Mitch Earleywine, PhD., of the State University of New York (Albany) has surveyed over 1,300 veterans and others who find cannabis very helpful with PTSD.
Cannabis Science Chief Financial Officer Richard C. Cowan stated, "Due to the magnitude and nature of the problem, it is clear why we are focusing our initial FDA pharmaceutical products on PTSD. The fact that Seroquel had $5 billion in sales last year is a strong indication of the potential market for Cannabis Science products."
One of Seroquel first backers, Richard Borison, former chief of psychiatry at the Charlie Norwood VA Medical Center, lost his medical license, was fined $4.26 million and went to prison for a swindle involving Seroquel's original clinical studies.
And last year, Seroquel manufacturer AstraZeneca agreed to pay $520 million to settle suits pertaining to clinical trials and illegal Seroquel marketing.
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Science Identifies Another Urgent Need for Its Pharmaceutical Products as Suicides and Sudden Deaths Among Vets With Post Traumatic Stress Disorder Linked to a Number of Widely-Prescribed FDA Approved Pharmaceuticals Such as Seroquel and Other Antipsychotics, Antidepressants, Mood Stabilizers, Sleep Inducers, Pain, and Seizure Medications
COLORADO SPRINGS, Colo., May 20, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, notes with great sadness that a widely prescribed medication has been linked to both suicides and sudden death among veterans suffering from PTSD. Numerous veterans who have contacted Cannabis Science have confirmed these problems.
According to an article by Martha Rosenberg, originally published on Alternet.org and published in March on NewsBlaze.com, at least 87 military men have died in the past six years while prescribed Seroquel and similar drugs. http://newsblaze.com/story/20100324080950rose.nb/topstory.ht…
Rosenberg reported, "Death certificates and other records collected by veteran family members suggest more than 100 similar deaths among Iraq and Afghanistan combat vets and other military personnel, many on PTSD cocktails with Seroquel and other antipsychotics, antidepressants, mood stabilizers, sleep inducers and pain and seizure medications."
Although not approved for PTSD, Pentagon purchases of Seroquel nearly doubled between 2003 and 2007. Elspeth Ritchie, medical director of the Army's Strategic Communications Office, told the Denver Post the drug is "increasingly utilized as an adjunct for PTSD." Seroquel had almost $5 billion in sales last year.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, noted, "Of course, after more than 5,000 years of use, cannabis has not been shown to have caused a single death, and it is now widely -- but illegally -- used by veterans and others with PTSD as we have reported. It is shameful that those who deserve the best treatment available are being denied access to cannabis while they are given a cocktail of powerful drugs that seems to be killing them."
On March 31, Cannabis Science issued a press release calling for public support for vets after the New York Times reported that VA Doctors are prohibited from "recommending" cannabis for Post Traumatic Stress Disorder (PTSD). Also, Cannabis Science has previously reported that Dr. Mitch Earleywine, PhD., of the State University of New York (Albany) has surveyed over 1,300 veterans and others who find cannabis very helpful with PTSD.
Cannabis Science Chief Financial Officer Richard C. Cowan stated, "Due to the magnitude and nature of the problem, it is clear why we are focusing our initial FDA pharmaceutical products on PTSD. The fact that Seroquel had $5 billion in sales last year is a strong indication of the potential market for Cannabis Science products."
One of Seroquel first backers, Richard Borison, former chief of psychiatry at the Charlie Norwood VA Medical Center, lost his medical license, was fined $4.26 million and went to prison for a swindle involving Seroquel's original clinical studies.
And last year, Seroquel manufacturer AstraZeneca agreed to pay $520 million to settle suits pertaining to clinical trials and illegal Seroquel marketing.
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Source: Cannabis Science, Inc.
Cannabis Science Acquires Two Revenue Producing Operations, a Medical Marijuana Growing Facility and a Dispensary to Facilitate Operational Growth, Research and Development of Pharmaceutical Cannabis Products in Colorado in Accordance With State Laws
COLORADO SPRINGS, Colo., May 24, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.
Richard Cowan, Cannabis Science CFO, stated, "Obviously, acquiring two revenue producing operations immediately changes the nature of Cannabis Science, giving us a positive cash flow stream much sooner than otherwise would have been possible. We are now entering a new phase of our business and we expect to expand these revenue streams immediately by the acquisition of a larger facility as previously announced to meet the demand for Cannabis Science products. Our main focus remains the development of pharmaceutical cannabis products for FDA approval. In fact, these acquisitions will improve our ability to develop pharmaceuticals and increase our ability to serve the rapidly growing patient community."
Currently, both operations are producing revenues in the hundreds of thousands of dollars and generate significant positive cash flow. The transaction was a share swap in which the company is issuing a total of 2,400,000 shares for both the acquisition of these operations and as compensation for a management contract that will add significant skills to our company's team. The seller of these facilities, Mr. Adam Pasquale, is joining the Cannabis Science management team as Director of Horticulture. Mr. Pasquale's responsibilities include overseeing these operations and implementing the company's plans to expand these areas of business across the country, as the laws allow. The Company is looking forward to regularly reporting its progress in its 5 key operations:
1. The Horticulture Division -- Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.
2. Analytical Labs -- State Of The Art Facilities Developing Cannabis Extracts and Pharmaceutical Grade Drugs.
3. Manufacturing -- Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.
4. Clinical Trials -- Initial FDA Clinical Trials Targeting Veterans Suffering From Chronic Pain and PTSD.
5. Distribution -- In State Dispensaries Today, National Pharmacies Tomorrow.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, said, "We view this transaction as key to our plans to develop standardized FDA quality pharmaceutical cannabis products. In addition, their profitability will facilitate our product development in accordance with State laws. These acquisitions will allow us to begin pre-testing to establish the efficacy of our pharmaceutical products prior to formal FDA human trials. We are in preliminary negotiations to establish similar operations in other States that have approved medical marijuana programs addressing the ever-increasing demands for medical marijuana as people learn the truth about marijuana's unique medical values. We are creating a new type of patient oriented pharmaceutical company that will foster social change, and this is a major step in that process."
Mr. Cowan added, "I am also very pleased to report that we are currently converting most of the company's debt into common equity. Adding revenues, eliminating debt, and clarifying the company's financial structure should help provide a higher per share price and valuation for the company. As a result of the debt conversions, the acquisition, and corporate expansions there are currently 65,570,574 shares outstanding and management expects to retire most of its debt by the end of June thereby eliminating a major source of risk. These developments should allow some of the larger funds and fund managers to invest substantially more in the company because of the reflection of our greater financial strength."
Richard Cowan continued, "Last January, the New York Times reported that a spokesperson for the U.S. National Institute on Drug Abuse (NIDA) admitted that the agency 'does not fund research focused on the potential medical benefits of marijuana.' The NIDA admission explains why these acquisitions are so important for us. It will not only facilitate our research and development; it will also serve as prototype for this sort of operation that we plan to replicate in other medical marijuana states, as well as in other countries. We think that having dispensaries with their own production facilities will allow us to produce 'Cannabis Science' branded products that will give patients the best medicine at the best prices. These transactions are further evidence of Dr. Melamede's ability to bridge the worlds of medical marijuana and hard science, and the patients – and our shareholders -- will benefit greatly from this important step. As previously announced, our other steps toward building the company include adding a much larger analytical research laboratories, facilities for developing and manufacturing various delivery modalities such as lozenges, sprays, topical creams etc., as well as wholesale distribution of both nutraceutical and pharmaceutical products."
The National Organization for the Reform of Marijuana Laws (NORML) explained the significance of this admission:
Under federal law, the agency must approve all clinical and preclinical research involving marijuana. NIDA strictly controls which investigators are allowed access to the federal government's lone research supply of pot – which is produced and stored at the University of Mississippi.
NIDA spokeswoman Shirley Simson told the Times: "As the National Institute on Drug Abuse, our focus is primarily on the negative consequences of marijuana use. We generally do not fund research focused on the potential beneficial medical effects of marijuana."
NIDA presently oversees an estimated 85 percent of the world's research on controlled substances.
Commenting on NIDA's admission NORML Deputy Director Paul Armentano said, "NIDA has finally admitted to the world the 'Catch-22' that has been plaguing medical marijuana advocates and patients. Lawmakers demand clinical research regarding the safety and efficacy of medical cannabis, but the agency in charge of such research denies these studies from ever taking place. It's tragic that these public officials have let political ideology, not science, determine American's health decisions."
In 2007, U.S. Drug Enforcement Administration (DEA) Administrative Law Judge Mary Ellen Bittner ruled that NIDA's monopolization of marijuana research is not "in the public interest," and ordered the federal government to allow private manufacturers to produce the drug for research purposes. In January of last year, DEA Deputy Administrator Michele Leonhart set aside Judge Bittner's ruling.
From http://norml.org/index.cfm?Group_ID=8092
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Freedman
Investor Relations
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Science Acquires Two Revenue Producing Operations, a Medical Marijuana Growing Facility and a Dispensary to Facilitate Operational Growth, Research and Development of Pharmaceutical Cannabis Products in Colorado in Accordance With State Laws
COLORADO SPRINGS, Colo., May 24, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.
Richard Cowan, Cannabis Science CFO, stated, "Obviously, acquiring two revenue producing operations immediately changes the nature of Cannabis Science, giving us a positive cash flow stream much sooner than otherwise would have been possible. We are now entering a new phase of our business and we expect to expand these revenue streams immediately by the acquisition of a larger facility as previously announced to meet the demand for Cannabis Science products. Our main focus remains the development of pharmaceutical cannabis products for FDA approval. In fact, these acquisitions will improve our ability to develop pharmaceuticals and increase our ability to serve the rapidly growing patient community."
Currently, both operations are producing revenues in the hundreds of thousands of dollars and generate significant positive cash flow. The transaction was a share swap in which the company is issuing a total of 2,400,000 shares for both the acquisition of these operations and as compensation for a management contract that will add significant skills to our company's team. The seller of these facilities, Mr. Adam Pasquale, is joining the Cannabis Science management team as Director of Horticulture. Mr. Pasquale's responsibilities include overseeing these operations and implementing the company's plans to expand these areas of business across the country, as the laws allow. The Company is looking forward to regularly reporting its progress in its 5 key operations:
1. The Horticulture Division -- Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.
2. Analytical Labs -- State Of The Art Facilities Developing Cannabis Extracts and Pharmaceutical Grade Drugs.
3. Manufacturing -- Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.
4. Clinical Trials -- Initial FDA Clinical Trials Targeting Veterans Suffering From Chronic Pain and PTSD.
5. Distribution -- In State Dispensaries Today, National Pharmacies Tomorrow.
Dr. Robert Melamede, PhD., Cannabis Science President and CEO, said, "We view this transaction as key to our plans to develop standardized FDA quality pharmaceutical cannabis products. In addition, their profitability will facilitate our product development in accordance with State laws. These acquisitions will allow us to begin pre-testing to establish the efficacy of our pharmaceutical products prior to formal FDA human trials. We are in preliminary negotiations to establish similar operations in other States that have approved medical marijuana programs addressing the ever-increasing demands for medical marijuana as people learn the truth about marijuana's unique medical values. We are creating a new type of patient oriented pharmaceutical company that will foster social change, and this is a major step in that process."
Mr. Cowan added, "I am also very pleased to report that we are currently converting most of the company's debt into common equity. Adding revenues, eliminating debt, and clarifying the company's financial structure should help provide a higher per share price and valuation for the company. As a result of the debt conversions, the acquisition, and corporate expansions there are currently 65,570,574 shares outstanding and management expects to retire most of its debt by the end of June thereby eliminating a major source of risk. These developments should allow some of the larger funds and fund managers to invest substantially more in the company because of the reflection of our greater financial strength."
Richard Cowan continued, "Last January, the New York Times reported that a spokesperson for the U.S. National Institute on Drug Abuse (NIDA) admitted that the agency 'does not fund research focused on the potential medical benefits of marijuana.' The NIDA admission explains why these acquisitions are so important for us. It will not only facilitate our research and development; it will also serve as prototype for this sort of operation that we plan to replicate in other medical marijuana states, as well as in other countries. We think that having dispensaries with their own production facilities will allow us to produce 'Cannabis Science' branded products that will give patients the best medicine at the best prices. These transactions are further evidence of Dr. Melamede's ability to bridge the worlds of medical marijuana and hard science, and the patients – and our shareholders -- will benefit greatly from this important step. As previously announced, our other steps toward building the company include adding a much larger analytical research laboratories, facilities for developing and manufacturing various delivery modalities such as lozenges, sprays, topical creams etc., as well as wholesale distribution of both nutraceutical and pharmaceutical products."
The National Organization for the Reform of Marijuana Laws (NORML) explained the significance of this admission:
Under federal law, the agency must approve all clinical and preclinical research involving marijuana. NIDA strictly controls which investigators are allowed access to the federal government's lone research supply of pot – which is produced and stored at the University of Mississippi.
NIDA spokeswoman Shirley Simson told the Times: "As the National Institute on Drug Abuse, our focus is primarily on the negative consequences of marijuana use. We generally do not fund research focused on the potential beneficial medical effects of marijuana."
NIDA presently oversees an estimated 85 percent of the world's research on controlled substances.
Commenting on NIDA's admission NORML Deputy Director Paul Armentano said, "NIDA has finally admitted to the world the 'Catch-22' that has been plaguing medical marijuana advocates and patients. Lawmakers demand clinical research regarding the safety and efficacy of medical cannabis, but the agency in charge of such research denies these studies from ever taking place. It's tragic that these public officials have let political ideology, not science, determine American's health decisions."
In 2007, U.S. Drug Enforcement Administration (DEA) Administrative Law Judge Mary Ellen Bittner ruled that NIDA's monopolization of marijuana research is not "in the public interest," and ordered the federal government to allow private manufacturers to produce the drug for research purposes. In January of last year, DEA Deputy Administrator Michele Leonhart set aside Judge Bittner's ruling.
From http://norml.org/index.cfm?Group_ID=8092
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Freedman
Investor Relations
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Cannabis Reports on Bloomberg News, 15 Members of Congress Led by Representative Barney Frank Support Dispensaries as Legitimate Businesses; Cannabis Science Value Increased for Pharmaceutical Research and Development; New Colorado Law Adds Protection
COLORADO SPRINGS, Colo., May 25, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is very pleased to report that 15 members of Congress led by U.S. Representative Barney Frank (D. MA) are urging the Treasury Department to set rules that encourage banks to provide financial services to medical marijuana clinics, which are lawful businesses.
Richard Cowan, Cannabis Science CFO, explained, "A number of members of Congress, led by Barney Frank (D. MA) and Jared Polis, (D. CO), have written Treasury Secretary Geithner urging the Treasury to issue 'formal written guidance' assuring banks they won't be targeted for doing business with companies that distribute medical marijuana. This is just one more important step toward a realistic federal policy on medical marijuana."
"Legitimate state-legal businesses are being denied access to banking services, which does not serve the public interest," the lawmakers said in a May 20 letter to Treasury Secretary Timothy F. Geithner, that was distributed today by Americans for Safe Access, a patient-advocacy group.
The letter was written by Representative Jared Polis, a Colorado Democrat whose state is one of at least 14 that have legalized marijuana for medical use. Bloomberg reports that Polis warned that denying financial services to medical marijuana dispensaries creates "an increased risk to public safety with potential theft or robbery that any cash-only or cash-reliant business faces" and makes it harder for vendors "to accurately account for tax liability."
"This is a growing effort by the states to regulate a legal trade, and the more states allow it, the more outcry there will be for the federal government to take action," Polis said. "The biggest barrier to these legal businesses is this banking issue."
The Company is also pleased to respond to the multiple inquiries regarding impact of its acquisition of a medical marijuana dispensary and organic cannabis growing facilities. Yesterday, Cannabis Science announced that it had acquired 100% of a private company, RockBrook Inc., located at Suite 323, 2865 South Colorado Blvd., Denver, Colorado 08222; Telephone: 303.756.0595. RockBrook is both a fully licensed dispensary providing patients with medical marijuana in Colorado and an experienced grower of medical cannabis in accordance with state laws.
In announcing the RockBrook acquisition, Dr. Robert Melamede, PhD., Cannabis Science President and CEO explained that this transaction is "key to our plans to develop standardized FDA quality pharmaceutical cannabis products."
Dr. Melamede added, "Owning a dispensary brings us much closer to the patients, and as we continually emphasize, Cannabis Science is a patient-based company. Cannabis is very different from other 'new' medicines in that thousands of patients are already using it in a wide variety of forms and formulations. We are now in a much better position to work with them to determine what works best for various health problems, and what the patients prefer."
Richard Cowan, Cannabis Science CFO, explained, "We will be in complete compliance with a new Colorado law regulating dispensaries, and the Federal government has indicated that it will not interfere in such operations. We will also be able to comply with the new law's requirement that a dispensary be able to produce 70% of the medicine sold in its dispensaries. Unlike other pharmaceutical companies that depend on a continuation of prohibition, we look forward to competing in a free market with 'Cannabis Science' branded products."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
COLORADO SPRINGS, Colo., May 25, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is very pleased to report that 15 members of Congress led by U.S. Representative Barney Frank (D. MA) are urging the Treasury Department to set rules that encourage banks to provide financial services to medical marijuana clinics, which are lawful businesses.
Richard Cowan, Cannabis Science CFO, explained, "A number of members of Congress, led by Barney Frank (D. MA) and Jared Polis, (D. CO), have written Treasury Secretary Geithner urging the Treasury to issue 'formal written guidance' assuring banks they won't be targeted for doing business with companies that distribute medical marijuana. This is just one more important step toward a realistic federal policy on medical marijuana."
"Legitimate state-legal businesses are being denied access to banking services, which does not serve the public interest," the lawmakers said in a May 20 letter to Treasury Secretary Timothy F. Geithner, that was distributed today by Americans for Safe Access, a patient-advocacy group.
The letter was written by Representative Jared Polis, a Colorado Democrat whose state is one of at least 14 that have legalized marijuana for medical use. Bloomberg reports that Polis warned that denying financial services to medical marijuana dispensaries creates "an increased risk to public safety with potential theft or robbery that any cash-only or cash-reliant business faces" and makes it harder for vendors "to accurately account for tax liability."
"This is a growing effort by the states to regulate a legal trade, and the more states allow it, the more outcry there will be for the federal government to take action," Polis said. "The biggest barrier to these legal businesses is this banking issue."
The Company is also pleased to respond to the multiple inquiries regarding impact of its acquisition of a medical marijuana dispensary and organic cannabis growing facilities. Yesterday, Cannabis Science announced that it had acquired 100% of a private company, RockBrook Inc., located at Suite 323, 2865 South Colorado Blvd., Denver, Colorado 08222; Telephone: 303.756.0595. RockBrook is both a fully licensed dispensary providing patients with medical marijuana in Colorado and an experienced grower of medical cannabis in accordance with state laws.
In announcing the RockBrook acquisition, Dr. Robert Melamede, PhD., Cannabis Science President and CEO explained that this transaction is "key to our plans to develop standardized FDA quality pharmaceutical cannabis products."
Dr. Melamede added, "Owning a dispensary brings us much closer to the patients, and as we continually emphasize, Cannabis Science is a patient-based company. Cannabis is very different from other 'new' medicines in that thousands of patients are already using it in a wide variety of forms and formulations. We are now in a much better position to work with them to determine what works best for various health problems, and what the patients prefer."
Richard Cowan, Cannabis Science CFO, explained, "We will be in complete compliance with a new Colorado law regulating dispensaries, and the Federal government has indicated that it will not interfere in such operations. We will also be able to comply with the new law's requirement that a dispensary be able to produce 70% of the medicine sold in its dispensaries. Unlike other pharmaceutical companies that depend on a continuation of prohibition, we look forward to competing in a free market with 'Cannabis Science' branded products."
Cannabis Science, Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Investor Relations
Mark J. Freedman
1.877.431.CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com
Antwort auf Beitrag Nr.: 39.585.332 von Hobbyaktien am 26.05.10 14:09:36ist noch jemand investiert ?
Antwort auf Beitrag Nr.: 40.315.327 von kool55 am 13.10.10 18:40:17wie ist der massive anstieg von montag zu erklären?
Antwort auf Beitrag Nr.: 40.315.487 von kool55 am 13.10.10 19:03:50hobbyaktien sind sie noch investiert ?
Antwort auf Beitrag Nr.: 40.322.584 von Belu1972 am 14.10.10 16:49:55@belu1972 seit wann sind sie investiert?
Antwort auf Beitrag Nr.: 40.323.067 von kool55 am 14.10.10 17:50:32Dienstag bei ,075 und selbst?
zum mit lesen http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
zum mit lesen http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Antwort auf Beitrag Nr.: 40.315.327 von kool55 am 13.10.10 18:40:17Ja ich bin noch investiert!!
Habe aber schon lange keine News mehr verfolgt, gibt es irgendwelche Neuigkeiten??
habe mir die aktie langfristig ins Depot gelegt!!
Mal abwarten, was passiert, bis 0,20 USD ist es noch ein weiter weg, ich weiß gar nicht mehr genau, wo ich eingestiegen bin, aber über 0,20 USD!!
Euch allen viel Erfolg!!
Habe aber schon lange keine News mehr verfolgt, gibt es irgendwelche Neuigkeiten??
habe mir die aktie langfristig ins Depot gelegt!!
Mal abwarten, was passiert, bis 0,20 USD ist es noch ein weiter weg, ich weiß gar nicht mehr genau, wo ich eingestiegen bin, aber über 0,20 USD!!
Euch allen viel Erfolg!!
Antwort auf Beitrag Nr.: 40.323.402 von Belu1972 am 14.10.10 18:26:38ja habe dienstag und mittwoch gekauft zu durchschnittlich 8 cent ....
ist ja heute wieder die reinste Freude
Antwort auf Beitrag Nr.: 40.332.631 von Belu1972 am 15.10.10 19:49:54allerdings! kann von mir aus noch einige wochen so weitergehen
Antwort auf Beitrag Nr.: 40.332.884 von kool55 am 15.10.10 20:24:45neues tageshoch bei 0,1538
hat nicht geklappt
geb das mal so ein
http://www.aktiencheck.de/forum/all/420061/thread
letzten Beitrag anklicken
geb das mal so ein
http://www.aktiencheck.de/forum/all/420061/thread
letzten Beitrag anklicken
das ist ja wirklich atemberaubend, was hier abgeht
Wenn das so weitergeht sind wir am Freitag bei $,50
Wenn das so weitergeht sind wir am Freitag bei $,50
Antwort auf Beitrag Nr.: 40.344.748 von Belu1972 am 18.10.10 21:17:42 bei smokefree innotec bin ich soeben eingestiegen
wow wow wow und wieder ein neues Video http://ih.advfn.com/videos/stock-chart/big-run-but-this-one-…
Gott sei Dank sind noch genug basher unterwegs und das Teil kann steigen
mich wundert es ein bischen, das hier so wenig los ist?
Wo sind denn blos die ganzen Marktschreier?
Gott sei Dank sind noch genug basher unterwegs und das Teil kann steigen
mich wundert es ein bischen, das hier so wenig los ist?
Wo sind denn blos die ganzen Marktschreier?
die ganzen dummen Marktschreier sollen ja bleiben wo der Pfeffer wächst und nicht der gute Hanf...jaja Leute die sich mit Cannabis beschäftigen schätze ich als "hinter den Vorhang guckend" und intelligent ein und passt nicht zu Marktschreiern! Gut so!
Ja das Kurs-Auf und Ab ist wirklich spannend und es ist noch mehr als genug Platz nach oben, ich glaube die kleinen Kursrückschläge den einen oder anderen Tag sollte man ignorieren, da nehmen Leute ihre fetten Gewinne mit und andere sind froh noch billig einzusteigen, bei dem Volumen und der Zukunft für Cannabis als Medizin gibts nur den Weg nach oben wenn die Firma nicht grundsätzlich was falsch macht!
Ja das Kurs-Auf und Ab ist wirklich spannend und es ist noch mehr als genug Platz nach oben, ich glaube die kleinen Kursrückschläge den einen oder anderen Tag sollte man ignorieren, da nehmen Leute ihre fetten Gewinne mit und andere sind froh noch billig einzusteigen, bei dem Volumen und der Zukunft für Cannabis als Medizin gibts nur den Weg nach oben wenn die Firma nicht grundsätzlich was falsch macht!
Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
hier der link:
http://www.finanznachrichten.de/nachrichten-2010-11/18425955…
hier der link:
http://www.finanznachrichten.de/nachrichten-2010-11/18425955…
Antwort auf Beitrag Nr.: 40.497.184 von WULLE1988 am 10.11.10 22:28:55
Cannabis Science Releases Operations Guidance On New Medicinal Cannabis Commercialization Deals
Cannabis Science, Inc. (OTCBB: CBIS), a US biotech company developing pharmaceutical cannabis products, is pleased to provide investor guidance on its previously announced Medicinal Cannabis Commercialization negotiations and current operational structures. Currently, Cannabis Science has some outstanding business opportunities in the final stages of closing. It anticipates announcing the first one within the next week. Some of these new deals are designed to bring its anti-cancer cannabis formulations and its other critical ailment formulations to the public through the FDA in the USA and more rapidly through other expanded markets around the world.
One of the larger deals the company expects to sign and announce within the next few days is a business relationship with a multi-million dollar pharmaceutical technology provider. Under the terms of the agreement, Cannabis Science will work closely with the technology provider to market and sell their co-branded products on an exclusive and non-exclusive basis with this new ground breaking technology in the Medical Cannabis industry. Cannabis Science sees this as an incredible opportunity to participate in an exciting growing technology company while at the same time advancing its medical marijuana medicine market and development.
The Company is in advanced stages of negotiations to contract for a joint-marketing program that will provide cancer patients with proprietary medical marijuana formulations for cancer treatment. According to the World Health Organization, 12 million cancer deaths are likely to occur worldwide by 2030. With the $47.7 billion cancer drug market projected to grow significantly over the coming decades, Cannabis Science is committed and focused on positioning itself as a key player in the medical cannabis cancer treatment sector.
Robert Melamede, Ph.D. and Cannabis Science CEO said, "We appreciate the dedication and patience that many of our investors have shown. We have been working diligently to provide a path in the complicated legal and regulatory environment that surrounds the medical cannabis industry that will benefit our shareholders and the countless people in need around the world who have been deprived of the health promoting benefits provided by this unique plant. These commercialization agreements will give us an opportunity to generate significant revenues for Cannabis Science We provide a further update and agreement details in the coming weeks as these commercial agreements are signed."
Cannabis Science, Inc. (OTCBB: CBIS), a US biotech company developing pharmaceutical cannabis products, is pleased to provide investor guidance on its previously announced Medicinal Cannabis Commercialization negotiations and current operational structures. Currently, Cannabis Science has some outstanding business opportunities in the final stages of closing. It anticipates announcing the first one within the next week. Some of these new deals are designed to bring its anti-cancer cannabis formulations and its other critical ailment formulations to the public through the FDA in the USA and more rapidly through other expanded markets around the world.
One of the larger deals the company expects to sign and announce within the next few days is a business relationship with a multi-million dollar pharmaceutical technology provider. Under the terms of the agreement, Cannabis Science will work closely with the technology provider to market and sell their co-branded products on an exclusive and non-exclusive basis with this new ground breaking technology in the Medical Cannabis industry. Cannabis Science sees this as an incredible opportunity to participate in an exciting growing technology company while at the same time advancing its medical marijuana medicine market and development.
The Company is in advanced stages of negotiations to contract for a joint-marketing program that will provide cancer patients with proprietary medical marijuana formulations for cancer treatment. According to the World Health Organization, 12 million cancer deaths are likely to occur worldwide by 2030. With the $47.7 billion cancer drug market projected to grow significantly over the coming decades, Cannabis Science is committed and focused on positioning itself as a key player in the medical cannabis cancer treatment sector.
Robert Melamede, Ph.D. and Cannabis Science CEO said, "We appreciate the dedication and patience that many of our investors have shown. We have been working diligently to provide a path in the complicated legal and regulatory environment that surrounds the medical cannabis industry that will benefit our shareholders and the countless people in need around the world who have been deprived of the health promoting benefits provided by this unique plant. These commercialization agreements will give us an opportunity to generate significant revenues for Cannabis Science We provide a further update and agreement details in the coming weeks as these commercial agreements are signed."
Tolle News auch unter www.finanznachrichten.de unter Cannabis!
Antwort auf Beitrag Nr.: 41.864.468 von Hobbyaktien am 29.07.11 12:49:31Will mir denn hier niemand Gesellschaft leisten??
So schlecht sieht das hier doch gar nicht aus oder wa smeint ihr??
Ich habe gerade nochmal nachgelegt!!
So schlecht sieht das hier doch gar nicht aus oder wa smeint ihr??
Ich habe gerade nochmal nachgelegt!!
Ich bin da
Bist du auch schon investiert??
Ich zocke den Wert schon eine ganze Weile.
Allerdings hab ich hier noch ein paar Positionen zu 0,26 und 0,21 USD drin.
Hab aber auch schon ein paar Mal Gewinne mitgenommen.
Aber die Positionen hab ich noch laufen, und eben nochmal bei 0,04 nachgelegt.
Solltest wenn du einsteigst über New York kaufen, in D war noch nie ein Handel, gibt es auch erst seit ein paar Tagen und lediglich über Berlin.
Ich finde die Story hier hoch interessant.
Wenn du mich fragst, knallt das hie rnoch gewaltig.
Schließlich kann man Cannabis Produkte nach FDA ZUlassung zumindest schon in Apotheken in Colorado erhalten.
Und die Ergebnisse können sich sehen lassen, aber alles wichtige und informative findest du auf deren Homepage.
Ich zocke den Wert schon eine ganze Weile.
Allerdings hab ich hier noch ein paar Positionen zu 0,26 und 0,21 USD drin.
Hab aber auch schon ein paar Mal Gewinne mitgenommen.
Aber die Positionen hab ich noch laufen, und eben nochmal bei 0,04 nachgelegt.
Solltest wenn du einsteigst über New York kaufen, in D war noch nie ein Handel, gibt es auch erst seit ein paar Tagen und lediglich über Berlin.
Ich finde die Story hier hoch interessant.
Wenn du mich fragst, knallt das hie rnoch gewaltig.
Schließlich kann man Cannabis Produkte nach FDA ZUlassung zumindest schon in Apotheken in Colorado erhalten.
Und die Ergebnisse können sich sehen lassen, aber alles wichtige und informative findest du auf deren Homepage.
Bin noch nicht so ganz davon überzeugt
Antwort auf Beitrag Nr.: 42.683.413 von Wohnwunsch am 01.02.12 20:29:21Kannst dich ja gerne mal in das Thema einarbeiten oder erstmal beobachten.
Ich zocke mit der schon mindestens seit Februar 2010.
Was mich skeptisch macht, ist warum steht der Kurs nicht höher, wenn alles so toll ist??
Deswegen bleibt hier auch immer bei mir eine feste Menge drin.
Ansonsten kaufe ich hin und wieder ein paar Aktien kurzfristig dazu um sie höher wieder abzuladen.
Ich zocke mit der schon mindestens seit Februar 2010.
Was mich skeptisch macht, ist warum steht der Kurs nicht höher, wenn alles so toll ist??
Deswegen bleibt hier auch immer bei mir eine feste Menge drin.
Ansonsten kaufe ich hin und wieder ein paar Aktien kurzfristig dazu um sie höher wieder abzuladen.
Denkst du diese Taktik ist bei dieser Bude sinnvoll ?
Antwort auf Beitrag Nr.: 42.683.831 von Wohnwunsch am 01.02.12 21:38:07Um ehrlich zu sein, denke ich das das die richtige Entscheidung ist.
Die Positionen die ich da oben gekauft hab, lasse ich laufen.
Wenn das hier was ganz großes wird, ist es super.
Weil ich dann immer noch profitiere und ich habe klare Prinzioien ich laufe keinem Kurs hinterher und fahre damit auch ganz gut.
Eine andere Aktie kommt bestimmt, denk ich mir dann.
Und wenn ich hier jedesmal was verdiene hab ich zumindest den Einsatz schon mal raus.
Also läßt man dann im Grunde nur noch den Gewinn laufen.
Das tiefste wo ich gekauft hatte, waren 0,025 uSD.
Die hab ich aber zu 0,042 USD damals verkauft, vor 2 Wochen oder so.
Ich zocke den Wert auch weiterhin.
Ist nur nix los hier im Forum.
Die Positionen die ich da oben gekauft hab, lasse ich laufen.
Wenn das hier was ganz großes wird, ist es super.
Weil ich dann immer noch profitiere und ich habe klare Prinzioien ich laufe keinem Kurs hinterher und fahre damit auch ganz gut.
Eine andere Aktie kommt bestimmt, denk ich mir dann.
Und wenn ich hier jedesmal was verdiene hab ich zumindest den Einsatz schon mal raus.
Also läßt man dann im Grunde nur noch den Gewinn laufen.
Das tiefste wo ich gekauft hatte, waren 0,025 uSD.
Die hab ich aber zu 0,042 USD damals verkauft, vor 2 Wochen oder so.
Ich zocke den Wert auch weiterhin.
Ist nur nix los hier im Forum.
Die News sind gut und besser denn je denn es liegen erste Beweise vor, dass es bei Basal-Karzinom hilft und Hautkrebs wird die neue Seuche der Menschheit in den nächsten Jahren werden.
Jetzt fragt sich nur wer am schnellsten ist, CBIS oder die Konkurrenz die ebenfalls am Einsatz von Cannabinoiden arbeitet.....momentan dürfte CBIS aber vorne liegen und wenn das jetzige Ergebnis publik wird und das Image von Cannabis zu Recht endlich wieder steigt dann dürfte hier sehr viel Potential drin stecken. Und der Preis für nen Share is immernoch mehr als günstig!
Jetzt fragt sich nur wer am schnellsten ist, CBIS oder die Konkurrenz die ebenfalls am Einsatz von Cannabinoiden arbeitet.....momentan dürfte CBIS aber vorne liegen und wenn das jetzige Ergebnis publik wird und das Image von Cannabis zu Recht endlich wieder steigt dann dürfte hier sehr viel Potential drin stecken. Und der Preis für nen Share is immernoch mehr als günstig!
Der erste der es begriffen hat.
Bist du auch schon drin?
Bist du auch schon drin?
So jetzt hab ich erstmal zu 0,034 USD nachgelegt.
Mal sehen wohin die Reise jetzt geht.
Mal sehen wohin die Reise jetzt geht.
Antwort auf Beitrag Nr.: 42.683.526 von Hobbyaktien am 01.02.12 20:48:02
sieht gut aus heute, hab meine Zockerpositionen erstmal wieder zu 0,045 USD plaziert.
Die andere Position bleibt long.
sieht gut aus heute, hab meine Zockerpositionen erstmal wieder zu 0,045 USD plaziert.
Die andere Position bleibt long.
Der Kurs explodiert und keiner merkt es.....
Antwort auf Beitrag Nr.: 42.792.001 von schiedo am 22.02.12 21:35:44wird schon bemerkt, habe leider nix flüssig aber der Stock ist schon länger auf dem Radar.
Kommt von knapp unter einem $cent - Hammer...
Kommt von knapp unter einem $cent - Hammer...
Also ich schaue mir den Wert jeden Tag an, da ich investiert bin und das schon seit 2009.
Hier und da mal rein und wieder raus, aber eine langfrisitge Position hab ich noch drin.
Und das bleibt auch so.
Ich freue mich wenn es hoch geht, hab aber auch kein Problem damit wenn es runter geht.
Bin sehr gespannt, wie es in 30 Minuten los geht.
Entweder derbe Gewinnmitnahmen oder aber sie schießt weiter hoch bis 0,12 USD.
Vorletetztes Jahr (2010), schoß sie auch rasant hoch bis 0,24xx USD und dann rauschte es genau so schnell wieder abwärts und noch weiter.
Bin gespannt, was diesmal passiert.
Hier und da mal rein und wieder raus, aber eine langfrisitge Position hab ich noch drin.
Und das bleibt auch so.
Ich freue mich wenn es hoch geht, hab aber auch kein Problem damit wenn es runter geht.
Bin sehr gespannt, wie es in 30 Minuten los geht.
Entweder derbe Gewinnmitnahmen oder aber sie schießt weiter hoch bis 0,12 USD.
Vorletetztes Jahr (2010), schoß sie auch rasant hoch bis 0,24xx USD und dann rauschte es genau so schnell wieder abwärts und noch weiter.
Bin gespannt, was diesmal passiert.
Ich hoffe du hast gestern einen guten EK gehabt oder bist schon draußen, hoffe das du nicht bei 0,09 USD gekauft hast.
Aber gleich sollte es wieder drehen, denke ich.
Nur wie weit ist die Frage, lohnt sich ein Zock??
Man wird sehen, ich glaube ich lasse die Finger davon.
Aber gleich sollte es wieder drehen, denke ich.
Nur wie weit ist die Frage, lohnt sich ein Zock??
Man wird sehen, ich glaube ich lasse die Finger davon.
Früher schoss der Kurs ohne relevante Nachrichten nach oben, darum kam er wieder zurück.
Das hat sich inzwischen geändert, Erfolgsmeldungen über Hautkrebsheilungen - FDA Zulassungen stehen bevor usw.
Der Kurs wird weiter marschieren. Nichts lässt Kurse schneller steigen als Fantasie, die hier vorhanden ist.
Das hat sich inzwischen geändert, Erfolgsmeldungen über Hautkrebsheilungen - FDA Zulassungen stehen bevor usw.
Der Kurs wird weiter marschieren. Nichts lässt Kurse schneller steigen als Fantasie, die hier vorhanden ist.
Hier köönt Ihr sehen, was die Amis im Message Boards so schreiben.
Die haben immer die neusten Narichten parat.
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Die haben immer die neusten Narichten parat.
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Ich schreibe lieber nicht das was ich zu diesem Wert denke.
Aber dazu schick ich dir mal eine kurze Mitteilung privat.
Hat sich ja wieder gut erholt 0,09 USD.
Aber dazu schick ich dir mal eine kurze Mitteilung privat.
Hat sich ja wieder gut erholt 0,09 USD.
Cannabis Science Chief Operating Officer Dr. Moe Afaneh, Pharm D., MBA, NRCC, Confirms Newest Cannabis Science Brand Product ...
Date : 02/24/2012 @ 1:55PM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&article=51348186&symbol=…
Date : 02/24/2012 @ 1:55PM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&article=51348186&symbol=…
Antwort auf Beitrag Nr.: 42.804.784 von Blankerhanz am 24.02.12 20:29:05Cannabis Science to launch new product line
PBR Staff Writer
Published 28 February 2012
Cannabis Science has identified the newest line of Cannabis Science Brand of Products and plans to launch the product immediately.
The company has begun negotiations for the manufacturing and national distribution of this new product line.
The negotiations will actively continue when the first prototypes are received by Cannabis to be reviewd by various nationwide product distributors, the company said.
Cannabis Science president Robert Melamede said the retail availability of these products should increase the company's revenue.
The company is working to enter the over-the-counter market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.
PBR Staff Writer
Published 28 February 2012
Cannabis Science has identified the newest line of Cannabis Science Brand of Products and plans to launch the product immediately.
The company has begun negotiations for the manufacturing and national distribution of this new product line.
The negotiations will actively continue when the first prototypes are received by Cannabis to be reviewd by various nationwide product distributors, the company said.
Cannabis Science president Robert Melamede said the retail availability of these products should increase the company's revenue.
The company is working to enter the over-the-counter market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.
Die Aktie steigt unaufhörlich und keiner will hier Geld verdienen.
Ich bin seit 0,065 € - in USA gekauft - dabei.
Wenn das alles klappt, steigt die Aktie noch in ungeahnte Höhen.
Einstein sagte: Wissen ist begrenzt dagegen ist Fantasie unbegrenzt...
Das trifft hier zu.
Ich bin seit 0,065 € - in USA gekauft - dabei.
Wenn das alles klappt, steigt die Aktie noch in ungeahnte Höhen.
Einstein sagte: Wissen ist begrenzt dagegen ist Fantasie unbegrenzt...
Das trifft hier zu.
Antwort auf Beitrag Nr.: 42.820.791 von schiedo am 28.02.12 19:17:28Ich sehe es täglich. Aber hier war noch nie sonderlich viel los bei dieser Aktie hier im Forum.
Im Moment freue ich mich auch über den Kursanstieg.
Ich habe meine Positionen bei 0,21 und 0,26 USD gekauft, bei den Pósitionen die ich noch drin habe.
Was meint ihr, wie hoch der Kurs noch gehen wird?
Ich halte sie erstmal weiter.
Im Moment freue ich mich auch über den Kursanstieg.
Ich habe meine Positionen bei 0,21 und 0,26 USD gekauft, bei den Pósitionen die ich noch drin habe.
Was meint ihr, wie hoch der Kurs noch gehen wird?
Ich halte sie erstmal weiter.
In den USA Foren steht, dass heute noch ein BIO Bericht kommen soll.
Kurs zieht vorbörslich stark an.
Die Party geht weiter solange keine negativen Nachrichten kommen.
Die Fantasie ist einfach zu groß....
Kurs zieht vorbörslich stark an.
Die Party geht weiter solange keine negativen Nachrichten kommen.
Die Fantasie ist einfach zu groß....
Antwort auf Beitrag Nr.: 42.826.273 von schiedo am 29.02.12 15:17:57Ist der Bericht schon draußen oder warum ging es auf einmal so stark nach unten??
Auf jeden Fall ist es gut, wenn das Volumen so hoch ist.
Auf jeden Fall ist es gut, wenn das Volumen so hoch ist.
Antwort auf Beitrag Nr.: 42.827.995 von Hobbyaktien am 29.02.12 18:11:15Es waren alles enge Stop Loss Auslöser. Dann kamen noch die ängstlichen und zittrigen Hände dazu.
Jetzt hat sich eine Bodenbildung gebildet und der Kurs steigt langsam aber sicher wieder an.
Ist mir auch lieber, als der gerade Strich nach oben. Das konnte nicht gutgehen, denn die Shorties deckten sich ein.
Die Konsolidierung ist gesund, die Aktie war ja auch stark überkauft. (Im roten Bereich)
Wenn morgen Nachrichten kommen, geht es wieder up.....
Jetzt hat sich eine Bodenbildung gebildet und der Kurs steigt langsam aber sicher wieder an.
Ist mir auch lieber, als der gerade Strich nach oben. Das konnte nicht gutgehen, denn die Shorties deckten sich ein.
Die Konsolidierung ist gesund, die Aktie war ja auch stark überkauft. (Im roten Bereich)
Wenn morgen Nachrichten kommen, geht es wieder up.....
Bin gespannt wie es hier weiter geht, bleibe hier auf jeden Fall langfristig dabei, hab den Wert schließlich auch schon über 2 Jahre im Depot.
Ob wir heute noch im Plus schließen?? denke das könnte noch im Bereich des möglichen sein.
Langfristig habe ich mir heute noch Elite Pha. dazugelegt und vor ein paar Tagen schon Gamesa.
Mal sehen wie sich die 3 Werte entwickeln.
Ob wir heute noch im Plus schließen?? denke das könnte noch im Bereich des möglichen sein.
Langfristig habe ich mir heute noch Elite Pha. dazugelegt und vor ein paar Tagen schon Gamesa.
Mal sehen wie sich die 3 Werte entwickeln.
Antwort auf Beitrag Nr.: 42.804.784 von Blankerhanz am 24.02.12 20:29:05
0,163
$
-0,01 $
-5,78 %
22:00:00 Vol: 116.271.351U:
Ziemlich heftiges Volumen, wenn man überlegt, dass nur 241,92 Mio Aktien auf dem Markt sind.
0,163
$
-0,01 $
-5,78 %
22:00:00 Vol: 116.271.351U:
Ziemlich heftiges Volumen, wenn man überlegt, dass nur 241,92 Mio Aktien auf dem Markt sind.
Naja, sehr viel Achterbahn im Moment.
Hoffe das die 0,15 Usd halten und das es dann wieder nach oben dreht.
Viele nehmen Gewinne mit, andere sind verunsichert und haben zittrige Hände, aber je mehr gehandelt wird auf hohem Niveau oberhalb der 0,15 USD.
Desto bessere Chancen hat man den Kurs langfristig oben zu halten.
Hoffe das die 0,15 Usd halten und das es dann wieder nach oben dreht.
Viele nehmen Gewinne mit, andere sind verunsichert und haben zittrige Hände, aber je mehr gehandelt wird auf hohem Niveau oberhalb der 0,15 USD.
Desto bessere Chancen hat man den Kurs langfristig oben zu halten.
Ich befürchte das Spiel mit den 0,24 Usd wiederholt sich, Montag oder spätestens Dienstag stehen wir wohl wieder bei 0,08 USd oder tiefer.
Ich bleibe trotzdem dabei.
Ich bleibe trotzdem dabei.
Antwort auf Beitrag Nr.: 42.829.781 von Hobbyaktien am 29.02.12 22:18:33
0,1165
$
-0,0465 $
-28,53 %
21:59:57Vol: 74.699.064U:
Und schon wieder fast 75 Mio gehandelte Aktien. Entweder geht es morgen wieder kräftig rauf oder weiter kräftig runter.
Ich denke die Eröffnung wird morgen so wie heute, erst weitere Panikverkäufe und dann ab ins Plus.
Wie es danach weiter geht, weiß keiner.
Aber ob es so kommt, wie ich vermute??
0,1165
$
-0,0465 $
-28,53 %
21:59:57Vol: 74.699.064U:
Und schon wieder fast 75 Mio gehandelte Aktien. Entweder geht es morgen wieder kräftig rauf oder weiter kräftig runter.
Ich denke die Eröffnung wird morgen so wie heute, erst weitere Panikverkäufe und dann ab ins Plus.
Wie es danach weiter geht, weiß keiner.
Aber ob es so kommt, wie ich vermute??
Ich glaube heute geht die Post ab........
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Dein Link kann man nicht öffnen zumindest steht da nicht viel.
Denke der Handelsverlauf wird so sein wie gestern, also um 0,10 Usd wenn nicht sogar tiefer werden wir schließen, viele nehmen heute vor dem WE noch gewinne mit, dass ist an der OTC öfter zu beobachten gewesen.
Denke der Handelsverlauf wird so sein wie gestern, also um 0,10 Usd wenn nicht sogar tiefer werden wir schließen, viele nehmen heute vor dem WE noch gewinne mit, dass ist an der OTC öfter zu beobachten gewesen.
Antwort auf Beitrag Nr.: 42.841.650 von Hobbyaktien am 02.03.12 16:02:08
Ohne Worte!!
Hier lohnt sich nur noch zocken, aber keine long POosition.
Zum Kotzen langsam.
Ohne Worte!!
Hier lohnt sich nur noch zocken, aber keine long POosition.
Zum Kotzen langsam.
Das heutige GAP ist somit geschlossen, nach den Regeln müsste es nun hochgehen.....
Antwort auf Beitrag Nr.: 42.841.739 von schiedo am 02.03.12 16:12:59Ich halte meine Stücke in jedem Fall fest.
Wie hoch müsste es denn normal jetzt gehen?
Wie hoch müsste es denn normal jetzt gehen?
Antwort auf Beitrag Nr.: 42.841.763 von Hobbyaktien am 02.03.12 16:16:25Ziemlich geringes Volumen zur Zeit, wenn das Volumen an zieht, kann es ziemlich schnell in eine Richtung gehen, sowohl nach oben als auch nach unten.
Gebildete Menschen werden schließlich profitieren 2 Minuten vor
Diejenigen von uns, genug über die Möglichkeiten von Cannabinoiden und der Tatsache, dass CBIS CEO Robert Melamede war schon immer an vorderster Front der Forschung in diese Richtung erzogen worden, erkennen, dass CBIS wird schließlich in einem großen Weg boomen. Diejenigen von uns, das erneute Aufflammen der professionellen und fundierten medizinischen Marihuana-bezogenen Dokumentationen, wissenschaftliche Arbeiten im Zusammenhang mit Cannabinoiden und der Endocannabinoid-System, das alle wichtigen Systeme im Menschen reguliert gesehen haben, haben keine Angst vor vorübergehender Rückschläge und nicht fokussieren unsere Aufmerksamkeit auf Daytrading dieser Aktie. Diejenigen von uns, den Durchbruch in der medizinischen Marihuana-Akzeptanz vor uns sehen, brauchen sich keine Sorgen über kurzfristige Trends, braucht sich nicht orientieren unser Handeln an bashers, die nicht wissen, was sie reden. Ja, hat Hanföl bereits in vielen Produkten vor verwendet. Das Öl CBIS sprechen, ist es etwas ganz anderes. Wer zuletzt lacht, lacht am besten ...
Aus den USA kopiert....
Diejenigen von uns, genug über die Möglichkeiten von Cannabinoiden und der Tatsache, dass CBIS CEO Robert Melamede war schon immer an vorderster Front der Forschung in diese Richtung erzogen worden, erkennen, dass CBIS wird schließlich in einem großen Weg boomen. Diejenigen von uns, das erneute Aufflammen der professionellen und fundierten medizinischen Marihuana-bezogenen Dokumentationen, wissenschaftliche Arbeiten im Zusammenhang mit Cannabinoiden und der Endocannabinoid-System, das alle wichtigen Systeme im Menschen reguliert gesehen haben, haben keine Angst vor vorübergehender Rückschläge und nicht fokussieren unsere Aufmerksamkeit auf Daytrading dieser Aktie. Diejenigen von uns, den Durchbruch in der medizinischen Marihuana-Akzeptanz vor uns sehen, brauchen sich keine Sorgen über kurzfristige Trends, braucht sich nicht orientieren unser Handeln an bashers, die nicht wissen, was sie reden. Ja, hat Hanföl bereits in vielen Produkten vor verwendet. Das Öl CBIS sprechen, ist es etwas ganz anderes. Wer zuletzt lacht, lacht am besten ...
Aus den USA kopiert....
Ich bleibe auf jeden Fall dabei egal was da kommt. Die Fantasie ist groß, die werden ihren Weg machen und Geld verdienen, nicht nur mit evtl Krebs-Medikamenten nach der Zulassung, sondern mit diversen Sonnenschutz und anderen Crems.
Nur der Geduldige macht hier hohen Gewinn, es fehlen nur noch die entsprechenden Nachrichten und der Kurs explodiert.
Nur der Geduldige macht hier hohen Gewinn, es fehlen nur noch die entsprechenden Nachrichten und der Kurs explodiert.
Antwort auf Beitrag Nr.: 42.843.092 von schiedo am 02.03.12 19:38:04Ich bin auch bei Elite eingestiegen, hast du die auch noch??
Hab da letztens auch mal einen Beitrag dort von dir gelesen.
Ich bin gespannt wie es bei den beiden Werten weiter geht, ansonsten hab ich noch Gamesa im Depot.
In welchen Werten bist du noch investiert??
Tja, bei Cannabis bleibt es weiterhin spannend, was auf jeden Fall gut ist, dass das Volumen abgenommen hat und wir momentan stabil an der 0,12 USD entlang laufen.
Hab da letztens auch mal einen Beitrag dort von dir gelesen.
Ich bin gespannt wie es bei den beiden Werten weiter geht, ansonsten hab ich noch Gamesa im Depot.
In welchen Werten bist du noch investiert??
Tja, bei Cannabis bleibt es weiterhin spannend, was auf jeden Fall gut ist, dass das Volumen abgenommen hat und wir momentan stabil an der 0,12 USD entlang laufen.
Heute in USA erschienen.
* RVBR * 0,046 Cent * angekündigt: SELL nicht weniger als $ 1,00 *** *** 4 Minuten vor
2012.03.02 Der Großaktionär, Olga Smolinkova angegeben,'' Der Wert der Vermögenswerte sind enorm und ich würde nicht einmal zur Abgabe eines Angebots denke unter 1,00 $ ***. ***'' Sie fügt hinzu:'' Die Gesellschaft ist stabil, und es sollte nicht verschenkt werden, da ihr Potenzial jederzeit gewährleistet ist, ein Minimum an Kapital zu ermöglichen, die Produktion um ein Vielfaches wachsen''.
Sentiment: Strong Buy
Bewertung:
* RVBR * 0,046 Cent * angekündigt: SELL nicht weniger als $ 1,00 *** *** 4 Minuten vor
2012.03.02 Der Großaktionär, Olga Smolinkova angegeben,'' Der Wert der Vermögenswerte sind enorm und ich würde nicht einmal zur Abgabe eines Angebots denke unter 1,00 $ ***. ***'' Sie fügt hinzu:'' Die Gesellschaft ist stabil, und es sollte nicht verschenkt werden, da ihr Potenzial jederzeit gewährleistet ist, ein Minimum an Kapital zu ermöglichen, die Produktion um ein Vielfaches wachsen''.
Sentiment: Strong Buy
Bewertung:
Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products
Date : 03/02/2012 @ 11:40AM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&article=51462658&symbol=…
etwas gute Nacht Lektüre
Date : 03/02/2012 @ 11:40AM
Source : Business Wire
http://ih.advfn.com/p.php?pid=nmona&article=51462658&symbol=…
etwas gute Nacht Lektüre
Antwort auf Beitrag Nr.: 42.843.176 von schiedo am 02.03.12 19:55:30Unter welchem Namen finde ich den wert hier bei wo?
Zitat von Hobbyaktien: Ich bin auch bei Elite eingestiegen, hast du die auch noch??
Hab da letztens auch mal einen Beitrag dort von dir gelesen.
Ich bin gespannt wie es bei den beiden Werten weiter geht, ansonsten hab ich noch Gamesa im Depot.
In welchen Werten bist du noch investiert??
Tja, bei Cannabis bleibt es weiterhin spannend, was auf jeden Fall gut ist, dass das Volumen abgenommen hat und wir momentan stabil an der 0,12 USD entlang laufen.
Bei Elite bin ich mit 30% Verlust raus. Bin heute mit dem Geld bei GALE eingestiegen nach guten Kommentaren aus den USA. Hier ist jede Menge Potential, bald FDA Zulassung vom Krebsmedikament. Die Aktie ist noch billig, heute schon schönen Gewinn gemacht, ich bleibe dort dabei - gute Aktie. Bei Elite war ich verzweifelt, schlechte Zahlen wenig Zukunft, Bargeld wird immer weniger und die Banken wollen keines mehr geben.Reißleine gezogen bevor alles weg ist.
Solltest Du auch machen und bei GALE einsteigen.
Antwort auf Beitrag Nr.: 42.843.256 von schiedo am 02.03.12 20:12:06Ich bleibe bei Elite erstmal dabei.
Bei Cannabis auch.
Gebe zu Gale ist ein interessanter Wert, aber die sind mir schon zu hoch gelaufen, kaufe fast nur Aktien die ganz am Boden sind.
Wenn Gale die Zulassung nicht bekommt, rauscht die bestimmt erstmal 70 - 80 % in die Tiefe.
Wenn es anders kommt steht sie bestimmt mindestens 5 x so hoch wie jetzt.
Aber das Risiko ist mir persönlich zu hoch.
Aber das muss jeder selber entscheiden.
Bei Cannabis auch.
Gebe zu Gale ist ein interessanter Wert, aber die sind mir schon zu hoch gelaufen, kaufe fast nur Aktien die ganz am Boden sind.
Wenn Gale die Zulassung nicht bekommt, rauscht die bestimmt erstmal 70 - 80 % in die Tiefe.
Wenn es anders kommt steht sie bestimmt mindestens 5 x so hoch wie jetzt.
Aber das Risiko ist mir persönlich zu hoch.
Aber das muss jeder selber entscheiden.
Antwort auf Beitrag Nr.: 42.843.092 von schiedo am 02.03.12 19:38:04
0,127
$
+0,0105 $
+9,01 %
21:59:58Vol: 46.988.403U:
Wenig Volumen, was nicht unbedingt schlecht sein muss, viele haben sich bestimmt long dick eingedeckt und halten an ihren Stücken fest.
der Abwärtstrend von gestern hat sich zum Glück nicht bestätigt.
Sah ganz stabil aus heute. Wenn gute News kommen gibt es steigende Kurse mit starkem Volumen, weil dann noch viele rein wollen.
Schönes Wochenende allen Mitlesern.
0,127
$
+0,0105 $
+9,01 %
21:59:58Vol: 46.988.403U:
Wenig Volumen, was nicht unbedingt schlecht sein muss, viele haben sich bestimmt long dick eingedeckt und halten an ihren Stücken fest.
der Abwärtstrend von gestern hat sich zum Glück nicht bestätigt.
Sah ganz stabil aus heute. Wenn gute News kommen gibt es steigende Kurse mit starkem Volumen, weil dann noch viele rein wollen.
Schönes Wochenende allen Mitlesern.
0,15
$
+0,023 $
+18,11 %
21:59:50Vol: 31.040.711U:
$
+0,023 $
+18,11 %
21:59:50Vol: 31.040.711U:
Trotz aller Probleme an der Börse hält sich unsere Aktie sehr gut - alles fällt, CBIS steigt. Besser geht nicht.....
DAs ist richtig. Allerdings sieht elite und gamesa net so gut aus heute.
Da tröstet Cannabis mich nur wenig.
Aber ich denke, man kann bald günstig einsteigen in andere Werte wie Coba & Co.
Da tröstet Cannabis mich nur wenig.
Aber ich denke, man kann bald günstig einsteigen in andere Werte wie Coba & Co.
Antwort auf Beitrag Nr.: 42.860.524 von Hobbyaktien am 06.03.12 20:15:57
0,1599
$
+0,0099 $
+6,60 %
22:00:01Vol: 37.940.682U:
0,1599
$
+0,0099 $
+6,60 %
22:00:01Vol: 37.940.682U:
Antwort auf Beitrag Nr.: 42.861.247 von Hobbyaktien am 06.03.12 22:18:33
0,152
$
-0,0079 $
-4,94 %
21:59:58Vol: 20.269.581
0,152
$
-0,0079 $
-4,94 %
21:59:58Vol: 20.269.581
0,147
$
-0,005 $
-3,29 %
21:59:42Vol: 26.275.944U:
$
-0,005 $
-3,29 %
21:59:42Vol: 26.275.944U:
Antwort auf Beitrag Nr.: 42.860.524 von Hobbyaktien am 06.03.12 20:15:57
0,1361
$
-0,0109 $
-7,41 %
21:59:54Vol: 9.338.124U:
0,1361
$
-0,0109 $
-7,41 %
21:59:54Vol: 9.338.124U:
Schöne W - formation kurz vor dem Ausbruch !!
http://www.advfn.com/p.php?pid=staticchart&s=NB%5ECBIS&t=37&…
http://www.advfn.com/p.php?pid=staticchart&s=NB%5ECBIS&t=37&…
Werden bald 30-50 Cent sehen .
Antwort auf Beitrag Nr.: 42.888.163 von Ecki68 am 12.03.12 15:53:18Wie kommst du darauf, dass hier bald ein Ausbruch nach oben kommt??
Im Moment fällt der kurs im Schnitt jeden Tag fast 10 % runter.
Und ich wüßte auch nicht was das stoppen könnte, wenn hier nicht bald mal wieder eine positive News kommt.
Und wie kommst du auf 0,30 - 0,50 Cent????
Ich bitte um eine kurze Aufklärung.
Im Moment fällt der kurs im Schnitt jeden Tag fast 10 % runter.
Und ich wüßte auch nicht was das stoppen könnte, wenn hier nicht bald mal wieder eine positive News kommt.
Und wie kommst du auf 0,30 - 0,50 Cent????
Ich bitte um eine kurze Aufklärung.
Antwort auf Beitrag Nr.: 42.889.288 von Hobbyaktien am 12.03.12 18:43:34Momentan fehlt hier ne Top News - vom Chart aus hat sich hier eine W-Formation gebildet ,was sich natürlich bei einem Pennystock schwer sagen lässt doch stimmt mich dies possitiv.
Schlusskurs heute sollte die 0.115 nicht unterschreiten um von einem W auszugehen.
Morgen dürfte dann mehr Dynamik in den Kurs kommen.
Gruss ecki 68
Ziel wenn possitve News kommen eben 30-50 Cent !! (meine Gefühl )
Schlusskurs heute sollte die 0.115 nicht unterschreiten um von einem W auszugehen.
Morgen dürfte dann mehr Dynamik in den Kurs kommen.
Gruss ecki 68
Ziel wenn possitve News kommen eben 30-50 Cent !! (meine Gefühl )
Antwort auf Beitrag Nr.: 42.889.814 von Ecki68 am 12.03.12 19:47:07Da bin ich ja mal gespannt, ich poste jeden Abend schon den Schlusskurs und den Umsatz, damit man die Entwicklung nachverfolgen kann, ich schaue mir das auch immer nachhaltig nochmal ganz gerne an, deswegen mache ich das überhaupt.
Ich bin ja mal gespannt, ob du mit deiner W Therapie da richtig liegst.
Möglich ist hier bei diesem Wert auf jeden Fall alles.
Ich bin ja mal gespannt, ob du mit deiner W Therapie da richtig liegst.
Möglich ist hier bei diesem Wert auf jeden Fall alles.
Antwort auf Beitrag Nr.: 42.890.262 von Hobbyaktien am 12.03.12 20:59:15
0,118
$
-0,0181 $
-13,30 %
21:00:00Vol: 27.425.320U:
Bin ja mal gespannt, ob das Volumen und der Kurs morgen anziehen, wie du behauptet hast bzw. vermutet.
0,118
$
-0,0181 $
-13,30 %
21:00:00Vol: 27.425.320U:
Bin ja mal gespannt, ob das Volumen und der Kurs morgen anziehen, wie du behauptet hast bzw. vermutet.
Antwort auf Beitrag Nr.: 42.890.262 von Hobbyaktien am 12.03.12 20:59:15Spätestens am 15.03.2012 sollte es richtig nach oben gehen ,da ist ein Shoortiestichtag - zulesen auf Investorhub.com !!
Ich sehe im Chart eher eine M- Formation, was nach den Regeln negativ zu beurteilen ist. Da ich selbst investiert bin, hoffe ich auf positive Nachrichten, was die M Formation
vergessen lässt.
Ansonsten bleibe ich bei meiner Ansicht, das hier sehe viel Fantasie vorhanden ist, dass uns noch viel Freude bereiten wird, wenn wir geduldig sind.
vergessen lässt.
Ansonsten bleibe ich bei meiner Ansicht, das hier sehe viel Fantasie vorhanden ist, dass uns noch viel Freude bereiten wird, wenn wir geduldig sind.
Angsthasen haben verkauft, Stop Loss ausgelöst, Einstiegskurse winken....
0,08 wir kommen (ich bin bei 0,095 raus und tschüss )
Antwort auf Beitrag Nr.: 42.890.425 von Hobbyaktien am 12.03.12 21:23:52
0,10
$
-0,018 $
-15,25 %
21:00:08Vol: 58.336.993U:
0,10
$
-0,018 $
-15,25 %
21:00:08Vol: 58.336.993U:
Antwort auf Beitrag Nr.: 42.894.154 von schiedo am 13.03.12 15:22:11Tja, wir werden noch sehen, wo die Reise langfristig hin geht.
Der andere Mitstreiter hat die nerven verloren.
Bald kommt der Kurd vllt. wieder in Regionen, wo ich mir ein paar zusätzliche Zockerpositionen gönne, bei 0,05 USD und tiefer.
Falls wir die Kurse nochmal sehen.
Der andere Mitstreiter hat die nerven verloren.
Bald kommt der Kurd vllt. wieder in Regionen, wo ich mir ein paar zusätzliche Zockerpositionen gönne, bei 0,05 USD und tiefer.
Falls wir die Kurse nochmal sehen.
Egal was kommt, ich bleibe dabei. Es kann doch nicht alles heiße Luft gewesen sein, dazu ist die Öffentlichkeit inzwischen zu stark einbezogen worden und Hoffnung der Krebskranken wurden geweckt, damit macht man kein Betrug.
Es dauert nur etwas.....
Es dauert nur etwas.....
Antwort auf Beitrag Nr.: 42.899.106 von schiedo am 14.03.12 11:37:01ch bleibe bin meiner long Posi auch dabei, egal was kommt.
Antwort auf Beitrag Nr.: 42.890.262 von Hobbyaktien am 12.03.12 20:59:15
Handelsplatz:BerlinOTCBB (CBIS)
0,109
$
+0,009 $
+9,00 %
20:59:46Vol: 17.937.994U:
Handelsplatz:BerlinOTCBB (CBIS)
0,109
$
+0,009 $
+9,00 %
20:59:46Vol: 17.937.994U:
Antwort auf Beitrag Nr.: 42.902.792 von Hobbyaktien am 14.03.12 21:17:06
Handelsplatz:BerlinOTCBB (CBIS)
0,1025
$
-0,0065 $
-5,96 %
20:59:57Vol: 9.112.593U:
Handelsplatz:BerlinOTCBB (CBIS)
0,1025
$
-0,0065 $
-5,96 %
20:59:57Vol: 9.112.593U:
Antwort auf Beitrag Nr.: 42.909.762 von Hobbyaktien am 15.03.12 21:16:30
0,098
$
-0,0045 $
-4,39 %
Kann hier noch jemand das Volumen nachreichen??
Das steht bei wo nicht mehr.
0,098
$
-0,0045 $
-4,39 %
Kann hier noch jemand das Volumen nachreichen??
Das steht bei wo nicht mehr.
Antwort auf Beitrag Nr.: 42.916.863 von Hobbyaktien am 16.03.12 22:55:06Laut maxblue. 9,6 Mio
Sieht aber im Chart nicht nach soviel Volumen aus.
Allen mitlesern ein Schönes WE.
Sieht aber im Chart nicht nach soviel Volumen aus.
Allen mitlesern ein Schönes WE.
Antwort auf Beitrag Nr.: 42.916.882 von Hobbyaktien am 16.03.12 22:59:34
0,09
$
-0,008 $
-8,16 %
20:59:54Vol: 7.283.995U:
0,09
$
-0,008 $
-8,16 %
20:59:54Vol: 7.283.995U:
Antwort auf Beitrag Nr.: 42.902.792 von Hobbyaktien am 14.03.12 21:17:06
0,09
$
20:59:54Vol: 21.493.118U:
0,09
$
20:59:54Vol: 21.493.118U:
Antwort auf Beitrag Nr.: 42.902.792 von Hobbyaktien am 14.03.12 21:17:06
0,0909
$
+0,0009 $
+1,00 %
20:58:58Vol: 11.741.442U:
0,0909
$
+0,0009 $
+1,00 %
20:58:58Vol: 11.741.442U:
Antwort auf Beitrag Nr.: 42.902.792 von Hobbyaktien am 14.03.12 21:17:06
0,089
$
-0,0019 $
-2,09 %
20:58:12Vol: 4.733.751U:
0,089
$
-0,0019 $
-2,09 %
20:58:12Vol: 4.733.751U:
Antwort auf Beitrag Nr.: 42.943.809 von Hobbyaktien am 22.03.12 21:22:27
0,09
$
+0,001 $
+1,12 %
23:20:00Vol: 3.237.226U:
0,09
$
+0,001 $
+1,12 %
23:20:00Vol: 3.237.226U:
Antwort auf Beitrag Nr.: 42.902.792 von Hobbyaktien am 14.03.12 21:17:06
0,088
$
-0,002 $
-2,22 %
22:56:43Vol: 3.403.619U:
0,088
$
-0,002 $
-2,22 %
22:56:43Vol: 3.403.619U:
Antwort auf Beitrag Nr.: 42.957.867 von Hobbyaktien am 26.03.12 22:21:21
Cannabis Science Reports Its First Documentary Release Date of April 5, 2012 “CHRONIC FUTURE - KILLING CANCER” A DOCUMENT...
Date : 03/27/2012 @ 2:03PM
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to announce that Muse Productions out of SCOTTSDALE, Arizona - announced today the Premier date of CHRONIC FUTURE - KILLING CANCER. The first of many Documentaries’ centering on the successful cancer treatments Cannabis Science has been reporting.
http://ih.advfn.com/p.php?pid=nmona&article=51790045&symbol=…
Date : 03/27/2012 @ 2:03PM
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to announce that Muse Productions out of SCOTTSDALE, Arizona - announced today the Premier date of CHRONIC FUTURE - KILLING CANCER. The first of many Documentaries’ centering on the successful cancer treatments Cannabis Science has been reporting.
http://ih.advfn.com/p.php?pid=nmona&article=51790045&symbol=…
Antwort auf Beitrag Nr.: 42.962.824 von Hobbyaktien am 27.03.12 19:19:29
0,1125
$
+0,0245 $
+27,84 %
22:59:56Vol: 33.278.224U:
0,1125
$
+0,0245 $
+27,84 %
22:59:56Vol: 33.278.224U:
.
cool
.
cool
.
Antwort auf Beitrag Nr.: 42.964.020 von zpo am 27.03.12 22:29:03
0,1065
$
-0,006 $
-5,33 %
22:59:48Vol: 15.228.135U:
0,1065
$
-0,006 $
-5,33 %
22:59:48Vol: 15.228.135U:
Antwort auf Beitrag Nr.: 42.962.824 von Hobbyaktien am 27.03.12 19:19:29
0,108
$
+0,0015 $
+1,41 %
22:59:42Vol: 5.085.391U:
0,108
$
+0,0015 $
+1,41 %
22:59:42Vol: 5.085.391U:
NBC Channel 12 News in Arizona Interviews Cannabis Science’s Dr. Melamede; Answering Questions & Discussing the New Documen...
Date : 03/30/2012 @ 11:20AM
Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce that Dr. Melamede was featured on NBC Channel 12 News in Arizona yesterday, March 29th, answering medical questions and discussing the new documentary “Chronic Future - Killing Cancer”, which will premier on April 5th, 2012, at the Harkins Theater on Shea and Scottsdale Road in Scottsdale.
http://ih.advfn.com/p.php?pid=nmona&article=51840597&symbol=…
Date : 03/30/2012 @ 11:20AM
Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce that Dr. Melamede was featured on NBC Channel 12 News in Arizona yesterday, March 29th, answering medical questions and discussing the new documentary “Chronic Future - Killing Cancer”, which will premier on April 5th, 2012, at the Harkins Theater on Shea and Scottsdale Road in Scottsdale.
http://ih.advfn.com/p.php?pid=nmona&article=51840597&symbol=…
.
läuft
.
läuft
.
Antwort auf Beitrag Nr.: 42.982.188 von zpo am 30.03.12 21:04:59
Handelsplatz:BerlinOTCBB (CBIS)
0,139
$
+0,031 $
+28,70 %
22:59:49Vol: 29.804.432U:
Handelsplatz:BerlinOTCBB (CBIS)
0,139
$
+0,031 $
+28,70 %
22:59:49Vol: 29.804.432U:
Eine NEWS jagt die Nächste...
Cannabis Science Continues Forward with FDA IND Process as Patients Report Successful Cancer Treatments
Date : 04/02/2012 @ 12:31PM
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing cannabis pharmaceutical and over the counter nutraceutical products, is pleased to report it is moving forward with its FDA IND process. We have kept the public up to date with self-medicated skin cancer patients who are benefiting from topical cannabis-based extracts. These patients have experienced dramatic reduction in tumor burden and for some apparent eradication of their skin cancers.
http://ih.advfn.com/p.php?pid=nmona&article=51866121&symbol=…
Cannabis Science Continues Forward with FDA IND Process as Patients Report Successful Cancer Treatments
Date : 04/02/2012 @ 12:31PM
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing cannabis pharmaceutical and over the counter nutraceutical products, is pleased to report it is moving forward with its FDA IND process. We have kept the public up to date with self-medicated skin cancer patients who are benefiting from topical cannabis-based extracts. These patients have experienced dramatic reduction in tumor burden and for some apparent eradication of their skin cancers.
http://ih.advfn.com/p.php?pid=nmona&article=51866121&symbol=…
0,1601
$
+0,0211 $
+15,18 %
22:59:44Vol: 43.331.184U:
$
+0,0211 $
+15,18 %
22:59:44Vol: 43.331.184U:
Antwort auf Beitrag Nr.: 42.992.275 von Hobbyaktien am 02.04.12 22:18:49
0,145
$
-0,0151 $
-9,43 %
22:59:55Vol: 25.779.269U:
0,145
$
-0,0151 $
-9,43 %
22:59:55Vol: 25.779.269U:
Cannabis Science Reports Second Cancer Patient Receives Clean Biopsy Report Confirming the Biopsy is Free of Cancer Cells
Date : 04/04/2012 @ 1:12PM
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.
http://ih.advfn.com/p.php?pid=nmona&article=51905666&symbol=…
Date : 04/04/2012 @ 1:12PM
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.
http://ih.advfn.com/p.php?pid=nmona&article=51905666&symbol=…
Antwort auf Beitrag Nr.: 43.003.532 von Blankerhanz am 04.04.12 20:09:05
0,165
$
+0,02 $
+13,79 %
22:59:48Vol: 28.947.887U:
0,165
$
+0,02 $
+13,79 %
22:59:48Vol: 28.947.887U:
Die Sause kann beginnen, die Fantasie ist riesengroß.
Werde weiter zukaufen, obwohl ich in der Gewinnzone liege.
Ich warte bis der Kurs mal schwächelt und Stop Loss-Kurse ausgelöst werden- dann schlage ich zu......
Werde weiter zukaufen, obwohl ich in der Gewinnzone liege.
Ich warte bis der Kurs mal schwächelt und Stop Loss-Kurse ausgelöst werden- dann schlage ich zu......
Antwort auf Beitrag Nr.: 43.008.926 von schiedo am 05.04.12 19:00:36
0,167
$
+0,002 $
+1,21 %
22:59:56Vol: 20.410.891U:
0,167
$
+0,002 $
+1,21 %
22:59:56Vol: 20.410.891U:
ist heute gar kein Handel in amerika??
Antwort auf Beitrag Nr.: 43.011.242 von Hobbyaktien am 06.04.12 15:52:35Am Montag wieder !
Cannabis-Extrakt verwendet werden, um Hautkrebs + kommenden Dokumentarfilm zu behandeln.
Freitag, 6 April, 2012 um 16.15 Uhr
[CMJ] in Cannabis-Extrakt, Dokumentarfilm, Karzinom, Hautkrebs
Mit mehr Beweise und Studien, die verschiedenen Verbindungen in Cannabis als erfolgreiche Formen der Behandlung von medizinischen Erkrankungen (zuletzt Hautkrebs) verwendet gefunden getan, ist es kaum verwunderlich, dass diese immer wieder umstrittene Anlage das Thema viel Aufmerksamkeit und Kontrolle ist, nicht nur von Forschern, sondern auch vom Staat und der nationalen Regierung. Viele alternative Medizin Praktiker und Anhänger werden von Medien und Internet, positive Ergebnisse zu übertragen Drehen, über Dokumentarfilme, wie die folgenden ein bevorstehendes unten.
... Vielleicht die größte Revolution zu dieser Geschichte ist der scheinbare Erfolg und die heilende Kraft, dass Cannabis bei der Verwendung zur Behandlung von Krebspatienten hat. Cannabis Science (NASD OTCBB: CBIS) ist eine bahnbrechende US-Biotech-Unternehmen, das die Entwicklung von pharmazeutischen Produkten ist Cannabis. Cannabis Science hat mit 4 Patienten, die Cannabis Science verwaltet genehmigt Extrakte arbeitete selbst behandeln Basalzellkarzinom und Plattenepithelkarzinom (Hautkrebs).
Der Film deckt alles vom Samen bis zum Erfolg in der politischen und medizinischen Bereich. Als die unglückliche dunkle Seite der Film auch beleuchtet und macht die Geschichte, wie die Regierung hat es vermieden, und die erfolgreiche medizinische Verwendung von Marihuana, und Jahrzehnte der Heuchelei und fehlgeleitete Messaging abgedeckt.
Foto-Dokumentation auf der Website Cannabis Science (www.cannabisscience.com), zeigt, dass konzentriertes Marihuana-Extrakt, topisch zu Hautkrebs angewendet wird, reduziert die Tumorlast und in einigen Fällen scheint der Krebs eliminiert haben, als durch eine Biopsie bestätigt.
Lesen Sie mehr:
http://www.lef.org/news/LefDailyNews.htm?NewsID=12610&Sectio…
Artikel erschien ursprünglich auf der klassischen Medizin Journal (http://www.classicalmedicinejournal.com/).
Siehe Website für kompletten Artikel Lizenzinformationen.
Freitag, 6 April, 2012 um 16.15 Uhr
[CMJ] in Cannabis-Extrakt, Dokumentarfilm, Karzinom, Hautkrebs
Mit mehr Beweise und Studien, die verschiedenen Verbindungen in Cannabis als erfolgreiche Formen der Behandlung von medizinischen Erkrankungen (zuletzt Hautkrebs) verwendet gefunden getan, ist es kaum verwunderlich, dass diese immer wieder umstrittene Anlage das Thema viel Aufmerksamkeit und Kontrolle ist, nicht nur von Forschern, sondern auch vom Staat und der nationalen Regierung. Viele alternative Medizin Praktiker und Anhänger werden von Medien und Internet, positive Ergebnisse zu übertragen Drehen, über Dokumentarfilme, wie die folgenden ein bevorstehendes unten.
... Vielleicht die größte Revolution zu dieser Geschichte ist der scheinbare Erfolg und die heilende Kraft, dass Cannabis bei der Verwendung zur Behandlung von Krebspatienten hat. Cannabis Science (NASD OTCBB: CBIS) ist eine bahnbrechende US-Biotech-Unternehmen, das die Entwicklung von pharmazeutischen Produkten ist Cannabis. Cannabis Science hat mit 4 Patienten, die Cannabis Science verwaltet genehmigt Extrakte arbeitete selbst behandeln Basalzellkarzinom und Plattenepithelkarzinom (Hautkrebs).
Der Film deckt alles vom Samen bis zum Erfolg in der politischen und medizinischen Bereich. Als die unglückliche dunkle Seite der Film auch beleuchtet und macht die Geschichte, wie die Regierung hat es vermieden, und die erfolgreiche medizinische Verwendung von Marihuana, und Jahrzehnte der Heuchelei und fehlgeleitete Messaging abgedeckt.
Foto-Dokumentation auf der Website Cannabis Science (www.cannabisscience.com), zeigt, dass konzentriertes Marihuana-Extrakt, topisch zu Hautkrebs angewendet wird, reduziert die Tumorlast und in einigen Fällen scheint der Krebs eliminiert haben, als durch eine Biopsie bestätigt.
Lesen Sie mehr:
http://www.lef.org/news/LefDailyNews.htm?NewsID=12610&Sectio…
Artikel erschien ursprünglich auf der klassischen Medizin Journal (http://www.classicalmedicinejournal.com/).
Siehe Website für kompletten Artikel Lizenzinformationen.
Hier könnt Ihr sehen, was die Amis so schreiben...
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Sieht schlecht aus bisher:
Aber vllt. ist es eine Möglichkeit günstig nachzulegen.
Aber vllt. ist es eine Möglichkeit günstig nachzulegen.
0,142
$
-0,025 $
-14,97 %
22:59:55Vol: 22.310.170U:
$
-0,025 $
-14,97 %
22:59:55Vol: 22.310.170U:
0,1299 ????????????????? Für mich laut Chart ist der SK: ca. 0,126 Dollar
$
-0,0121 $
-8,52 %
22:59:35Vol: 18.851.748U:
$
-0,0121 $
-8,52 %
22:59:35Vol: 18.851.748U:
0,13
$
+0,004 $
+3,17 %
22:59:57Vol: 24.474.877U:
$
+0,004 $
+3,17 %
22:59:57Vol: 24.474.877U:
0,139
$
+0,009 $
+6,92 %
22:59:02Vol: 6.607.266U:
$
+0,009 $
+6,92 %
22:59:02Vol: 6.607.266U:
Chronic Future: Killing Cancer Premiered on April 5; Cannabis Science's CEO Dr. Robert Melamede & Filmmaker Henry Miller Weig...
Date : 04/12/2012 @ 1:45PM
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is thrilled to provide an update on the premiere of Chronic Future: Killing Cancer, a film by Henry Miller and Cory Pritchard. It tells the story of the attempt by Arizona's governor to close down medical marijuana dispensaries, and introduces patient after patient, with debilitating ailments, where medical marijuana has successfully treated the disease. Cannabis Science's CEO, Dr. Robert Melamede, was interviewed for the film about the success the company has seen with patients self-administering cannabis oil to their squamous cell carcinomas, and reducing their tumor burden, even apparently eradicating tumors as determined by biopsy.
http://ih.advfn.com/p.php?pid=nmona&article=51985808&symbol=…
Date : 04/12/2012 @ 1:45PM
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is thrilled to provide an update on the premiere of Chronic Future: Killing Cancer, a film by Henry Miller and Cory Pritchard. It tells the story of the attempt by Arizona's governor to close down medical marijuana dispensaries, and introduces patient after patient, with debilitating ailments, where medical marijuana has successfully treated the disease. Cannabis Science's CEO, Dr. Robert Melamede, was interviewed for the film about the success the company has seen with patients self-administering cannabis oil to their squamous cell carcinomas, and reducing their tumor burden, even apparently eradicating tumors as determined by biopsy.
http://ih.advfn.com/p.php?pid=nmona&article=51985808&symbol=…
0,141
$
+0,002 $
+1,44 %
22:59:32Vol: 7.395.953U:
$
+0,002 $
+1,44 %
22:59:32Vol: 7.395.953U:
Chronic Future: Killing Cancer Premiered on April 5; Cannabis Science's CEO Dr. Robert Melamede & Filmmaker Henry Miller Weig...
Date :
04/12/2012 @ 1:45PM
Source :
Business Wire
Stock :
Cannabis Science Inc. (CBIS)
Quote :
0.141 0.002 (1.44%) @ 4:13PM
Chronic Future: Killing Cancer Premiered on April 5; Cannabis Science's CEO Dr. Robert Melamede & Filmmaker Henry Miller Weig...
Print
Cannabis Science (OTCBB:CBIS)
Intraday Stock Chart
Today : Friday 13 April 2012
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is thrilled to provide an update on the premiere of Chronic Future: Killing Cancer, a film by Henry Miller and Cory Pritchard. It tells the story of the attempt by Arizona's governor to close down medical marijuana dispensaries, and introduces patient after patient, with debilitating ailments, where medical marijuana has successfully treated the disease. Cannabis Science's CEO, Dr. Robert Melamede, was interviewed for the film about the success the company has seen with patients self-administering cannabis oil to their squamous cell carcinomas, and reducing their tumor burden, even apparently eradicating tumors as determined by biopsy.
The film premiered April 5, 2012 in Scottsdale, Arizona, followed by 3 showings per day. The first five showings were sold out, with the following ones close to sold out. Henry Miller states, "There were over 3,500 people who showed up for tickets throughout the day. We got 3 standing ovations for the very first showing. Every state that has legal medical marijuana is part of our formula to fight for federal justice and their acknowledgement of scientific reality. We touched every state. I'm getting calls from people all over the world asking how they can get the film. I haven't had one negative response. [Dr. Melamede] is a genuine, sincere person; a beautiful soul. We couldn't ask for a better doctor to be representing this." Miller has received calls from Japan, China, India, Russia, Great Britain, Germany, Australia, South Africa, France, and Canada.
In addition to the 3,500 viewers who showed up for tickets, the movie has caught the attention of celebrities such as Angelina Jolie. Miller has "tweeted with Angelina Jolie, who saw the clips, and says she hopes it will end world hunger." Henry Miller hopes to be interviewed by Howard Stern, 60 Minutes, Good Morning America, Anderson Cooper, John Stewart, Oprah, David Letterman, and Jimmy Kimmel, just to name a few. Miller says, "The celebrities are coming out and seeing what we're doing, and are willing to help us and support us."
Dr. Robert Melamede commented, "As evidenced by the demographics of the population attending the opening, it's quite apparent that medical marijuana has moved out of the counterculture and into the mainstream of well to do American citizens. People have already contacted me about the availability of our treatment for skin cancer."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Von wann ist diese Meldung???
Habe sie unter deinem Link gefunden und sie hat sich direkt geöffnet, aber es gab dort kein datum!!
Date :
04/12/2012 @ 1:45PM
Source :
Business Wire
Stock :
Cannabis Science Inc. (CBIS)
Quote :
0.141 0.002 (1.44%) @ 4:13PM
Chronic Future: Killing Cancer Premiered on April 5; Cannabis Science's CEO Dr. Robert Melamede & Filmmaker Henry Miller Weig...
Cannabis Science (OTCBB:CBIS)
Intraday Stock Chart
Today : Friday 13 April 2012
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is thrilled to provide an update on the premiere of Chronic Future: Killing Cancer, a film by Henry Miller and Cory Pritchard. It tells the story of the attempt by Arizona's governor to close down medical marijuana dispensaries, and introduces patient after patient, with debilitating ailments, where medical marijuana has successfully treated the disease. Cannabis Science's CEO, Dr. Robert Melamede, was interviewed for the film about the success the company has seen with patients self-administering cannabis oil to their squamous cell carcinomas, and reducing their tumor burden, even apparently eradicating tumors as determined by biopsy.
The film premiered April 5, 2012 in Scottsdale, Arizona, followed by 3 showings per day. The first five showings were sold out, with the following ones close to sold out. Henry Miller states, "There were over 3,500 people who showed up for tickets throughout the day. We got 3 standing ovations for the very first showing. Every state that has legal medical marijuana is part of our formula to fight for federal justice and their acknowledgement of scientific reality. We touched every state. I'm getting calls from people all over the world asking how they can get the film. I haven't had one negative response. [Dr. Melamede] is a genuine, sincere person; a beautiful soul. We couldn't ask for a better doctor to be representing this." Miller has received calls from Japan, China, India, Russia, Great Britain, Germany, Australia, South Africa, France, and Canada.
In addition to the 3,500 viewers who showed up for tickets, the movie has caught the attention of celebrities such as Angelina Jolie. Miller has "tweeted with Angelina Jolie, who saw the clips, and says she hopes it will end world hunger." Henry Miller hopes to be interviewed by Howard Stern, 60 Minutes, Good Morning America, Anderson Cooper, John Stewart, Oprah, David Letterman, and Jimmy Kimmel, just to name a few. Miller says, "The celebrities are coming out and seeing what we're doing, and are willing to help us and support us."
Dr. Robert Melamede commented, "As evidenced by the demographics of the population attending the opening, it's quite apparent that medical marijuana has moved out of the counterculture and into the mainstream of well to do American citizens. People have already contacted me about the availability of our treatment for skin cancer."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Von wann ist diese Meldung???
Habe sie unter deinem Link gefunden und sie hat sich direkt geöffnet, aber es gab dort kein datum!!
0,138
$
-0,003 $
-2,13 %
22:59:09Vol: 4.962.307U:
$
-0,003 $
-2,13 %
22:59:09Vol: 4.962.307U:
0,122
$
-0,016 $
-11,59 %
22:59:39Vol: 15.082.443U:
$
-0,016 $
-11,59 %
22:59:39Vol: 15.082.443U:
Und schon wieder fast 5 % im Minus!!
0,116
$
-0,006 $
-4,92 %
22:59:29Vol: 15.913.617U:
0,116
$
-0,006 $
-4,92 %
22:59:29Vol: 15.913.617U:
0,122
$
+0,006 $
+5,17 %
22:59:45Vol: 5.188.688U:
$
+0,006 $
+5,17 %
22:59:45Vol: 5.188.688U:
0,1205
$
-0,0015 $
-1,23 %
22:59:50Vol: 4.690.942U:
$
-0,0015 $
-1,23 %
22:59:50Vol: 4.690.942U:
Geld
0,114
€
-0,0065 $
-5,39 %
22:57:38Vol: U:
0,114
€
-0,0065 $
-5,39 %
22:57:38Vol: U:
0,117
$
+0,003 $
+2,63 %
22:59:32Vol: 5.364.047U:
$
+0,003 $
+2,63 %
22:59:32Vol: 5.364.047U:
Antwort auf Beitrag Nr.: 43.057.522 von Hobbyaktien am 18.04.12 22:16:44
0,114
$
-0,003 $
-2,56 %
22:58:29Vol: 2.285.621U:
0,114
$
-0,003 $
-2,56 %
22:58:29Vol: 2.285.621U:
Antwort auf Beitrag Nr.: 38.363.801 von Lawuki2005 am 11.11.09 11:12:30
0,111
$
-0,003 $
-2,63 %
22:58:57Vol: 2.930.015U:
0,111
$
-0,003 $
-2,63 %
22:58:57Vol: 2.930.015U:
Antwort auf Beitrag Nr.: 38.363.801 von Lawuki2005 am 11.11.09 11:12:30
0,1085
$
-0,0025 $
-2,25 %
22:59:57Vol: 2.726.118U:
0,1085
$
-0,0025 $
-2,25 %
22:59:57Vol: 2.726.118U:
Antwort auf Beitrag Nr.: 38.363.801 von Lawuki2005 am 11.11.09 11:12:30
0,1069
$
-0,0016 $
-1,47 %
22:59:51Vol: 2.761.063U:
0,1069
$
-0,0016 $
-1,47 %
22:59:51Vol: 2.761.063U:
Antwort auf Beitrag Nr.: 43.057.522 von Hobbyaktien am 18.04.12 22:16:44
0,098
$
-0,0089 $
-8,33 %
22:59:53Vol: 9.548.421U:
0,098
$
-0,0089 $
-8,33 %
22:59:53Vol: 9.548.421U:
Antwort auf Beitrag Nr.: 43.057.522 von Hobbyaktien am 18.04.12 22:16:44
Die Aktie steigt ständig und keiner merkt es....
Antwort auf Beitrag Nr.: 43.143.192 von schiedo am 09.05.12 19:53:30doch doch, manche merken es, aber "hobbyaktien" vermüllt diesen Thread hier so derbe mit seinen unnötigen und vor allem primitiv kopierten und platzverschwenderischen und optisch hässlichen Kursinfos, dass man es eher leid ist sich hier durchzukämpfen.
@hobbyaktien: Unterlass mal bitte diese Kursinfos, wir sind doch nicht zu blöd uns selbst mit wenigen Klicks über Kurse und deren Verläufe zu informieren. Desweiteren kopierste dass nur irgendwo raus und korrigierst nichtmal die Zeilenformatierung, da steht das Dollarzeichen alleine ne Zeile tiefer und jeder Beitrag verschlingt das 5fache an Platz wie er es müsste. Meiner Ansicht nach wird der Thread dadurch nur unübersichtlich und hässlich.
Also machs entweder besser und optisch ansprechender oder lass es ganz.
mfG
@hobbyaktien: Unterlass mal bitte diese Kursinfos, wir sind doch nicht zu blöd uns selbst mit wenigen Klicks über Kurse und deren Verläufe zu informieren. Desweiteren kopierste dass nur irgendwo raus und korrigierst nichtmal die Zeilenformatierung, da steht das Dollarzeichen alleine ne Zeile tiefer und jeder Beitrag verschlingt das 5fache an Platz wie er es müsste. Meiner Ansicht nach wird der Thread dadurch nur unübersichtlich und hässlich.
Also machs entweder besser und optisch ansprechender oder lass es ganz.
mfG
Ich glaube, jetzt geht es los, die Fantasie ist jedenfalls schon da....
Neuster Beitrag von heute:
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Neuster Beitrag von heute:
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
naja so toll ist der Bericht nun auch nicht, da euphorisiert die Google-Übersetzung durch unangemessen falsche Übersetzung ja einiges;-)
zu den Fakten CBIS geht nen Vertrag mit Dutch Passion ein, einer bekannten Drogenhanfsamenbank aus den Niederlanden.
Da ich mich in diesem Bereich auskenne kann ich auch sagen, dass es eine bekannte und eine der besten Hanf-Samenbanken ist, aber es gibt unzählige andere und mindestens genauso gute.
Was jetzt an dieser Story toll sein soll kann ich nicht nachvollziehen, denn Hanfsamenbanken gibts in verschiedenen Ländern wie Sand am Meer und die Beschaffung von Samen war nie ein Problem, noch dazu wo man wenn man eine Mutterpflanze mit den gewünschten Eigenschaften hat, eh nur noch klont und keine Pflanzen aus Samen zieht, besonders für medizinische Zwecke, da ein Klon immer die Eigenschaften der Mutterpflanze hat und ausserdem einen deutlichen Zeitvorteil liefert.
Die Zusammenarbeit kann nur einen einzigen Sinn haben, nämlich die Nutzung der Dutch-Passion-Erfahrung zur Züchtung neuer spezieller Cannabis-Sorten mit anderem Cannabinoid-Profilen.
Für Dutch-Passion ist das sicherlich der Knaller, aber CBIS hätte sich auch andere "Breeder"(Züchter) wie SensiSeeds zur Zusammenarbeit holen können, welche meiner Ansicht nach für diese Zwecke besser geeignet wären, da SensiSeeds mit der niederländischen Regierung für das niederländische Apotheken-Gras zusammenarbeitet und weltweit den besten Ruf hat.
Dutch-Passion ist aus medizinischer Sicht bisher dazu im Vergleich unbekannt und hat eher anspruchsvolle Hobby-und Profikiffer mit Samen versorgt.
zu den Fakten CBIS geht nen Vertrag mit Dutch Passion ein, einer bekannten Drogenhanfsamenbank aus den Niederlanden.
Da ich mich in diesem Bereich auskenne kann ich auch sagen, dass es eine bekannte und eine der besten Hanf-Samenbanken ist, aber es gibt unzählige andere und mindestens genauso gute.
Was jetzt an dieser Story toll sein soll kann ich nicht nachvollziehen, denn Hanfsamenbanken gibts in verschiedenen Ländern wie Sand am Meer und die Beschaffung von Samen war nie ein Problem, noch dazu wo man wenn man eine Mutterpflanze mit den gewünschten Eigenschaften hat, eh nur noch klont und keine Pflanzen aus Samen zieht, besonders für medizinische Zwecke, da ein Klon immer die Eigenschaften der Mutterpflanze hat und ausserdem einen deutlichen Zeitvorteil liefert.
Die Zusammenarbeit kann nur einen einzigen Sinn haben, nämlich die Nutzung der Dutch-Passion-Erfahrung zur Züchtung neuer spezieller Cannabis-Sorten mit anderem Cannabinoid-Profilen.
Für Dutch-Passion ist das sicherlich der Knaller, aber CBIS hätte sich auch andere "Breeder"(Züchter) wie SensiSeeds zur Zusammenarbeit holen können, welche meiner Ansicht nach für diese Zwecke besser geeignet wären, da SensiSeeds mit der niederländischen Regierung für das niederländische Apotheken-Gras zusammenarbeitet und weltweit den besten Ruf hat.
Dutch-Passion ist aus medizinischer Sicht bisher dazu im Vergleich unbekannt und hat eher anspruchsvolle Hobby-und Profikiffer mit Samen versorgt.
Antwort auf Beitrag Nr.: 43.349.963 von BiggSnoop am 03.07.12 23:56:22Meine Anerkennung, da spricht der Fachmann......
Scheinbar gibt es einen neuen Chart bei Cannabis.
Kann hier vllt. jemand diesen neuen Cannabis Chart hier einfügen??
Kann hier vllt. jemand diesen neuen Cannabis Chart hier einfügen??
Antwort auf Beitrag Nr.: 43.428.910 von Hobbyaktien am 26.07.12 22:22:34Neu an der Börse USOTC - CBIS
Hast du auch einen Chart??
Oder sonst jemand, den er hier einstellen kann??
Oder sonst jemand, den er hier einstellen kann??
Antwort auf Beitrag Nr.: 43.431.586 von Hobbyaktien am 27.07.12 15:30:21eingeben: www.ADVFN.de dann CBIS (Börse USOTC) = Realtime Chart
Antwort auf Beitrag Nr.: 43.437.640 von schiedo am 30.07.12 15:01:28Kannst du hier keinen Chart eingeben??
Ich bin bei ADVFN nicht angemeldet!!
Ich bin bei ADVFN nicht angemeldet!!
Antwort auf Beitrag Nr.: 43.438.616 von Hobbyaktien am 30.07.12 19:33:49Es funktioniert nicht, es ist alles doch kostenlos nach der Anmeldung. Alle Charts die es gibt sind vorhanden und vieles mehr...
Das beste was ich je hatte mit Speicherung.
Das beste was ich je hatte mit Speicherung.
Es geht aufwärts !
/Users/herbertschildt/Desktop/Google Übersetzer.webarchive
/Users/herbertschildt/Desktop/Google Übersetzer.webarchive
Antwort auf Beitrag Nr.: 43.486.460 von schiedo am 13.08.12 11:53:11hoffentlich!!!!! Bin heute auch mal wieder vorsichtig rein
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=85883…
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=85883…
Bin mit Verlust raus.
Alle Anzeichen sprechen für eine Pleite aufgrund der hohen Schulden und geringen Einnahmen. So schreiben es die Amis
Allen Anderen viel GlücK.
Alle Anzeichen sprechen für eine Pleite aufgrund der hohen Schulden und geringen Einnahmen. So schreiben es die Amis
Allen Anderen viel GlücK.
Ich warte mit meinem Körbchen noch auf der 0,038 USD zum nachfüllen.
Antwort auf Beitrag Nr.: 43.431.417 von schiedo am 27.07.12 14:53:58Ich glaube nicht das Cannabis ein Pleitekanidat ist!!!
1) Wenn alles so schlecht ist, hätten die nicht den Index gewechselt.
2) Wollte Cannabis immer eigenständig bleiben und das Potenzial haben sie auch, klar sieht das im Moment noch finanziell düster aus.
3) Ich glaube an Cannabis und zudem gibt es mit Sicherheit noch viele Pharmaunternehmen, die dann Interesse hätten Cannabis zu kaufen!!
Und auch das würde wieder für steigende Kurse sorgen.
Ich habe immer noch meine Long-Posi und werde bei 0,038 USD mal wieder eine kleine Zockerposition ins Rennen schicken.
Hat bisher immer ganz gut geklappt.
1) Wenn alles so schlecht ist, hätten die nicht den Index gewechselt.
2) Wollte Cannabis immer eigenständig bleiben und das Potenzial haben sie auch, klar sieht das im Moment noch finanziell düster aus.
3) Ich glaube an Cannabis und zudem gibt es mit Sicherheit noch viele Pharmaunternehmen, die dann Interesse hätten Cannabis zu kaufen!!
Und auch das würde wieder für steigende Kurse sorgen.
Ich habe immer noch meine Long-Posi und werde bei 0,038 USD mal wieder eine kleine Zockerposition ins Rennen schicken.
Hat bisher immer ganz gut geklappt.
Antwort auf Beitrag Nr.: 43.527.523 von Hobbyaktien am 23.08.12 22:16:37
Sie fängt seit gestern wieder an, richtig nach oben zu rennen!!
Ich bin immer noch nur mit meiner long Posi dabei.
da ich die andere wieder mit gewinn geschmissen habe, vor ein paar Wochen.
Sie fängt seit gestern wieder an, richtig nach oben zu rennen!!
Ich bin immer noch nur mit meiner long Posi dabei.
da ich die andere wieder mit gewinn geschmissen habe, vor ein paar Wochen.
Wow das Baby könnte wieder wie letztes Jahr ganz nach oben schießen: schaut euch mal die OTC-Seite an - wurde so ziemlich von jeden Penny-Brief im Ami-Land empfohlen, daher auch das schöne Voluminen:
http://www.otcmarkets.com/stock/CBIS/news
http://www.otcmarkets.com/stock/CBIS/news
strong buy:
Mid-Day Update On Most Active Stocks: (OTCQB: CBIS), (OTCQB: AMBS).
Nov 09, 2012 (ACCESSWIRE-TNW via COMTEX) -- New York -- Cannabis Science Inc. (OTCQB: CBIS) is extending its gains from Thursday in mid-day trading today. CBIS has been gaining momentum on the back of some positive developments for the medical marijuana industry. In today's trading, the stock is up 26.09% to $0.0870 on volume of 27.92 million, which is nearly four times the daily average volume of 6.32 million.
CBIS has now gained more than 87% in the last three trading sessions. The technical indicators for CBIS are giving strong bullish signals; therefore the rally is likely to continue. The stock has broken through its 200-day moving average. The MACD chart for CBIS is also giving strong buy signal.
Mid-Day Update On Most Active Stocks: (OTCQB: CBIS), (OTCQB: AMBS).
Nov 09, 2012 (ACCESSWIRE-TNW via COMTEX) -- New York -- Cannabis Science Inc. (OTCQB: CBIS) is extending its gains from Thursday in mid-day trading today. CBIS has been gaining momentum on the back of some positive developments for the medical marijuana industry. In today's trading, the stock is up 26.09% to $0.0870 on volume of 27.92 million, which is nearly four times the daily average volume of 6.32 million.
CBIS has now gained more than 87% in the last three trading sessions. The technical indicators for CBIS are giving strong bullish signals; therefore the rally is likely to continue. The stock has broken through its 200-day moving average. The MACD chart for CBIS is also giving strong buy signal.
Antwort auf Beitrag Nr.: 43.807.544 von JohnAsh am 09.11.12 16:41:55Ich bin hier schon ein paar Jahre dabei und gehe davon aus, dass der Kurs in kürzester Zeit die 0,20 USD wieder überschreiten sollte.
Danach wird es dann aber auch genau so schnell wieder bergab gehen und sich erstmal wieder gegen 0,09 Usd einpendeln.
Und danach wird es wieder weiter runter gehen, Richtung 0,05 USD.
So war es bisher sehr sehr oft.
Aber warten wir mal ab. Ich freue mich schon auf die nächste Woche.
Alles nur meine Einschätzung.
Allen erstmal ein schönes WE.
Danach wird es dann aber auch genau so schnell wieder bergab gehen und sich erstmal wieder gegen 0,09 Usd einpendeln.
Und danach wird es wieder weiter runter gehen, Richtung 0,05 USD.
So war es bisher sehr sehr oft.
Aber warten wir mal ab. Ich freue mich schon auf die nächste Woche.
Alles nur meine Einschätzung.
Allen erstmal ein schönes WE.
@hobbyaktien - sehe dieses genauso wie du und hätte es nicht besser formulieren können- selbe spiel wie letztes Jahr, darum lohnt es sich ja auch wieder dabei zu sein
So siehts aus!!
Nur man darf den Ausstieg nicht verpassen.
Meine Posi liegt noch bei ca. 0,24 USD. Würde sie aber auch etwas niedriger verkaufen.
Um dann nachher wieder unten einzusammeln.
Aber ich habe mit anderen Positionen schon ganz gut verdient, in den letzten Jahren, hier bei Cannabis.
Nur man darf den Ausstieg nicht verpassen.
Meine Posi liegt noch bei ca. 0,24 USD. Würde sie aber auch etwas niedriger verkaufen.
Um dann nachher wieder unten einzusammeln.
Aber ich habe mit anderen Positionen schon ganz gut verdient, in den letzten Jahren, hier bei Cannabis.
Antwort auf Beitrag Nr.: 43.811.513 von Hobbyaktien am 11.11.12 16:07:54Beth Israel Deaconess Medical Center, bestätigt Harvard Medical School Study Cannabis Science Ansatz zur Entwicklung von CS-TATI-1 bis Kaposi Sarkom Inhibit
http://finance.yahoo.com/news/...coness-medical-center-17050…
Cannabidiol hemmt Wachstum und den programmierten Zelltod in Kaposi-Sarkom-assoziierten Herpesvirus-infizierten Endothelium
COLORADO SPRINGS, Colorado, 12. November 2012 / PRNewswire / - Cannabis Science, Inc., (CBIS) gibt bekannt, Harvard Medical School Versionen Peer-Review-Studie in den Genes & Cancer Journal stark darauf hindeutet, dass Cannabidiol hemmt und induziert programmierten Zelltod Tod im Kaposi-Sarkom-assoziierten Herpesvirus-infizierten Endothel. Diese Ergebnisse aus der Studie an der Harvard Medical School Unterstützung Cannabis Science-Ansatz zur Entwicklung von CS-TATI-1 zu hemmen Kaposi-Sarkom.
Cannabis Science President & CEO, Dr. Robert Melamede erklärt: "Wir sind sehr ermutigt, die Veröffentlichung des Harvard-Studie, die die Fähigkeit phytocannabinoids um Kaposi-Zellen zu hemmen zeigt sehen. Die Harvard-Ergebnisse bestätigen und unterstreichen die Richtung, die wir mit entwickelt unsere erste Medikament CS-TATI-1 bis Kaposi-Sarkom zu hemmen. Cannabis Science ist in den Prozess der Einreichung mehrerer Konzept Blätter öffentlich geförderten Forschungsprogrammen zur CS-TATI-1 in die Klinik zu bewegen so schnell wie möglich zur Zufriedenheit der behördlichen Überprüfung für Kommerzialisierung. "
David Purdy, CEO & Founder, Welt-Aids-Institut sagt: "Diese bahnbrechende Harvard-Studie zur Untersuchung der Auswirkungen auf die KS durch Cannabinoide ist eine grundlegende Spiel-Wechsler in der Behandlung einer Krankheit, die eine der häufigsten Ursachen von AIDS-Todesfälle ist in der Welt. In der Tat hat es eine steile Rückgang der Zinsen in KS Behandlung Forschung in der Aktivistin Welt trotz der Verwüstung auf dem afrikanischen Kontinent von diesem bestimmten AIDS-Krankheit verursacht. "
http://finance.yahoo.com/news/...coness-medical-center-17050…
Cannabidiol hemmt Wachstum und den programmierten Zelltod in Kaposi-Sarkom-assoziierten Herpesvirus-infizierten Endothelium
COLORADO SPRINGS, Colorado, 12. November 2012 / PRNewswire / - Cannabis Science, Inc., (CBIS) gibt bekannt, Harvard Medical School Versionen Peer-Review-Studie in den Genes & Cancer Journal stark darauf hindeutet, dass Cannabidiol hemmt und induziert programmierten Zelltod Tod im Kaposi-Sarkom-assoziierten Herpesvirus-infizierten Endothel. Diese Ergebnisse aus der Studie an der Harvard Medical School Unterstützung Cannabis Science-Ansatz zur Entwicklung von CS-TATI-1 zu hemmen Kaposi-Sarkom.
Cannabis Science President & CEO, Dr. Robert Melamede erklärt: "Wir sind sehr ermutigt, die Veröffentlichung des Harvard-Studie, die die Fähigkeit phytocannabinoids um Kaposi-Zellen zu hemmen zeigt sehen. Die Harvard-Ergebnisse bestätigen und unterstreichen die Richtung, die wir mit entwickelt unsere erste Medikament CS-TATI-1 bis Kaposi-Sarkom zu hemmen. Cannabis Science ist in den Prozess der Einreichung mehrerer Konzept Blätter öffentlich geförderten Forschungsprogrammen zur CS-TATI-1 in die Klinik zu bewegen so schnell wie möglich zur Zufriedenheit der behördlichen Überprüfung für Kommerzialisierung. "
David Purdy, CEO & Founder, Welt-Aids-Institut sagt: "Diese bahnbrechende Harvard-Studie zur Untersuchung der Auswirkungen auf die KS durch Cannabinoide ist eine grundlegende Spiel-Wechsler in der Behandlung einer Krankheit, die eine der häufigsten Ursachen von AIDS-Todesfälle ist in der Welt. In der Tat hat es eine steile Rückgang der Zinsen in KS Behandlung Forschung in der Aktivistin Welt trotz der Verwüstung auf dem afrikanischen Kontinent von diesem bestimmten AIDS-Krankheit verursacht. "
Antwort auf Beitrag Nr.: 43.811.513 von Hobbyaktien am 11.11.12 16:07:54@hobbyakien: wie schätzt du die lage ein? gibt es paralleln zu den letzten jahren?
Schwer zu sagen.
ALso meistens war es so, dass es innerhalb von 3 bis 4 Tagen, nur steul nach oben ging, danach ging es aber noch schneller wieder runter.
Ein oder zweimal gab es aber auch vorher kleinere Gewinnmitnahme wie gestern, zuletzt konnte man das im Januar 2012 beobachten.
Da war es auch so wie es aktuell ist.
Mal abwarten. Auch ich habe keine Glaskugel.
Ich vermute aber, dass es weiter nach oben geht, in den nächsten Tagen.
ALso meistens war es so, dass es innerhalb von 3 bis 4 Tagen, nur steul nach oben ging, danach ging es aber noch schneller wieder runter.
Ein oder zweimal gab es aber auch vorher kleinere Gewinnmitnahme wie gestern, zuletzt konnte man das im Januar 2012 beobachten.
Da war es auch so wie es aktuell ist.
Mal abwarten. Auch ich habe keine Glaskugel.
Ich vermute aber, dass es weiter nach oben geht, in den nächsten Tagen.
Was geht hier ab !!!In den USA steigt Cannabis täglich und hier kaum bekannt !?
Tja, so siehts aus!!
In Ami scheint Cannabis wohl bekannter zu sein.
Mich stört es nicht, wenn es hier so ruhig ist.
In Ami scheint Cannabis wohl bekannter zu sein.
Mich stört es nicht, wenn es hier so ruhig ist.
du hast recht ,so kann man sich eindecken, in aller Ruhe :-)
Stehe hier an der Seitenlinie und warte auf Erfolgsmeldungen........
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_…
Hattest du hier nicht vor kurzem noch geschrieben, dass Cannabis Pleite geht und mit Verlust geschmissen??
Weil alles so schlecht ist??
Weil alles so schlecht ist??
Antwort auf Beitrag Nr.: 43.872.215 von Hobbyaktien am 28.11.12 19:01:55ich habe damals geschrieben, dass sie durch die schlechten Zahlen vor der Pleite stehen könnten. Das ist heute auch noch so.Falls sie aber Gelder zu Forschungszwecken bekommen sollten und Erfolge sichtbar werden, bin ich sofort dabei. Aber bis heute nichts dergleichen..... -- darum stehe ich an der Seitenlinie und habe Geduld.
Bin aber in Stemcells investiert und mache mir hier grosse Hoffnungen, weil sie ca. 20 Mill. Forschungsgelder bekommen haben.
Bin aber in Stemcells investiert und mache mir hier grosse Hoffnungen, weil sie ca. 20 Mill. Forschungsgelder bekommen haben.
Ist hier jemand noch drin?
Interessant:
http://seekingalpha.com/article/1159931-why-3-marijuana-symp…
Google Übersetzung:
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_t&hl=de&ie=UTF-8&eotf=1&u=http://seekingalpha.com/article/1159931-why-3-marijuana-symp…
http://seekingalpha.com/article/1159931-why-3-marijuana-symp…
Google Übersetzung:
http://translate.google.de/translate?sl=en&tl=de&js=n&prev=_t&hl=de&ie=UTF-8&eotf=1&u=http://seekingalpha.com/article/1159931-why-3-marijuana-symp…
Antwort auf Beitrag Nr.: 44.109.390 von Waldek112 am 06.02.13 14:08:38
Ja, ich bin hier noch investiert und zwar langfristig!!
Aber sonst ist hier recht wenig los, deswegen schaue ich hier auch nur sehr selten rein, auf den Kurs schaue ich allerdings täglich ein paar mal, denn wenn es mal hoch geht, geht es recht zügig.
Genauso auch mal wieder in die andere Richtung.
Ja, ich bin hier noch investiert und zwar langfristig!!
Aber sonst ist hier recht wenig los, deswegen schaue ich hier auch nur sehr selten rein, auf den Kurs schaue ich allerdings täglich ein paar mal, denn wenn es mal hoch geht, geht es recht zügig.
Genauso auch mal wieder in die andere Richtung.
Noch jemand hier investiert, außer meine Wenigkeit??
Ich habe mir letzte Woche nochmal eine kleine kurzfristige Zockerposition
ins Depot gelegt.
Die langfristige Posi bleibt auf Dauer bestehen!!
Wünsche allen ein schönes WE.
Ich habe mir letzte Woche nochmal eine kleine kurzfristige Zockerposition
ins Depot gelegt.
Die langfristige Posi bleibt auf Dauer bestehen!!
Wünsche allen ein schönes WE.
Bin auch noch drin. Bin mal gespannt ob aus denen noch was wird...
Es könnte bald wieder drehen, wenn ich mir die Chartentwicklung so ansehe, gebe darauf aber keine Garantie.
Keine Empfehlung zu irgendwas.
Keine Empfehlung zu irgendwas.
Es kommt leben in die aktie. Wenn Montag Volumen reinkommt, dann Holla die Waldfee.
Ich habe meine Zockerposi mit 25 % Gewinn heute verkauft!
Meine Long Posi bleibt aber weiterhin bestehen!
Ich weiß nicht, ob es jetzt noch weiter hoch geht oder nochmal Richtung 4 Cent dreht.
Lieber erstmal Gewinne sichern und bei 4 Cent wieder nachkaufen!!
Meine Long Posi bleibt aber weiterhin bestehen!
Ich weiß nicht, ob es jetzt noch weiter hoch geht oder nochmal Richtung 4 Cent dreht.
Lieber erstmal Gewinne sichern und bei 4 Cent wieder nachkaufen!!
Warum ist die AKtie hochgegangen? Gab es News?
Ich habe keine News gefunden!
Aber die Aktie schwankt öfter mal stärker, egal ob mit oder ohne News!
Aber die Aktie schwankt öfter mal stärker, egal ob mit oder ohne News!
Kann hier jemand bitte mal einen Realtime Chart von Cannabi einstellen?
Wäre super nett.
Wäre super nett.
Antwort auf Beitrag Nr.: 45.305.615 von Hobbyaktien am 22.08.13 18:56:50
Hi!
Vielen Dank für den Chart!
Leider ist der 15 Minuten zeitverzögert.
Kannst du noch einen originalen realtime Chart einstellen?
Habe mir jetzt wieder eine Zockerposi zu 0,0351 USD ins Depot gelegt.
Meine langfristige posi, behalte ich sowieso.
Vielen Dank für den Chart!
Leider ist der 15 Minuten zeitverzögert.
Kannst du noch einen originalen realtime Chart einstellen?
Habe mir jetzt wieder eine Zockerposi zu 0,0351 USD ins Depot gelegt.
Meine langfristige posi, behalte ich sowieso.
Ist hier irgendjemand noch dabei. Gerade die letzten Anstiege müssten doch zu mindest mal einen Kommentar entlocken können.
Seit der Legalisierung in Colorado scheint alles wo Cannabis draufsteht gekauft zu werden aber wie könnte es eurer Meinung nach hier weitergehen?
VG
WB
Seit der Legalisierung in Colorado scheint alles wo Cannabis draufsteht gekauft zu werden aber wie könnte es eurer Meinung nach hier weitergehen?
VG
WB
warte bis Washington cannabis legalisisert und kauf die Greengrow tech bei ca 0,21 momentan bei 0,41
mediswipe
green grow tech
und medical marijuana
mediswipe
green grow tech
und medical marijuana
Was ist denn das für eine Antwort?
Also erst einmal geht es hier um Cannabis Science und nicht um andere Aktien! Bitte beachte die Boardregeln!!!!
Zu CBIS kann ich nur sagen, ich bin rein, weil es die Firma schon ne ganze Weile gibt, sie Erfahrung mit so nem Zeug haben und mit Sicherheit von dem "Kiffer-Boom" profitieren werden.
Die Marktkapitalisierung macht mir etwas Sorgen, da ich keine anständigen Unternehmenszahlen gefunden habe....
....ABER die Aktie ist längst noch ein "Nachholer" im "Spliff-Boom", daher bin ich heute bei 0,116€ rein.
Wollen wir hoffen, dass diese Aktie den Boom der anderen noch nachholt
Übrigens ist das, was ich hier von mir gebe nur meine eigene Meinung und keineswegs eine Empfehlung
Hat jemand Unternehmenszahlen für mich?
Leider hab ich hier schon wieder nen Dämpfer nach meinem kleinen Gewinn heute: http://www.marketwatch.com/investing/stock/CBIS/news
Zu CBIS kann ich nur sagen, ich bin rein, weil es die Firma schon ne ganze Weile gibt, sie Erfahrung mit so nem Zeug haben und mit Sicherheit von dem "Kiffer-Boom" profitieren werden.
Die Marktkapitalisierung macht mir etwas Sorgen, da ich keine anständigen Unternehmenszahlen gefunden habe....
....ABER die Aktie ist längst noch ein "Nachholer" im "Spliff-Boom", daher bin ich heute bei 0,116€ rein.
Wollen wir hoffen, dass diese Aktie den Boom der anderen noch nachholt
Übrigens ist das, was ich hier von mir gebe nur meine eigene Meinung und keineswegs eine Empfehlung
Hat jemand Unternehmenszahlen für mich?
Leider hab ich hier schon wieder nen Dämpfer nach meinem kleinen Gewinn heute: http://www.marketwatch.com/investing/stock/CBIS/news
Hab nur das hier gefunden... Daten vom Ende September.
$462 cash
$288 thousand total current assets
$3.5 million total current liabilities
$70 thousand revenue
$1.1 million net loss
$462 cash
$288 thousand total current assets
$3.5 million total current liabilities
$70 thousand revenue
$1.1 million net loss
Na die haben ja echt ne Menge Cash
Antwort auf Beitrag Nr.: 46.341.467 von meisterpeppo am 30.01.14 11:00:58
also meine Wiese ist es nicht, aber bei Cannabis Playern könnte man sich mal SKTO anschauen/im "Auge behalten".
Die könnten, meinem Eindruck nach, gerade "vielleicht wirklich was aufbauen". Alleeeine in q3 haben sie wohl $0.005/Aktie nach Hause gebracht, wäre auf 1 Quartalsbasis -fully dilluted- KGV 6. Und die scheinen noch einiges am "anlaufen" zu haben. Ich steck nicht drin in der Bude, aber das, bisschen, was ich dazu gesehen habe sieht doch etwas danach aus:
www.otcmarkets.com/financialReportViewer?symbol=SKTO&id=1137…
www.otcmarkets.com/stock/SKTO/filings
http://finance.yahoo.com/q/h?s=SKTO&t=2014-01-31T12:50:00-05…
Gruß
P.
also meine Wiese ist es nicht, aber bei Cannabis Playern könnte man sich mal SKTO anschauen/im "Auge behalten".
Die könnten, meinem Eindruck nach, gerade "vielleicht wirklich was aufbauen". Alleeeine in q3 haben sie wohl $0.005/Aktie nach Hause gebracht, wäre auf 1 Quartalsbasis -fully dilluted- KGV 6. Und die scheinen noch einiges am "anlaufen" zu haben. Ich steck nicht drin in der Bude, aber das, bisschen, was ich dazu gesehen habe sieht doch etwas danach aus:
www.otcmarkets.com/financialReportViewer?symbol=SKTO&id=1137…
www.otcmarkets.com/stock/SKTO/filings
http://finance.yahoo.com/q/h?s=SKTO&t=2014-01-31T12:50:00-05…
Gruß
P.
CBIS Provides Growth Guidance on its Medicine Dispensing Systems (MDS) Exclusive & Non-Exclusive Agreements
CBIS Sees Canada as Flagship Market Launch
COLORADO SPRINGS, Colo., Feb. 3, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, provides shareholder clarity and growth guidance for its gross profit sharing exclusive and non-exclusive agreement in select markets with MDS, a subsidiary of Medbox, Inc. Under the terms of the agreement Cannabis Science has a 50/50 gross profit exclusive on any and all MDS equipment sales in Canada and other select markets. Both CBIS and MDS have multiple opportunities in Canada based on recent developments with medical cannabis in that market. Other countries will follow pursuant to the agreement as CBIS moves forward aggressively in Europe and South America.
Details of the Cannabis Science and MDS agreement are as follows:
Cannabis Science and MDS signed a Worldwide Distribution Agreement effective August 10, 2011.
Pursuant to the terms of the agreement, Cannabis Science enjoys certain worldwide rights as MDS's exclusive and non-exclusive distributor of all MDS products for the Continents of Asia, Africa, North America, South America, Antarctica, Europe, and Australia/Oceania as set forth below;
Asia (All exclusive, excluding Russia, the Ukraine, Georgia, Belarus, Estonia, and Latvia)
Africa (All exclusive)
North America (All exclusive, excluding the United States of America)
South America (All non-exclusive)
Antarctica (All non-exclusive)
Europe (All exclusive, excluding United Kingdom)
Australia/Oceania (All exclusive)
The companies shall jointly share in the proceeds on placement of specialized cannabis dispensing safes in cultivation facilities for use in mitigating inventory and dispensing to personnel for delivery to the end user. Cannabis Science shall solely derive additional revenue by licensing its formulations and products to existing MDS clinics as well as newly formed clinics worldwide, as permitted by law.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
dorothy.bray@cannabisscience.com
Tel: 1.888.777.0658
www.cannabisscience.com
info@cannabisscience.com
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
SOURCE Cannabis Science, Inc.
Timestamp:
February 03, 2014 08:26:25 EST
WebSite:
http://www.cannabisscience.com
S.PN .R2 CBIS CBIS CBIS CO.PN .CO OTC.PN HEA.PN .HEALTH SPM.PN .MEDICAL LIC.PN .ADVERTISING
CBIS Sees Canada as Flagship Market Launch
COLORADO SPRINGS, Colo., Feb. 3, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, provides shareholder clarity and growth guidance for its gross profit sharing exclusive and non-exclusive agreement in select markets with MDS, a subsidiary of Medbox, Inc. Under the terms of the agreement Cannabis Science has a 50/50 gross profit exclusive on any and all MDS equipment sales in Canada and other select markets. Both CBIS and MDS have multiple opportunities in Canada based on recent developments with medical cannabis in that market. Other countries will follow pursuant to the agreement as CBIS moves forward aggressively in Europe and South America.
Details of the Cannabis Science and MDS agreement are as follows:
Cannabis Science and MDS signed a Worldwide Distribution Agreement effective August 10, 2011.
Pursuant to the terms of the agreement, Cannabis Science enjoys certain worldwide rights as MDS's exclusive and non-exclusive distributor of all MDS products for the Continents of Asia, Africa, North America, South America, Antarctica, Europe, and Australia/Oceania as set forth below;
Asia (All exclusive, excluding Russia, the Ukraine, Georgia, Belarus, Estonia, and Latvia)
Africa (All exclusive)
North America (All exclusive, excluding the United States of America)
South America (All non-exclusive)
Antarctica (All non-exclusive)
Europe (All exclusive, excluding United Kingdom)
Australia/Oceania (All exclusive)
The companies shall jointly share in the proceeds on placement of specialized cannabis dispensing safes in cultivation facilities for use in mitigating inventory and dispensing to personnel for delivery to the end user. Cannabis Science shall solely derive additional revenue by licensing its formulations and products to existing MDS clinics as well as newly formed clinics worldwide, as permitted by law.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
dorothy.bray@cannabisscience.com
Tel: 1.888.777.0658
www.cannabisscience.com
info@cannabisscience.com
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
SOURCE Cannabis Science, Inc.
Timestamp:
February 03, 2014 08:26:25 EST
WebSite:
http://www.cannabisscience.com
S.PN .R2 CBIS CBIS CBIS CO.PN .CO OTC.PN HEA.PN .HEALTH SPM.PN .MEDICAL LIC.PN .ADVERTISING
Was ist hier los?
Antwort auf Beitrag Nr.: 46.387.844 von donerwetter am 05.02.14 22:54:43
Hat doch eh keiner eine Ahnung, von daher nimm nicht an dass Du Dir zu anderen etwas nimmst.
Gruß
P.
Hat doch eh keiner eine Ahnung, von daher nimm nicht an dass Du Dir zu anderen etwas nimmst.
Gruß
P.
Hallo ich denk das hier sehr viel mehr drin ist. Morgen sollte wieder was gehen ist ziemlich heiss. Gewinn mitnehmen und wieder billig rein
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: ohne Quellenangabe, ggf. neu überarbeitet einstellen
Antwort auf Beitrag Nr.: 46.419.286 von batman1975 am 10.02.14 21:23:13Der Konsum von Cannabis hat eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es Tausende von peer-reviewed wissenschaftlichen Publikationen, die die zugrunde liegenden biochemischen Wege, die Cannabinoide modulieren dokumentieren.
Bei Cannabis Science, verwenden wir einen frag Ansatz zur Erforschung und Entwicklung neuartiger Cannabinoid-basierte Therapien, um das Leben der Patienten zu verbessern. Von der Einleitung, haben unsere Gründer zur Förderung und Aufrechterhaltung einer kühnen, Pioniergeist zu fördern, die wahre Natur von Innovationen, von dem bahnbrechenden Ideen gedeihen und sich in evidenzbasierten Lösungen verpflichtet.
Wir sind auf eine enge Zusammenarbeit mit lokalen, nationalen und internationalen Zulassungsbehörden, um den Zugang zu qualitativ hochwertigen, erstklassigen Cannabinoid-Arzneimittel zu den kritisch Bedarf an neuen Behandlungsmethoden für lebensbedrohlichen und schwächenden Bedingungen bieten gewidmet. Die Cannabis Science klinischen Studie Material kommt von den Anbau-und Produktionseinrichtungen, die GMP-konform sind und übertraf damit hohen Qualitätsstandard Industrie-und Lebensmittelverarbeitungsanforderungen.
Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil-Charakterisierung und klinische Forschung zu entwickeln, produzieren und vermarkten neue therapeutische Ansätze für die Behandlung von Beschwerden, die durch mehrere kritische Krebs und Infektionen zu altersbedingten Krankheiten.
Produkte, allgemein beschrieben, sind medizinische Cannabinoid-Formulierungen von einem oder mehreren der Cannabinoid-Verbindungen, die in der Cannabispflanze gefunden entwickelt. Unsere Unmittelbares Ziel ist es eine der wichtigsten Krankheiten in der Welt, Krebs zu behandeln.
CS-S/BCC1 ist in Vorbereitung zur klinischen Phase-I-Studien innerhalb von ein bis 2 Jahre geben. Dieses Produkt ist für die topische Verabreichung in Phase-I-Studie getestet wird, mit einer Anzeige für Hautkrebs formuliert.
CS-TATI1 ist in der präklinischen Entwicklung mit der Indikation für Infektionskrankheit. In Übereinstimmung mit Daten März von Forschern an der Berg Sinai School of Medicine veröffentlicht wurde, fand, dass Cannabinoide hemmen TAT induzierte Migration auf TAT über Cannabinoid-2-Rezeptoren (CB2), die potenzielle Anwendungen in der HIV und anderen Infektionskrankheiten hat.
Im Jahr 2013 legte Cannabis Science Patentanmeldung N2010968 in Europa mit dem Titel "Zusammensetzung für die Behandlung von Neuropsychologische Störungen." Der Gegenstand des Patents ist die Entwicklung von Cannabinoid-basierte Formulierungen, eine Vielzahl von neurologisch-Erkrankungen wie Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) und Angst zu behandeln. Die erste Formulierung in der Reihe der neurologisch-Störung gezielt Produkte ist der prä-klinischen Entwicklung und Nutzung der Erfindung in Lebensmitteln durch ein Lizenzabkommen mit Partnerunternehmen, ENDOCAN Corporation, Inc. Und Cannabis Science, werden diese auf der gleichen Zeit mit Bewegung Entwicklung pharmazeutischer Qualität.
Basis & Philosophy Basis & Philosophie
Cannabis Pflanzen haben umfangreiche Geschichte der medizinischen und landwirtschaftlichen Nutzung aus Tausenden von Jahren.
Bis heute Hunderte von natürlichen Bestandteilen, die mehrere chemische Klassen wurden isoliert und aus der Cannabis-Pflanze identifiziert.
Einige Schlüssel Phytocannabinoiden sind:
Tetrahydrocannabinol (THC)Cannabidiol (CBD)Cannabigerol (CBG)Cannabichromen (CBC)Cannabinol (CBN)
Diese Cannabinoide gehören zur chemischen Klasse der terpenophenolics, von denen 85 wurden eindeutig in Cannabis identifiziert, darunter die psychoaktive Cannabinoid THC. Einige Anwendungen von Cannabinoiden wurden auch in Peer-Review-Literatur wie zur Linderung von Übelkeit und Stimulierung des Appetits für Menschen mit AIDS und Krebs etabliert. Weitere bekannte Anwendungen sind lindert chronische Schmerzen, reduziert Muskelkrämpfe mit Multipler Sklerose und Rückenmarksverletzungen verbunden.
Die Pharmakologie von THC wurde vielfach untersucht, während viele andere Cannabinoide identifiziert sind immer noch schlecht pharmakologisch und biologisch ist, mit neuen Aktivitäten für Cannabinoide konsequent entdeckt.
Cannabis Science wird die Entwicklung neuartiger Ansätze zur Cannabisbasis der weltweit tödlichsten Krankheiten zu behandeln. Wir lernen von Patienten über die heilende Wirkung von Cannabis-Medikamenten.Unsere unmittelbare Schwerpunkt ist die Entwicklung von innovativen Krebstherapien.
Zukünftigen Bemühungen des Unternehmens zählen Infektionskrankheiten, neurologische Verhaltensstörungen wie Aufmerksamkeitsstörungen, posttraumatischen Belastungsstörung und einer Anwendung der anti-inflammatorische Aktivitäten von Cannabis bei der Behandlung von altersbedingten Krankheiten.
Das Endocannabinoid-System von allen Wirbeltieren besaß regelt alle Körpersysteme und hält die Homöostase. Als solche sind die Mechanismen der biologischen Wirkung Phytocannabinoiden "mehrdimensional.
Während die Konzentration auf unsere Kernaktivitäten der Entdeckung und Entwicklung von Behandlungen, die einen sinnvollen Unterschied in das Leben der Patienten machen wird, bleiben wir bewusst, dass wir andere Aufgaben zu den Ärzten, die unsere Medikamente, Gesundheitsbehörden auf der ganzen Welt, unsere Aktionäre, unsere Mitarbeiter zu nutzen, und die Gemeinden, in denen wir leben und arbeiten. Wir sind stets bemüht, unsere unternehmerische Verantwortung Standards und Aktivitäten zu verbessern, die Umsetzung umfassender ethischer Standards und Durchführung Patienten und die Gemeinschaft fortschreitende Initiativen.
Diese Prinzipien spiegeln die Mission der Cannabis Science, innovative Therapeutika für bislang ungedeckten medizinischen Bedarf zu liefern.
Als Branchenführer, berät und führt andere aufstrebende Unternehmen, die Cannabis Science glaubt, hat eine bevorzugte Geschäftsmodell, eine, die zu einem wichtigen Geschäftsmodell in der Zukunft fällig werden Cannabis Science. Unsere Beratung ist auf der gesamten "Samen auf den Verkauf" mit einem Fokus auf Bio-Pharma-Entwicklungsprozess.
Cannabis Science ist einer der am längsten bestehende Unternehmen in der Cannabis-Geschäft.
Wir glauben, dass der richtige Weg ist, um in der Branche von einem bio-pharmazeutischen Standpunkt aus, in einer Weise, die Cannabinoid-basierte Produkte, die Endocannabinoid-System, um mehrere Bedingungen zu behandeln modulieren kann. Wissenschaftlich, wissen wir, das ist der Beginn einer der größten Erweiterungen der Medizin und Industrie, die wir je in unserem Leben erfahren
www.cannabisscience.com
Bei Cannabis Science, verwenden wir einen frag Ansatz zur Erforschung und Entwicklung neuartiger Cannabinoid-basierte Therapien, um das Leben der Patienten zu verbessern. Von der Einleitung, haben unsere Gründer zur Förderung und Aufrechterhaltung einer kühnen, Pioniergeist zu fördern, die wahre Natur von Innovationen, von dem bahnbrechenden Ideen gedeihen und sich in evidenzbasierten Lösungen verpflichtet.
Wir sind auf eine enge Zusammenarbeit mit lokalen, nationalen und internationalen Zulassungsbehörden, um den Zugang zu qualitativ hochwertigen, erstklassigen Cannabinoid-Arzneimittel zu den kritisch Bedarf an neuen Behandlungsmethoden für lebensbedrohlichen und schwächenden Bedingungen bieten gewidmet. Die Cannabis Science klinischen Studie Material kommt von den Anbau-und Produktionseinrichtungen, die GMP-konform sind und übertraf damit hohen Qualitätsstandard Industrie-und Lebensmittelverarbeitungsanforderungen.
Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil-Charakterisierung und klinische Forschung zu entwickeln, produzieren und vermarkten neue therapeutische Ansätze für die Behandlung von Beschwerden, die durch mehrere kritische Krebs und Infektionen zu altersbedingten Krankheiten.
Produkte, allgemein beschrieben, sind medizinische Cannabinoid-Formulierungen von einem oder mehreren der Cannabinoid-Verbindungen, die in der Cannabispflanze gefunden entwickelt. Unsere Unmittelbares Ziel ist es eine der wichtigsten Krankheiten in der Welt, Krebs zu behandeln.
CS-S/BCC1 ist in Vorbereitung zur klinischen Phase-I-Studien innerhalb von ein bis 2 Jahre geben. Dieses Produkt ist für die topische Verabreichung in Phase-I-Studie getestet wird, mit einer Anzeige für Hautkrebs formuliert.
CS-TATI1 ist in der präklinischen Entwicklung mit der Indikation für Infektionskrankheit. In Übereinstimmung mit Daten März von Forschern an der Berg Sinai School of Medicine veröffentlicht wurde, fand, dass Cannabinoide hemmen TAT induzierte Migration auf TAT über Cannabinoid-2-Rezeptoren (CB2), die potenzielle Anwendungen in der HIV und anderen Infektionskrankheiten hat.
Im Jahr 2013 legte Cannabis Science Patentanmeldung N2010968 in Europa mit dem Titel "Zusammensetzung für die Behandlung von Neuropsychologische Störungen." Der Gegenstand des Patents ist die Entwicklung von Cannabinoid-basierte Formulierungen, eine Vielzahl von neurologisch-Erkrankungen wie Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) und Angst zu behandeln. Die erste Formulierung in der Reihe der neurologisch-Störung gezielt Produkte ist der prä-klinischen Entwicklung und Nutzung der Erfindung in Lebensmitteln durch ein Lizenzabkommen mit Partnerunternehmen, ENDOCAN Corporation, Inc. Und Cannabis Science, werden diese auf der gleichen Zeit mit Bewegung Entwicklung pharmazeutischer Qualität.
Basis & Philosophy Basis & Philosophie
Cannabis Pflanzen haben umfangreiche Geschichte der medizinischen und landwirtschaftlichen Nutzung aus Tausenden von Jahren.
Bis heute Hunderte von natürlichen Bestandteilen, die mehrere chemische Klassen wurden isoliert und aus der Cannabis-Pflanze identifiziert.
Einige Schlüssel Phytocannabinoiden sind:
Tetrahydrocannabinol (THC)Cannabidiol (CBD)Cannabigerol (CBG)Cannabichromen (CBC)Cannabinol (CBN)
Diese Cannabinoide gehören zur chemischen Klasse der terpenophenolics, von denen 85 wurden eindeutig in Cannabis identifiziert, darunter die psychoaktive Cannabinoid THC. Einige Anwendungen von Cannabinoiden wurden auch in Peer-Review-Literatur wie zur Linderung von Übelkeit und Stimulierung des Appetits für Menschen mit AIDS und Krebs etabliert. Weitere bekannte Anwendungen sind lindert chronische Schmerzen, reduziert Muskelkrämpfe mit Multipler Sklerose und Rückenmarksverletzungen verbunden.
Die Pharmakologie von THC wurde vielfach untersucht, während viele andere Cannabinoide identifiziert sind immer noch schlecht pharmakologisch und biologisch ist, mit neuen Aktivitäten für Cannabinoide konsequent entdeckt.
Cannabis Science wird die Entwicklung neuartiger Ansätze zur Cannabisbasis der weltweit tödlichsten Krankheiten zu behandeln. Wir lernen von Patienten über die heilende Wirkung von Cannabis-Medikamenten.Unsere unmittelbare Schwerpunkt ist die Entwicklung von innovativen Krebstherapien.
Zukünftigen Bemühungen des Unternehmens zählen Infektionskrankheiten, neurologische Verhaltensstörungen wie Aufmerksamkeitsstörungen, posttraumatischen Belastungsstörung und einer Anwendung der anti-inflammatorische Aktivitäten von Cannabis bei der Behandlung von altersbedingten Krankheiten.
Das Endocannabinoid-System von allen Wirbeltieren besaß regelt alle Körpersysteme und hält die Homöostase. Als solche sind die Mechanismen der biologischen Wirkung Phytocannabinoiden "mehrdimensional.
Während die Konzentration auf unsere Kernaktivitäten der Entdeckung und Entwicklung von Behandlungen, die einen sinnvollen Unterschied in das Leben der Patienten machen wird, bleiben wir bewusst, dass wir andere Aufgaben zu den Ärzten, die unsere Medikamente, Gesundheitsbehörden auf der ganzen Welt, unsere Aktionäre, unsere Mitarbeiter zu nutzen, und die Gemeinden, in denen wir leben und arbeiten. Wir sind stets bemüht, unsere unternehmerische Verantwortung Standards und Aktivitäten zu verbessern, die Umsetzung umfassender ethischer Standards und Durchführung Patienten und die Gemeinschaft fortschreitende Initiativen.
Diese Prinzipien spiegeln die Mission der Cannabis Science, innovative Therapeutika für bislang ungedeckten medizinischen Bedarf zu liefern.
Als Branchenführer, berät und führt andere aufstrebende Unternehmen, die Cannabis Science glaubt, hat eine bevorzugte Geschäftsmodell, eine, die zu einem wichtigen Geschäftsmodell in der Zukunft fällig werden Cannabis Science. Unsere Beratung ist auf der gesamten "Samen auf den Verkauf" mit einem Fokus auf Bio-Pharma-Entwicklungsprozess.
Cannabis Science ist einer der am längsten bestehende Unternehmen in der Cannabis-Geschäft.
Wir glauben, dass der richtige Weg ist, um in der Branche von einem bio-pharmazeutischen Standpunkt aus, in einer Weise, die Cannabinoid-basierte Produkte, die Endocannabinoid-System, um mehrere Bedingungen zu behandeln modulieren kann. Wissenschaftlich, wissen wir, das ist der Beginn einer der größten Erweiterungen der Medizin und Industrie, die wir je in unserem Leben erfahren
www.cannabisscience.com
Es scheint Boom-Zeiten in Arizona für medizinisches Marihuana Umsatz werden.Laut einem Artikel, den ich geschickt wurde, gekrönt medizinischen Marihuana-Verkaufs vierzig Millionen Dollar in diesem Jahr. 2014 sieht noch heller sein. Unten ist der Artikel, die mir von meinen Freunden in gesendetazmarijuana.com :
Ein Bericht 2013 von der Arizona Department of Health Services hat ergeben, dass in den letzten 12 Monaten Arizona Apotheken verkauft haben rund 40 Millionen US-Dollar in Marihuana (einschließlich Esswaren ). Diese Zahl zählt Arizona in den fünf größten medizinischen Marihuana-Märkte in den Vereinigten Staaten, wenn sie auf einen Jahresumsatz.
Derzeit gibt es 77 Apotheken , die in Arizona. Das beläuft sich auf knapp über $ 500.000 Umsatz pro Apotheke , aber viele von denen 77 Apotheken in den letzten Monaten eröffnet. Also in der Realität, machte ein paar Arizona Apotheken Millionen, während die anderen gerade erst eröffnet und vielleicht ein paar hunderttausend gemacht haben.
Bei so vielen Ausgabestellen in Betrieb, werden die einen Jahresumsatz von Marihuana erwartet im Jahr 2014 deutlich erhöht.
Haben Sie für medizinisches Marihuana in Arizona zu qualifizieren ? Wenn dem so ist, finden Sie eine Arizona Marihuana Arzt hier.
Ein Bericht 2013 von der Arizona Department of Health Services hat ergeben, dass in den letzten 12 Monaten Arizona Apotheken verkauft haben rund 40 Millionen US-Dollar in Marihuana (einschließlich Esswaren ). Diese Zahl zählt Arizona in den fünf größten medizinischen Marihuana-Märkte in den Vereinigten Staaten, wenn sie auf einen Jahresumsatz.
Derzeit gibt es 77 Apotheken , die in Arizona. Das beläuft sich auf knapp über $ 500.000 Umsatz pro Apotheke , aber viele von denen 77 Apotheken in den letzten Monaten eröffnet. Also in der Realität, machte ein paar Arizona Apotheken Millionen, während die anderen gerade erst eröffnet und vielleicht ein paar hunderttausend gemacht haben.
Bei so vielen Ausgabestellen in Betrieb, werden die einen Jahresumsatz von Marihuana erwartet im Jahr 2014 deutlich erhöht.
Haben Sie für medizinisches Marihuana in Arizona zu qualifizieren ? Wenn dem so ist, finden Sie eine Arizona Marihuana Arzt hier.
!
Dieser Beitrag wurde von ArbiMod moderiert. Grund: Spam, Werbung
Es gibt NEWS:
http://ih.advfn.com/p.php?pid=nmona&article=61154033
COLORADO SPRINGS, Colo., Feb. 20, 2014 /PRNewswire/ -- (OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, has agreed to finance $1 million to satisfy its current capital requirements. Cannabis Science is raising the $1 million through private placement. The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering.
The financing is being headed by affiliates and associates followed by an assorted group of individuals that have shown a strong interest in moving Cannabis Science's projects forward immediately. Initial commitments exceed $100,000.00 and the Company has received the first $50,000.00. The intended projects include fast tracking cancer initiatives and its observational studies for the existing CBN patent the Company filed last year. Information about that patent can be found here:
http://cannabisscience.com/index.php/news-media/news-release…
"The market has shown an overwhelming interest in our story. This comes at the perfect time as our projects are coming to a point of maturity that will allow us to take the next important steps forward. These steps should create revenues that will support Cannabis Science going forward on an ongoing basis," stated Robert Kane, CFO of Cannabis Science.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
http://ih.advfn.com/p.php?pid=nmona&article=61154033
COLORADO SPRINGS, Colo., Feb. 20, 2014 /PRNewswire/ -- (OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, has agreed to finance $1 million to satisfy its current capital requirements. Cannabis Science is raising the $1 million through private placement. The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering.
The financing is being headed by affiliates and associates followed by an assorted group of individuals that have shown a strong interest in moving Cannabis Science's projects forward immediately. Initial commitments exceed $100,000.00 and the Company has received the first $50,000.00. The intended projects include fast tracking cancer initiatives and its observational studies for the existing CBN patent the Company filed last year. Information about that patent can be found here:
http://cannabisscience.com/index.php/news-media/news-release…
"The market has shown an overwhelming interest in our story. This comes at the perfect time as our projects are coming to a point of maturity that will allow us to take the next important steps forward. These steps should create revenues that will support Cannabis Science going forward on an ongoing basis," stated Robert Kane, CFO of Cannabis Science.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Antwort auf Beitrag Nr.: 46.497.315 von JOtheViper am 20.02.14 16:53:22Salut
Just 4 Fun
à bientôt
OC
Just 4 Fun
à bientôt
OC
Antwort auf Beitrag Nr.: 46.513.465 von occitania am 24.02.14 15:28:45Salut
http://ireport.cnn.com/docs/DOC-1094726#
à bientôt
OC
http://ireport.cnn.com/docs/DOC-1094726#
à bientôt
OC
Antwort auf Beitrag Nr.: 46.513.789 von occitania am 24.02.14 16:16:10Salut
http://finance.yahoo.com/news/primco-management-enters-joint…
à bientôt
OC
http://finance.yahoo.com/news/primco-management-enters-joint…
à bientôt
OC
Antwort auf Beitrag Nr.: 46.513.835 von occitania am 24.02.14 16:20:28Salut
Links die ich brauche
http://www.nasdaq.com/symbol/cbis
http://www.marketwatch.com/investing/Stock/CBIS
Euch noch 1 schönen Tag
à bientôt
OC
Links die ich brauche
http://www.nasdaq.com/symbol/cbis
http://www.marketwatch.com/investing/Stock/CBIS
Euch noch 1 schönen Tag
à bientôt
OC
Antwort auf Beitrag Nr.: 46.518.491 von occitania am 25.02.14 11:53:10Salut
Ich glaube hier wird verwässert oder ?
à bientôt
OC
Ich glaube hier wird verwässert oder ?
à bientôt
OC
Hat sich doch gut gehalten gestern. Der gesamte Markt war rot. Die 0,17 ist ein starker Boden.
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Postings von Doppel-IDs!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Postings von Doppel-IDs!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Postings von Doppel-IDs
Antwort auf Beitrag Nr.: 46.523.981 von nordkappe am 26.02.14 06:33:55Salut
Aus I-Hub
http://www.cnbc.com/id/101412302
à bientôt
OC
à propos:2x 1 Million AH bei CBIS...
Dillution ?
Aus I-Hub
http://www.cnbc.com/id/101412302
à bientôt
OC
à propos:2x 1 Million AH bei CBIS...
Dillution ?
Antwort auf Beitrag Nr.: 46.526.451 von occitania am 26.02.14 12:50:04Salut
http://www.marketwatch.com/story/ntrr-tax-bonanza-could-conv…
à bientôt
OC
http://www.marketwatch.com/story/ntrr-tax-bonanza-could-conv…
à bientôt
OC
Warum schmiert der Kurs so ab?
Weil nach neuen Werten, wie Abattis Bioceuticals gesucht wird.
Diese News treibt den Kurs seit gestern wieder
http://finance.yahoo.com/news/cannabis-science-operational-f…
http://finance.yahoo.com/news/cannabis-science-operational-f…
Antwort auf Beitrag Nr.: 47.091.558 von rep am 03.06.14 10:11:21Neue Mehrheitsverhältnisse dazu siehe 8-.K von gestern.
Da ist Musik drin diese Woche.
Da ist Musik drin diese Woche.
Hat jemand eine Meinung zum jetzigen Zeitpunkt?
Gruss.
Gruss.
Cannabis Science Inc. (CBIS) Details:Cannabis Science, Inc. entwickelt, produziert und vermarktet phytocannabinoid-basierte pharmazeutische Produkte. Es entwickelt Medikamente zu Autismus, Blutdruck, Krebs und Krebsnebenwirkungen und andere Krankheiten, einschließlich der allgemeinen Erhaltung der Gesundheit zu behandeln. Das Unternehmen entwickelt CS-TATI-1 für neu diagnostizierte und Behandlungs-erfahrenen Patienten mit Medikamenten-resistenten HIV-Stämme; CS-S / BCC-1 für Basis-und Plattenepithelkarzinome; und eine proprietäre Cannabis-basierte Therapie für neurologische Erkrankungen. Darüber hinaus bietet es einen Online-Video-basierte medizinische Cannabisbildungssystem, das verschiedene Kurse, wie medizinische Cannabisgesetz, medizinische Marihuana, Kochen, Gartenbau, und Knospe Beschickung. Das Unternehmen hat eine Lizenzvereinbarung mit Apotheker Genetik Investments LLC. zu verschiedenen Marken Formulierungen für Kalifornien medizinischen Cannabis Markt. Cannabis Science, Inc. ist in Colorado Springs, Colorado.
Detaillierte CBIS: US Firmenbeschreibung ...
www.cannabisscience.com
http://translate.google.de/translate?hl=de&sl=en&u=http://in…
Detaillierte CBIS: US Firmenbeschreibung ...
www.cannabisscience.com
http://translate.google.de/translate?hl=de&sl=en&u=http://in…
Antwort auf Beitrag Nr.: 48.042.598 von Vaterland am 15.10.14 14:03:55Cannabis Science, Inc. (CBIS) Schilder Drug Development and Laboratory Services Agreement mit ImmunoClin Corporation (IMCL); Zusammenarbeit zu klinischen Studien und Formulierungen des Unternehmens Proprietary Cannabinoid-basierte Produkte Voraus
COLORADO SPRINGS., Sept. 29 2014 / PRNewswire / - Cannabis Science, Inc. ( OTCQB: CBIS ), ein US-Unternehmen, spezialisiert auf Cannabis-basierte Formulierung der Arzneimittelentwicklung und der damit verbundenen Beratungs, hat sich in einem Labor-Services-Vertrag mit ImmunoClin Corporation (IMCL) durch seine hundert eingetragen ige Tochtergesellschaft in Großbritannien, ImmunoClin Ltd, ein Unternehmen im Gesundheitswesen mit mehr als 13 Jahre Erfahrung in der Bereitstellung Premiere Labor und die damit verbundenen Vor-und klinischen Forschungsdienstleistungen im kommerziellen Maßstab.
"Mit ImmunoClin Erfolgsbilanz bei der Unterstützung der Biotechnologie, Pharma und Lebensmittelunternehmen sowie öffentliche Institutionen in der pharmazeutischen und Nahrungsergänzungsmittel Entwicklungsprojekte, wir sind begeistert, diese langfristige Beziehung zwischen ImmunoClin und CBIS in der Cannabinoid-Forschungsfeld zu initiieren. Wir weiter von der profitieren Tatsache, dass ImmunoClin Gründer Dr. Dorothy Bray, ist eine klinische Entwicklungsexperte und dient derzeit als Direktor, Präsident und CEO beider Unternehmen, wodurch reibungslose und effektive Zusammenarbeit gewährleistet ", erklärte Herr Mario S. Lap, Direktor und Präsident der European Operations, Cannabis Science, Inc.
"Mit dem Vertrag in Kraft, wollen wir schnell und effizient zu Cannabis Science in der Entwicklung proprietärer Formulierungen seiner Cannabinoid-basierte Produkte, um Patienten in Not helfen zu bringen", sagte Khadija Benlhassan, Ph.D., Direktor und Chief Scientific Officer, ImmunoClin Corporation.
Cannabis Science wird erwartet, dass ImmunoClin Cannabinoid-basierte Arzneimittelformulierung in den Labors in den kommenden Wochen beginnen, einschließlich der erweiterten Entwicklung des Cannabis Science proprietären neurologische Droge, vorläufig als "CS-Neuro-1" bezeichnet. Dieser Vertrag ergänzt die Agrar-und Forschungsprogramme des Unternehmens in Spanien, Italien und anderen europäischen Ländern.
"Cannabis Science freut sich auf die Zusammenarbeit mit ImmunoClin in der Entwicklung der CS-Neuro-1, CS-TATI-1, CS-S / BCC-1 und andere Produkte der Cannabis Science-Pipeline, die wir glauben, wird das Leben der Verbesserung Menschen auf der ganzen Welt ", schloss Herr Lap.
Über ImmunoClin Corporation,
ImmunoClin Corporation ist ein USA Healthcare-Unternehmen mit Hauptsitz in Washington, DC, USA, Europa-Zentrale und Laboreinrichtungen in London, Großbritannien und Labors im Zentrum von Paris, Frankreich. ImmunoClin konzentriert sich auf die Entwicklung von Innovationen personalisierte und präventive Strategien zu entzündlichen Bedingungen, die die zugrunde liegende Ursache von Krankheiten in mehrere Bedingungen die Mehrheit der menschlichen Bevölkerung beeinflussen, sind zu kämpfen: Infektionen, Krebs, Herz-Kreislauf-Krankheit und Demenz, einschließlich Alzheimer-Krankheit. Darüber hinaus bietet ImmunoClin wählen Drittunternehmen mit spezialisierten Labor-und Forschungsdienstleistungen.
Über Cannabis Science, Inc.
Cannabis Science, Inc., nutzt die einzigartige Verständnis der metabolischen Prozesse, neuartige Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Veröffentlichungen, die die zugrunde liegenden biochemischen Wege, die Cannabinoide modulieren dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil Charakterisierung und klinische Forschung zu entwickeln, zu produzieren und zu vermarkten neue therapeutische Ansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheiten verursacht. Unser Fokus liegt zunächst auf Hautkrebs und neurologischen Erkrankungen.
Zukunftsgerichtete Aussagen
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Securities Act von 1933 und Abschnitt 21E des Securities Act von 1934 eine Erklärung, Wörter wie "antizipieren", "suchen", beabsichtigen ", mit" glauben, "," schätzen "," erwarten "," projizieren "," planen "oder ähnliche Ausdrücke können als" zukunftsgerichtete Aussagen "im Sinne des Private Securities Litigation Reform Act von 1995 einige oder alle der Ereignisse oder Ergebnisse die in diesen zukunftsgerichteten Aussagen erheblich abweichen. Faktoren, die dazu führen oder dazu beitragen, diese Unterschiede sind die künftigen US-und die Weltwirtschaft, die Auswirkungen des Wettbewerbs und der Gesellschaft unabhängig von bestehenden Vorschriften in Bezug auf die Nutzung und Entwicklung von Cannabis-basierte Medikamente erwartet . Cannabis Science, Inc., hat keine Verpflichtung und beabsichtigt nicht, die Ergebnisse dieser zukunftsgerichteten Aussagen zu aktualisieren.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investitionsanfragen
Robert Kane, CFO und Direktor
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Unternehmensberater, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.
https://translate.google.de/translate?sl=en&tl=de&js=y&prev=…
COLORADO SPRINGS., Sept. 29 2014 / PRNewswire / - Cannabis Science, Inc. ( OTCQB: CBIS ), ein US-Unternehmen, spezialisiert auf Cannabis-basierte Formulierung der Arzneimittelentwicklung und der damit verbundenen Beratungs, hat sich in einem Labor-Services-Vertrag mit ImmunoClin Corporation (IMCL) durch seine hundert eingetragen ige Tochtergesellschaft in Großbritannien, ImmunoClin Ltd, ein Unternehmen im Gesundheitswesen mit mehr als 13 Jahre Erfahrung in der Bereitstellung Premiere Labor und die damit verbundenen Vor-und klinischen Forschungsdienstleistungen im kommerziellen Maßstab.
"Mit ImmunoClin Erfolgsbilanz bei der Unterstützung der Biotechnologie, Pharma und Lebensmittelunternehmen sowie öffentliche Institutionen in der pharmazeutischen und Nahrungsergänzungsmittel Entwicklungsprojekte, wir sind begeistert, diese langfristige Beziehung zwischen ImmunoClin und CBIS in der Cannabinoid-Forschungsfeld zu initiieren. Wir weiter von der profitieren Tatsache, dass ImmunoClin Gründer Dr. Dorothy Bray, ist eine klinische Entwicklungsexperte und dient derzeit als Direktor, Präsident und CEO beider Unternehmen, wodurch reibungslose und effektive Zusammenarbeit gewährleistet ", erklärte Herr Mario S. Lap, Direktor und Präsident der European Operations, Cannabis Science, Inc.
"Mit dem Vertrag in Kraft, wollen wir schnell und effizient zu Cannabis Science in der Entwicklung proprietärer Formulierungen seiner Cannabinoid-basierte Produkte, um Patienten in Not helfen zu bringen", sagte Khadija Benlhassan, Ph.D., Direktor und Chief Scientific Officer, ImmunoClin Corporation.
Cannabis Science wird erwartet, dass ImmunoClin Cannabinoid-basierte Arzneimittelformulierung in den Labors in den kommenden Wochen beginnen, einschließlich der erweiterten Entwicklung des Cannabis Science proprietären neurologische Droge, vorläufig als "CS-Neuro-1" bezeichnet. Dieser Vertrag ergänzt die Agrar-und Forschungsprogramme des Unternehmens in Spanien, Italien und anderen europäischen Ländern.
"Cannabis Science freut sich auf die Zusammenarbeit mit ImmunoClin in der Entwicklung der CS-Neuro-1, CS-TATI-1, CS-S / BCC-1 und andere Produkte der Cannabis Science-Pipeline, die wir glauben, wird das Leben der Verbesserung Menschen auf der ganzen Welt ", schloss Herr Lap.
Über ImmunoClin Corporation,
ImmunoClin Corporation ist ein USA Healthcare-Unternehmen mit Hauptsitz in Washington, DC, USA, Europa-Zentrale und Laboreinrichtungen in London, Großbritannien und Labors im Zentrum von Paris, Frankreich. ImmunoClin konzentriert sich auf die Entwicklung von Innovationen personalisierte und präventive Strategien zu entzündlichen Bedingungen, die die zugrunde liegende Ursache von Krankheiten in mehrere Bedingungen die Mehrheit der menschlichen Bevölkerung beeinflussen, sind zu kämpfen: Infektionen, Krebs, Herz-Kreislauf-Krankheit und Demenz, einschließlich Alzheimer-Krankheit. Darüber hinaus bietet ImmunoClin wählen Drittunternehmen mit spezialisierten Labor-und Forschungsdienstleistungen.
Über Cannabis Science, Inc.
Cannabis Science, Inc., nutzt die einzigartige Verständnis der metabolischen Prozesse, neuartige Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Veröffentlichungen, die die zugrunde liegenden biochemischen Wege, die Cannabinoide modulieren dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil Charakterisierung und klinische Forschung zu entwickeln, zu produzieren und zu vermarkten neue therapeutische Ansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheiten verursacht. Unser Fokus liegt zunächst auf Hautkrebs und neurologischen Erkrankungen.
Zukunftsgerichtete Aussagen
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Securities Act von 1933 und Abschnitt 21E des Securities Act von 1934 eine Erklärung, Wörter wie "antizipieren", "suchen", beabsichtigen ", mit" glauben, "," schätzen "," erwarten "," projizieren "," planen "oder ähnliche Ausdrücke können als" zukunftsgerichtete Aussagen "im Sinne des Private Securities Litigation Reform Act von 1995 einige oder alle der Ereignisse oder Ergebnisse die in diesen zukunftsgerichteten Aussagen erheblich abweichen. Faktoren, die dazu führen oder dazu beitragen, diese Unterschiede sind die künftigen US-und die Weltwirtschaft, die Auswirkungen des Wettbewerbs und der Gesellschaft unabhängig von bestehenden Vorschriften in Bezug auf die Nutzung und Entwicklung von Cannabis-basierte Medikamente erwartet . Cannabis Science, Inc., hat keine Verpflichtung und beabsichtigt nicht, die Ergebnisse dieser zukunftsgerichteten Aussagen zu aktualisieren.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investitionsanfragen
Robert Kane, CFO und Direktor
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Unternehmensberater, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.
https://translate.google.de/translate?sl=en&tl=de&js=y&prev=…
Antwort auf Beitrag Nr.: 48.042.709 von Vaterland am 15.10.14 14:11:28Homepage in Deutsch hier: https://translate.googleusercontent.com/translate_c?act=url&…
Antwort auf Beitrag Nr.: 48.042.739 von Vaterland am 15.10.14 14:13:07https://translate.googleusercontent.com/translate_c?act=url&…
Cannabinoid Overview Cannabinoid-Übersicht
https://translate.googleusercontent.com/translate_c?act=url&…
https://translate.googleusercontent.com/translate_c?act=url&…
Cannabis Science Mitteilungen positiven Laborbefunden aus der EU Certified sowie seine eigenen einzigartigen Cannabis Stämme G ...
Cannabis Science, Inc. (QB) (USOTC: CBIS)
Intraday Aktien-Chart
Heute: Dienstag 28. Oktober 2014
COLORADO SPRINGS, 28. Oktober 2014 / PRNewswire / - Cannabis Science, Inc.. (OTC: CBIS), ein US-Unternehmen, spezialisiert auf Cannabis Formulierung basierten Medikamentenentwicklung und der damit verbundenen Beratungs ist sehr zufrieden mit den Laboranalyseberichte es Vor kurzem erhielt. Die Prüfung der Cannabis geerntet mit EU zertifiziert sowie seine eigenen einzigartigen Stämmen produziert Endergebnisse anzeigt, dass ganze Extrakten hergestellt wird nach oben von 20% CBD und weniger als 10% THC enthalten werden. Darüber hinaus sind andere eindeutige Kennungen vorhanden, die mehrere Authentifizierungen auf der Grundlage ihrer signifikanten Art benötigen.
Diese Zahlen sind signifikant auf Basis von Nutzungsdaten und erwartete Behandlungen für viele der Unternehmen gezielte Beschwerden. Das Unternehmen setzt die Untersuchung sowohl seine einzigartige Cannabinoid-Stämme sowie vielversprechende Stämme aus der ganzen Welt für mehrere präklinische Wirkstoffentwicklungsprogramme Targeting Krebs, neurologische Erkrankungen, und ein paar andere gezielte kritische Krankheiten bekannt gegeben.
Herr Mario S. Lap, Direktor und Präsident der European Operations, erklärte: "Der aktuelle Fortschritt ist sehr spannend auf der Grundlage der Zahlen und der Zahl der Ernten haben wir bisher verarbeitet. Kritisch in der Anfangsphase unserer Arzneimittel Diese Daten empfangen Entwicklungsprogramme. Wir sind jetzt auf dem erfolgreichen Skalierbarkeit und Portabilität in Richtung Gesamtextrakte Targeting GMP Produktionsanforderungen für unsere präklinischen Programme konzentriert. Dazu gehören intensive Forschung und Durchführung von Labortests, die in der Cannabispflanze enthaltenen aktiven Bestandteile. Wir glauben, das Potenzial Heil Anwendungen mit Cannabis haben positive Behandlungen Ergebnisse für jeden unserer gezielten Beschwerden gezeigt. "
Über Cannabis Science, Inc.
Cannabis Science, Inc., nutzt seine einzigartige Verständnis der metabolischen Prozesse, neue Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Publikationen, die die zugrunde liegenden biochemischen Wege, Cannabinoide modulieren dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Medikamentenentwicklung, medizinische Charakterisierung und klinische Forschung zu entwickeln, herzustellen und zu vermarkten neue therapeutische Ansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheiten verursacht. Unser Fokus liegt zunächst auf Hautkrebs und neurologischen Erkrankungen.
http://ih.advfn.com/p.php?pid=nmona&article=64194984
Cannabis Science, Inc. (QB) (USOTC: CBIS)
Intraday Aktien-Chart
Heute: Dienstag 28. Oktober 2014
COLORADO SPRINGS, 28. Oktober 2014 / PRNewswire / - Cannabis Science, Inc.. (OTC: CBIS), ein US-Unternehmen, spezialisiert auf Cannabis Formulierung basierten Medikamentenentwicklung und der damit verbundenen Beratungs ist sehr zufrieden mit den Laboranalyseberichte es Vor kurzem erhielt. Die Prüfung der Cannabis geerntet mit EU zertifiziert sowie seine eigenen einzigartigen Stämmen produziert Endergebnisse anzeigt, dass ganze Extrakten hergestellt wird nach oben von 20% CBD und weniger als 10% THC enthalten werden. Darüber hinaus sind andere eindeutige Kennungen vorhanden, die mehrere Authentifizierungen auf der Grundlage ihrer signifikanten Art benötigen.
Diese Zahlen sind signifikant auf Basis von Nutzungsdaten und erwartete Behandlungen für viele der Unternehmen gezielte Beschwerden. Das Unternehmen setzt die Untersuchung sowohl seine einzigartige Cannabinoid-Stämme sowie vielversprechende Stämme aus der ganzen Welt für mehrere präklinische Wirkstoffentwicklungsprogramme Targeting Krebs, neurologische Erkrankungen, und ein paar andere gezielte kritische Krankheiten bekannt gegeben.
Herr Mario S. Lap, Direktor und Präsident der European Operations, erklärte: "Der aktuelle Fortschritt ist sehr spannend auf der Grundlage der Zahlen und der Zahl der Ernten haben wir bisher verarbeitet. Kritisch in der Anfangsphase unserer Arzneimittel Diese Daten empfangen Entwicklungsprogramme. Wir sind jetzt auf dem erfolgreichen Skalierbarkeit und Portabilität in Richtung Gesamtextrakte Targeting GMP Produktionsanforderungen für unsere präklinischen Programme konzentriert. Dazu gehören intensive Forschung und Durchführung von Labortests, die in der Cannabispflanze enthaltenen aktiven Bestandteile. Wir glauben, das Potenzial Heil Anwendungen mit Cannabis haben positive Behandlungen Ergebnisse für jeden unserer gezielten Beschwerden gezeigt. "
Über Cannabis Science, Inc.
Cannabis Science, Inc., nutzt seine einzigartige Verständnis der metabolischen Prozesse, neue Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Publikationen, die die zugrunde liegenden biochemischen Wege, Cannabinoide modulieren dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Medikamentenentwicklung, medizinische Charakterisierung und klinische Forschung zu entwickeln, herzustellen und zu vermarkten neue therapeutische Ansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheiten verursacht. Unser Fokus liegt zunächst auf Hautkrebs und neurologischen Erkrankungen.
http://ih.advfn.com/p.php?pid=nmona&article=64194984
Demand For Cannabis Science Drug Increases As Company Moves Into 2nd Stage Of Protocols For Pre-Clinical Drug Development, Thanks To Positive Laboratory Results From Its Operations In Spain
The successful results, which indicate a successful pre-clinical development launch,include both EU-certified strains and the Company's own unique strains.
COLORADO SPRINGS, Colo., Nov. 13, 2014 /PRNewswire via COMTEX/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce it is moving into 2nd stage cannabinoid production in Spain.
"These events are sparking a much higher demand from the general public regarding access to medical cannabis and information regarding how it can be used to treat various illnesses and disease," said Raymond C. Dabney, President, CEO, Co-Founder and Director of the company. "We are investigating other significant target cannabinoids for increased production."
He said the company is also on track to deliver extensive data on CBD and THC levels, along with treatment regimes for many of its targeted ailments.
"Our year-round growing capabilities give us the ability to meet the growing demand based on the number of delivery methods we are developing for various critical ailments," said Mario S. Lap, Director and President of European Operations. "We will be providing our formulation and developing scalability and portability for our pre-clinical programs that will target GMP production requirements. We're also setting up other patient groups in Spain and other countries to use formulations we developed."
The company's cannabinoid winter production crop is expected to handle its current demand of medications for several targeted ailments. The company is performing 2nd phase experiments and preparing the post-experiment production grow to start early 2015.
The previous testing of the harvested cannabis, which included EU-certified crops as well as the company's own unique strains, produced end results indicating that its whole extracts produced unique identifiers that require multiple authentications based on their significant nature.
"The progress is very exciting thus far," said Dabney. "The data we've received is critical and enables us to focus on successful intensive research and conduct laboratory tests of the active constituents for regiment production. The company believes the potential medicinal applications using cannabis have shown positive treatments results for many targeted ailments."
About Cannabis Science, Inc.Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking StatementsThis Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.Mr. Mario S. Lap, Director, President of European Operationswww.cannabisscience.cominfo@cannabisscience.comTel: 1.888.777.0658
Investment InquiriesRobert Kane, CFO & Directorrobert.kane@cannabisscience.comTel: 1.561.420.4824
Cannabis Science, Inc.Raymond C. Dabney, Management Consultant, Co-Founderraymond@cannabisscience.comTel: 1.310.650.3788
SOURCE Cannabis Science, Inc.
http://rt.prnewswire.com/rt.gif?NewsItemId=LA66226&Transmiss…
www.prnewswire.com
Copyright (C) 2014 PR Newswire. All rights reserved
http://www.otcmarkets.com/stock/CBIS/news
The successful results, which indicate a successful pre-clinical development launch,include both EU-certified strains and the Company's own unique strains.
COLORADO SPRINGS, Colo., Nov. 13, 2014 /PRNewswire via COMTEX/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce it is moving into 2nd stage cannabinoid production in Spain.
"These events are sparking a much higher demand from the general public regarding access to medical cannabis and information regarding how it can be used to treat various illnesses and disease," said Raymond C. Dabney, President, CEO, Co-Founder and Director of the company. "We are investigating other significant target cannabinoids for increased production."
He said the company is also on track to deliver extensive data on CBD and THC levels, along with treatment regimes for many of its targeted ailments.
"Our year-round growing capabilities give us the ability to meet the growing demand based on the number of delivery methods we are developing for various critical ailments," said Mario S. Lap, Director and President of European Operations. "We will be providing our formulation and developing scalability and portability for our pre-clinical programs that will target GMP production requirements. We're also setting up other patient groups in Spain and other countries to use formulations we developed."
The company's cannabinoid winter production crop is expected to handle its current demand of medications for several targeted ailments. The company is performing 2nd phase experiments and preparing the post-experiment production grow to start early 2015.
The previous testing of the harvested cannabis, which included EU-certified crops as well as the company's own unique strains, produced end results indicating that its whole extracts produced unique identifiers that require multiple authentications based on their significant nature.
"The progress is very exciting thus far," said Dabney. "The data we've received is critical and enables us to focus on successful intensive research and conduct laboratory tests of the active constituents for regiment production. The company believes the potential medicinal applications using cannabis have shown positive treatments results for many targeted ailments."
About Cannabis Science, Inc.Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking StatementsThis Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.Mr. Mario S. Lap, Director, President of European Operationswww.cannabisscience.cominfo@cannabisscience.comTel: 1.888.777.0658
Investment InquiriesRobert Kane, CFO & Directorrobert.kane@cannabisscience.comTel: 1.561.420.4824
Cannabis Science, Inc.Raymond C. Dabney, Management Consultant, Co-Founderraymond@cannabisscience.comTel: 1.310.650.3788
SOURCE Cannabis Science, Inc.
http://rt.prnewswire.com/rt.gif?NewsItemId=LA66226&Transmiss…
www.prnewswire.com
Copyright (C) 2014 PR Newswire. All rights reserved
http://www.otcmarkets.com/stock/CBIS/news
November 20, 2014 - 7:17 AM EST
closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
Cannabis Science Advances its Move into African Market from HIV to Cancer to the Ebola Virus With a Series of High-Level Meetings in Washington, D.C.
Focused Efforts, Clinical Initiatives, Research Centers, and Furthering Health Education while Establishing Relationships with Multiple Governments and Non-Governmental Organizations
COLORADO SPRINGS, Colo., Nov. 20, 2014 /PRNewswire/ -- As part of its multi-pronged move into Africa, the CEO of Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, joined a delegation lead by Melvin Foote, Founder, President & CEO of the Constituency for Africa (CFA) that met with Congresswoman Karen D. Bass (D-CA) and other key stakeholders.
On Tuesday, Cannabis Science President & CEO Raymond C. Dabney and Director & COO Chad S. Johnson, Esq., joined a 20-person delegation from the CFA that met with Congresswoman Karen D. Bass (D-CA), ranking member of the House Subcommittee on Africa, to discuss U.S. - Africa priorities.
The CFA delegation included Melvin Foote, CFA, Founder, President and CEO; Dr. Roscoe Moore, CFA Interim Chairman and a Special Senior Advisor to Cannabis Science; Dr. Johnnetta B. Cole, Director of the Smithsonian National Museum on African Art; Darius Mans, President of Africare; Mamadou Beye, Director of International Relations for Chevron; former U.S. Ambassador to the Republic of the Congo Dr. Robin R. Sanders; Dr. Monde Muyangwa, Director of the Africa Program of the Woodrow Wilson Center; and other key stakeholders.
"The meetings went very well. From HIV to Cancer to the Ebola virus, it's clear that Africa should be a focus for the unique cannabinoid therapeutic approaches that Cannabis Science is working to develop. We're targeting very serious health issues with success and that's why we're making some very strategic inroads in the region. We're very pleased with the reception we're getting, both in Washington and Africa itself," said Mr. Dabney.
Priority issues included the renewal of the African Growth and Opportunity Act (AGOA); the U.S. response to the Ebola crisis; the priority of STEM in Africa; Diaspora engagement; and follow-up to the U.S. - Africa Leaders Summit.
Melvin Foote stated, "It is always great to sit down with Congresswoman Karen Bass, who has firmly established herself as a 'point person' for Africa in the U.S. Congress. She is on top of the issues, tireless in her pursuit of rational decisions and very much a team builder. CFA feels it an honor and duty to support Congresswoman Bass in her efforts to craft a forward-thinking and responsive agenda for Africa in the United States."
"I want to congratulate Melvin Foote, Dr. Roscoe Moore, and all the members of the delegation for their ongoing leadership and interest in health and wellness in Africa. Time is of the essence, and their leadership is essential," added Dabney.
A former Assistant U.S. Surgeon General, Dr. Moore also served as the principal liaison between the U.S. Department of Health and Human Services and various Ministries of Health in Africa, focusing on the development of infrastructure and technical support for the delivery of preventive and curative health needs. In his role with Cannabis Science, Moore serves as an advisor on clinical research and how best to focus company initiatives to address global public health issues.
Mr. Melvin P. Foote is a pioneer in the field of African Affairs. He has over 35 years of experience and has worked in over 30 African countries. And he is recognized as a leading expert on issues related to African policies and programs. Mr. Foote is also the founder of a dynamic CFA-related program called the African American Unity Caucus (AAUC). The AAUC is a broad-based coalition of African-American and African leaders of Africa-focused organizations and groups, to promote pan-Africanism and to link Diaspora leaders in the Western Hemisphere with the African Union (AU), the coordinating forum of the nations of Africa. Further, Mr. Foote serves as an advisor to the African Union's Ambassador to Washington and as a consultant to the World Bank on African Diaspora issues.
"We're very excited to announce that Cannabis Science is preparing this aggressive move into the African market with possible acquisitions and clinical initiatives. We're discussing research centers, furthering health education there, and establishing ongoing relationships with multiple governments and non-governmental organizations," concluded Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
SOURCE Cannabis Science, Inc.
Source: PR Newswire (November 20, 2014 - 7:17 AM EST)
News by QuoteMedia
www.quotemedia.com
http://marijuanaindex.org/industry-news-item/
closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
Cannabis Science Advances its Move into African Market from HIV to Cancer to the Ebola Virus With a Series of High-Level Meetings in Washington, D.C.
Focused Efforts, Clinical Initiatives, Research Centers, and Furthering Health Education while Establishing Relationships with Multiple Governments and Non-Governmental Organizations
COLORADO SPRINGS, Colo., Nov. 20, 2014 /PRNewswire/ -- As part of its multi-pronged move into Africa, the CEO of Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, joined a delegation lead by Melvin Foote, Founder, President & CEO of the Constituency for Africa (CFA) that met with Congresswoman Karen D. Bass (D-CA) and other key stakeholders.
On Tuesday, Cannabis Science President & CEO Raymond C. Dabney and Director & COO Chad S. Johnson, Esq., joined a 20-person delegation from the CFA that met with Congresswoman Karen D. Bass (D-CA), ranking member of the House Subcommittee on Africa, to discuss U.S. - Africa priorities.
The CFA delegation included Melvin Foote, CFA, Founder, President and CEO; Dr. Roscoe Moore, CFA Interim Chairman and a Special Senior Advisor to Cannabis Science; Dr. Johnnetta B. Cole, Director of the Smithsonian National Museum on African Art; Darius Mans, President of Africare; Mamadou Beye, Director of International Relations for Chevron; former U.S. Ambassador to the Republic of the Congo Dr. Robin R. Sanders; Dr. Monde Muyangwa, Director of the Africa Program of the Woodrow Wilson Center; and other key stakeholders.
"The meetings went very well. From HIV to Cancer to the Ebola virus, it's clear that Africa should be a focus for the unique cannabinoid therapeutic approaches that Cannabis Science is working to develop. We're targeting very serious health issues with success and that's why we're making some very strategic inroads in the region. We're very pleased with the reception we're getting, both in Washington and Africa itself," said Mr. Dabney.
Priority issues included the renewal of the African Growth and Opportunity Act (AGOA); the U.S. response to the Ebola crisis; the priority of STEM in Africa; Diaspora engagement; and follow-up to the U.S. - Africa Leaders Summit.
Melvin Foote stated, "It is always great to sit down with Congresswoman Karen Bass, who has firmly established herself as a 'point person' for Africa in the U.S. Congress. She is on top of the issues, tireless in her pursuit of rational decisions and very much a team builder. CFA feels it an honor and duty to support Congresswoman Bass in her efforts to craft a forward-thinking and responsive agenda for Africa in the United States."
"I want to congratulate Melvin Foote, Dr. Roscoe Moore, and all the members of the delegation for their ongoing leadership and interest in health and wellness in Africa. Time is of the essence, and their leadership is essential," added Dabney.
A former Assistant U.S. Surgeon General, Dr. Moore also served as the principal liaison between the U.S. Department of Health and Human Services and various Ministries of Health in Africa, focusing on the development of infrastructure and technical support for the delivery of preventive and curative health needs. In his role with Cannabis Science, Moore serves as an advisor on clinical research and how best to focus company initiatives to address global public health issues.
Mr. Melvin P. Foote is a pioneer in the field of African Affairs. He has over 35 years of experience and has worked in over 30 African countries. And he is recognized as a leading expert on issues related to African policies and programs. Mr. Foote is also the founder of a dynamic CFA-related program called the African American Unity Caucus (AAUC). The AAUC is a broad-based coalition of African-American and African leaders of Africa-focused organizations and groups, to promote pan-Africanism and to link Diaspora leaders in the Western Hemisphere with the African Union (AU), the coordinating forum of the nations of Africa. Further, Mr. Foote serves as an advisor to the African Union's Ambassador to Washington and as a consultant to the World Bank on African Diaspora issues.
"We're very excited to announce that Cannabis Science is preparing this aggressive move into the African market with possible acquisitions and clinical initiatives. We're discussing research centers, furthering health education there, and establishing ongoing relationships with multiple governments and non-governmental organizations," concluded Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
SOURCE Cannabis Science, Inc.
Source: PR Newswire (November 20, 2014 - 7:17 AM EST)
News by QuoteMedia
www.quotemedia.com
http://marijuanaindex.org/industry-news-item/
Cannabis Science Advances its Move into African Market from HIV to Cancer to the Ebola Virus With a Series of High-Level Meetings in Washington, D.C.
http://ih.advfn.com/p.php?pid=nmona&article=64502785
http://ih.advfn.com/p.php?pid=nmona&article=64502785
Antwort auf Beitrag Nr.: 48.369.791 von Vaterland am 20.11.14 14:02:14Ist hier noch jemand investiert??
Also ich bin es noch.
Frage mich aber, ob sich das ganze hier nochmal zum
guten wendet.
Wie ist die Einschätzung von anderen hier bei Wallstreet online?
Also ich bin es noch.
Frage mich aber, ob sich das ganze hier nochmal zum
guten wendet.
Wie ist die Einschätzung von anderen hier bei Wallstreet online?
Antwort auf Beitrag Nr.: 50.323.461 von Hobbyaktien am 03.08.15 21:14:10Habe auch ein wenig Kohle hier investiert.
Im Moment sieht es so aus als ob das Geld weg ist.
Liegen lassen und mal sehen was es in ein paar Jahre so wert ist.
Falls es diesen Verein so lange gibt.
Im Moment sieht es so aus als ob das Geld weg ist.
Liegen lassen und mal sehen was es in ein paar Jahre so wert ist.
Falls es diesen Verein so lange gibt.
Antwort auf Beitrag Nr.: 50.331.813 von prego_1 am 04.08.15 21:05:02Ich bin hier seit 2009 immer mal wieder investiert gewesen.
Mal schauen wo es hingeht.
Die Aktie war schon mal so niedrig. Und dann ist Sie auch von 1,6 auf über 6 Cent hoch geschossen.
Ich weiß gar nicht, ob man das im Chart noch sehen kann.
Da war der Wert noch in den Pinksheets.
Ich werde auch kein Stück zu diesen Kursen abgeben, da nehme ich lieber
einen Totalverlust in Kauf.
Aber derzeit laufen meine Aktien nicht so.
Neben Cannabis bin ich noch in Aeterna Zentaris, Naturals Splendid, Barrick Gold, Twitter und Long auf Gold. Mal sehen wie das alles endet.
Mal schauen wo es hingeht.
Die Aktie war schon mal so niedrig. Und dann ist Sie auch von 1,6 auf über 6 Cent hoch geschossen.
Ich weiß gar nicht, ob man das im Chart noch sehen kann.
Da war der Wert noch in den Pinksheets.
Ich werde auch kein Stück zu diesen Kursen abgeben, da nehme ich lieber
einen Totalverlust in Kauf.
Aber derzeit laufen meine Aktien nicht so.
Neben Cannabis bin ich noch in Aeterna Zentaris, Naturals Splendid, Barrick Gold, Twitter und Long auf Gold. Mal sehen wie das alles endet.
Na hier geht's ja rund.
Antwort auf Beitrag Nr.: 50.427.729 von Ulfred am 18.08.15 18:23:44Mmhhh frage mich nur warum es hier so rund geht???!
Für ein einsteigen villeicht etwas zuspät.
Für ein einsteigen villeicht etwas zuspät.
News gestern
COLORADO SPRINGS, CO - (Marketwired) - am 08/18/15 - Cannabis Science, Inc. (ROSA OTC: CBIS), eine US-amerikanische Gesellschaft, die sich auf die Entwicklung von haschischbasierten Arzneimitteln spezialisiert, ist zufrieden, den Verschluss und die Ausgabe der vorher abgelegten Dividendenaktienausschüttung, wie abgelegt, mit dem S.E.C. auf einem Endgültigen Formular 14C am 18. August 2011, dem Endgültigen Formular 14C bekannt zu geben, das (REGEL 14C-101) ablegt. Die Gesellschaft hat auch vor, eine andere Informationsbehauptung abzulegen, um neue Aktionäre bis heute unterzubringen, um eine ähnliche Dividendenausschüttung zu erhalten, allen Aktionären in darauf zu bringen, was die Gesellschaft als eine merkliche Wachstumskurve denkt. Die Gesellschaft nimmt an sich zu beschleunigen sein aktueller FDA hat Rauschgiftentwicklungsprogramme ins Visier genommen, und breiten Sie seine Staat-für-Staat-Initiativen aus. Erhöhung des Aktionärswerts ist von erster Bedeutung für jeden beteiligt; zu diesem Ende wird sich die Gesellschaft um ein einzigartiges Handelssymbol bewerben, um sich einzustellen, eine Reihe von $ 15-25 Millionen US-Dollar, es finanzierend, hat für die kürzlich geschaffene Klasse der Dividendenausschüttung Üblich Ein Lager aktiv verhandelt, und verfolgt formell einen nachgedachten Auflistung zu NASDAQ. Die Gesellschaft nimmt an zu beginnen, das ganze neue Strukturenprogramm ohne Rückspalt am Ende des Monats abzulegen.Cannabis Science, Inc. (die "Gesellschaft") möchte seine aktuellen und ehemaligen Aktionäre bezüglich der vorher genehmigten Aktiendividende aktualisieren, die auf einem Endgültigen Formular 14C mit der Kommission am 18. August 2011 abgelegt wurde. Die Gesellschaft wird sich bemühen, um die Aktiendividende auszugeben, die ein neuer Anteil der Klasse Eine Stammaktie für jeden zehn Stammaktien ist, bezüglich deren sie sich am 31. Dezember 2010 bekannt haben. Zusätzlich zu dieser Dividende hat die Gesellschaft vor, eine neue Informationsbehauptung entsprechend dem Abschnitt 14 (C) abzulegen, um eine neue Dividende Aktionären bezüglich am 9. Oktober 2015 auszugeben. Die Gesellschaft hat vor, die Billigung zu suchen, eine Dividende eines Anteils der Klasse Eine Stammaktie für jedes Hundert Anteile auszugeben, die von Aktionären der Aufzeichnung bezüglich am 9. Oktober 2015 besessen sind. Beide Dividenden werden auch eine Befugnis tragen, die jedem Aktionär der Aufzeichnung eine Aktienkaufbefugnis geben wird, die aus einer Auswahl besteht, einen zusätzlichen Anteil der Klasse Eine Stammaktie für jeden speziellen erhaltenen Dividendenanteil zu kaufen. Jede Befugnis wird in einen Anteil der Klasse Ein Lager zu einem Preis von 1.00 $ pro Anteil auf die Dauer von drei Monaten exercisable sein, nachdem alle vorgeschlagenen Änderungen offiziell gewirkt haben. Die Gesellschaft plant auch, sich um ein einzigartiges und getrenntes Handelssymbol um seine Anteile der Klasse Eine Stammaktie zu bewerben.
"Wir sind sehr aufgeregt, um unseren allen Aktionären eine Dividendenausschüttung zu geben und mit dem Geschäft in der Nähe auszukommen. Es ist eine lange und sehr aufregende Straße mit vielen Gelegenheiten gewesen, die wir entlang dem Weg gesammelt haben. Wir glauben, dass diese Dividendenstruktur unseren vorherigen und aktuellen Aktionären der Aufzeichnung eine hervorragende Gelegenheit gibt, auf der Aktiendividendenausschüttung Kapital anzuhäufen, um eine andere Anlagenbasis für sie zu schaffen, während die Gesellschaft die neue Klasse von Allgemeinen Anteile mit einem höheren Wert zu compl verwertet
Offenbar gehts mitm Grass wieder rund...hier is der Zug leider schon weg...
Antwort auf Beitrag Nr.: 50.432.820 von sundancer-ch am 19.08.15 10:54:10Ob der Zug schon weg ist schwer Zusagen könnte auch der Anfang von einer Mega Rallye sein villeicht sind kurzfristig 30-40 Cent drin.
Aber jetzt einsteigen ist zu gefährlich. Schluskurs gestern 0,035 $ Cent hier werden aktuell 0,044€ Cent gezahlt das kann sehr böse ins Auge gehen kann muss aber nicht ich warte erstmal auf die Amis.
Aber jetzt einsteigen ist zu gefährlich. Schluskurs gestern 0,035 $ Cent hier werden aktuell 0,044€ Cent gezahlt das kann sehr böse ins Auge gehen kann muss aber nicht ich warte erstmal auf die Amis.
Antwort auf Beitrag Nr.: 50.432.952 von Edison09 am 19.08.15 11:04:50Also ich habe in Stuttgart eben welche zu 0,032 €-Cent bekommen.
Dafür habe ich es mal riskiert (überschaubarer Einsatz)
Dafür habe ich es mal riskiert (überschaubarer Einsatz)
zu heißes Eisen für mich...RSI schon richtig warm
Antwort auf Beitrag Nr.: 50.433.174 von Moneyplus am 19.08.15 11:27:09Warum so ungeduldig???es ist besser abzuwarten bis die Amis eröffnen.
Die Taxen zubeobachten ab 15uhr den Trend kann man dan ablesen wo die Reise heute hingeht.
Aber dein EK ist ja noch einigermaßen ok.
Habe so ein gutes Gefühl das sich hier ein Mega zock aufbaut.
Die Taxen zubeobachten ab 15uhr den Trend kann man dan ablesen wo die Reise heute hingeht.
Aber dein EK ist ja noch einigermaßen ok.
Habe so ein gutes Gefühl das sich hier ein Mega zock aufbaut.
Antwort auf Beitrag Nr.: 50.433.282 von Edison09 am 19.08.15 11:40:11Habe jetzt erst einmal - zu einem für mich heute moderatem Kurs und nicht zu 0,044 - den Fuß drin.
Man weiß ja nicht, was die Amis nachher machen.
Sollten wir nochmal abtauchen (unter 0,03 €) würde ich mit der selben Shareanzahl nachlegen (wäre insgesamt aber immer noch unter € 800 Einsatz, also hop oder top)
Man weiß ja nicht, was die Amis nachher machen.
Sollten wir nochmal abtauchen (unter 0,03 €) würde ich mit der selben Shareanzahl nachlegen (wäre insgesamt aber immer noch unter € 800 Einsatz, also hop oder top)
Antwort auf Beitrag Nr.: 50.433.366 von Moneyplus am 19.08.15 11:46:56Viel Glück
Antwort auf Beitrag Nr.: 50.433.546 von Edison09 am 19.08.15 12:03:30Danke, Dir auch
Also ich werte es als positives Zeichen, dass sich hier überhaupt mal wieder was rührt. Hab mal verbilligt.
Antwort auf Beitrag Nr.: 50.433.174 von Moneyplus am 19.08.15 11:27:09Taxen ziehen schon richtig an 0,0395 zu 0,041
Mega zock sieht gut aus
Antwort auf Beitrag Nr.: 50.435.919 von Edison09 am 19.08.15 15:47:58Habe mir um 12:59:59 noch eine Position dazu gekauft......
Viel Erfolg allen hier...
http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
Viel Erfolg allen hier...
http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
Mmh. War's das schon?
Antwort auf Beitrag Nr.: 50.436.303 von Ulfred am 19.08.15 16:30:36Nö....
Paar Gewinnmitnahmen nichts wildes
Antwort auf Beitrag Nr.: 50.436.516 von Edison09 am 19.08.15 16:50:20Industry News Release August 18, 2015 - 9:35 AM EDT
http://marijuanaindex.com/industry-news-item/
Cannabis Science to Issue Dividend Payouts for Previous and Current Shareholders, a $15-25 Million Capital Raise for FDA and Other Clinical Drug Development Programs as Well as a Proposed NASDAQ Up Listing
COLORADO SPRINGS, CO--(Marketwired - Aug 18, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011, the Definitive Schedule 14C filing (RULE 14c-101). The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout, to bring all shareholders in on what the Company considers a landmark growth curve. The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives. Increasing shareholder value is of foremost importance for everyone involved; to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock, and formally pursue a contemplated up listing to NASDAQ. The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.
Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011. The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010. In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015. The Company intends to seek the approval to issue a dividend of one share of Class A common stock for each one hundred shares owned by shareholders of record as of October 9, 2015. Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received. Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect. The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.
"We are very excited to give our all shareholders a dividend payout and get on with the business at hand. It's been a long and very exciting road, with lots of opportunities we have collected along the way. We believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster. As regulation changes swiftly in such an enormous burgeoning industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. We believe our team of Scientific Advisors gives us the unique opportunity to strive for excellence in our drug development programs as their track record speaks volumes for themselves. Our expansion program will be fueled by the growing market and demand," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.310.650.3788
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Mr. Derwin A. Wallace
Finance & Investor Relations
info@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.404.500.4950
http://marijuanaindex.com/industry-news-item/
Cannabis Science to Issue Dividend Payouts for Previous and Current Shareholders, a $15-25 Million Capital Raise for FDA and Other Clinical Drug Development Programs as Well as a Proposed NASDAQ Up Listing
COLORADO SPRINGS, CO--(Marketwired - Aug 18, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011, the Definitive Schedule 14C filing (RULE 14c-101). The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout, to bring all shareholders in on what the Company considers a landmark growth curve. The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives. Increasing shareholder value is of foremost importance for everyone involved; to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock, and formally pursue a contemplated up listing to NASDAQ. The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.
Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011. The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010. In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015. The Company intends to seek the approval to issue a dividend of one share of Class A common stock for each one hundred shares owned by shareholders of record as of October 9, 2015. Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received. Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect. The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.
"We are very excited to give our all shareholders a dividend payout and get on with the business at hand. It's been a long and very exciting road, with lots of opportunities we have collected along the way. We believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster. As regulation changes swiftly in such an enormous burgeoning industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. We believe our team of Scientific Advisors gives us the unique opportunity to strive for excellence in our drug development programs as their track record speaks volumes for themselves. Our expansion program will be fueled by the growing market and demand," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.310.650.3788
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Mr. Derwin A. Wallace
Finance & Investor Relations
info@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.404.500.4950
Die 0,05$ ist wichtig das wir die heute noch durchbrechen (Psychisch)
Antwort auf Beitrag Nr.: 50.436.822 von Edison09 am 19.08.15 17:15:18Shares moving into stronger hands. Harder to get shares below .04 now. This is going way up
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Das sehe ich genau so wie der Kollege drüben....
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Das sehe ich genau so wie der Kollege drüben....
Kommt nicht so richtig aus der Pötte starker Widerstand ist 0,042.
Villeicht heute Abend da ziehen die Kurse immer richtig an an der OTC
Villeicht heute Abend da ziehen die Kurse immer richtig an an der OTC
Bei 42 scheint irgendwie der Deckel drauf zu sein.
Antwort auf Beitrag Nr.: 50.437.176 von Ulfred am 19.08.15 17:49:10Schonwieder abgeprallt echt nervig egal Hauptsache die 0,04 hält für heute
Na geht doch die letzen 6 min hatten es nochmal so richtig in sich.
Sk weit über 0,04cent ich bin sehr optimistisch für morgen nächste Hürde sollte zwischen 0,048-0,05 erst sein.
Kann gut möglich sein das nun jeden Tag zwischen 20-30% weiter up geht Phantasie ist reichlich da tippe mal auf die zweite epoxy.
Gestern über 100% heute keine spür von abverkauf im Gegenteil jeder kleiner rücksetzer wurde sofort aufgefangen.
Volumen ist weiterhin gigantisch.
Gute nicht euch allen.
Sk weit über 0,04cent ich bin sehr optimistisch für morgen nächste Hürde sollte zwischen 0,048-0,05 erst sein.
Kann gut möglich sein das nun jeden Tag zwischen 20-30% weiter up geht Phantasie ist reichlich da tippe mal auf die zweite epoxy.
Gestern über 100% heute keine spür von abverkauf im Gegenteil jeder kleiner rücksetzer wurde sofort aufgefangen.
Volumen ist weiterhin gigantisch.
Gute nicht euch allen.
Gute Nacht
Bin raus außer Spesen nichts gewesen.
Kleiner Tipp Q Bericht durchlesen die sind total überschuldet woher wollen die bitte das Geld für ne Dividende her nehmen.
Alles verarsche....
Kleiner Tipp Q Bericht durchlesen die sind total überschuldet woher wollen die bitte das Geld für ne Dividende her nehmen.
Alles verarsche....
Hallo,
entschuldigt bitte die provokative Frage, aber ist diese Cannabis-Geschichte hier etwas Fundamentales oder reiner Zock?
Bin als Befürworter der Cannabis-Medikation auf diesen Thread gestossen.
Schöne Grüße
ER
entschuldigt bitte die provokative Frage, aber ist diese Cannabis-Geschichte hier etwas Fundamentales oder reiner Zock?
Bin als Befürworter der Cannabis-Medikation auf diesen Thread gestossen.
Schöne Grüße
ER
Antwort auf Beitrag Nr.: 50.442.273 von Edison09 am 20.08.15 10:22:21Sehe ich nicht so...
http://otcshortrehttp://otcshortreport.com/index.php?index=C…
http://otcshortrehttp://otcshortreport.com/index.php?index=C…
Antwort auf Beitrag Nr.: 50.442.282 von EnergyRango am 20.08.15 10:22:44Strong Buy: http://www.barchart.com/quotes/stocks/CBIS
Antwort auf Beitrag Nr.: 50.442.273 von Edison09 am 20.08.15 10:22:21
Kann schon sein, trotzdem kann man noch nicht wissen, ob der Zock bereits vorbei ist. Der Kurs in Deutschland sagt darüber nichts aus. Komisch, dass du nicht noch abwartest, was heute in Übersee passiert.
Zitat von Edison09: Bin raus außer Spesen nichts gewesen.
Kleiner Tipp Q Bericht durchlesen die sind total überschuldet woher wollen die bitte das Geld für ne Dividende her nehmen.
Alles verarsche....
Kann schon sein, trotzdem kann man noch nicht wissen, ob der Zock bereits vorbei ist. Der Kurs in Deutschland sagt darüber nichts aus. Komisch, dass du nicht noch abwartest, was heute in Übersee passiert.
Schau dir die Taxen an dann weist du warum ich schon vor us Start raus bin.
Wenn hier einmal Verkaufsdruck rein kommt stürzt das Teil ins bodenlose.
Und ich verbrenne ungerne mein Geld.
Viel Glück noch
Wenn hier einmal Verkaufsdruck rein kommt stürzt das Teil ins bodenlose.
Und ich verbrenne ungerne mein Geld.
Viel Glück noch
Villeicht geht es auch weiter up,keine Ahnung hoffe es aber für euch.
Geht jedenfalls gut los. Solche Zocks dauern nach meiner Erfahrung schon ein paar Tage.
Ok, scheint es doch gewesen zu sein.
Antwort auf Beitrag Nr.: 50.446.995 von Ulfred am 20.08.15 17:35:15Nö,glaube ich eigentlich nicht...To Issue Dividend Payouts For Previous And Current Shareholders, A $15 25 Million Capital Raise For Fda And Other Clinical Drug Development Programs As Well As A Proposed Nasdaq Up Listing [Market News Publishing (US)]
CANNABIS SCIENCE INC
CANNABIS SCIENCE INC ("CBIS-0") - To Issue Dividend Payouts For Previous And Current Shareholders, A - $15-25 Million Capital Raise For Fda And Other Clinical Drug - Development Programs As Well As A Proposed Nasdaq Up Listing
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011, the Definitive Schedule 14C filing (RULE 14c-101). The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout, to bring all shareholders in on what the Company considers a landmark growth curve. The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives. Increasing shareholder value is of foremost importance for everyone involved; to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock, and formally pursue a contemplated up listing to NASDAQ. The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.
Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011. The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010. In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015. The Company intends to seek the approval to issue a dividend of one share of Class A common stock for each one hundred shares owned by shareholders of record as of October 9, 2015. Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received. Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect. The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.
"We are very excited to give our all shareholders a dividend payout and get on with the business at hand. It's been a long and very exciting road, with lots of opportunities we have collected along the way. We believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster. As regulation changes swiftly in such an enormous burgeoning industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. We believe our team of Scientific Advisors gives us the unique opportunity to strive for excellence in our drug development programs as their track record speaks volumes for themselves. Our expansion program will be fueled by the growing market and demand," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
TEL: 1.310.650.3788 Mr. Raymond C. Dabney TEL: 1.888.889.0888 President & CEO, Co-Founder raymond@cannabisscience.com Cannabis Science, Inc.
TEL: 1.888.889.0888 Mr. Robert Kane, Director & CFO info@cannabisscience.com Cannabis Science, Inc.
TEL: 1.404.500.4950 Mr. Derwin A. Wallace
OTCBB closing price for CBIS-0 Date: 2015/08/17 Closing Price: 0.02
____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto416)366-8881 Vancouver604)689-1101 Fax604)689-1106 © (c) 2015 Market News Publishing Inc.
CANNABIS SCIENCE INC
CANNABIS SCIENCE INC ("CBIS-0") - To Issue Dividend Payouts For Previous And Current Shareholders, A - $15-25 Million Capital Raise For Fda And Other Clinical Drug - Development Programs As Well As A Proposed Nasdaq Up Listing
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011, the Definitive Schedule 14C filing (RULE 14c-101). The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout, to bring all shareholders in on what the Company considers a landmark growth curve. The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives. Increasing shareholder value is of foremost importance for everyone involved; to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock, and formally pursue a contemplated up listing to NASDAQ. The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.
Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011. The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010. In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015. The Company intends to seek the approval to issue a dividend of one share of Class A common stock for each one hundred shares owned by shareholders of record as of October 9, 2015. Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received. Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect. The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.
"We are very excited to give our all shareholders a dividend payout and get on with the business at hand. It's been a long and very exciting road, with lots of opportunities we have collected along the way. We believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster. As regulation changes swiftly in such an enormous burgeoning industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. We believe our team of Scientific Advisors gives us the unique opportunity to strive for excellence in our drug development programs as their track record speaks volumes for themselves. Our expansion program will be fueled by the growing market and demand," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
TEL: 1.310.650.3788 Mr. Raymond C. Dabney TEL: 1.888.889.0888 President & CEO, Co-Founder raymond@cannabisscience.com Cannabis Science, Inc.
TEL: 1.888.889.0888 Mr. Robert Kane, Director & CFO info@cannabisscience.com Cannabis Science, Inc.
TEL: 1.404.500.4950 Mr. Derwin A. Wallace
OTCBB closing price for CBIS-0 Date: 2015/08/17 Closing Price: 0.02
____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto416)366-8881 Vancouver604)689-1101 Fax604)689-1106 © (c) 2015 Market News Publishing Inc.
Antwort auf Beitrag Nr.: 50.480.820 von Vaterland am 25.08.15 10:56:28und hier auf Google Deutsch.. Um Dividendenzahlungen für frühere und aktuelle Anteilinhaber, A $ 15 25 Million Kapital für die FDA und andere klinische Medikamentenentwicklung sowie Ausgabe A Vorgeschlagene TecDAX Listing [Market News Publishing (US)]
Cannabis Science Inc.
Cannabis Science Inc. ("CBIS-0") - $ 15-25 Million Kapitalbeschaffung für die FDA und andere klinische Droge - - Entwicklungsprogramme sowie eine vorgeschlagene TecDAX Listing Um Dividendenzahlungen für frühere und aktuelle Anteilinhaber, Eine Ausgabe
Cannabis Science, Inc., ein US-Unternehmen, spezialisiert auf die Entwicklung von Medikamenten auf Cannabisbasis, freut sich, die Schließung und die Erteilung der früher eingereichten Dividendenanteil Ausschüttung verkünden, wie bei der SEC eingereicht über eine endgültige Spielplan 14C am 18. August 2011 die endgültige Spielplan 14C Anmeldetag (Artikel 14c-101). Die Gesellschaft beabsichtigt auch, eine andere Information Statement-Datei, um neue Aktionäre bis dato unterzubringen, um eine ähnliche Dividende zu erhalten, an alle Aktionäre auf, was die Gesellschaft betrachtet einen Meilenstein Wachstumskurve zu bringen. Das Unternehmen erwartet, beschleunigen ihren aktuellen FDA gezielte Medikamentenentwicklungsprogramme und erweitern ihre Staats-by-Staat Initiativen. Steigerung des Shareholder Value Dabei ist vor allem für alle Beteiligten; zu diesem Zweck wird die Gesellschaft für eine einzigartige Handelssymbol gelten für eine $ 15 aufnehmen - 25 Millionen USD liegen Finanzierung wurde aktiv Verhandlungen für die neu erstellte Klasse von Ausschüttungs Gemeinsamen Eine Aktie und formal eine bis in Erwägung gezogen Auflistung NASDAQ verfolgen. Das Unternehmen erwartet die Einreichung der vollständigen neuen Struktur Programm ohne Reverse Split durch die Ende des Monats zu beginnen.
Cannabis Science, Inc. (das "Unternehmen") möchte zu aktualisieren, ihren gegenwärtigen und ehemaligen Aktionäre in Bezug auf die zuvor genehmigten Aktiendividende, die sich auf einen endgültigen Zeitplan 14C mit der Kommission am 18. August eingereicht wurde, 2011. Die Gesellschaft wird sich nach besten Kräften um die Dividende, die eine neue Aktie der Klasse A Stammaktien für je zehn Aktien der Stammaktien, die sie als der Besitz 31. Dezember 2010. Zusätzlich zu dieser Dividende ist auszustellen, beabsichtigt die Gesellschaft, eine neue Information Statement gemäß einreichen § 14 (C), um eine neue Dividende an die Aktionäre als des 9. Oktober auszustellen, beabsichtigt 2015. Die Gesellschaft, die Zustimmung zu suchen, eine Dividende von einer Aktie der Klasse A Stammaktien für je 100 Aktien durch die Aktionäre der Aufzeichnung wie der Besitz ausstellen 9. Oktober 2015. Beide Dividenden führen auch einen Haftbefehl, die geben jedem Aktionär der Aufzeichnung einen Aktien-Warrant, bestehend aus einer Option auf eine zusätzliche Aktie der Klasse A Stammaktien für jede Aktie Sonderdividende erhalten kaufen. Jeder Optionsschein wird nach all den vorgeschlagenen Änderungen offiziell in Kraft treten ausübbar in eine Aktie der Klasse A Aktien zu einem Preis von $ 1,00 pro Aktie für einen Zeitraum von drei Monaten. Das Unternehmen plant auch, für einen einzigartigen und separaten Handelssymbol für seine Aktien der Klasse A des Stammkapitals beantragen.
"Wir sind sehr aufgeregt, um unsere alle Aktionären eine Dividende und wieder mit dem Geschäft an der Hand. Es war ein langer und sehr spannend Straße, mit vielen Möglichkeiten, die wir haben auf dem Weg gesammelt. Wir glauben, dass diese Dividende Struktur verleiht unseren bisherigen und aktuellen Aktionäre der Aufzeichnung eine hervorragende Gelegenheit, um über den Anteil Ausschüttung um eine weitere Asset-Basis für sie zu schaffen zu profitieren, während das Unternehmen nutzt die neue Klasse von gemeinsamen A-Aktien mit einem höheren Mehrwert für unsere Verhandlungen für eine viel größere Mittel zu schieben über unser Medikamentenentwicklungsprogramme nach vorne viel schneller. Als Regeländerungen schnell in einer solchen enormen aufkeimende Industrie, schafft es Möglichkeiten, und es kann Hürden für die gleichen Möglichkeiten zu schaffen. Wir müssen Flüssigkeit zu bleiben und zu bewegen, wie die Vorschriften zu bewegen. Wir glauben, dass unser Team von Scientific Advisors gibt uns die einmalige Gelegenheit, für Spitzenleistungen in unserem Medikamentenentwicklung streben wie ihre Erfolgsbilanz spricht für sich selbst. Unsere Expansionsprogramm wird von dem wachsenden Markt und die Nachfrage angeheizt werden ", erklärte Herr Raymond C. Dabney, President & CEO, Co- Gründer, Cannabis Science Inc.
Über Cannabis Science, Inc.
Cannabis Science, Inc. nutzt seine einzigartige Verständnis der metabolischen Prozesse, neue Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Publikationen, die die zugrundeliegende biochemische Stoffwechselwege, die Cannabinoide zu modulieren, zu dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil Charakterisierung und klinische Forschung zu entwickeln, herzustellen, zu vermarkten und neue Therapieansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheit verursacht. Unser Hauptaugenmerk liegt auf Hautkrebs, HIV / AIDS, und neurologischen Erkrankungen. CS-S / BCC-1, CS-TATI-1 und CS-NEURO-1, jeweils: Die Gesellschaft ist mit der Forschung und Entwicklung von firmeneigenen Medikamenten als ein Teil dieser anfängliche Schwerpunkt fortfahren.
Zukunftsgerichtete Aussagen Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Securities Act von 1933 und Abschnitt 21E des Securities Act von 1934. Aussagen Wörter wie "antizipieren", "zu suchen, mit" die Absicht, "," glauben "," schätzen "," erwarten "," projizieren "," planen "oder ähnliche Ausdrücke dazu geeignet sein könnten" zukunftsgerichtete Aussagen "im Sinne des Private Securities Litigation Reform Act von 1995. Einige oder alle die Ereignisse oder Ergebnisse von diesen zukunftsgerichteten Aussagen erwarteten erheblich abweichen. Faktoren, die verursachen oder dazu beitragen, diese Unterschiede sind, die Zukunft der USA und die Weltwirtschaft, die Auswirkungen des Wettbewerbs und der Gesellschaft Vertrauen auf bestehenden Vorschriften über die Verwendung und Entwicklung von Cannabis-basierte Medikamente. Cannabis Science, Inc. hat keinerlei Verpflichtung und beabsichtigt nicht, die Ergebnisse von diesen vorausschauenden Aussagen zu aktualisieren.
TEL: 1.310.650.3788 Mr. Raymond C. Dabney Telefon: 1.888.889.0888 President & CEO, Mitbegründer raymond@cannabisscience.com Cannabis Science, Inc.
TEL: 1.888.889.0888 Mr. Robert Kane, Director & CFO info@cannabisscience.com Cannabis Science, Inc.
TEL: 1.404.500.4950 Mr. Derwin A. Wallace
OTCBB Schlusskurs CBIS-0 Datum: 2015.08.17 Schlusskurs: 0,02
____________________________________________________________
(c) 2015 Market News Publishing Inc. Alle Rechte vorbehalten.
Toronto: (416) 366-8881 Vancouver: (604) 689-1101 Fax: (604) 689-1106 © (c) 2015 Market News Publishing Inc.
Cannabis Science Inc.
Cannabis Science Inc. ("CBIS-0") - $ 15-25 Million Kapitalbeschaffung für die FDA und andere klinische Droge - - Entwicklungsprogramme sowie eine vorgeschlagene TecDAX Listing Um Dividendenzahlungen für frühere und aktuelle Anteilinhaber, Eine Ausgabe
Cannabis Science, Inc., ein US-Unternehmen, spezialisiert auf die Entwicklung von Medikamenten auf Cannabisbasis, freut sich, die Schließung und die Erteilung der früher eingereichten Dividendenanteil Ausschüttung verkünden, wie bei der SEC eingereicht über eine endgültige Spielplan 14C am 18. August 2011 die endgültige Spielplan 14C Anmeldetag (Artikel 14c-101). Die Gesellschaft beabsichtigt auch, eine andere Information Statement-Datei, um neue Aktionäre bis dato unterzubringen, um eine ähnliche Dividende zu erhalten, an alle Aktionäre auf, was die Gesellschaft betrachtet einen Meilenstein Wachstumskurve zu bringen. Das Unternehmen erwartet, beschleunigen ihren aktuellen FDA gezielte Medikamentenentwicklungsprogramme und erweitern ihre Staats-by-Staat Initiativen. Steigerung des Shareholder Value Dabei ist vor allem für alle Beteiligten; zu diesem Zweck wird die Gesellschaft für eine einzigartige Handelssymbol gelten für eine $ 15 aufnehmen - 25 Millionen USD liegen Finanzierung wurde aktiv Verhandlungen für die neu erstellte Klasse von Ausschüttungs Gemeinsamen Eine Aktie und formal eine bis in Erwägung gezogen Auflistung NASDAQ verfolgen. Das Unternehmen erwartet die Einreichung der vollständigen neuen Struktur Programm ohne Reverse Split durch die Ende des Monats zu beginnen.
Cannabis Science, Inc. (das "Unternehmen") möchte zu aktualisieren, ihren gegenwärtigen und ehemaligen Aktionäre in Bezug auf die zuvor genehmigten Aktiendividende, die sich auf einen endgültigen Zeitplan 14C mit der Kommission am 18. August eingereicht wurde, 2011. Die Gesellschaft wird sich nach besten Kräften um die Dividende, die eine neue Aktie der Klasse A Stammaktien für je zehn Aktien der Stammaktien, die sie als der Besitz 31. Dezember 2010. Zusätzlich zu dieser Dividende ist auszustellen, beabsichtigt die Gesellschaft, eine neue Information Statement gemäß einreichen § 14 (C), um eine neue Dividende an die Aktionäre als des 9. Oktober auszustellen, beabsichtigt 2015. Die Gesellschaft, die Zustimmung zu suchen, eine Dividende von einer Aktie der Klasse A Stammaktien für je 100 Aktien durch die Aktionäre der Aufzeichnung wie der Besitz ausstellen 9. Oktober 2015. Beide Dividenden führen auch einen Haftbefehl, die geben jedem Aktionär der Aufzeichnung einen Aktien-Warrant, bestehend aus einer Option auf eine zusätzliche Aktie der Klasse A Stammaktien für jede Aktie Sonderdividende erhalten kaufen. Jeder Optionsschein wird nach all den vorgeschlagenen Änderungen offiziell in Kraft treten ausübbar in eine Aktie der Klasse A Aktien zu einem Preis von $ 1,00 pro Aktie für einen Zeitraum von drei Monaten. Das Unternehmen plant auch, für einen einzigartigen und separaten Handelssymbol für seine Aktien der Klasse A des Stammkapitals beantragen.
"Wir sind sehr aufgeregt, um unsere alle Aktionären eine Dividende und wieder mit dem Geschäft an der Hand. Es war ein langer und sehr spannend Straße, mit vielen Möglichkeiten, die wir haben auf dem Weg gesammelt. Wir glauben, dass diese Dividende Struktur verleiht unseren bisherigen und aktuellen Aktionäre der Aufzeichnung eine hervorragende Gelegenheit, um über den Anteil Ausschüttung um eine weitere Asset-Basis für sie zu schaffen zu profitieren, während das Unternehmen nutzt die neue Klasse von gemeinsamen A-Aktien mit einem höheren Mehrwert für unsere Verhandlungen für eine viel größere Mittel zu schieben über unser Medikamentenentwicklungsprogramme nach vorne viel schneller. Als Regeländerungen schnell in einer solchen enormen aufkeimende Industrie, schafft es Möglichkeiten, und es kann Hürden für die gleichen Möglichkeiten zu schaffen. Wir müssen Flüssigkeit zu bleiben und zu bewegen, wie die Vorschriften zu bewegen. Wir glauben, dass unser Team von Scientific Advisors gibt uns die einmalige Gelegenheit, für Spitzenleistungen in unserem Medikamentenentwicklung streben wie ihre Erfolgsbilanz spricht für sich selbst. Unsere Expansionsprogramm wird von dem wachsenden Markt und die Nachfrage angeheizt werden ", erklärte Herr Raymond C. Dabney, President & CEO, Co- Gründer, Cannabis Science Inc.
Über Cannabis Science, Inc.
Cannabis Science, Inc. nutzt seine einzigartige Verständnis der metabolischen Prozesse, neue Behandlungsansätze für eine Reihe von Krankheiten, für die gegenwärtigen Behandlungen und Verständnis noch nicht zufriedenstellend ist. Cannabinoide haben eine umfangreiche Geschichte, die Tausende von Jahren zurück, und derzeit gibt es eine wachsende Zahl von Experten begutachteten wissenschaftlichen Publikationen, die die zugrundeliegende biochemische Stoffwechselwege, die Cannabinoide zu modulieren, zu dokumentieren. Das Unternehmen arbeitet mit führenden Experten in der Entwicklung von Medikamenten, Heil Charakterisierung und klinische Forschung zu entwickeln, herzustellen, zu vermarkten und neue Therapieansätze für die Behandlung von Krankheiten, die durch Infektionen sowie für altersbedingte Krankheit verursacht. Unser Hauptaugenmerk liegt auf Hautkrebs, HIV / AIDS, und neurologischen Erkrankungen. CS-S / BCC-1, CS-TATI-1 und CS-NEURO-1, jeweils: Die Gesellschaft ist mit der Forschung und Entwicklung von firmeneigenen Medikamenten als ein Teil dieser anfängliche Schwerpunkt fortfahren.
Zukunftsgerichtete Aussagen Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne von Abschnitt 27A des Securities Act von 1933 und Abschnitt 21E des Securities Act von 1934. Aussagen Wörter wie "antizipieren", "zu suchen, mit" die Absicht, "," glauben "," schätzen "," erwarten "," projizieren "," planen "oder ähnliche Ausdrücke dazu geeignet sein könnten" zukunftsgerichtete Aussagen "im Sinne des Private Securities Litigation Reform Act von 1995. Einige oder alle die Ereignisse oder Ergebnisse von diesen zukunftsgerichteten Aussagen erwarteten erheblich abweichen. Faktoren, die verursachen oder dazu beitragen, diese Unterschiede sind, die Zukunft der USA und die Weltwirtschaft, die Auswirkungen des Wettbewerbs und der Gesellschaft Vertrauen auf bestehenden Vorschriften über die Verwendung und Entwicklung von Cannabis-basierte Medikamente. Cannabis Science, Inc. hat keinerlei Verpflichtung und beabsichtigt nicht, die Ergebnisse von diesen vorausschauenden Aussagen zu aktualisieren.
TEL: 1.310.650.3788 Mr. Raymond C. Dabney Telefon: 1.888.889.0888 President & CEO, Mitbegründer raymond@cannabisscience.com Cannabis Science, Inc.
TEL: 1.888.889.0888 Mr. Robert Kane, Director & CFO info@cannabisscience.com Cannabis Science, Inc.
TEL: 1.404.500.4950 Mr. Derwin A. Wallace
OTCBB Schlusskurs CBIS-0 Datum: 2015.08.17 Schlusskurs: 0,02
____________________________________________________________
(c) 2015 Market News Publishing Inc. Alle Rechte vorbehalten.
Toronto: (416) 366-8881 Vancouver: (604) 689-1101 Fax: (604) 689-1106 © (c) 2015 Market News Publishing Inc.
Antwort auf Beitrag Nr.: 50.480.844 von Vaterland am 25.08.15 10:58:09"Das Unternehmen erwartet die Einreichung der vollständigen neuen Struktur Programm ohne Reverse Split durch die Ende des Monats zu beginnen" Ist ja nicht mehr so lange dann....
Wäre natürlich geil, wenn hier echt was dran wäre. Der Markt wartet auf jeden Fall ab.
Antwort auf Beitrag Nr.: 50.482.401 von Ulfred am 25.08.15 13:08:02August 25, 2015 Cannabis Science Inc (OTCMKTS:CBIS) Launches Preliminary CBIS Products
by Jason Williams
Cannabis Science Inc (OTCMKTS:CBIS) reported that initial CBIS products have been launched under their deal with the “Cannabis Science Research Foundation.” The initial launch is for test marketing and the findings will play a vital role prior to the large-scale rollouts. The company’s products are being sold in various locations in California. As of now, there are at least three to four private and public dispensaries to buy the products.
The expert view
Raymond C. Dabney, the CEO of Cannabis Science, said that they have recorded previous success with self medicating patient usage and they expect similar results from this launch. The company has received several requests from these patients across world seeking treatments for different critical diseases.
The CEO said that they are relieved to release the initial products in California to receive self-medicating patients’ response on their products. Cannabis Science has no scarcity of diverse products to be introduced for different ailments, as each patient has unique needs to treat their personal ailments.
The plans
Dabney added that the company will be launching various product dosages, delivery procedures, in various jurisdictions as per the regulatory stipulations. They look forward to providing more information about locations and products as it becomes available.
The California new CBIS product launches are due to company’s research and distribution deal signed with Cannabis Science Research Foundation. The entity is responsible for the launch and distribution of the company’s products under CBIS brand for its initial State-by-State measures. The CSRF license distribution deal is needed to fulfill the committed focus Cannabis Science has on its U.S. FDA drug development plans.
In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) declined more than 3% to close the trading session at $0.0290. The decline came at a share volume of 8.26 million compared to average monthly share volume of 10.24 million. After the recent decline, the market cap of Cannabis Science stands at $37.18 millions
------------------------------------------------------------
http://www.journaltranscript.com/2015/08/cannabis-science-in…/
by Jason Williams
Cannabis Science Inc (OTCMKTS:CBIS) reported that initial CBIS products have been launched under their deal with the “Cannabis Science Research Foundation.” The initial launch is for test marketing and the findings will play a vital role prior to the large-scale rollouts. The company’s products are being sold in various locations in California. As of now, there are at least three to four private and public dispensaries to buy the products.
The expert view
Raymond C. Dabney, the CEO of Cannabis Science, said that they have recorded previous success with self medicating patient usage and they expect similar results from this launch. The company has received several requests from these patients across world seeking treatments for different critical diseases.
The CEO said that they are relieved to release the initial products in California to receive self-medicating patients’ response on their products. Cannabis Science has no scarcity of diverse products to be introduced for different ailments, as each patient has unique needs to treat their personal ailments.
The plans
Dabney added that the company will be launching various product dosages, delivery procedures, in various jurisdictions as per the regulatory stipulations. They look forward to providing more information about locations and products as it becomes available.
The California new CBIS product launches are due to company’s research and distribution deal signed with Cannabis Science Research Foundation. The entity is responsible for the launch and distribution of the company’s products under CBIS brand for its initial State-by-State measures. The CSRF license distribution deal is needed to fulfill the committed focus Cannabis Science has on its U.S. FDA drug development plans.
In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) declined more than 3% to close the trading session at $0.0290. The decline came at a share volume of 8.26 million compared to average monthly share volume of 10.24 million. After the recent decline, the market cap of Cannabis Science stands at $37.18 millions
------------------------------------------------------------
http://www.journaltranscript.com/2015/08/cannabis-science-in…/
Antwort auf Beitrag Nr.: 50.482.401 von Ulfred am 25.08.15 13:08:02CBIS ist Mitglied von Marijuana Index Global Das ist schon eine Hausnummer
http://marijuanaindex.com/financial-data/?qm_page=94025&qm_s…
http://marijuanaindex.com/financial-data/?qm_page=94025&qm_s…
Gut unterwegs.
Zug fährt ab.
Antwort auf Beitrag Nr.: 50.502.138 von Ulfred am 27.08.15 15:49:32http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
Antwort auf Beitrag Nr.: 50.508.246 von Vaterland am 28.08.15 10:19:51http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
Antwort auf Beitrag Nr.: 50.502.138 von Ulfred am 27.08.15 15:49:32
Real-Time Best Bid & Ask0.04 / 0.0408
Real-Time Best Bid & Ask0.04 / 0.0408
Kann jemand Realtime reinstellen?? Vielen Dank im Voraus
Antwort auf Beitrag Nr.: 50.511.288 von nimbus77 am 28.08.15 16:20:55News out http://ih.advfn.com/p.php?pid=nmona&article=68392190
Antwort auf Beitrag Nr.: 50.550.317 von Vaterland am 03.09.15 13:57:12Information Statement -All Other (definitive) (def 14c)
Date : 09/17/2015 @ 6:05AM
Source : Edgar (US Regulatory)
http://ih.advfn.com/p.php?pid=nmona&article=68550302
Bald geht es los.....
Date : 09/17/2015 @ 6:05AM
Source : Edgar (US Regulatory)
http://ih.advfn.com/p.php?pid=nmona&article=68550302
Bald geht es los.....
Antwort auf Beitrag Nr.: 50.653.161 von Vaterland am 18.09.15 11:22:51Cannabis Science, Inc.
6946 N Academy Blvd, Suite B #254
Colorado Springs CO 80918
To the Shareholders:
The purpose of this Information Statement is to inform the holders of record, as of the close of business on September 2, 2015, of shares of the common stock with voting power of Cannabis Science, Inc., a Nevada corporation (the “Company”), that our Board of Directors and one shareholder holding 67% of our voting power as of the Record Date have giving written consent as of September 2, 2015, to approve the following:
(1)
To issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol (the “New Dividend”).
(2)
To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol (the “Previous Dividend”).
(3)
To amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000 (the “Share Increase”).
These actions were approved on September 2, 2015, by our Board of Directors and one shareholder who holds a majority of the Company’s voting power. We anticipate an effective date of October 6, 2015, or as soon thereafter as practicable in accordance applicable law, including the Nevada Revised Statutes (“NRS”).
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
No action is required by you. The accompanying information statement is furnished only to inform our shareholders of the actions described above before they take place in accordance with the NRS and Rule 14c of the Securities Exchange Act of 1934, as amended. This Information Statement is first mailed to you on or about September 16, 2015.
Please feel free to call us at (888) 889-0888 should you have any questions on the enclosed Information Statement.
Date: September 16, 2015
For the Board of Directors of
Cannabis Science, Inc.
By:
/s/ Raymond C. Dabney
Raymond C. Dabney
Chief Executive Officer and Director
2
THIS INFORMATION STATEMENT IS BEING PROVIDED TO
YOU BY THE BOARD OF DIRECTORS OF THE COMPANY
WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE
REQUESTED NOT TO SEND US A PROXY
Cannabis Science, Inc.
6946 N Academy Blvd, Suite B #254
Colorado Springs CO 80918
INFORMATION STATEMENT
(Definitive)
September 16, 2015
GENERAL INFORMATION
This Information Statement has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the holders (the “Stockholders”) of the common stock, par value $0.001 per share (the “Common Stock”), of Cannabis Science, Inc., a Nevada Corporation (the “Company”), to notify such Stockholders that on or about September 2, 2015 , the Company received written consents in lieu of a meeting of Stockholders from one holder of 1,000,000 shares of Series A Preferred Stock representing 67% of the our total 1,279,805,296 issued and outstanding shares of voting stock of the Company (the “Majority Stockholder”) to: (1) issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol. (2) To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol. (3) To amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000
On September 2, 2015, the Board approved the above actions, subject to approval by the Stockholders.
We are not aware of any substantial interest, direct or indirect, by security holders or otherwise, that is in opposition to matters of action taken. In addition, pursuant to the laws of Nevada, the actions taken by majority written consent in lieu of a special shareholder meeting do not create appraisal or dissenters’ rights.
Our board of directors determined to pursue shareholder action by majority written consent presented by our outstanding shares of stock entitled to vote in an effort to reduce the costs and management time required to hold a special meeting of shareholders and to implement the above action to our shareholders in a timely manner.
The above actions will become effective 20 days following the mailing to the Stockholders of the Definitive Information Statement, or as soon thereafter as is practicable.
3
WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND A PROXY.
OUTSTANDING VOTING SECURITIES OF THE COMPANY
As of the date of the consent by the Majority Stockholder, on September 2, 2015, the Company had 1,279,805,296 shares of Common Stock issued and outstanding, and there were 1,000,000 shares of Series A Preferred Stock issued and outstanding. Each share of outstanding Common Stock is entitled to one vote on matters submitted for Stockholder approval and the holders of the Series A Preferred Stock are entitled to 67% of the total vote on all matters to be voted on by the holders of the Company's common stock.
On September 2, 2015, the holders of 1,000,000 shares of Series A Preferred Stock (or 67% of the Company’s total voting stock then outstanding) executed and delivered to the Company a written consent approving the New Dividend, paying out the Previous Dividend and the Share Increase (collectively the “Actions”). As the Actions were approved by the Majority Stockholder, no proxies are being solicited with this Information Statement.
The NRS provides in substance that unless the Company’s Articles provides otherwise, Stockholders may take action without a meeting of stockholders and without prior notice if a consent or consents in writing, setting forth the action so taken, is signed by the Stockholders having not less than the minimum number of votes that would be necessary to take such action at a meeting at which all shares entitled to vote thereon were present.
INFORMATION ON CONSENTING STOCKHOLDERS
Pursuant to the Company’s Bylaws and the NRS, a vote by the holders of at least a majority of the voting shares is required to effect the Action described herein. As of the Record Date, the Company had 1,279,805,296 common shares issued and outstanding and entitled to vote, which for voting purposes are entitled to one vote per share and 1,000,000 Series A Preferred Shares issued and outstanding and entitled to vote, which for voting purposes are entitled to 67% of the votes entitled to vote. The consenting Majority Stockholder is the record and beneficial owners of a total of 1,000,000 shares of the Company’s Series A Preferred stock, which represents 67% of the total number of voting shares. The consenting Majority Stockholder voted in favor of the Actions described herein in a written consent, dated September 2, 2015. No consideration was paid for the consent. The consenting stockholders’ name, affiliation with the Company and beneficial holdings are as follows:
Title of Class
Name and Address of Beneficial Owner
Amount and Nature of beneficial ownership
Percentage of Class (1)
Percentage of Voting Power (2)
Series A Preferred Stock
Bogat Family Trust (3)
c/o Cannabis Science Inc.
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
1,000,000
100%
67%
1.
Percentage of class is based on 1,000,000 shares of Series A Preferred Stock issued and outstanding as of September 2, 2015. Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act. The persons and entities named in the table have sole voting and sole investment power with respect to the shares set forth opposite that person’s name, subject to community property laws, where applicable.
2.
Percentage of voting power is calculated based on Series A Preferred Stock holders representing 67% of the total number of voting shares.
3.
Raymond Dabney, our President and Chief Executive Officer is the Trustee of the Bogat Family Trust.
ACTION: TO ISSUE THE NEW DIVIDEND
To approve the decision of our Board of Directors to issue a dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of the current common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
On September 2, 2015, our Board of Directors approved, subject to receiving the approval of the holder of a majority of our outstanding capital stock, to issue a dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-refundable share purchase warrant for each 100 shares of the current common stock that they previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
As of the date the New Dividend was approved by our Board and the Majority Stockholder, there were 1,279,805,296 shares of our common stock issued and outstanding.
4
Share Dividend
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue a dividend to holders of our current common stock so they received 1 share of Class A common stock for each 100 shares of the current common stock that they previously owned as of the Record Date. These shares will be mailed to the shareholders directly from our transfer agent without any action require on the part of our shareholders.
Warrants
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue one non-transferable share purchase warrant for each 100 shares of the current common stock that shareholders previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
ACTION: TO ISSUE THE PREVIOUS DIVIDEND
To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
Share Dividend
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue a dividend to holders of our current common stock so they received 1 share of Class A common stock for each 100 shares of the current common stock that they previously owned as of the Record Date. These shares will be mailed to the shareholders directly from our transfer agent without any action require on the part of our shareholders.
Warrants
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue one non-transferable share purchase warrant for each 100 shares of the current common stock that shareholders previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
ACTION: TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF FROM 1,500,000,000 TO 3,000,000,000
On September 2, 2015, our Board of Directors approved, subject to receiving the approval of the holder of a majority of our outstanding voting stock, an amendment and restatement of our Articles of Incorporation (the “Restated Articles”), to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000 (the “Share Increase”). The Majority Stockholder approved the Restated Articles pursuant to a written consent dated as of September 2, 2015. The Restated Articles effecting the share increase will become effective following filing with the Secretary of State of the State of Nevada, which will occur promptly following the 20th day after the filing of the Definitive Information Statement.
We are currently authorized by our Certificate of Incorporation to issue 1,500,000,000 shares of common stock, $0.001 par value per share, 100,000,000 shares of Series A common stock, $0.001 par value per shares and 1,000,000 shares of Preferred Stock, $0.001 par value per share. Pursuant to the Amendment we will increase the number of common shares we are authorized to issue to 3,000,000,000 shares of common stock, $0.001 par value per share. As of the date the Amendment was approved by our Board and the Majority Stockholder, there were 1,279,805,296 shares of our common stock issued and outstanding.
5
Reasons for the Share Increase
Our Board believes it is in our best interests and the best interests of our stockholders to increase the number of authorized shares of our common stock to allow for the issuance of shares of our common stock or other securities in connection with such potential issuances and such other purposes as the Board determines. The Board believes that the Share Increase will afford the Company greater flexibility in seeking capital and potential acquisition targets. The Board has no immediate plans, understandings, agreement or commitments to issue shares of Common Stock for any purposes.
Effect of the Share Increase
The increase in the authorized number of shares of our common stock will permit our Board to issue additional shares of our common stock without further approval of our stockholders, and our Board does not intend to seek stockholder approval prior to any issuance of the authorized capital stock unless stockholder approval is required by applicable law or stock market or exchange requirements. Our issuance of additional shares of common stock may result in substantial dilution to our existing stockholders, and such issuances may not require stockholder approval.
Anti-Takeover
We presently do not have in place provisions which may have an anti-takeover effect. The increase in the authorized number of shares of our common stock did not result from our knowledge of any specific effort to accumulate our securities or to obtain control of us by means of a merger, tender offer, proxy solicitation in opposition to management or otherwise, and we did not take such action to increase the authorized shares of our common stock to enable us to frustrate any efforts by another party to acquire a controlling interest or to seek representation on our Board.
The issuance of additional shares of our common stock may have a dilutive effect on earnings per share and on the equity and voting power of existing security holders of our common stock. It may also adversely affect the market price of our common stock. However, if additional shares are issued in transactions whereby favorable business opportunities are provided, the market price of our common stock may increase.
The holders of our common stock are entitled to one vote for each share held of record on all matters to be voted on by our stockholders.
The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.
6
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following information table sets forth certain information regarding the Common Stock owned on September 2, 2015 by (i) each person who is known by the Company to own beneficially more than 5% of its outstanding Common Stock, (ii) each director and officer, and (iii) all officers and directors as a group:
Names and Address (1)
Number of Shares Owned
Percentage (2)
Raymond C. Dabney (3)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
73,649,333 (4)
5.8%
Chad S. Johnson (5)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
21,669,544
1.7%
Robert Kane (6)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
10,623,345
0.8%
Mario Lap (7)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
15,000,000 (8)
1.2%
All Directors And Officers As A Group
120,942,222
9.5%
1.
The person named in this table has sole voting and investment power with respect to all shares of common stock reflected as beneficially owned.
2.
Based on 1,279,805,296 shares of common stock outstanding as of September 2, 2015.
3.
Raymond C. Dabney is our President, Chief Executive Officer and a Director.
4.
Includes 22,726,000 shares held personally, 45,923,333 shares held by Bogat Family Trust, for which Mr. Dabney is a trustee, and 5,000,000 shares held by Pacific One Financial Services Ltd., a Company which Mr. Dabney owns 80.1% of.
5.
Chad S. Johnson is our Secretary, Chief Operating Officer, General Counsel and a Director.
6.
Robert Kane is our Chief Financial Officer and a Director.
7.
Mario Lap is a Director.
8.
Includes 5,000,000 shares held personally and 10,000,000 shares held by MLS Lap BV, a company which Mr. Lap has voting and investment control over.
http://ih.advfn.com/p.php?pid=nmona&article=68550302" target="_blank" rel="nofollow ugc noopener">http://ih.advfn.com/p.php?pid=nmona&article=68550302
6946 N Academy Blvd, Suite B #254
Colorado Springs CO 80918
To the Shareholders:
The purpose of this Information Statement is to inform the holders of record, as of the close of business on September 2, 2015, of shares of the common stock with voting power of Cannabis Science, Inc., a Nevada corporation (the “Company”), that our Board of Directors and one shareholder holding 67% of our voting power as of the Record Date have giving written consent as of September 2, 2015, to approve the following:
(1)
To issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol (the “New Dividend”).
(2)
To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol (the “Previous Dividend”).
(3)
To amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000 (the “Share Increase”).
These actions were approved on September 2, 2015, by our Board of Directors and one shareholder who holds a majority of the Company’s voting power. We anticipate an effective date of October 6, 2015, or as soon thereafter as practicable in accordance applicable law, including the Nevada Revised Statutes (“NRS”).
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
No action is required by you. The accompanying information statement is furnished only to inform our shareholders of the actions described above before they take place in accordance with the NRS and Rule 14c of the Securities Exchange Act of 1934, as amended. This Information Statement is first mailed to you on or about September 16, 2015.
Please feel free to call us at (888) 889-0888 should you have any questions on the enclosed Information Statement.
Date: September 16, 2015
For the Board of Directors of
Cannabis Science, Inc.
By:
/s/ Raymond C. Dabney
Raymond C. Dabney
Chief Executive Officer and Director
2
THIS INFORMATION STATEMENT IS BEING PROVIDED TO
YOU BY THE BOARD OF DIRECTORS OF THE COMPANY
WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE
REQUESTED NOT TO SEND US A PROXY
Cannabis Science, Inc.
6946 N Academy Blvd, Suite B #254
Colorado Springs CO 80918
INFORMATION STATEMENT
(Definitive)
September 16, 2015
GENERAL INFORMATION
This Information Statement has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the holders (the “Stockholders”) of the common stock, par value $0.001 per share (the “Common Stock”), of Cannabis Science, Inc., a Nevada Corporation (the “Company”), to notify such Stockholders that on or about September 2, 2015 , the Company received written consents in lieu of a meeting of Stockholders from one holder of 1,000,000 shares of Series A Preferred Stock representing 67% of the our total 1,279,805,296 issued and outstanding shares of voting stock of the Company (the “Majority Stockholder”) to: (1) issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol. (2) To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol. (3) To amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000
On September 2, 2015, the Board approved the above actions, subject to approval by the Stockholders.
We are not aware of any substantial interest, direct or indirect, by security holders or otherwise, that is in opposition to matters of action taken. In addition, pursuant to the laws of Nevada, the actions taken by majority written consent in lieu of a special shareholder meeting do not create appraisal or dissenters’ rights.
Our board of directors determined to pursue shareholder action by majority written consent presented by our outstanding shares of stock entitled to vote in an effort to reduce the costs and management time required to hold a special meeting of shareholders and to implement the above action to our shareholders in a timely manner.
The above actions will become effective 20 days following the mailing to the Stockholders of the Definitive Information Statement, or as soon thereafter as is practicable.
3
WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND A PROXY.
OUTSTANDING VOTING SECURITIES OF THE COMPANY
As of the date of the consent by the Majority Stockholder, on September 2, 2015, the Company had 1,279,805,296 shares of Common Stock issued and outstanding, and there were 1,000,000 shares of Series A Preferred Stock issued and outstanding. Each share of outstanding Common Stock is entitled to one vote on matters submitted for Stockholder approval and the holders of the Series A Preferred Stock are entitled to 67% of the total vote on all matters to be voted on by the holders of the Company's common stock.
On September 2, 2015, the holders of 1,000,000 shares of Series A Preferred Stock (or 67% of the Company’s total voting stock then outstanding) executed and delivered to the Company a written consent approving the New Dividend, paying out the Previous Dividend and the Share Increase (collectively the “Actions”). As the Actions were approved by the Majority Stockholder, no proxies are being solicited with this Information Statement.
The NRS provides in substance that unless the Company’s Articles provides otherwise, Stockholders may take action without a meeting of stockholders and without prior notice if a consent or consents in writing, setting forth the action so taken, is signed by the Stockholders having not less than the minimum number of votes that would be necessary to take such action at a meeting at which all shares entitled to vote thereon were present.
INFORMATION ON CONSENTING STOCKHOLDERS
Pursuant to the Company’s Bylaws and the NRS, a vote by the holders of at least a majority of the voting shares is required to effect the Action described herein. As of the Record Date, the Company had 1,279,805,296 common shares issued and outstanding and entitled to vote, which for voting purposes are entitled to one vote per share and 1,000,000 Series A Preferred Shares issued and outstanding and entitled to vote, which for voting purposes are entitled to 67% of the votes entitled to vote. The consenting Majority Stockholder is the record and beneficial owners of a total of 1,000,000 shares of the Company’s Series A Preferred stock, which represents 67% of the total number of voting shares. The consenting Majority Stockholder voted in favor of the Actions described herein in a written consent, dated September 2, 2015. No consideration was paid for the consent. The consenting stockholders’ name, affiliation with the Company and beneficial holdings are as follows:
Title of Class
Name and Address of Beneficial Owner
Amount and Nature of beneficial ownership
Percentage of Class (1)
Percentage of Voting Power (2)
Series A Preferred Stock
Bogat Family Trust (3)
c/o Cannabis Science Inc.
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
1,000,000
100%
67%
1.
Percentage of class is based on 1,000,000 shares of Series A Preferred Stock issued and outstanding as of September 2, 2015. Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act. The persons and entities named in the table have sole voting and sole investment power with respect to the shares set forth opposite that person’s name, subject to community property laws, where applicable.
2.
Percentage of voting power is calculated based on Series A Preferred Stock holders representing 67% of the total number of voting shares.
3.
Raymond Dabney, our President and Chief Executive Officer is the Trustee of the Bogat Family Trust.
ACTION: TO ISSUE THE NEW DIVIDEND
To approve the decision of our Board of Directors to issue a dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of the current common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
On September 2, 2015, our Board of Directors approved, subject to receiving the approval of the holder of a majority of our outstanding capital stock, to issue a dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-refundable share purchase warrant for each 100 shares of the current common stock that they previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
As of the date the New Dividend was approved by our Board and the Majority Stockholder, there were 1,279,805,296 shares of our common stock issued and outstanding.
4
Share Dividend
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue a dividend to holders of our current common stock so they received 1 share of Class A common stock for each 100 shares of the current common stock that they previously owned as of the Record Date. These shares will be mailed to the shareholders directly from our transfer agent without any action require on the part of our shareholders.
Warrants
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue one non-transferable share purchase warrant for each 100 shares of the current common stock that shareholders previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
ACTION: TO ISSUE THE PREVIOUS DIVIDEND
To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company’s current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
Share Dividend
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue a dividend to holders of our current common stock so they received 1 share of Class A common stock for each 100 shares of the current common stock that they previously owned as of the Record Date. These shares will be mailed to the shareholders directly from our transfer agent without any action require on the part of our shareholders.
Warrants
Upon the effectiveness of the Company’s proposed corporate actions, the Company will issue one non-transferable share purchase warrant for each 100 shares of the current common stock that shareholders previously owned as of the record date, October 9, 2015. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90 days from the date Class A common stock commences trading under its own unique symbol.
ACTION: TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF FROM 1,500,000,000 TO 3,000,000,000
On September 2, 2015, our Board of Directors approved, subject to receiving the approval of the holder of a majority of our outstanding voting stock, an amendment and restatement of our Articles of Incorporation (the “Restated Articles”), to increase the number of authorized shares of common stock we may issue from 1,500,000,000 to 3,000,000,000 (the “Share Increase”). The Majority Stockholder approved the Restated Articles pursuant to a written consent dated as of September 2, 2015. The Restated Articles effecting the share increase will become effective following filing with the Secretary of State of the State of Nevada, which will occur promptly following the 20th day after the filing of the Definitive Information Statement.
We are currently authorized by our Certificate of Incorporation to issue 1,500,000,000 shares of common stock, $0.001 par value per share, 100,000,000 shares of Series A common stock, $0.001 par value per shares and 1,000,000 shares of Preferred Stock, $0.001 par value per share. Pursuant to the Amendment we will increase the number of common shares we are authorized to issue to 3,000,000,000 shares of common stock, $0.001 par value per share. As of the date the Amendment was approved by our Board and the Majority Stockholder, there were 1,279,805,296 shares of our common stock issued and outstanding.
5
Reasons for the Share Increase
Our Board believes it is in our best interests and the best interests of our stockholders to increase the number of authorized shares of our common stock to allow for the issuance of shares of our common stock or other securities in connection with such potential issuances and such other purposes as the Board determines. The Board believes that the Share Increase will afford the Company greater flexibility in seeking capital and potential acquisition targets. The Board has no immediate plans, understandings, agreement or commitments to issue shares of Common Stock for any purposes.
Effect of the Share Increase
The increase in the authorized number of shares of our common stock will permit our Board to issue additional shares of our common stock without further approval of our stockholders, and our Board does not intend to seek stockholder approval prior to any issuance of the authorized capital stock unless stockholder approval is required by applicable law or stock market or exchange requirements. Our issuance of additional shares of common stock may result in substantial dilution to our existing stockholders, and such issuances may not require stockholder approval.
Anti-Takeover
We presently do not have in place provisions which may have an anti-takeover effect. The increase in the authorized number of shares of our common stock did not result from our knowledge of any specific effort to accumulate our securities or to obtain control of us by means of a merger, tender offer, proxy solicitation in opposition to management or otherwise, and we did not take such action to increase the authorized shares of our common stock to enable us to frustrate any efforts by another party to acquire a controlling interest or to seek representation on our Board.
The issuance of additional shares of our common stock may have a dilutive effect on earnings per share and on the equity and voting power of existing security holders of our common stock. It may also adversely affect the market price of our common stock. However, if additional shares are issued in transactions whereby favorable business opportunities are provided, the market price of our common stock may increase.
The holders of our common stock are entitled to one vote for each share held of record on all matters to be voted on by our stockholders.
The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.
6
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following information table sets forth certain information regarding the Common Stock owned on September 2, 2015 by (i) each person who is known by the Company to own beneficially more than 5% of its outstanding Common Stock, (ii) each director and officer, and (iii) all officers and directors as a group:
Names and Address (1)
Number of Shares Owned
Percentage (2)
Raymond C. Dabney (3)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
73,649,333 (4)
5.8%
Chad S. Johnson (5)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
21,669,544
1.7%
Robert Kane (6)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
10,623,345
0.8%
Mario Lap (7)
6946 N Academy Blvd
Suite B #254
Colorado Springs, CO 80918
15,000,000 (8)
1.2%
All Directors And Officers As A Group
120,942,222
9.5%
1.
The person named in this table has sole voting and investment power with respect to all shares of common stock reflected as beneficially owned.
2.
Based on 1,279,805,296 shares of common stock outstanding as of September 2, 2015.
3.
Raymond C. Dabney is our President, Chief Executive Officer and a Director.
4.
Includes 22,726,000 shares held personally, 45,923,333 shares held by Bogat Family Trust, for which Mr. Dabney is a trustee, and 5,000,000 shares held by Pacific One Financial Services Ltd., a Company which Mr. Dabney owns 80.1% of.
5.
Chad S. Johnson is our Secretary, Chief Operating Officer, General Counsel and a Director.
6.
Robert Kane is our Chief Financial Officer and a Director.
7.
Mario Lap is a Director.
8.
Includes 5,000,000 shares held personally and 10,000,000 shares held by MLS Lap BV, a company which Mr. Lap has voting and investment control over.
http://ih.advfn.com/p.php?pid=nmona&article=68550302" target="_blank" rel="nofollow ugc noopener">http://ih.advfn.com/p.php?pid=nmona&article=68550302
Ich beabsichtige, hier mal eine überschaubare Summe zu investieren. Hat irgend jemand ein bischen Ahnung von diesem Unternehmen und kann mir freundlicherweise etwas dazu sagen ?
Vielen Dank schon mal im voraus.......
Vielen Dank schon mal im voraus.......
Da bricht das Ding jetzt endlich mal aus und verdoppelt sich in wenigen Tagen und keiner will dabei gewesen sein !!
Na gut, dann freu´ ich mich eben alleine.....
.
Na gut, dann freu´ ich mich eben alleine.....
.
Antwort auf Beitrag Nr.: 51.980.999 von Baroni am 15.03.16 09:03:22Ich hab mich auch gefreut. ich denke da geht bald was großes ab. Der cannabis Sektor heizt sich auf. 2016 soll episch werden. bis 2020 soll der Markt explodieren.
Antwort auf Beitrag Nr.: 52.022.651 von corecidex am 21.03.16 08:10:24Seh ich ganz genau so. Die Renaissance der Hanfpflanze zu medizinischen Zwecken wird gewaltig sein.
Willkommen im Club......
Willkommen im Club......
Antwort auf Beitrag Nr.: 52.024.751 von Baroni am 21.03.16 12:06:11Naja bisher besteht der Club nur aus und 2en Der olle Dabney wird sich schon was einfallen lassen um den Kurs hochzutreiben.
Wird der Hammer sehr zeitnah das Baby.......CBIS....
Der beeindruckende Anstieg der letzten Handelstage lässt eigentlich nur 2 Schlußfolgerungen zu, entweder wir bekommen in Kürze eine absolute Hammermeldung präsentiert, oder aber wir haben einen Shortsquezze erster Güte gesehen, dann rauscht der Kurs irgendwann genauso schnell wieder runter wie er gestiegen ist. Alles in allem eine sehr knifflige Situation wenn man zum jetzigen Zeitpunkt noch einsteigen, respektive nachlegen will. Was mich allerdings sehr wundert, ist die Tatsache, dass ich mich nicht erinnern kann, in den letzten 15 Jahren eine derartige Aktienperformance mit gleichzeitiger Totenstille im entsprechenden Diskussionsforum erlebt zu haben.
Sehr speziell.......
Sehr speziell.......
Antwort auf Beitrag Nr.: 52.072.490 von Baroni am 29.03.16 09:33:03Also der Anstieg ist zwar gut aber im Vergleich mit de Spikes über die letzten 5 Jahre immer noch am Anfang. Totenstille hier, aber jede Menge Postings im Ihub Chat.
Antwort auf Beitrag Nr.: 52.073.543 von corecidex am 29.03.16 11:37:41Cannabis Science CEO Excited as Record Date for Gifted Shares Approaches Tomorrow, Thursday, March 31st, 2016, and the New 360,000 Sq. Ft., Nevada Facility Moves to Design Phase
COLORADO SPRINGS, CO -- (Marketwired) -- 03/30/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has announced that the Cannabis Science CEO is excited as record date for gifted shares approaches fast, tomorrow, Thursday, March 31st, 2016, and the new 360,000 sq. ft. facility in Nevada moves into design phase.
The Company will update a secure website platform to include forms for shareholders to report their share ownership and attach any required documentation for transmission directly to Cannabis Science. This will help streamline the process and get shareholders their gifted shares more quickly.
In the same vein as the previously announced 360,000 sq. ft. educational, drug development deal in Nevada has moved into design phase, and the Company has identified other large parcels of land for similar drug development facilities in California. A map of the Nevada facility will be included on the Company website as the Company gets further into the design process and the Company will announce the new land deals in California after signing has been completed.
Cannabis Science has been approached by several investor shareholders and industry professionals looking to expand and capitalize on the Nevada deal. The Company is negotiating with new investors and industry professionals to become a part of the Cannabis Science Research Park, which will help spur new drug research, development, and ultimately manufacturing in addition to scientific contribution and studies.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated bythese forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 813-500-7332
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 310.650.3788
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Source: Cannabis Science, Inc
COLORADO SPRINGS, CO -- (Marketwired) -- 03/30/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has announced that the Cannabis Science CEO is excited as record date for gifted shares approaches fast, tomorrow, Thursday, March 31st, 2016, and the new 360,000 sq. ft. facility in Nevada moves into design phase.
The Company will update a secure website platform to include forms for shareholders to report their share ownership and attach any required documentation for transmission directly to Cannabis Science. This will help streamline the process and get shareholders their gifted shares more quickly.
In the same vein as the previously announced 360,000 sq. ft. educational, drug development deal in Nevada has moved into design phase, and the Company has identified other large parcels of land for similar drug development facilities in California. A map of the Nevada facility will be included on the Company website as the Company gets further into the design process and the Company will announce the new land deals in California after signing has been completed.
Cannabis Science has been approached by several investor shareholders and industry professionals looking to expand and capitalize on the Nevada deal. The Company is negotiating with new investors and industry professionals to become a part of the Cannabis Science Research Park, which will help spur new drug research, development, and ultimately manufacturing in addition to scientific contribution and studies.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated bythese forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 813-500-7332
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 310.650.3788
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Source: Cannabis Science, Inc
Kann mir jemand sagen, was es mit den loyalty gift shares des CEO auf sich hat ?
Antwort auf Beitrag Nr.: 52.192.159 von wayne001 am 14.04.16 20:03:19der ceo verschenkt aktien an alle die bei cbis investiert sind. da gibts auf der cbis website ein formular, wo man da was eintragen kann. ich glaube allerdings nicht wirklich daran.
Hallo zusammen, gibt's hier erfahrene Anleger die mir paar tipps geben können, ob sich ein Einstieg lohnt oder sollte man lieber andere Unternehmen im Bereich Cannabis bzw. Hanf auf dem Schirm haben evtl. Unternehmen die starke/große Investoren haben, gibt's da etwas interessantes zurzeit?
Antwort auf Beitrag Nr.: 53.000.566 von fabfab am 05.08.16 18:17:42zockerpapier, alles oder nix
Antwort auf Beitrag Nr.: 53.009.077 von corecidex am 07.08.16 20:51:41Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients Nachrichtenquelle: Marketwired | 28.09.2016, 16:40 | 209 | 0 | 0 IRVINE, CA--(Marketwired - Sep 28, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize target medicines for target ailments.
These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list. Initial Target Ailments: try { Ads_TFM_AD('CADX1'); } catch(e) {} Cancers, PTSD, HIV/AIDS, Asthma, COPD, pain management, management of appetite disorders, headaches, joint and muscle pain, menstrual pain, sleep aid, seizure spectrum disorders, cold & flu, psoriasis, and others. Each study will be conducted through MD status doctor monitoring systems. Legal self-medicating patients who wish to participate in each study are urged to submit an application early to the company to ensure their place and receive their products early. As well, the company is releasing its cancer target formulation that has had previous success in the management of certain types of cancer such as basal cell carcinoma, a common form of skin cancer. By conducting more critical ailment studies, the company moves much closer to full pharmaceutical development and commercialization. The company website is being updated to accommodate each target ailment and once the products reach dispensary shelves, we will reach out to the many self-medicating patients looking to participate in one of the many studies. We will provide instructions on where to pick up their meds and how to attain their tracking package.
The company's new cannabis-based inhalant treatment for asthma and COPD self-medicating patients has a large interest for initial applicants. The new Natural Body & Soul Healing Balm for chronic ache and pain sufferers, the Relief Tonic for immune system bolstering, and the Solace Drops for sleep deprivation relief saw similar results in applicant interest. These products and more are on their way to select California dispensaries and study participants will receive further instructions from the company. "Everything is coming full circle for our company. Just as we're launching our new cannabis-based medication product lines, I have been invited to speak at Harvard Medical School, which will present us with the opportunity to tell our story to highly ambitious, and talented thought leaders, while inspiring the minds of our future leaders to lead on," said Director, President, CEO & Co-Founder, Raymond C. Dabney, "Opportunities abound, and I am very excited to meet additional colleagues of like mind and spirit to help to run more effective drug development programs." Presenting at one of the nation's most prestigious medical schools creates vast opportunity for research collaboration, cannabis-industry inspiration and expansion, and drug development as a whole. It is a huge landmark for a cannabis research and drug manufacturing company to be invited to speak at such an important academic event, and that goes to show the progress the company has made in its research and development.
Additionally, Mr. Dabney's presentation opens up the floor for cannabis research discussion, innovation, and collaboration opportunities. As these initial batches of products reach patients' hands, the company will shift its focus to expanding distribution and developing new medications to improve the lives of people suffering with other ailments. About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission. Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer (CMO) allen.herman@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Investor Relations Teresa Misenheimer teresa@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney Director, President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832
Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients | wallstreet-online.de - Vollständiger Artikel unter:
http://www.wallstreet-online.de/nachricht/8958537-cannabis-s…
These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list. Initial Target Ailments: try { Ads_TFM_AD('CADX1'); } catch(e) {} Cancers, PTSD, HIV/AIDS, Asthma, COPD, pain management, management of appetite disorders, headaches, joint and muscle pain, menstrual pain, sleep aid, seizure spectrum disorders, cold & flu, psoriasis, and others. Each study will be conducted through MD status doctor monitoring systems. Legal self-medicating patients who wish to participate in each study are urged to submit an application early to the company to ensure their place and receive their products early. As well, the company is releasing its cancer target formulation that has had previous success in the management of certain types of cancer such as basal cell carcinoma, a common form of skin cancer. By conducting more critical ailment studies, the company moves much closer to full pharmaceutical development and commercialization. The company website is being updated to accommodate each target ailment and once the products reach dispensary shelves, we will reach out to the many self-medicating patients looking to participate in one of the many studies. We will provide instructions on where to pick up their meds and how to attain their tracking package.
The company's new cannabis-based inhalant treatment for asthma and COPD self-medicating patients has a large interest for initial applicants. The new Natural Body & Soul Healing Balm for chronic ache and pain sufferers, the Relief Tonic for immune system bolstering, and the Solace Drops for sleep deprivation relief saw similar results in applicant interest. These products and more are on their way to select California dispensaries and study participants will receive further instructions from the company. "Everything is coming full circle for our company. Just as we're launching our new cannabis-based medication product lines, I have been invited to speak at Harvard Medical School, which will present us with the opportunity to tell our story to highly ambitious, and talented thought leaders, while inspiring the minds of our future leaders to lead on," said Director, President, CEO & Co-Founder, Raymond C. Dabney, "Opportunities abound, and I am very excited to meet additional colleagues of like mind and spirit to help to run more effective drug development programs." Presenting at one of the nation's most prestigious medical schools creates vast opportunity for research collaboration, cannabis-industry inspiration and expansion, and drug development as a whole. It is a huge landmark for a cannabis research and drug manufacturing company to be invited to speak at such an important academic event, and that goes to show the progress the company has made in its research and development.
Additionally, Mr. Dabney's presentation opens up the floor for cannabis research discussion, innovation, and collaboration opportunities. As these initial batches of products reach patients' hands, the company will shift its focus to expanding distribution and developing new medications to improve the lives of people suffering with other ailments. About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission. Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer (CMO) allen.herman@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Investor Relations Teresa Misenheimer teresa@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney Director, President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832
Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients | wallstreet-online.de - Vollständiger Artikel unter:
http://www.wallstreet-online.de/nachricht/8958537-cannabis-s…
Antwort auf Beitrag Nr.: 53.404.287 von Vaterland am 04.10.16 13:49:10ASK in USA derzeit bei 0.02 vor Börse....
http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
So eine Mega Performance und nix los hier !!
Unglaublich.....
Unglaublich.....
Antwort auf Beitrag Nr.: 53.504.982 von Baroni am 19.10.16 09:21:37Es wird sehr viel im amerikanischen Investors Hub diskutiert. Bin gespannt wie es weitergeht.
Habe mich gestern mit 320% Gewinn verabschiedet.
Danke CBIS, hätte ich dir garnicht zugetraut.....
Danke CBIS, hätte ich dir garnicht zugetraut.....
Antwort auf Beitrag Nr.: 53.522.751 von Baroni am 21.10.16 09:04:44die rallye geht nach einer kurzen konsolidierung von 1 oder 2 tagen weiter (meine meinung) anstiegspotenzial bis zum 8.11.
Antwort auf Beitrag Nr.: 53.532.183 von corecidex am 22.10.16 17:49:122016-11-10T16:25:08Z Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over 1,000 Acres Targeting Property/Drug Development
Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over
1,000 Acres Targeting Property/Drug Development in
California and Nevada as Industry Opens Up
IRVINE, CA -- (Marketwired) -- 11/10/16 -- Cannabis Science, Inc.
(OTC PINK: CBIS), a U.S. company specializing in the development of
cannabis-based medicines, is prepared to move in on new opportunities
in California and Nevada markets following the election cycle. The
Company is now targeting over 1,000 acres in California and Nevada
for property and drug development programs. The post-election plan
includes new products, new dispensaries, and new strategic
agreements.
"After closing the last land deal we announced for over 300 acres, we
are now on to something much larger on a combined scale. This land
package goes right in line with our other large deals in California
and Nevada. These land deals put us in a very favorable position for
high growth moving forward. Coupled with completing our in-house
laboratory, new drug programs, and our new website, we have some very
exciting developments coming in the near future and we feel ready to
meet the demands of more patients than ever before, and the timing
couldn't be better. With the tremendous support for Proposition 64
and other pro-cannabis initiatives across the nation Cannabis Science
is positioned to become a market leader," said Director, President,
CEO & Co-Founder, Raymond C. Dabney.
Both California and Nevada voted to legalize marijuana for
recreational adult use, which carries a host of benefits for Cannabis
Science, as it allows more pathways for customers to attain the
company's products. Considering that California alone has the sixth
largest economy in the world in terms of GDP, this opens a very large
market for the company to reach.
Recently, articles have been released stating that cannabis sales in
Colorado are slated to exceed alcohol sales only a couple of years'
post-legislation. In California's much larger market, this type of
consumer support in the cannabis industry has huge potential to drive
Cannabis Science's bottom line.
In preparation, the company has been rapidly expanding its drug
development land deals in order to produce more products and meet
demand increases. Additionally, the company is negotiating
distribution deals with new dispensaries across the state to cast a
wider net and reach more patients. The company's most recent new
products, including a pain relief product, an immune system
bolsterer, and a sleep aid, are very accessible, even to first-time
patients.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history dating
back thousands of years, and currently, there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal characterization,
and clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers, HIV/AIDS, and neurological conditions. The Company
is proceeding with the research and development of its proprietary
drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and
CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Act of 1934. A statement containing words such as
"anticipate," "seek," intend," "believe," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated
by these forward-looking statements may not occur. Factors that could
cause or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc., does not undertake any
duty nor does it intend to update the results of these
forward-looking statements. Safe Harbor Statement. The Private
Securities Litigation Reform Act of 1995 provides a 'safe harbor' for
forward looking statements. Certain of the statements contained
herein, which are not historical facts are forward looking statements
with respect to events, the occurrence of which involved risks and
uncertainties. These forward- looking statements may be impacted,
either positively or negatively, by various factors. Information
concerning potential factors that could affect the company are
detailed from time to time in the company's reports filed with the
Securities and Exchange Commission.
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over
1,000 Acres Targeting Property/Drug Development in
California and Nevada as Industry Opens Up
IRVINE, CA -- (Marketwired) -- 11/10/16 -- Cannabis Science, Inc.
(OTC PINK: CBIS), a U.S. company specializing in the development of
cannabis-based medicines, is prepared to move in on new opportunities
in California and Nevada markets following the election cycle. The
Company is now targeting over 1,000 acres in California and Nevada
for property and drug development programs. The post-election plan
includes new products, new dispensaries, and new strategic
agreements.
"After closing the last land deal we announced for over 300 acres, we
are now on to something much larger on a combined scale. This land
package goes right in line with our other large deals in California
and Nevada. These land deals put us in a very favorable position for
high growth moving forward. Coupled with completing our in-house
laboratory, new drug programs, and our new website, we have some very
exciting developments coming in the near future and we feel ready to
meet the demands of more patients than ever before, and the timing
couldn't be better. With the tremendous support for Proposition 64
and other pro-cannabis initiatives across the nation Cannabis Science
is positioned to become a market leader," said Director, President,
CEO & Co-Founder, Raymond C. Dabney.
Both California and Nevada voted to legalize marijuana for
recreational adult use, which carries a host of benefits for Cannabis
Science, as it allows more pathways for customers to attain the
company's products. Considering that California alone has the sixth
largest economy in the world in terms of GDP, this opens a very large
market for the company to reach.
Recently, articles have been released stating that cannabis sales in
Colorado are slated to exceed alcohol sales only a couple of years'
post-legislation. In California's much larger market, this type of
consumer support in the cannabis industry has huge potential to drive
Cannabis Science's bottom line.
In preparation, the company has been rapidly expanding its drug
development land deals in order to produce more products and meet
demand increases. Additionally, the company is negotiating
distribution deals with new dispensaries across the state to cast a
wider net and reach more patients. The company's most recent new
products, including a pain relief product, an immune system
bolsterer, and a sleep aid, are very accessible, even to first-time
patients.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history dating
back thousands of years, and currently, there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal characterization,
and clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers, HIV/AIDS, and neurological conditions. The Company
is proceeding with the research and development of its proprietary
drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and
CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Act of 1934. A statement containing words such as
"anticipate," "seek," intend," "believe," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated
by these forward-looking statements may not occur. Factors that could
cause or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc., does not undertake any
duty nor does it intend to update the results of these
forward-looking statements. Safe Harbor Statement. The Private
Securities Litigation Reform Act of 1995 provides a 'safe harbor' for
forward looking statements. Certain of the statements contained
herein, which are not historical facts are forward looking statements
with respect to events, the occurrence of which involved risks and
uncertainties. These forward- looking statements may be impacted,
either positively or negatively, by various factors. Information
concerning potential factors that could affect the company are
detailed from time to time in the company's reports filed with the
Securities and Exchange Commission.
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Antwort auf Beitrag Nr.: 53.674.251 von Vaterland am 11.11.16 15:10:09Lieber Leser, vielerorts wird über die mögliche Legalisierung von Cannabis diskutiert. Schon jetzt ist der Gebrauch jedoch zu bestimmten medizinischen Zwecken erlaubt. Zu den Profiteuren dieser Entwicklung zählt mit Sicherheit auch das Unternehmen Cannabis Science. Hier hat man sich der Entwicklung von Medikamenten verschrieben hat, die Cannabis beinhalten. Zuletzt gab es gute Neuigkeiten, denn es wurde gemeldet, dass man mit der Entwicklung zweier neuer Medikamente begonnen hat, die bei der Schmerztherapie angewendet werden sollen. Man plant, diese insbesondere bei diabetischen neuropathischen Schmerz und bei Fibromyalgie einzusetzen.
Medikamente wirken als Pflaster
Fibromyalgie ist eine Krankheit, an der weltweit etwa 2 bis 8 Prozent der Bevölkerung erkrankt sind. Die Erkrankung ist sowohl chronisch als bislang auch nicht heilbar. Es handelt sich um eine Schmerzerkrankung. Das Besondere an den Medikamenten von Cannabis Science ist, dass sie als Pflaster wirken. Die Inhalte werden so über die Haut in den Körper des Patienten übertragen. Dies hat z. B. den großen Vorteil, dass eine Überdosis quasi ausgeschlossen werden kann. Die Aktie hat zuletzt die Aufmerksamkeit der Anleger erregen können, weil sich der Kurs innerhalb weniger Wochen vervierfachen konnte. Dennoch ist eine gewisse Portion an Volatiliät nicht von der Hand zu weisen.
http://www.ariva.de/news/cannabis-science-der-kurs-hat-sich-…
Medikamente wirken als Pflaster
Fibromyalgie ist eine Krankheit, an der weltweit etwa 2 bis 8 Prozent der Bevölkerung erkrankt sind. Die Erkrankung ist sowohl chronisch als bislang auch nicht heilbar. Es handelt sich um eine Schmerzerkrankung. Das Besondere an den Medikamenten von Cannabis Science ist, dass sie als Pflaster wirken. Die Inhalte werden so über die Haut in den Körper des Patienten übertragen. Dies hat z. B. den großen Vorteil, dass eine Überdosis quasi ausgeschlossen werden kann. Die Aktie hat zuletzt die Aufmerksamkeit der Anleger erregen können, weil sich der Kurs innerhalb weniger Wochen vervierfachen konnte. Dennoch ist eine gewisse Portion an Volatiliät nicht von der Hand zu weisen.
http://www.ariva.de/news/cannabis-science-der-kurs-hat-sich-…
Antwort auf Beitrag Nr.: 53.674.272 von Vaterland am 11.11.16 15:11:53Capitol Alert November 5, 2016 9:45 AM Peter Thiel opens wallet for pot legalization in California
http://www.sacbee.com/news/politics-government/capitol-alert…
http://www.sacbee.com/news/politics-government/capitol-alert…
Antwort auf Beitrag Nr.: 53.684.193 von Vaterland am 13.11.16 16:16:36da geht wohl in naher Zukunft noch was?
Antwort auf Beitrag Nr.: 53.684.823 von corecidex am 13.11.16 19:33:19Ja
sieht gut aus heute
Wird Zeit für den Jahresstart nach oben
Wird Zeit für den Jahresstart nach oben
Antwort auf Beitrag Nr.: 54.027.029 von Schablonski am 06.01.17 16:43:15hier scheint was im busch zu sein.aktie mit chartausbruch!! bin mal paar long zu 0,079.
Antwort auf Beitrag Nr.: 54.110.534 von sw1975 am 18.01.17 15:56:10
1. ziel 0,20 erst mal.hängt vermutlich mit der landesweiten legalisierung zusammen.
1. ziel 0,20 erst mal.hängt vermutlich mit der landesweiten legalisierung zusammen.
Antwort auf Beitrag Nr.: 54.110.654 von sw1975 am 18.01.17 16:09:33dickes volumen drüben. fast 40 mio durch nach einer stunde.gestern schon erhöhtes volumen von 90 den ganzen tag.
die läuft heute noch über 0,10 meiner meinung nach.
die läuft heute noch über 0,10 meiner meinung nach.
Antwort auf Beitrag Nr.: 54.110.927 von sw1975 am 18.01.17 16:31:24600k aus dem ask gerissen zu 0,087 sehr sportlich.wenn die nicht weiter läuft dann weiss ich auch nicht.
Antwort auf Beitrag Nr.: 54.111.257 von sw1975 am 18.01.17 16:57:53erstaunlicherweise ziemlich ruhig hier.für mich ein gutes zeichen.
Gar nichts läuft...
Antwort auf Beitrag Nr.: 54.112.088 von sw1975 am 18.01.17 18:27:18Geh zu SD pushen...
Antwort auf Beitrag Nr.: 54.113.018 von Maik1969 am 18.01.17 20:25:28einstieg verpasst?? den chartausbruch sieht wohl jeder blinde und das unter enormen volumen.oder sagen wir extrem höheres durchschnittsvolumen.hol dir lieber morgen noch welche.die 0,20 kommen bald.
Antwort auf Beitrag Nr.: 54.114.323 von sw1975 am 19.01.17 02:07:04January 19, 2017 MarketNewsUpdates.com: Rise in Innovative Cannabis Services Including Travel Experiences Providing New Revenue Opportunities
PALM BEACH, Florida, January 19, 2017 /PRNewswire/ --
The cannabis industry continues to grow into a multi-billion dollar segment of the economy while innovators and investors are finding ways to capitalize off the momentum with new products and services for producing significant revenue streams. Cannabis companies in focus in the market include: Cannabis Science, Inc. (OTC: CBIS), Marijuana Company of America, Inc. (OTC: MCOA), Rocky Mountain High Brands, Inc. (OTC: RMHB), Puration, Inc. (OTC: PURA).
ML Capital Group (Trading on the OTC Market under the symbol MLCG) today announced a preliminary $1 million 2017 sales forecast. Management has published an online presentation detailing the forecast that is based on: Current annual sales approaching $400,000 annually; Record 2016 fourth quarter sales performance, and Entry into Cannabis Tourism through a pending acquisition. Read this and more news for ML Capital Group at http://marketnewsupdates.com/news/mlcg.html
The Company recently announced record sale performance for the fourth quarter of 2016. The Company also recently announced its entry into the cannabis sector through the pending acquisition of Spanish Peaks ScrumpDelicacies and a corresponding partnership with Puration, Inc. (OTC:PURA). In a presentation published today, management details a preliminary $1 million 2017 forecast based on its introduction of a Cannabis Tourism offering on top of the ongoing growth from its existing luxury tourism business. View the entire MLCG forecast presentation at this link: MLCG 2017 LUXURY TOURISM SALES FORECAST TO INCLUDE NEW CANNABIS TOURS.
In other sector related activity, market performance and recent developments:
Cannabis Science, Inc. (OTC: CBIS) closed up over 17% on Wednesday trading over 118 Million shares by the market close. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
Marijuana Company of America, Inc. (OTC: MCOA) closed up at $0.07 trading over 22 Million shares by the market close. Marijuana Company of America is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.
Rocky Mountain High Brands, Inc. (OTCQB: RMHB) closed up over 5% on Wednesday trading over 9 Million shares by the market close. Rocky Mountain High Brands, a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water announced this week a February launch of its powerful GPS based geofencing software advertising system in the Los Angeles market.
Puration, Inc. (OTC: PURA) closed up over 25% on Wednesday trading over 8.9 Million shares by the market close. PURA recently announced plans for the official launch its EVERx Cannabinoil (CBD) Infused Water at a major industry trade show in March 2017. Working with Alkame Holdings' (ALKM) wholly owned subsidiary Xtreme Technologies, PURA has developed the EVERx CBD Infused Sports Drink with 10 mg of CBD in a 16.9 oz bottle
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by ML Capital Group. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com - +1(561)325-8757
SOURCE MarketNewsUpdates.com
PALM BEACH, Florida, January 19, 2017 /PRNewswire/ --
The cannabis industry continues to grow into a multi-billion dollar segment of the economy while innovators and investors are finding ways to capitalize off the momentum with new products and services for producing significant revenue streams. Cannabis companies in focus in the market include: Cannabis Science, Inc. (OTC: CBIS), Marijuana Company of America, Inc. (OTC: MCOA), Rocky Mountain High Brands, Inc. (OTC: RMHB), Puration, Inc. (OTC: PURA).
ML Capital Group (Trading on the OTC Market under the symbol MLCG) today announced a preliminary $1 million 2017 sales forecast. Management has published an online presentation detailing the forecast that is based on: Current annual sales approaching $400,000 annually; Record 2016 fourth quarter sales performance, and Entry into Cannabis Tourism through a pending acquisition. Read this and more news for ML Capital Group at http://marketnewsupdates.com/news/mlcg.html
The Company recently announced record sale performance for the fourth quarter of 2016. The Company also recently announced its entry into the cannabis sector through the pending acquisition of Spanish Peaks ScrumpDelicacies and a corresponding partnership with Puration, Inc. (OTC:PURA). In a presentation published today, management details a preliminary $1 million 2017 forecast based on its introduction of a Cannabis Tourism offering on top of the ongoing growth from its existing luxury tourism business. View the entire MLCG forecast presentation at this link: MLCG 2017 LUXURY TOURISM SALES FORECAST TO INCLUDE NEW CANNABIS TOURS.
In other sector related activity, market performance and recent developments:
Cannabis Science, Inc. (OTC: CBIS) closed up over 17% on Wednesday trading over 118 Million shares by the market close. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
Marijuana Company of America, Inc. (OTC: MCOA) closed up at $0.07 trading over 22 Million shares by the market close. Marijuana Company of America is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.
Rocky Mountain High Brands, Inc. (OTCQB: RMHB) closed up over 5% on Wednesday trading over 9 Million shares by the market close. Rocky Mountain High Brands, a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water announced this week a February launch of its powerful GPS based geofencing software advertising system in the Los Angeles market.
Puration, Inc. (OTC: PURA) closed up over 25% on Wednesday trading over 8.9 Million shares by the market close. PURA recently announced plans for the official launch its EVERx Cannabinoil (CBD) Infused Water at a major industry trade show in March 2017. Working with Alkame Holdings' (ALKM) wholly owned subsidiary Xtreme Technologies, PURA has developed the EVERx CBD Infused Sports Drink with 10 mg of CBD in a 16.9 oz bottle
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by ML Capital Group. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com - +1(561)325-8757
SOURCE MarketNewsUpdates.com
Antwort auf Beitrag Nr.: 54.118.772 von Vaterland am 19.01.17 15:44:21Real-Time Best Bid & Ask0.0999 / 0.10 US
Antwort auf Beitrag Nr.: 54.118.808 von Vaterland am 19.01.17 15:48:32http://ih.advfn.com/stock-market/USOTC/cannabis-science-inc-…
Antwort auf Beitrag Nr.: 54.118.832 von Vaterland am 19.01.17 15:50:10http://www.otcmarkets.com/stock/CBIS/news
Antwort auf Beitrag Nr.: 54.118.874 von Vaterland am 19.01.17 15:53:49100 % BUY https://www.barchart.com/stocks/quotes/CBIS/opinion
Antwort auf Beitrag Nr.: 54.118.922 von Vaterland am 19.01.17 15:56:45Ist das jetzt ein Zeichen zum Ausstieg?
Marijuana Stocks: Second Week Of 2017 At 9.5% To 12.9% Returns From The January Effect
http://seekingalpha.com/article/4037019-marijuana-stocks-sec…
Schon wir mal, ob diese Prognose wirklich zutrifft.
http://seekingalpha.com/article/4037019-marijuana-stocks-sec…
Schon wir mal, ob diese Prognose wirklich zutrifft.
Ende mit BUY!
Da lag ich aber falsch! Puh
was geht denn da?
was geht denn da?
Antwort auf Beitrag Nr.: 54.122.504 von Maik1969 am 19.01.17 22:08:59http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Cannabis Science Distributors Sells Out of Initial Test Batch of CBIS Metered Dose Inhalers (MDI), Notes Consumer High-Demand for the CBIS Inhaler in California[/b
http://seekingalpha.com/pr/16723081-cannabis-science-distrib…
http://seekingalpha.com/pr/16723081-cannabis-science-distrib…
Antwort auf Beitrag Nr.: 54.163.511 von Nissie am 25.01.17 16:12:40January 26th, 2017Top 2 Marijuana Stocks With HUGE Upside Potential
http://www.otcmarkets.net/otcqpink/top-2-marijuana-stocks-wi…
http://www.otcmarkets.net/otcqpink/top-2-marijuana-stocks-wi…
Marijuana Stocks And The January Effect: N=229 Stocks Up An Average Of 51%
http://seekingalpha.com/article/4040570-marijuana-stocks-jan…
http://seekingalpha.com/article/4040570-marijuana-stocks-jan…
ist ja merkwürdig, keiner schreibt etwas, es werden immer nur Links eingesetzt
Frage: für die Nichtsogutenglischkönner - hätte man da auch was in Deutsch?
Frage: für die Nichtsogutenglischkönner - hätte man da auch was in Deutsch?
CBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017
https://seekingalpha.com/pr/16781983-cbis-ramps-production-r…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/pr/16781983-cbis-ramps-production-r…
https://seekingalpha.com/pr/16781983-cbis-ramps-production-r…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/pr/16781983-cbis-ramps-production-r…
CBIS Subsidiary, Cannabis Science Europe GmbH, Acquires Majority Shares of German Bio Med GmbH Jinvator to Facilitate European Expansions, New Products, and Additional Clinical Studies
https://seekingalpha.com/pr/16791874-cbis-subsidiary-cannabi…
https://seekingalpha.com/pr/16791874-cbis-subsidiary-cannabi…
Cannabis Science's Acquisition Raises More Questions Than Answer[/b
https://seekingalpha.com/article/4061003-cannabis-sciences-a…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/article/4061003-cannabis-sciences-a…
https://seekingalpha.com/article/4061003-cannabis-sciences-a…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/article/4061003-cannabis-sciences-a…
Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts[/b
https://seekingalpha.com/pr/16845171-cannabis-science-inc-re…
Ob diese news den Kurs positiv beeinflussen?
https://seekingalpha.com/pr/16845171-cannabis-science-inc-re…
Ob diese news den Kurs positiv beeinflussen?
Moin. Todenstimmung oder wird da noch etwas!?
Ich war mal investiert, bin aber wieder vor nem Jahr wieder raus. Geht da noch mal etwas oder ist das Ding Dood?
Ich war mal investiert, bin aber wieder vor nem Jahr wieder raus. Geht da noch mal etwas oder ist das Ding Dood?
Hat jemand Ahnung warum bei der Marktkap. der kurs soo niedrig ist?
Scheint so als wäre die Firma schon lange im Sektor.
Aber irgendwie fehlt wohl noch die Haupteinnahne Quelle. Oder ein Blockbuster.
Der Kurs war ja schon mal bei 2,10 Dollar!!!
Wird mal zeit wieder über 1Dollar zu kommen.
Scheint so als wäre die Firma schon lange im Sektor.
Aber irgendwie fehlt wohl noch die Haupteinnahne Quelle. Oder ein Blockbuster.
Der Kurs war ja schon mal bei 2,10 Dollar!!!
Wird mal zeit wieder über 1Dollar zu kommen.
Dienstag wird man sehen ob das Ding weiter fliegt! Frohes Fest allen bis dahin.
Antwort auf Beitrag Nr.: 56.536.106 von herku am 23.12.17 11:23:52Alles super gut gelaufen
Auch das Volumen passt. Gestern in U.S. 125 Mill..
https://globenewswire.com/news-release/2017/12/28/1275862/0/…
... da warten wir mal den Januar ab....
... da warten wir mal den Januar ab....
Dienstag starten wir schon viel höher ins neue Jahr!
Kurse um 0,15 Euro noch diese Woche?
Close nahe dem Tageshoch unter krassem Volumen. Bei dem aktuellen Cannabis-Hype, könnte ich mir Kurse um 0,15 Euro bis zum Ende der Woche vorstellen. Das wären aktuell nochmal 50%. CBIS läuft mMn immer näher zum 52-Wochen Hoch.
Könnte mir vorstellen, dass allmählich Kaufpanik aufkommt und niemand den Zug verpassen will. Wie gesagt, das Sentiment ist zZt extrem Bullish. Wenn jetzt im Laufe des Januars noch News kommen, sollte es nochmal einen ordentlichen Schub geben mMn.
Viel Glück allen!
NEWS - NEWS - NEWS - NEWS - NEWS - NEWS
Cannabis Science Negotiates With Crown Baus Capital Corp (OTC: CBCA) for Future Blockchain Cryptocurrency ICO Growth While Adding Strength to its Pharmacy Openings and Pharmaceutical Drug Development Programs RVINE, CA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC Pink: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce its intent to partner with its sister company, Crown Baus Capital Corporation (OTC Pink: CBCA), to strengthen CBIS’ planned blockchain crypto-currency ICO offering.
Details of the CBIS and CBCA cryptocurrency blockchain arrangement are expected to be finalized and announced shortly. Mr. Dabney and his management team are working to make the best deal structure for all shareholders involved, including a CBIS equity stake in CBCA or vice versa. Working together is in the best interests of both CBCA and CBIS as this type of relationship leverages the capabilities, experience, and expertise of both Companies. CBIS seeks to link the capital structure of CBCA with its upcoming asset backed blockchain cryptocurrency ICO, as well as leverage the pharmacies and pharmaceutical drug development programs currently underway as well as in the robust pipeline.
https://finance.yahoo.com/news/cannabis-science-negotiates-c…
News hat wohl noch keiner auf dem Schirm :-O
Hab noch schnell nachgelegt. Die News scheinen noch nicht viele bemerkt zu haben.
Antwort auf Beitrag Nr.: 56.600.444 von Muusmann am 03.01.18 15:01:41Hauptsache ich Trottel bin heute morgen noch bei 0,117 mit 40k eingestiegen.
Hätte ich mir eigentlich denken können, da wo ich investiere geht´s bergab !!
Jetzt heißt es dann halt mal abwarten
Hätte ich mir eigentlich denken können, da wo ich investiere geht´s bergab !!
Jetzt heißt es dann halt mal abwarten
Antwort auf Beitrag Nr.: 56.620.640 von Adler-Lui am 04.01.18 21:33:59keine Panik, geht wieder nach Norden. Ganz sicher, nur ein wenig Geduld.
Nach dem Anstieg mussten Gewinnmitnahmen kommen. Der Hype steht doch erst am Anfang.
Auch wenn Trump die Uhren zurückdrehen will, der Zug rollt.....
Auch wenn Trump die Uhren zurückdrehen will, der Zug rollt.....
Antwort auf Beitrag Nr.: 56.623.805 von Miser am 05.01.18 09:31:53
Warten wir es ab...Der Sturz gestern war enorm...
Die Trump-Administration will die Legalisierung zurücknehmen.
Ja möchte er gerne, aber die US-Bundesstaaten wollen nicht auf die Steuereinnahmen verzichten.
15% sind schon eine Hausnummer. Da geht es um Mrd. und die können sie sehr gut gebrauchen. Wenn dann wird es ein harter fight.
15% sind schon eine Hausnummer. Da geht es um Mrd. und die können sie sehr gut gebrauchen. Wenn dann wird es ein harter fight.
Antwort auf Beitrag Nr.: 56.624.273 von anmima am 05.01.18 10:03:18Jau..mal abwarten, was daraus wird!
(hatte diese Nachricht von gestern schon in einem anderen Foren-Thread https://www.wallstreet-online.de/diskussion/1240110-41-50/ca… mit Unbehagen gepostet )
(hatte diese Nachricht von gestern schon in einem anderen Foren-Thread https://www.wallstreet-online.de/diskussion/1240110-41-50/ca… mit Unbehagen gepostet )
Vermot zeigt, wer im Staat das Sagen hat! http://thehill.com/homenews/state-watch/367526-vermont-house…
0,12 Euro mindestens morgen meiner Meinung nach
Morgen kommt bestimmt wieder Kaufpanik auf. 0,12 Euro halte ich für mehr als realistisch. Den Grund dafür sehe ich in dem beständigen US - Kurs. Trotz des immensen Abverkaufs vor wenigen Tagen, kam der Kurs unter krassem Volumen nahezu auf Ausgangsbasis zurück. Sobald in den nächsten 3 Wochen News über die Eröffnung der Dispensaries veröffentlicht werden, können hier schnell Kurse um 0,20 Euro realistisch werden. Kurz vor Börsenschluss wurden nochmal über 2,7 Millionen Aktien auf Tageshoch gekauft in den USA. Ich glaube fest an mindestens 30% morgen.
Viel Spaß allen!
Chart Stuttgart
Auf einen erfolgreichen Tag!
Ja, die Aussichten stimmen. Wenn sie auch nur annähernd so umgesetzt werden, dann ist man hier gut
aufgestellt......
aufgestellt......
Antwort auf Beitrag Nr.: 56.658.245 von Miser am 09.01.18 09:36:34Also wird mehr oder weniger empfohlen in diese aktien zu investieren
Wieso ist die überhaupt noch bei ca 11ct wenn schon Apotheken stehen usw.
Hört sich doch alles sehr gut und weit an.
Hört sich doch alles sehr gut und weit an.
Das Ding wird wie immer abstürzen. Die Frage ist nur, wann. Zocken ist ok, aber man sollte sich darüber im Klaren sein, dass das hier eine wertlose Bude ist.
Antwort auf Beitrag Nr.: 56.660.825 von Ginelli83 am 09.01.18 13:02:29.... weil 2,55 Mrd. Aktien ausgegeben wurden = MK 304 Mill.$
https://finance.yahoo.com/news/cannabis-science-prepares-grand-opening-131437607.html
Gruß
Tiger
Gruß
Tiger
MORE HOGWASH -
Yesterday Raymond C. Dabney stated CBIS HAD the contracts and today ... they are 'actively pursuing' those contracts.
Cannabis Science Actively Pursuing U.S. Federal Government Contracts and Is Preparing Applications for Submission While Confirming the CBIS Security Team (CBISST) is Ready for Action
IRVINE, CA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC:CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has been actively pursuing contracts under its registration of SAM with three North American Industry Classification System (NAICS) Codes: 541711 – Research and Development in Biotechnology 621511 – Medical Laboratories 624230 – Emergency and Other Relief Services.
Cannabis Science has located and is preparing applications for submission under two of the above three codes and expects these applications to be submitted very soon. Having this information immediately available also allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, including research & development projects, supply needs, up to a pandemic alert requirement or other emergency requirements.
“There is a certain level of clearance Cannabis Science has received from the Defense Logistics Agency’s CAGE Program Office at the U.S. Department of Defense for the Federal Commercial and Government Entity (CAGE) Code program that allows CBIS instant access to U.S. Federal Government contract procurement and that puts the Company directly in line to benefit from the cannabinoid-based medicines industry,” stated Cannabis Science Inc., President & CEO, Co- Founder, Mr. Raymond C. Dabney.
“As for the U.S. Federal Government, we believe we have a significant role to play, as a private sector stakeholder, as well as a company that can support federally-funded contracts and grant opportunities as an experienced contractor. It is our goal to provide patients safe access to the pharmacies and to the drugs they want to heal their critical ailments, also that their personal information is secure.
“This currently is a volatile industry and we clearly see a need to filter out bad influences and bad information there to deceive and confuse the masses. We are educating, building pharmacies, laboratories, and medical centers; patient data protection is of the highest security priority.
“The Cannabis Science security team is here to secure and protect CBIS and all of its proprietary information, operational components, its assets, its people, and most important its valuable public and private patient information. We have experts on the security team that are required for certain situations in support of the worldwide federally funded contracts we are applying for and our current nationwide operations and growth. I am constantly and consistently being updated by assessments the security team is providing that consist of internal and external assessments, then actions are and will be taken accordingly,” stated Cannabis Science Inc., President & CEO, Co- Founder, Mr. Raymond C. Dabney.
The CBIS Security Team (CBISST)
The Cannabis Science Security Team has 30 plus years’ experience in government, private, personal and public security and consists of members from the LAPD, LA Sheriff’s Department, SWAT, Peace Officers, California Guard Card holders armed and unarmed, US Intelligence community, State of Colorado Certified Private Investigators, also the original Nuclear Security Assessment team member used by the United States Air Force.
CBISST team members have experience in global intelligence and have conducted performance based security assessments on all the Air Force's highest priority resources including nuclear weapon storage facilities, the US nation’s highest resources, as well as specializing in risk mitigation, banking, payment processing, executive, asset, and cash movement.
Cannabis Science Security Department is also planning for expansion. While the Newport Beach, California office will expand personnel and capabilities, we are projecting an expansion in the number of contracts, employees and consultants. Our current plan is to add a 4-person Network Security & Vulnerability Branch. CBISST believes that these new capabilities, as well as our continued return customer business base, will again provide us with unique opportunities in both the civilian and government contracting markets.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Informationconcerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Contact Information
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Source: Cannabis Science, Inc.
© 2018 GlobeNewswire, Inc.
Yesterday Raymond C. Dabney stated CBIS HAD the contracts and today ... they are 'actively pursuing' those contracts.
Cannabis Science Actively Pursuing U.S. Federal Government Contracts and Is Preparing Applications for Submission While Confirming the CBIS Security Team (CBISST) is Ready for Action
IRVINE, CA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC:CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has been actively pursuing contracts under its registration of SAM with three North American Industry Classification System (NAICS) Codes: 541711 – Research and Development in Biotechnology 621511 – Medical Laboratories 624230 – Emergency and Other Relief Services.
Cannabis Science has located and is preparing applications for submission under two of the above three codes and expects these applications to be submitted very soon. Having this information immediately available also allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, including research & development projects, supply needs, up to a pandemic alert requirement or other emergency requirements.
“There is a certain level of clearance Cannabis Science has received from the Defense Logistics Agency’s CAGE Program Office at the U.S. Department of Defense for the Federal Commercial and Government Entity (CAGE) Code program that allows CBIS instant access to U.S. Federal Government contract procurement and that puts the Company directly in line to benefit from the cannabinoid-based medicines industry,” stated Cannabis Science Inc., President & CEO, Co- Founder, Mr. Raymond C. Dabney.
“As for the U.S. Federal Government, we believe we have a significant role to play, as a private sector stakeholder, as well as a company that can support federally-funded contracts and grant opportunities as an experienced contractor. It is our goal to provide patients safe access to the pharmacies and to the drugs they want to heal their critical ailments, also that their personal information is secure.
“This currently is a volatile industry and we clearly see a need to filter out bad influences and bad information there to deceive and confuse the masses. We are educating, building pharmacies, laboratories, and medical centers; patient data protection is of the highest security priority.
“The Cannabis Science security team is here to secure and protect CBIS and all of its proprietary information, operational components, its assets, its people, and most important its valuable public and private patient information. We have experts on the security team that are required for certain situations in support of the worldwide federally funded contracts we are applying for and our current nationwide operations and growth. I am constantly and consistently being updated by assessments the security team is providing that consist of internal and external assessments, then actions are and will be taken accordingly,” stated Cannabis Science Inc., President & CEO, Co- Founder, Mr. Raymond C. Dabney.
The CBIS Security Team (CBISST)
The Cannabis Science Security Team has 30 plus years’ experience in government, private, personal and public security and consists of members from the LAPD, LA Sheriff’s Department, SWAT, Peace Officers, California Guard Card holders armed and unarmed, US Intelligence community, State of Colorado Certified Private Investigators, also the original Nuclear Security Assessment team member used by the United States Air Force.
CBISST team members have experience in global intelligence and have conducted performance based security assessments on all the Air Force's highest priority resources including nuclear weapon storage facilities, the US nation’s highest resources, as well as specializing in risk mitigation, banking, payment processing, executive, asset, and cash movement.
Cannabis Science Security Department is also planning for expansion. While the Newport Beach, California office will expand personnel and capabilities, we are projecting an expansion in the number of contracts, employees and consultants. Our current plan is to add a 4-person Network Security & Vulnerability Branch. CBISST believes that these new capabilities, as well as our continued return customer business base, will again provide us with unique opportunities in both the civilian and government contracting markets.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Informationconcerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Contact Information
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Source: Cannabis Science, Inc.
© 2018 GlobeNewswire, Inc.
IRVINE, CA, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has established a Construction Project Management Team (CPMT) to work closely with its Security Team (CBISST) to coordinate and support the Company’s aggressive growth initiatives, which include the establishment of a number of CBIS Pharmacies in Los Angeles and eventually nationwide, as well as CBIS Medical Centers that will facilitate the Company’s direct interaction with its patients.
“The CBIS CPMT will have overall planning, coordination, and control responsibilities for CBIS projects from initiation to completion,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “CPMT will manage and help ensure the functional and financial viability of our projects. With the construction industry experts we have on our CPMT, as well as the experienced security professionals on our CBISST, we expect our plans to build and expand CBIS Pharmacies and Medical Centers throughout California and the U.S. to be streamlined, secure, and completed on-time and within budget.”
As part of its activities, the CBISST will develop a Facility Security Plan (FSP). This plan is a critical component of CBIS’ security program. The guidelines for CBIS’ FSP are based on recognized industry best practices and provide broad recommendations for the protection of CBIS facilities and CBIS employees, contractors, patients and visitors. CBIS’ FSP will be generally applicable to all buildings and facilities operated and occupied by CBIS employees, including but not limited to:
• Buildings and facilities owned or leased by CBIS;
• CBIS leased rooms or suites within privately owned buildings;
• Stand-alone CBIS facilities;
• CBIS campuses, research laboratories, medical centers, offices and pharmacies; and
• Individual facilities on CBIS campuses and special-use facilities where appropriate.
The CBIS Construction Project Management Team and the CBIS Security Team will work hand in hand to deliver robust secure environments wherever CBIS is operating. The Security Team will conduct various threat assessments, which is the process of identifying or evaluating entities, actions, or occurrences (natural or man-made) that possess or indicate the potential to harm or destroy CBIS assets. The threat assessment will consider the full spectrum of threats (i.e., natural, criminal, terrorist, accidental, etc.) for a given facility/location. Threat data can be derived from various resources including security organizations, intelligence community reports and assessments, as well as state and local authorities. The CBIS Security Team will periodically produce a Design-Basis Threat Report (DBT) that will be used to identify a broad range of threats to CBIS facilities and will be updated regularly based on threat trends and data provided. For example, the crime rates in areas surrounding CBIS facilities will be assessed as an indicator of the type of criminal activity that may put CBIS facilities at risk.
The Risk Management Process for CBIS’ facilities will include an Interagency Security Committee (ISC) Standard that is the key starting point for the development of a Facility Security Plan (FSP). Once the FSP is applied, other critical elements will be added to make the plan a more robust document. The Facility Profile for each CBIS asset will be fully-considered in the development of each FSP. Profile factors will include:
• Type of facility (e.g., single or multi-story, campus, mixed-use, etc.);
• Population (e.g., single or multi-tenant, care center, visitors, etc.);
• Mission and critical functions conducted at the facility (e.g., dispensary operations, patient administration, operations center, patient information center, continuity of operations [COOP] site, etc.);
• Utilities (e.g., power, water, gas, communications, etc.); and
• The most current facility diagrams, construction documents and specifications.
“The formation of CBIS’ Construction Project Management and Security Teams give our Company important access to construction and security experts,” stated Mr. Dabney. “This will help the Company implement our expansion plans and establish CBIS Pharmacies and Medical Centers in California and throughout the U.S. We expect this important development to support our planned revenue growth in 2018 and to create value for our shareholders.”
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Contact Information
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
“The CBIS CPMT will have overall planning, coordination, and control responsibilities for CBIS projects from initiation to completion,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “CPMT will manage and help ensure the functional and financial viability of our projects. With the construction industry experts we have on our CPMT, as well as the experienced security professionals on our CBISST, we expect our plans to build and expand CBIS Pharmacies and Medical Centers throughout California and the U.S. to be streamlined, secure, and completed on-time and within budget.”
As part of its activities, the CBISST will develop a Facility Security Plan (FSP). This plan is a critical component of CBIS’ security program. The guidelines for CBIS’ FSP are based on recognized industry best practices and provide broad recommendations for the protection of CBIS facilities and CBIS employees, contractors, patients and visitors. CBIS’ FSP will be generally applicable to all buildings and facilities operated and occupied by CBIS employees, including but not limited to:
• Buildings and facilities owned or leased by CBIS;
• CBIS leased rooms or suites within privately owned buildings;
• Stand-alone CBIS facilities;
• CBIS campuses, research laboratories, medical centers, offices and pharmacies; and
• Individual facilities on CBIS campuses and special-use facilities where appropriate.
The CBIS Construction Project Management Team and the CBIS Security Team will work hand in hand to deliver robust secure environments wherever CBIS is operating. The Security Team will conduct various threat assessments, which is the process of identifying or evaluating entities, actions, or occurrences (natural or man-made) that possess or indicate the potential to harm or destroy CBIS assets. The threat assessment will consider the full spectrum of threats (i.e., natural, criminal, terrorist, accidental, etc.) for a given facility/location. Threat data can be derived from various resources including security organizations, intelligence community reports and assessments, as well as state and local authorities. The CBIS Security Team will periodically produce a Design-Basis Threat Report (DBT) that will be used to identify a broad range of threats to CBIS facilities and will be updated regularly based on threat trends and data provided. For example, the crime rates in areas surrounding CBIS facilities will be assessed as an indicator of the type of criminal activity that may put CBIS facilities at risk.
The Risk Management Process for CBIS’ facilities will include an Interagency Security Committee (ISC) Standard that is the key starting point for the development of a Facility Security Plan (FSP). Once the FSP is applied, other critical elements will be added to make the plan a more robust document. The Facility Profile for each CBIS asset will be fully-considered in the development of each FSP. Profile factors will include:
• Type of facility (e.g., single or multi-story, campus, mixed-use, etc.);
• Population (e.g., single or multi-tenant, care center, visitors, etc.);
• Mission and critical functions conducted at the facility (e.g., dispensary operations, patient administration, operations center, patient information center, continuity of operations [COOP] site, etc.);
• Utilities (e.g., power, water, gas, communications, etc.); and
• The most current facility diagrams, construction documents and specifications.
“The formation of CBIS’ Construction Project Management and Security Teams give our Company important access to construction and security experts,” stated Mr. Dabney. “This will help the Company implement our expansion plans and establish CBIS Pharmacies and Medical Centers in California and throughout the U.S. We expect this important development to support our planned revenue growth in 2018 and to create value for our shareholders.”
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Contact Information
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Hallo Zusammen,
Wollte in einen Cannabis Wert in den USA einsteigen.
Weiß nicht Leute... CBIS ist mir nicht Geheuer.
Bin heute in den USA TRTC und MCIG eingestiegen.
Star
Wollte in einen Cannabis Wert in den USA einsteigen.
Weiß nicht Leute... CBIS ist mir nicht Geheuer.
Bin heute in den USA TRTC und MCIG eingestiegen.
Star
Antwort auf Beitrag Nr.: 56.691.338 von Startrader2012 am 11.01.18 21:26:46
Aha, interessant.....
Zitat von Startrader2012: Hallo Zusammen,
Wollte in einen Cannabis Wert in den USA einsteigen.
Weiß nicht Leute... CBIS ist mir nicht Geheuer.
Bin heute in den USA TRTC und MCIG eingestiegen.
Star
Aha, interessant.....
Antwort auf Beitrag Nr.: 56.696.993 von Miser am 12.01.18 13:09:35Nicht Geheuer:
- Aktienanzahl/Marktkapitalisierung
- Umsatz/Gewinn
- Insiderhandel
- Nachrichtenlage: Viel Gefasel, nichts Greifbares...
Dennoch, vielleicht ist ja etwas Tolles an dem Wert wovon ich nichts weiß oder nicht beachte. Davon weiß ich aktuell leider nichts oder habs übersehen
Wünsche Euch viel Glück!
- Aktienanzahl/Marktkapitalisierung
- Umsatz/Gewinn
- Insiderhandel
- Nachrichtenlage: Viel Gefasel, nichts Greifbares...
Dennoch, vielleicht ist ja etwas Tolles an dem Wert wovon ich nichts weiß oder nicht beachte. Davon weiß ich aktuell leider nichts oder habs übersehen
Wünsche Euch viel Glück!
Antwort auf Beitrag Nr.: 56.697.818 von Startrader2012 am 12.01.18 14:18:27Bin auf diesen Artikel gestoßen ohne auf die schnelle beurteilen zu können was daran wahr ist.
https://www.nanalyze.com/2017/01/cannabis-science-cbis-scary…
Will hier keine Panik schüren. Recherchiert bitte selbst. Deren Homepage scheint aktuell off zu sein, zumindest komm ich nicht rein.
Star
https://www.nanalyze.com/2017/01/cannabis-science-cbis-scary…
Will hier keine Panik schüren. Recherchiert bitte selbst. Deren Homepage scheint aktuell off zu sein, zumindest komm ich nicht rein.
Star
Antwort auf Beitrag Nr.: 56.698.844 von Startrader2012 am 12.01.18 15:32:01Die Webseite ist hier zu finden - https://www.cannabisscience.com/
NEWS vom 10.01.2018
Cannabis Science Announces its Construction Project Management (CPMT) Teams in Support of the Company’s Initiative to Establish Pharmacies and Medical Centers in California and Throughout the U.S.
NEWS vom 10.01.2018
Cannabis Science Announces its Construction Project Management (CPMT) Teams in Support of the Company’s Initiative to Establish Pharmacies and Medical Centers in California and Throughout the U.S.
Antwort auf Beitrag Nr.: 56.699.150 von gamechanger am 12.01.18 15:56:04Danke funktioniert!
Der gesamte Cannabis Sektor heut am abkacken. CBIS hält sich klar besser als TRTC/MCIG. Mal sehn was der Tag noch so bringt. Bzgl. CBIS hab ich mittel- und langfristig die größten Bedenken.
Ja, viele scheinbar gute News. Doch wie in dem Link beschrieben nichts greifbares...
Werde übers WE nochmal checken.
Viel Erfolg!
Der gesamte Cannabis Sektor heut am abkacken. CBIS hält sich klar besser als TRTC/MCIG. Mal sehn was der Tag noch so bringt. Bzgl. CBIS hab ich mittel- und langfristig die größten Bedenken.
Ja, viele scheinbar gute News. Doch wie in dem Link beschrieben nichts greifbares...
Werde übers WE nochmal checken.
Viel Erfolg!
Antwort auf Beitrag Nr.: 56.700.368 von Startrader2012 am 12.01.18 17:18:39Die hohen Umsätze bei der NASDAQ deuten auf ein reges Kauf-Interesse von Investoren hin!
Was halter ihr von cannabis sience
Nach wie vor furchteinflössend was News und Online Auftritte angeht. Auf FB beispielsweise viele schöne nichts aussagende Bilder.
Vorsicht ist bei dieser Bude angebracht..
Vorsicht ist bei dieser Bude angebracht..
Was wurde eigentlich aus dem loyalty gift shares Programm ? Also ich habe bislang keine Gratisaktien bekommen, jemand von euch ?
Na tut sich hier noch was? Verkaufen die irgendwann mal oder ist da alles Forschung?
Wie wird bei dennen Umsatz generiert?
Hat die Firma schon mal irgendwo Werbung für sich gemacht?
Wer kennt die Firma überhaupt! Muss doch mal was kommen!
Wie wird bei dennen Umsatz generiert?
Hat die Firma schon mal irgendwo Werbung für sich gemacht?
Wer kennt die Firma überhaupt! Muss doch mal was kommen!
...und wieder Monate ins Land gezogen ohne irgendwelche News..der Kurs bewegt sich auch kaum..nur die Richtung zeigt nach unten..ziemlich "maues" Projekt, dass Ganze :-(
Gibts hier irgendwelche Neuigkeiten von dem Unternehmen ?
Nein, nicht das wüste. Ich dachte schon ich bin allein hier.
Antwort auf Beitrag Nr.: 59.715.093 von Lokfahrmeister am 25.01.19 22:18:35Heute richtig gutes Handelsvolumen und auf Tageshöchsrkurs geschlossen. Da kommt die nächsten Tage etwas.
Antwort auf Beitrag Nr.: 59.740.323 von Lokfahrmeister am 29.01.19 22:33:20
https://www.ariva.de/forum/cannabis-science-kurz-vor-dem-dur…
https://www.ariva.de/forum/cannabis-science-kurz-vor-dem-dur…
Nabend,
CBIS, der Cannabis Schock überhaupt.
Der Kauf von US Werten MCIG und TRTC war ein Fehler. Noch mit einem blauen Auge davon gekommen. Die USA hinkt im Cannabis Sektor hinterher.
Aber CBIS... Horror
CBIS, der Cannabis Schock überhaupt.
Der Kauf von US Werten MCIG und TRTC war ein Fehler. Noch mit einem blauen Auge davon gekommen. Die USA hinkt im Cannabis Sektor hinterher.
Aber CBIS... Horror
Moin. Bin neu hier. Produziert die Bude eigentlich etwas oder gibt der Chef nur PR-Pressemails mit Absichtsbekundungen raus?
Moin,
Außer irgendwelchen tollen PR Events leider nichts.
Das Video auf der Homepage sagt irgendwie schon alles über diese Bude.
Außer irgendwelchen tollen PR Events leider nichts.
Das Video auf der Homepage sagt irgendwie schon alles über diese Bude.
Antwort auf Beitrag Nr.: 59.770.791 von Startrader2012 am 01.02.19 18:25:57Also so schnell wie möglich wieder raus:!?
Antwort auf Beitrag Nr.: 59.771.187 von derma-80 am 01.02.19 18:55:34Ja raus hier, einfach unlimitiert verkaufen.... Bevor die BUDE voll abkackt.
Hi Derma,
es laufen immer wieder mal Zocks. Fundamental ist dieser Laden nichts wert.
Der Chef Dabney, ein Blender der seines gleichen sucht.
Hab eben nochmal nach Zahlen gesucht. Vergeblich! Für 2018 nichts zu finden. Nicht mal auf deren HP!
https://cannabisscience.com/investors/sec-filings" target="_blank" rel="nofollow ugc noopener">https://cannabisscience.com/investors/sec-filings
es laufen immer wieder mal Zocks. Fundamental ist dieser Laden nichts wert.
Der Chef Dabney, ein Blender der seines gleichen sucht.
Hab eben nochmal nach Zahlen gesucht. Vergeblich! Für 2018 nichts zu finden. Nicht mal auf deren HP!
https://cannabisscience.com/investors/sec-filings" target="_blank" rel="nofollow ugc noopener">https://cannabisscience.com/investors/sec-filings
Verbleib von Cannabis Science
Hallo, kann mir jemand etwas über den aktuellen Verbleib dieser Aktie sagen?Danke im voraus
Kalateh
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-1,06 | |
+22,27 | |
-5,29 | |
-4,10 | |
0,00 | |
-16,67 | |
0,00 | |
-2,13 | |
+2,88 | |
-7,92 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
119 | ||
74 | ||
52 | ||
49 | ||
37 | ||
35 | ||
35 | ||
34 | ||
33 | ||
32 |